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CAR-MODIFIED T CELLS CAPABLE OF DISTINGUISHING MALIGNANT CELLS FROM 
NORMAL CELLS 
Hillary Gibbons Caruso, B.S. 
 
Advisory Professor: Laurence Cooper, M.D., Ph.D. 
 
 T cells can be redirected to target tumor-associated antigen (TAA) by genetic 
modification to express a chimeric antigen receptor (CAR), which fuses the specificity 
derived from an antibody to T-cell activation domains to result in lysis of TAA-expressing 
cells. Due to the potential for on-target, off-tissue toxicity, CAR+ T-cell therapy is currently 
limited to unique or lineage-restricted TAAs. Glioblastoma, a grade IV brain malignancy, 
overexpresses epidermal growth factor receptor (EGFR) in 40-50% of patients. EGFR also 
has widespread normal tissue expression. To target EGFR on glioblastoma while reducing 
the potential for normal tissue toxicity, EGFR-specific CAR generated from cetuximab, 
Cetux-CAR, was transiently expressed in T cells by RNA-modification. RNA-modified CAR+ 
T cells demonstrated similar cytotoxicity against EGFR+ cells, including normal renal cells, 
as DNA-modified CAR+ T cells. However, RNA-modified T cells lost CAR expression over 
time, concomitant with loss of functional specificity to EGFR. Transient expression of CAR 
limits potential for off-tissue toxicity at the expense of anti-tumor activity, and does not 
protect normal tissue from immediate toxicity. Recognizing that EGFR is overexpressed at a 
higher density on glioblastoma relative to normal tissue, we generated an EGFR-specific 
CAR from nimotuzumab, an EGFR-specific antibody with reduced binding to low density 
EGFR. While Cetux-CAR+ T cells produced cytokine and mediated lysis independent of 
EGFR density, function of Nimo-CAR+ T cells directly correlated with the EGFR density of 
targets, with reduced activity in response to low density EGFR, but equivalent activity in 
response to high density EGFR relative to Cetux-CAR+ T cells. Cetux-CAR+ T cells and 
Nimo-CAR+ T cells demonstrated equivalent control of intracranial glioma xenograft with 
intermediate EGFR density, but only Cetux-CAR+ T cells controlled xenografts with low 
EGFR density. In sum, transient expression of CAR has the potential to reduce long-term 
toxicity to normal tissue, but at the expense of anti-tumor activity. Rational design of CAR 
based on an antibody with reduced binding to low density EGFR generated EGFR-specific 
CAR able to tune T-cell function to antigen density resulting in discrimination of high EGFR 
density on malignant cells from low EGFR density on normal tissue. 
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CHAPTER 1 
Introduction 
1.1 T cells 
T cells are a lymphocyte of the adaptive immune system characterized by sensitive and 
highly specific response to foreign antigen (1).  CD8 T cells, or cytotoxic T cells, are capable 
of initiating target cells lysis upon recognition of foreign antigen, whereas CD4 T cells, or 
helper T cells, support immune responses, primarily through secretion of cytokines.  Both 
CD8 T cells and CD4 T cells recognize peptide in the context of presentation by major 
histocompatibility complex (MHC) through the αβ T cell receptor (TCR).  CD8 and CD4 
function as co-receptors, binding to MHC class I and MHC class II, respectively, to facilitate 
T cell recognition of foreign peptide. 
1.1.1 Structure and function of T-cell receptor in T-cell activation 
Each TCR is a heterodimer composed of disulfide-linked α and β chains, which are 
composed of two immunoglobulin-like domains each, a variable and constant domain, 
anchored into the cell membrane via a transmembrane region and short cytoplasmic tail with 
no intrinsic signaling capacity.  The variable domain is formed from recombination of 
variable (V), diversity (D), and joining (J) gene segments in β chain, and V and J segments 
in the α chain in a process known as VDJ recombination.  The large magnitude of 
permutations that can result from VDJ-rearrangement generates a remarkable range of T-
cell specificities for peptide presented in MHC (pepMHC). The TCR is expressed on the T-
cell surface in association with three CD3 signaling dimers (δε, γε, and ζζ) through polar 
interactions among the transmembrane domains, such that δε and γε associate with each 
other on one side of the αβ TCR and ζζ is on the other (2).  Because the ζ chain has a small 
extracellular domain, one face of the αβ TCR open for dimerization, which has been 
proposed as a mechanism for TCR signal transduction (3, 4).  Each CD3 subunit contains 
immunoreceptor tyrosine-based activation motifs (ITAMs), which become phosphorylated 
following TCR recognition of pepMHC by Src kinase family member Lck to initiate a 
signaling cascade (1).  ZAP-70 is recruited to phosphorylated ITAMs and phosphorylates 
two adaptor proteins, lymphocyte cytosolic protein 2 (SLP-76) and linker of activated T cells 
(LAT), a palmitoylated transmembrane protein with a long cytoplasmic domain containing 
many phosphorylation sites which recruits many proteins to form a signalosome (5).  
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Proteins recruited to the signalosome include: SLP-76, growth factor receptor-bound protein 
2 (Grb2), Grb2-related adaptor downstream of signaling (GADS), phospholipase C γ1 
(PLCγ-1), inducible T cell kinase (Itk), Nck, and Vav1. Nck and Vav1 are adaptor molecules 
the regulate actin cytoskeleton reorganization. PLCγ-1 is phosphorylated by Itk and 
hydrolyzes phosphatidylinositol 4,5-biphosphate (PIP2) into two second messengers, 
diacylglycerol (DAG) and inositol triphosphate (IP3). DAG activates signaling through protein 
kinase C-θ (PKCθ) to ultimately activate transcription factor nuclear factor κ-light-chain-
enhancer of activated B cells (NFκB), and mitogen activated protein kinase (MAPK) 
pathways extracellular regulated kinase 1/2 (Erk1/2), p38, and c-Jun n-terminal kinases 
(JNK). IP3 triggers release of Ca2+ from the endoplasmic reticulum to ultimately activate the 
transcription factor nuclear factor of activated T cells (NFAT). 
T-cell activation and signaling is tightly integrated with cytoskeleton organization (6-
8).  The actinomyosin cytoskeleton is important before and during T-cell activation by 
influencing T-cell motility while scanning for antigen prior to TCR triggering, providing 
scaffolding to assemble signalosome during TCR triggering, and translocating TCR 
signaling clusters prior to termination of signaling.  Evidence of the necessity for cytoskeletal 
mediation of T-cell signaling comes from the potent inhibitory activity of actin 
depolymerization agents latrunculin A and cytochalasin D on T-cell activation (9, 10).  
Recently, actin remodeling has been shown to be a requirement for initiation of T-cell 
signaling (11).  Actin restricts lateral diffusion of molecules in the cell membrane, and has 
been shown to sequester signaling intermediates, but the exact contribution the actin 
cytoskeleton makes to T-cell signaling has yet to be completely elucidated (12, 13). 
1.1.2   Impact of T-cell receptor affinity on T-cell function 
The binding kinetics of an individual TCR molecule to pepMHC can be described by 
an association rate, or on-rate of binding (kon) and dissociation rate, or off-rate of binding 
(koff) (14).  A relationship between these two biochemical parameters is used to derive a 
dissociation constant (Kd) to describe the overall affinity TCR/pepMHC interaction, such that: 
Kd= koffkon 
A half-life (t1/2) for the interaction of TCR with pepMHC can be derived from the koff by the 
equation:  
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t1 2� = ln 2koff  
Typically, these binding parameters are derived from surface plasmon resonance (SPR) 
assays, in which immobilized pepMHC interact with free TCR in solution, and Kd is equal to 
the concentration of unbound TCR when the concentration of unbound pepMHC equals the 
concentration of bound pepMHC.  Wild type TCR affinities producing productive T-cell 
responses are often described as low affinity, particularly relative to kinetics described for 
antibody interaction with antigen, and are characterized by slow on-rates and intermediate 
off-rates of binding with pepMHC (14). 
Altering binding affinity of pepMHC ligands for TCR has demonstrated the distinct 
impact of low affinity interactions on T-cell signaling, including reduced phosphorylation of 
CD3ζ, calcium release, granule polarization, downregulation of TCR, and activation of 
MAPK pathways (15-21).  However, the parameter of TCR binding primarily correlating with 
T-cell function has been a matter of extensive debate (14). Evidence supports both Kd and 
koff as determinants of T-cell function (15, 16, 22-25).  The kinetic proofreading model of T 
cell triggering suggested that dissociation rates must be sufficiently long for signaling and T-
cell activation to take place.  This has been contradicted by findings that TCRs with short 
half-lives can produce functional responses and that T-cell activation can take place in a 
matter of seconds following TCR interaction with pepMHC (25, 26).  Additionally, it has been 
observed that excessively long half-lives of interactions can result in impaired T-cell function 
(27, 28).  When combined with the observation that multiple TCR can be internalized 
following interaction with a single pepMHC complex (29), it has been hypothesized in such 
prolonged interactions, serial triggering of multiple TCR by a  single pepMHC complex is 
impaired, resulting in impaired T-cell activation.  This addendum to kinetic proofreading 
model, termed the optimal dwell time model, purports a window of dissociation rates in 
which functional TCR/pepMHC binding can occur (27).  The requirement of serial triggering 
for TCR triggering has also been called into question, as it has been observed that T cells 
require interaction with as little as 3 pepMHC to induce target lysis (30).  Additionally, 
engineered TCRs with very long half-lives, up to 425 minutes, are capable of producing 
functional T-cell responses (31, 32).  It seems that serial triggering for T-cell activation may 
be a requirement when pepMHC is limiting, such that increasing pepMHC density can 
dispense the requirement for serial triggering (33).  Subsequent studies have evaluated the 
contribution of association rate of binding to T-cell activity.  In transgenic TCR systems 
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evaluating peptides with altered affinity, T-cell activity was found to correlate with 
association rate and not dissociation rate of binding (16, 24, 25).  The high degree of 
correlation between Kd and koff values and the small range of kon values in many datasets 
complicates determining the roles of individual biochemical parameters on T-cell function.  
By analyzing datasets of TCR and pepMHC binding pairs that minimized the correlation 
between Kd and koff and included a wider dynamic range of kon values, Aleksic, et.al. 
proposed a model such that T-cell confinement, derived from the mathematical relationship 
of kon, koff and diffusion of TCR and pepMHC in their respective membranes, accounts for 
the duration of TCR/pepMHC interaction and resulting T-cell function (34).  Interestingly, this 
model can reduce to simpler models.  When kon is fast relative to diffusion rate, confinement 
time is proportional to Kd, however, when kon is slow relative to diffusion rate, confinement is 
governed solely by the koff because the TCR/pepMHC will diffuse without multiple binding 
events.  Thus, previously contradictory studies can be resolved within one model of TCR 
triggering (26, 34). 
Discrepancies between previous studies can also be accounted for by 
methodological differences. Read-outs of T-cell function vary from study to study, and 
include proliferation, phosphorylation of signaling molecules, cytokine production, and lytic 
capacity.  It has been demonstrated that TCRs elicit effector responses in an TCR clone-
specific and antigen-dose dependent hierarchy, such that some responses are more easily 
triggered at low antigen doses than others (17).  Thus, differences in TCR clone employed 
in the study and functional read-outs complicate inter-study comparisons.  It has been 
described that T-cell activation is achieved by a cumulative signal, which can be reached at 
different time points for different ligands, such that low affinity ligands induce functional T-
cell responses, including calcium release, upregulation of activation marker CD69, and 
proliferation, kinetically delayed relative to higher affinity ligands (16, 35, 36). Therefore, 
difference in assay time points may also contribute to differences in findings. 
Recently, studies have acknowledged an inherent limitation in measuring TCR 
binding kinetics in three-dimensional (3D) assays.  In 3D kinetic assays, one binding partner 
is immobilized, while the other is free in solution. This does not mimic conditions of 
physiological T-cell activation, in which both binding partners are constrained to two-
dimensional (2D) movement within their respective cell membranes, which ensures proper 
orientation of molecules and limits intercellular volume to increase the likelihood of 
TCR/pepMHC binding (37, 38).  Accordingly, Huang et. al. developed two 2D mechanical 
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assays to measure TCR binding kinetic to pepMHC (37).  Association and dissociation rates 
measured in 2D were accelerated and characterized by broader ranges relative to 3D 
measurements. All 2D kinetic parameters, Kd, koff and kon, correlated with T-cell function.  In 
contrast to 3D assays, in which durable interaction through slow koff resulted in enhanced T-
cell function, faster 2D koff correlated with superior T-cell function.  Interestingly, disrupting 
cytoskeletal involvement in T-cell signaling by actin depolymerization results in 2D kinetic 
measurements similar to 3D measurements, indicating cytoskeletal involvement in 
destabilizing TCR/pepMHC interaction (38).  Similarly, measurement of binding in a 2D cell-
free system described dissociation rates equivalent to those obtained from 3D assays (39).  
Thus, an integrated process involving dynamic cellular processes and cytoskeletal 
rearrangement during T cell interaction with antigen presenting cells influences the rates of 
association and dissociation between TCR and pepMHC.    
1.1.3   TCR clustering during T-cell activation 
While monomeric affinity describes the kinetic association and dissociation of 
individual TCR/pepMHC interactions, avidity describes the contribution of multiple 
TCR/pepMHC binding pairs to stabilizing interactions and enhancing T-cell activation.  Prior 
to TCR ligation with pepMHC, TCRs are present in oligomeric structures termed 
“nanoclusters”, facilitated by cholesterol and sphingomyelin in the cell membrane (40-43).  
These static preformed TCR aggregates are hypothesized to contain 2-20 TCR αβ pairs, 
and increase sensitivity to low antigen doses by enhancing avidity of interaction (40, 43).   In 
fact, the size of the nanocluster has been shown to be directly related to antigen sensitivity 
(42). Additional clustering of TCR following engagement by multivalent pepMHC complexes 
is a requirement for complete T-cell activation (4, 44). Formations of microclusters, 
containing 30-300 TCR, initiate T-cell signaling, and precede establishment of a mature 
immunological synapse (45-48). The size and number of TCR microclusters increases with 
ligand density or agonist strength (49).  Agonist- and actin-dependent, TCR microclusters 
co-localize with activated Lck, ZAP-70, and LAT, and provide a scaffold for signal 
amplification (9, 49).  Thus, the formation of nanocluster of TCRs prior to antigen interaction 
enhances sensitivity to antigen through increased avidity, and formation of microclusters 
after antigen interaction amplify signal and contribute to overall T-cell functional response. 
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1.1.4   Immunological synapse formation during T-cell activation 
An immunological synapse describes the stable interaction between a T cell and 
antigen presenting cell (APC), characterized by highly orchestrated molecular organization 
and cytoskeletal rearrangement within the T cell.  The synapse is organized in a bullseye 
configuration with three distinct concentric rings of molecules, termed supramolecular 
activation clusters (SMAC).  The central SMAC (cSMAC) is traditionally characterized by 
high density of TCR, while the peripheral SMAC (pSMAC) contains adhesion molecules, 
such as intercellular adhesion molecule-1 (ICAM-1).  The distal SMAC (dSMAC) typically 
contains molecules with long extracellular domains, such as CD45.  The synapse is not 
required for transient T cell activation, as initiation of signaling and directed cytotoxicity can 
occur before the establishment of a stable immune synapse (30, 46, 50). However, the 
immunological synapse forms stable interactions between T cells and APCs on the order of 
hours and promotes continuous signaling to reach full effector function (51). The cSMAC 
enhances signaling by localizing TCR, pepMHC, and intracellular signaling molecules, such 
as Lck in a small, defined region, facilitating rapid molecular associations.  The cSMAC is a 
site of both increased TCR triggering and TCR degradation and functions to amplify weak 
signals while tempering strong signals by enhancing downregulation of TCR (52-54). In the 
case of weak agonists, zeta chain is only partially phosphorylated and triggers minimal 
downregulation of TCR (17, 53, 55).  However, in the case of a strong agonist, intense 
signaling and phosphorylation enhances TCR degradation, tempering T-cell signaling and 
activation. Thus, the balance between enhanced signaling and TCR degradation that occurs 
in the cSMAC facilitates further distinction of T cell activation and function induced strength 
of TCR/pepMHC interaction. 
1.1.5   Contribution of pepMHC density to T-cell activation 
In vivo, a correlation has been found between high antigen density, stability of 
interaction between T cells and pepMHC on dendritic cells, and cytolytic function, indicating 
the role of antigen density in contributing to overall avidity of T-cell interaction with pepMHC 
and influence on T-cell activation (56, 57).  Low affinity of pepMHC can be compensated by 
increasing pepMHC density to increase the number of TCRs triggered (17, 59, 60).  
Triggering an equivalent number of TCR with high affinity, low density pepMHC and low 
affinity, high density pepMHC can elicit similar levels of T-cell proliferation (29, 61).   
However, pepMHC affinity and density can have distinct influences on T-cell activation. 
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Gottschalk, et.al. described that while increasing antigen density can compensate for low 
affinity to induce T cell proliferation, defects in interleukin-2 (IL-2) production could not be 
compensated by increased antigen (60).  Microarray analysis revealed two distinct groups of 
genes: those regulated by cumulative TCR signal and thus able to be compensated by 
increasing density of low affinity antigen and those regulated by affinity of TCR/pepMHC 
interaction and not able to be compensated by increasing antigen density. Disparate ability 
of quantity of antigen to compensate for affinity of interaction in the induction of certain gene 
subsets indicates that increasing the avidity of interaction may not be able to overcome the 
influence of weak monomeric affinity of TCR/pepMHC interactions to achieve T-cell 
functional responses equivalent to more stable interactions (57).  Therefore, affinity of 
monomeric TCR and avidity influenced by antigen density can have distinct influences on T-
cell signaling, activation, and function. 
1.1.6   Impact of TCR affinity and pepMHC density in vivo 
Enhancing TCR affinity results in increased antigen sensitivity and functional avidity 
in vitro and in vivo, up to a certain threshold (23, 62).  However, superior function of high 
affinity T cells in vitro does not necessarily correlate to better in vivo function.  In a 
vaccination model, high affinity ligand, beyond a certain ceiling, demonstrated attenuated T-
cell responses in vivo, characterized by reduced in vivo expansion, accumulation, and 
diminished cytokine production upon restimulation (63).  Likewise, in a model of microbial 
infection, low affinity ligands for TCR demonstrate T-cell activation, but curtailed expansion 
and shorter duration in lymphoid organs (64).  In vivo tumor models also demonstrate that 
CD8 T cells with high affinity TCRs lose cytotoxic function after tumor infiltration, and are 
deleted in the tumor and peripheral lymphoid tissues (65-67).  Thus, it is likely a window of 
intermediate affinity exists in which T cells demonstrate optimal in vivo responses, including 
expansion, cytotoxic function, and memory formation.  However, due to the complex nature 
of pepMHC presentation, TCR interaction with pepMHC, and the role of antigen density 
influencing T cell avidity, it is unlikely that any single biochemical parameter universally 
determines optimal T cell function. 
T cells with high-affinity TCRs have demonstrated loss of specificity and cross-reactivity 
to self-peptides (68, 69).  In a clinical study with a high-affinity, engineered TCR directed to 
MAGE-A3 for treatment of melanoma and myeloma, 2/2 patients died of cardiogenic shock 
days after T-cell infusions with autopsies revealing severe myocardial damage and T-cell 
8 
 
infiltration (70). Subsequent studies identified that MAGE-A3 TCR was cross-reactive with 
titin, which is expressed on the striated muscle tissue of the heart, resulting in T-cell 
activation and elimination of cardiomyocytes in vitro, demonstrating loss of specificity 
attributed to affinity maturation of TCR (71).  One hypothesis for the development of such 
cross-reactivity is that enhancing affinity for MHC reduces peptide sensitivity, and therefore, 
enhancing affinity in portions of TCR that interact only with peptide may prevent 
development of cross-reactivity to self-peptide (72). 
1.2 T-cell immunotherapy for cancer 
The theory of cancer immunoediting suggests that when the immune system is capable 
of recognizing cancer cells, tumor growth is inhibited (73). Tumors are thought to develop 
through evasion of immune detection through two primary mechanisms: central and 
peripheral tolerance (74, 75). Central tolerance is obtained during T-cell development by 
deletion of T cells with self-reactive TCRs, necessary to protect the host from autoimmune 
responses.  Tumors often overexpress self-antigens, but self-tolerized T cells are unable to 
mount functional response to these antigens.  Peripheral tolerance is often exploited by 
tumors and describes the blunting of immune responses due to cultivation of an 
immunosuppressive microenvironment (76-78). 
Cancer immunotherapy approaches aim to reactivate the immune system to recognize 
tumors as foreign and mediate their destruction. Though many cell types can be employed 
to achieve anti-tumor effects, T cells provide unique antigen-specificity, ability to extravasate 
and home to chemo-attractants, and potential to establish immunological memory and 
mediate tumor regression upon relapse.  Vaccination can be employed to activate T cells 
within cancer patients in response to antigenic peptide unique to tumor, but requires a pre-
existing population of T cells with TCR responsive to introduced peptide and activation must 
overcome mechanisms of immune suppression (79). To overcome some of these limitations, 
patient’s autologous T cells can be manipulated ex vivo, outside the influence of an 
immunosuppressive tumor, and re-infused for tumor immunotherapy (74). Some of the 
earliest successes in adoptive T-cell therapy isolated tumor-infiltrating lymphocytes (TIL) 
from tumors for selection for reactivity to tumor antigen and ex vivo expansion to restore 
effector function prior to re-infusion into patients with melanoma (80-82).  Importantly, these 
early seminal studies delimited the requirement for persistent T-cell responses for effective 
anti-tumor responses (83, 84).  However, this strategy still requires the presence of 
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endogenous TCR with specificity for unique tumor antigen.  To overcome this limitation, T 
cells can be genetically modified to redirect their specificity through two primary 
mechanisms: introduction of genetically engineered αβ TCR or artificial, engineered TCR 
commonly referred to as chimeric antigen receptor (CAR) (74). 
1.2.1   Chimeric antigen receptors: Overview 
A CAR is formed from the single chain variable fragment (scFv) of a monoclonal 
antibody (mAb) with desired specificity fused by a flexible linker to an extracellular hinge 
region, often a member of the immunoglobulin class G (IgG), followed by a transmembrane 
and intracellular signaling domain (Figure 1) (85).  A major advantage of CAR-based 
genetic modification over engineered αβ TCRs is that CAR is capable of recognizing antigen 
independent of MHC presentation and therefore overcomes limitations of allelic diversity of 
MHC for broad application to wider subset of patients and overcomes MHC downregulation 
on tumors as an immune escape mechanism (86, 87). 
1.2.2   Genetic modification of primary T cells  
Two primary strategies exist for permanent integration of CAR into host T cell DNA: 
viral transduction and non-viral plasmid integration.  Initial CAR clinical trials utilized γ-
retrovirus transduction to express CAR, which show an integration preference for 
transcriptional start sites (88, 89).  Although no evidence of genotoxicity has been observed 
in trials with γ-retrovirally transduced T-cells, gene therapy for X-linked severe combined 
immunodeficiency (SCID) patients demonstrated the potential for insertional mutagenesis 
and genotoxicity (90, 91).  Integration of γ-retrovirus into gene encoding LIM-only protein-2 
(LMO-2), associated with lymphocyte proliferation and leukemia, resulted in aberrant 
overexpression of LMO-2 transcript resulting in development of monoclonal lymphocytosis 
(91).  Self-inactivating lentiviruses have proven to be a good vehicle for gene therapy 
because they can deliver a large DNA cargo load, efficiently transduce T cells, and 
demonstrate reduced susceptibility to promoter silencing relative to retroviruses (74, 89).  
While lentiviruses do not show preference for integration at transcriptional start sites as seen 
with γ-retroviruses, they do show a predilection for transcriptionally active units, shown by 
higher integration frequency into gene-coding segments of DNA (89).  However, lentiviral 
vectors are expensive to produce; therefore a low cost alternative to speed translation to 
clinical testing is desirable. Sleeping Beauty (SB) is a non-viral gene transfer system in 
which the genetic cargo load is expressed as a transposon between two inverted repeats  
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Figure 1. Schematic representation of CARs.  First generation CARs fuse the specificity 
of the scFv domain from a monoclonal antibody to a flexible linker and IgG hinge domain 
attached to CD3-ζ transmembrane and cytosolic signaling domains.  Second generation 
CARs include an additional costimulatory domain upstream of CD3-ζ, such as CD28 or 4-
1BB, which contains transmembrane region and cytosolic signaling domains.  Third 
generation CARs include two costimulatory domains upstream of CD3-ζ, often CD28 and 4-
1BB or OX40. 
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containing direct repeated sequences (IR/DR) and is co-expressed with a transposase 
enzyme, SB11, which can cut and paste the genetic cargo into the host cell genome at sites 
of TA dinucleotide repeats (92-94). SB gene-transfer system is advantageous because it (i) 
does not show integration bias for transcriptionally active sites, (ii) has reduced capacity of 
remobilization due to fish-derivation of SB transposition elements, and (iii) is low-cost 
relative to lentiviral vectors (89, 92). Transfer of transposon containing CAR and SB11 
transposase is achieved via electroporation of resting peripheral blood mononuclear cells 
(PBMCs).  CAR transfer via the SB system results in stable CAR integration and expression 
(93, 94). Subsequent culture of T cells on artificial antigen presenting cells (aAPC) 
expressing antigen can cull out CAR-expressing T cells over time by selective propagation 
of CAR-expressing T cells.  aAPC can be genetically modified to express costimulatory 
molecules, providing additional opportunities to support T-cell expansion and reprogram 
function during ex vivo culture (95-97). 
1.2.3   Structure and function of CAR 
Originally, T-cell activation via CAR was achieved through inclusion of intracellular 
CD3-ζ, termed a first generation CAR (85). T cells expressing first generation CARs 
demonstrated modest anti-tumor activity, presumably due to limited in vivo expansion and 
persistence (98-100).  Second generation CARs were engineered to include a costimulatory 
signaling endodomain and have been shown to enhance CAR-mediated T-cell function.  
The most commonly described second generation CAR includes signaling through CD28, 
which resulted in increased proliferation, upregulation of anti-apoptotic genes, production of 
interferon-γ (IFN-γ) and IL-2, in vivo persistence and anti-tumor efficacy (101, 102, 104). 
Moreover, inclusion of CD28 signaling is also associated with increased resistance to 
immunosuppressive regulatory T cells (103). Interestingly, enhanced function of CAR 
containing CD28 endodomain over CAR signaling through CD3-ζ only was only apparent 
when target cells had no expression of CD86, the natural ligand for CD28 (105).  Inclusion 
of other costimulatory domains has been investigated, including CD137 (4-1BB), CD134 
(OX-40), CD244, CD27, and inducible costimulator (ICOS) (106-110). CARs containing 4-
1BB endodomains result in improved in vivo persistence, anti-tumor activity, and tumor 
infiltration relative to first generation or CD28-containing second generation CARs, and have 
been associated with recent reports of clinical success targeting CD19 on B-cell 
malignancies (106, 111, 112).  Third generation CARs have also been evaluated, in which a 
third endodomain is included to further augment T cell function. The most studied 
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combinations are CD28-41BB-CD3ζ and CD28-OX40-CD3ζ. Whether either of these 
configurations exhibit functional advantage over second generation CARs is unclear.  While 
one study showed increased anti-tumor activity of a CAR containing CD28-41BB-CD3ζ 
signaling domains, another found no appreciable difference relative to 41BB-CD3ζ CAR 
alone (106, 113). A study comparing CAR signaling through CD28-OX40-CD3ζ and CD28-
41BB-CD3ζ found that inclusion of OX40 increased sensitivity to low density antigen and 
increased lytic potential of T cells, but 41BB did not (114, 115). The optimal combination of 
CAR endodomains is undetermined and the subject of ongoing clinical investigation. 
The distance of the epitope recognized by CAR scFv from the cell membrane can 
impact antigen sensitivity.  It has been reported that targeting epitopes distal from the cell 
surface impaired lytic function in response to all levels of antigen expression, caused by 
both impaired T-cell degranulation and impaired targeting of granules due to delivery 
distance from the membrane (115-117).  James, et.al. demonstrated this phenomenon was 
independent of affinity of CAR interaction with antigen by truncating the CD22 receptor such 
that a previously distal epitope was made membrane-proximal and showing the ability of 
CD22-specific CAR T cells to target cells expressing truncated CD22 was restored.  The 
hinge region also influences T-cell interaction with target cells by impacting the length and 
flexibility of the CAR.  Optimal hinge region length seems to vary from CAR to CAR, with 
reports of hinge regions enhancing and reducing function in the context of different 
specificities (118, 119).  Recently, ROR1-specific CARs were shown to have superior anti-
tumor activity with hinge regions of intermediate length (119).  Because the distance 
between T cell and target cells during CAR interaction with antigen is determined both by 
epitope distance from membrane and length of hinge, and the impact of one on T-cell 
function is not without the influence of the other (118).  Therefore, in the absence of specific 
rules that govern hinge length and epitope location, empirical evaluation of combinations of 
scFvs and hinge regions should be used to determine optimal CAR design. 
1.2.4   CAR affinity and avidity in T-cell activation 
The impact of affinity of scFv used in CAR design has not been evaluated in depth.  
Endogenous TCRs are described to have wild type affinities much lower than the 
monoclonal antibodies used to redirect CAR specificity, however, CD8 co-receptor binding 
to pepMHC can enhance avidity up to 106 over wild type affinity (31, 66).  Because CAR 
binds surface antigen independent of MHC presentation, CAR interaction with antigen is 
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unlikely to benefit from increased avidity through co-receptor binding.  Thus, the difference 
in overall avidity between wild type TCRs and CAR is unknown, but may not be as extensive 
as previously thought. 
Design of multiple CARs specific for human epidermal growth factor receptor 2 
(HER2) based on a library of affinity matured scFvs described a minimum threshold of CAR 
affinity that needed to be met to induce T-cell activity against HER2-expressing targets, but 
above which T-cell activity was not improved (120).  The scFvs from which CAR were 
derived differed primarily in koff with little variation in kon values, and thus higher affinity was 
due to prolonged association with antigen, not change in rates of association with antigen. 
Importantly, affinity of HER2-specific CARs above the minimum affinity threshold did not 
correlate with increased antigen sensitivity or function.  Recently, CARs specific for ROR1 
for the treatment of murine model of mantle cell lymphoma with varying affinity of scFv were 
evaluated to determine the impact of affinity on CAR-mediated T-cell function.  In this study, 
the scFv with increased affinity was achieved by both increasing kon and decreasing koff.  
Higher affinity ROR-1-specific CAR was associated with increased T-cell function, measured 
by increased cytokine production, proliferation, and in vivo anti-tumor efficacy, analogous to 
observations with affinity-matured TCRs (119).   
The role of affinity in CAR design is impacted by factors that influence avidity, such 
as CAR expression density and antigen expression density (Figure 2). A minimum CAR 
density required for T-cell activation has been defined, below which CAR-mediated T-cell 
activation is abrogated.  Above a maximum CAR density, however, T cells undergo 
increased apoptotic death following interaction with antigen (121). However, within this 
window, CAR density does not appear to impact T-cell activation (122). In conditions where 
both CAR expression and antigen expression are low, CAR-mediated T-cell activation is 
impaired (123).  This phenomenon appears to be dependent on affinity, such that high 
affinity CAR+ T cells have impaired function when CAR and antigen expression is low, but 
low affinity CAR+ T cells do not (124).   
In sum, these data suggest maximal CAR-dependent T-cell activation is determined 
by overall binding avidity, contributed to by affinity, density of CAR expression, and density 
of antigen expression (119). Further studies are required to elucidate the role of CAR 
affinity, and the individual roles for on- and off-rate binding in CAR+ T cell function. 
 
14 
 
   
Figure 2. Influence of affinity and avidity in CAR/antigen interactions.  CAR-dependent 
activation of T cells can be influenced by affinity of the scFv of CAR, density of antigen on 
target cell surface and density of CAR on T-cell surface, of which the latter two affect avidity 
of interactions.  Cumulative CAR-dependent T-cell activation is determined by a combination 
of all three variables.  
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1.2.5   Mechanisms of CAR-mediated T cell activation 
Mechanisms used by CAR to elicit functional T-cell responses and basic structural 
interactions of CAR with T-cell signaling molecules are not well understood. In CAR 
harboring CD3ζ transmembrane domain, CAR can signal through homodimerization or 
heterodimerization through association with endogenous TCR complex (125, 126). Mutation 
of highly polar amino acids associated with endogenous CD3ζ was associated with impaired 
dimerization of CAR and interaction with endogenous CD3ζ and TCR, both of which reduced 
T-cell activation. However, in studies with a second-generation CAR expressing CD28 
transmembrane and cytosolic domains, eliminating endogenous TCR expression by 
targeting with zinc finger nucleases (ZFN), and therefore precluding expression of CD3ζ 
from the T-cell surface, showed no reduction in CAR-mediated T-cell function (127).  
Second generation CARs are capable of dimerization through mutation of proline to serine 
at amino acid position 241 in the IgG4 scaffold region to create a predisposition for 
interchain disulfide bond formation and dimerization (128).  Analysis of CAR in reducing and 
non-reducing western blots revealed bands of predicted monomeric size (69 kDa) and 
oligomeric size (190 kDa), respectively, indicating the CAR undergoes some degree of static 
clustering in T-cell membrane.  In sum, these data suggest that CAR can signal independent 
of the endogenous TCR complex; however this interaction is crucial for activation of CAR+ T 
cells in the absence of second generation transmembrane and endodomain.  In the 
presence of second generation endodomain, association with endogenous CD3-ζ may be 
dispensable for T-cell activation. Both CAR configurations support some degree of 
dimerization/oligomerization on the surface of the T cells, but whether or not the CAR forms 
aggregates after initiation of signaling is currently unknown. 
While serial triggering appears to be an important mechanism mediating wild-type 
TCR sensitivity to low levels of antigen expression, recent studies have suggested CARs do 
not signal by serial triggering.  Mathematically modeling CAR triggering based on Verhulst 
equation for population growth suggested that CAR triggering can be described akin to 
endogenous TCR triggering in a special condition in which serial triggering is abrogated 
(122).  This may partially explain reduced sensitivity of CAR relative to wild type TCRs, such 
that CARs require higher CAR expression and higher antigen density to induce functional T-
cell responses. Descriptions of downregulation and serial triggering of CAR have currently 
been described for first generation CARs, and the impact of costimulation through second 
generation CAR recognition of antigen in these processes has not been determined. 
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1.2.6   CARs in the clinic: hematological malignancies 
Early phase clinical trials evaluating efficacy of CARs are numerous, with upwards of 
20 phase I/II trials targeting CD19 antigen for B-cell malignancies alone in a number of 
different CAR configurations (85, 129).  The most commonly studied configurations contain 
CD28-CD3ζ or 41BB-CD3ζ endodomains.  Early clinical trial reports include evidence of 
anti-tumor efficacy, long-term B-cell aplasia, and acute toxicity related to elevated serum 
inflammatory cytokine (Table 1) (101, 112, 130-134, 136-138).  Early clinical trials with first 
generation CD19-specific CARs revealed minimal anti-tumor efficacy due to failed T-cell 
persistence (130). A trial comparing CD19-specific second generation CAR containing 
CD28-CD3ζ signaling domains and first generation CAR containing CD3ζ signaling domain 
by infusing both populations simultaneously into patients demonstrated improved 
persistence of second generation CAR over first generation CAR (101). Lymphoablative 
preconditioning prior to CAR+ T-cell transfer appears to improve objective clinical responses.  
Infusion of CD19 CAR T cells with CD28-CD3ζ endodomain demonstrated no clinical 
response in the absence of a preconditioning regimen, but stable disease and lymph node 
mass reduction was achieved in patients when CAR+ T cells were administered following 
cyclophosphamide preconditioning (133, 136, 137). Notably, clinical trials at University of 
Pennsylvania for adult patients with relapsed chronic lymphocytic leukemia (CLL) and 
pediatric patients with relapsed acute lymphoblastic leukemia (ALL) have demonstrated 
remarkable efficacy with 2 of 3 and 1 of 2 patients achieving complete responses, 
respectively (111, 112, 138).  Anti-tumor efficacy was associated with in vivo expansion of T 
cells, transient toxicity related to elevated serum cytokine, long-term persistence of CAR+ T 
cells and persistent B-cell aplasia. One patient with pediatric ALL treated with CD19-
redirected CAR T cell demonstrated transient response and relapse of CD19neg tumor, 
indicating tumor escape can occur via outgrowth of antigen negative tumor cells (111).  
Recent reports from trials at Memorial Sloan Kettering also demonstrate remarkable 
efficacy, achieving complete remission in 14 of 16 patients, again concomitant with toxicity 
associated with elevated serum cytokine (131, 132).  Optimal preconditioning regimen, CAR 
configuration, and dosing schedule are still components of on-going clinical investigation, 
but CD19-specific CAR+ T cells demonstrate significant promise for treatment of B-cell 
lineage malignancies. 
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Table 1. Results of clinical trials with CD19-specific CAR+ T cells. Summary of 
published results from clinical trials targeting B-lineage malignancies with CD19-specific 
CAR+ T cells, highlighting differences in CAR configuration, preconditioning regimen and 
specific outcomes, such as observed tumor regression, B-cell aplasia apparent greater than 
3 months following T-cell treatment, and induction of cytokine-associated toxicity. 
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1.2.7  CARs in the clinic: solid malignancies 
Beyond targeting hematological malignancies, CARs have been developed for 
treatment of solid tumors.  Initial clinical trials targeting carbonic anhydrase IX (CAIX) and α-
folate receptor for treatment of renal cell carcinoma and ovarian cancer, respectively, 
demonstrated no clinical response and limited persistence of CAR-modified T cells (139, 
140).  Clinical trial of a CAR redirected to GD2 for treatment of neuroblastoma demonstrated 
regression or necrosis in half of treated patients and complete response persisting longer 
than 6 weeks in 3 of 11 patients (141, 142). Two clinical trials have revealed the potential for 
detrimental on-target, off-tissue toxicity.  Targeting renal cell carcinoma with CAR redirected 
to CAIX showed activity against normal tissue CAIX expression, resulting in damage to bile 
ducts and reversible cholangitis (140).  Infusion of HER2-redirected CAR T cells for 
treatment of colorectal cancer resulted in respiratory distress and death in one patient 
following massive T-cell infiltration to the lungs, attributed to normal tissue expression of 
HER2 in pulmonary tissue (143). Additional trials have been initiated with CARs targeting 
various antigens, such as carcinoembryonic antigen (CEA) for colorectal cancer, epidermal 
growth factor receptor variant III (EGFRvIII) and interleukin-13 receptor α2 (IL13Rα2) for 
glioblastoma, mesothelin for mesothelioma, and vascular endothelial growth factor receptor 
2 (VEGFR-2) to target angiogenic processes, due to promising preclinical data (144-153). 
Early trials have highlighted some difficulties in extending CAR T-cell therapy, which 
has shown success in treatment of hematological malignancies.  T cells must extravasate 
and home to sites of solid tumors to exert therapeutic efficacy.  Engineering T cells with 
chemokine co-receptors can induce T-cell homing to chemokine produced by tumors.  
Engineering T cells with CXCR2 to redirect to CXCL1 and CXCL8 secretion by melanoma 
results in enhanced tumor infiltration and anti-tumor activity (154).  Likewise, expressing 
CCR2 in mesothelin- and GD2-specific CAR+ T cells for treatment of mesothelioma and 
neuroblastoma, respectively, or expressing CCR4 in CD30-specific CAR T cells for Hodgkin 
lymphoma demonstrate enhanced tumor infiltration and anti-tumor activity when compared 
to CAR-modified T cells without engineered homing molecules (155-157). 
1.2.8   Safety and toxicity of genetically modified T cells  
Initial clinical trials with genetically engineered T cells have demonstrated the 
potential for toxicity. Currently, there are four primary mechanisms of toxicity of genetically 
engineered T cells: (i) on-target, off-tissue, (ii) off-target, (iii) cytokine-induced, and (iv) 
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anaphylactic response due to immune response to foreign CAR moieties (Figure 3).  On-
target, off-tissue toxicity refers to toxicity against normal cells expressing tumor antigen, e.g. 
bile duct destruction after treatment with CAIX-specific CAR and activity against pulmonary 
tissue after treatment with HER2-specific CAR (140, 143).  Off-target toxicity refers to cross-
reactivity with unintended antigen resulting in T-cell activation and destruction of normal 
tissue. While this has not been documented with CAR T-cell treatment, off-target toxicity has 
been noted in T-cell trials with high affinity αβ TCRs specific for MAGE-A3 cross-reacting 
with titin, a protein expressed in striated muscle, resulting in cardiovascular arrest and death 
in two patients (70, 71).  Cytokine-induced toxicity is associated with in vivo T-cell expansion 
and tumor destruction, resulting in release of high levels of inflammatory cytokines, such as 
IFN-γ, tumor necrosis factor-α (TNF-α), and interleukin-6 (IL-6), causing high fevers and 
hypotension (111, 112, 131, 132, 158).  This has been noted in clinical trials with CD19-
specific CAR T cells for B-cell malignancies and is directly correlated with tumor burden at 
the time of treatment. Corticosteroid treatment can curb inflammatory responses to treat 
these toxicities, however, there is concern that treating with steroids will also impair anti-
tumor efficacy of CAR T-cell therapy (158).  Treatment using IL-6 antagonist tocilizumab can 
rapidly reverse cytokine-induced toxicity, and may not negatively impact T-cell activity (111).  
Mouse models of syngeneic B-cell lymphomas from patients treated with CD19-specific 
CAR T cells containing CD28-CD3ζ endodomain configuration did not show any acute 
toxicity due to cytokine release, potentially due to altered metabolic profile of mice (159). 
Finally, recent trials with multiple infusions of CAR with scFv derived from murine sequences 
has resulted in anaphylaxis and cardiac arrest in one patient, most likely due to intermittent 
dosing schedule and development of IgE antibodies in response to murine scFv of CAR 
(160). 
Strategies to limit toxicity are paramount for continued development of CAR+ T-cell 
therapies for clinical application. Introduction of suicide genes has been employed to result 
in T-cell death following treatment with a chemical inducer to specifically ablate T cells in the 
event of observed toxicity.  Initially, T cells were modified with herpes simplex derived 
thymidine kinase (HSV-TK) to result in ablation of T cells upon treatment with ganciclovir.  
However, HSV-TK proved to be highly immunogenic, eliciting anti-transgene immune 
responses that negatively affected T-cell persistence (161, 162).  A novel inducible caspase 
9 (iCasp9) has been developed in which a chemical inducer of dimerization (CID), AP1903, 
can be introduced into patient to induce iCasp9 dimerization and activation to initiate T-cell  
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Figure 3. Potential mechanisms of toxicity of CAR+ T cells.  Depiction of four potential 
mechanisms of toxicity of CAR+ T-cell treatments.  On-target, off-tissue toxicity (top, left) 
describes CAR+ T-cell recognition of antigen expressed on normal tissue.  Off-target toxicity 
(top, right), describes the potential for non-specific CAR+ T-cell recognition of normal tissue.  
While this has not been observed in CAR+ T cells, loss of specificity has been described with 
T cells modified to express engineered TCRs.  Cytokine-induced toxicity (bottom, left) 
describes toxicity mediated by CAR+ T-cell activation and release of inflammatory cytokines, 
as described in clinical trials with CD19-specific CAR+ T cells. Anaphylactic response 
(bottom, right) describes development of an IgE immune response to foreign CAR moieties 
that activates mast cell degranulation. This response was proposed to be the cause of 
anaphylaxis in one patient treated with an intermittent dosing schedule of mesothelin-
specific CAR+ T cells. 
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apoptosis.  This strategy is appealing as it has proven highly effective in elimination of 
iCasp9 T cells, resulting in >90% T cell elimination within 30 minutes of CID administration 
and reversal of T-cell related toxicity and the inducing agent is otherwise biologically inert, 
enhancing safety (163, 164). 
An alternative strategy to limit CAR+ T-cell persistence is to introduce CAR as RNA 
species.  CD19-specific CAR, mesothelin-specific CAR, and HER2-specific CAR have been 
transiently expressed by RNA transfer in human primary T cells (152, 165-169).  CAR 
transgene is placed under control of T7 promoter, and RNA is transcribed in vitro from 
linearized DNA template by incubation with T7 polymerase, then subsequently transferred to 
activated T cells by electroporation. Prior T-cell activation is crucial for efficient RNA transfer 
as is typically achieved via activation with anti-CD3 and CD28 antibodies coated on 
microbeads in the presence of IL-2 (165, 169).  RNA-modification is generally more efficient 
and less-toxic than DNA-modification, primarily attributed to smaller size of transcripts.  RNA 
transcripts have been optimized to increase stability (152).  Three primary determinants of 
stability of in vitro transcribed RNA are (i) presence of 3’ untranslated region (UTR), (ii) long 
poly tail, which can be included in DNA template and in vitro transcribed or added after 
transcription by E. coli poly(A) polymerase (E-PAP), and (iii) use of RNA cap analog to 
ensure incorporation in proper orientation, thereby increasing the number of “readable” 
transcripts.  Expression of CAR from introduced mRNA is directly correlated to amount of 
RNA transferred, therefore, this system allows for efficient, high expression of transcript 
(165, 167).  Thus, both quality and quantity of RNA transcript affects the levels and duration 
of CAR expression. Increased expression of CAR prolonged the duration of CAR expression 
and specific lysis, but did not increase lytic ability at any given time point. On average, CAR 
expression remains detectable 5-7 days from RNA transfer.   
While this strategy limits potential for deleterious long-term on-target, off-tissue 
toxicity, it also limits anti-tumor potential of T cells. Although multiple infusions can reduce 
tumor burden and prolong survival, tumors recur after cessation of treatment. Therefore anti-
tumor efficacy can be inferior to treatment with lentivirally-introduced CAR (152, 167).  
Investigations of dosing and preconditioning have identified that lymphodepletion 
immediately before infusion and weighted split-dosing, with one larger, front-loaded dose 
followed by smaller maintenance doses result in superior anti-tumor activity of RNA-modified 
CAR+ T cells (168). 
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1.3   Glioblastoma multiforme 
Glioblastoma multiforme is a classified as a grade IV central nervous system (CNS) 
tumor of astrocytic origin.  Despite aggressive investigation of new therapeutic approaches, 
patients diagnosed with glioblastoma still face dismal prognosis, with median survival from 
diagnosis around 12 months with current standard of care, which includes surgical resection 
of tumor and treatment with chemotherapeutic alkylating agent temozolomide and whole-
brain radiotherapy (170). Glioblastoma is characterized as a diffuse and heterogenous 
tumor, both hallmarks giving rise to difficulties in successful treatment (171).  While 
glioblastoma can involve any neuroatomical structure, it is most common in cerebral 
hemispheres.  Total microscopic resection cannot be achieved due to diffuse nature, and 
remnant cells are often the source of disease recurrence.  Glioblastoma arises from two 
distinct routes: primary, in which glioblastoma is diagnosed de novo, or secondary, in which 
glioblastoma progresses from initial diagnosis of a lower grade glioma (172, 173).  Primary 
glioblastoma typically arises in older patients, and is associated with epidermal growth 
factore receptor (EGFR) gene amplification, phosphatase and tensin homolog (PTEN) 
mutation, absence of isocitrate dehydrogenase (IDH) mutations and accounts for 95% of 
diagnosed glioblastomas.  In contrast, secondary glioblastoma is more commonly diagnosed 
in younger patients, and is associated with lack of EGFR amplification, p53 mutations, IDH 
mutations and accounts for ~5% of diagnosed glioblastomas.  Age is an important 
prognostic indicator of survival with older patients having significant worse survival 
outcomes than younger patients (174, 175). 
1.3.1   Heterogeneity of glioblastoma 
Gene expression profiling categorizes glioblastomas into several subtypes.  Initially, 
Phillips, et. al. described 3 subtypes characterized by distinct genetic signatures:  proneural, 
proliferative, and mesenchymal.  More recently, the Cancer Genome Atlas defined four 
subtypes: classical, proneural, mesenchymal and neural.  The mesenchymal and proneural 
subtypes match previous descriptions of primary and secondary glioblastomas, respectively.  
Mesenchymal subtypes show mesenchymal differentiation and occur in older patients, 
associated with abnormal EGFR amplification and PTEN loss, while proneural show 
neuronal differentiation, occur in younger patients and are associated with better outcomes.   
The molecular heterogeneity of glioblastoma is incredibly complex and varies widely 
from patient to patient.  Commonly described genomic alterations in glioblastoma include: 
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Loss of heterozygosity of chromosome 10q, loss/mutation of PTEN, O-6-methylguanine-
DNA-methyltransferase (MGMT) promoter methylation, mutations of p53, IDH1 and IDH2 
mutations, loss of p16/INK4A, and EGFR gene amplification and overexpression (171, 173, 
176-178).  Loss of heterozygosity of chromosome 10q is frequently described in primary and 
secondary glioblastoma patients, although more commonly in older patients, and is 
associated with poor survival (173, 174, 179).  PTEN deletion is due to loss of 
heterozygosity at chromosome 10q and occurs in 50-70% of primary glioblastoma and 54-
63% of secondary glioblastoma patients (173, 178). PTEN inhibits signaling through 
phosphoinositol-3-kinase (PI3K)/Akt pathway by inhibiting Akt phosphorylation.  Thus, loss 
of PTEN results in dysregulated signaling through PI3K/Akt and is associated with poor 
prognosis (180). MGMT is a DNA repair protein that can remove alkyl groups for the O6 
position of guanine, a common mechanism of cell toxicity of chemotherapeutic agents like 
temozolomide (178, 181).  Epigenetic silencing MGMT by promoter methylation results in 
defective DNA repair, and is associated with favorable prognosis of glioblastoma patients.  
TP53 encodes a well described tumor suppressor protein that is commonly mutated in 
glioblastoma. TP53 mutations occur in about 30% of primary glioblastomas and 50% of 
secondary glioblastomas.  So far, TP53 mutation status has not been associated with 
prognosis (173, 182).  IDH is an enzyme of the citric acid cycle, which is involved in 
metabolic cell processes, including oxidative stress and respiration and lipid synthesis.  
Mutation of IDH1 or IDH2 occurs in ~10% of glioblastomas, more frequently in younger 
patients, and confers a prognostic advantage (176). P16/INK4A binds cyclin-dependent 
kinase 4 (CDK4) and inhibits its formation of complex with cyclin D1, which inhibits 
phosphorylation of retinoblastoma protein (Rb), a tumor suppressor protein responses for 
inhibiting cell proliferation.  Loss of p16/INK4A occurs in 20-57% of glioblastoma patients.  
There is a significant association between loss of p16/INK4A and EGFR amplification (173, 
175, 178, 183). 
1.3.2   EGFR amplification and overexpression in glioblastoma 
One of the most common gene-amplified and overexpressed oncogene in 
glioblastoma is EGFR, present in 40-50% of patients (176, 181). The epidermal growth 
factor receptor family contains four tyrosine kinase receptors, including EGFR/ErbB, 
Her2/ErbB2, ErbB3, and ErbB4.  The first family member, EGFR, is expressed on many  
normal tissues and commonly overexpressed and/or mutated  in many cancers, including 
head and neck, lung, esophagus, stomach, colon, kidney, bladder, breast, uterus, cervix, 
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ovarian, prostate, and brain (184, 185). EGFR is composed of an extracellular region with 
four domains with distinct function (domains I, II, III, and IV), a transmembrane region, a 
tyrosine kinase domain and a C-terminal domain.  Ligands that bind EGFR include 
epidermal growth factor (EGF), transforming growth factor α (TGF-α), and amphiregulin.  
Ligands bind the extracellular domains I and III, which frees the dimerization arm of domain 
II from its interaction with domain IV to interact with another molecule of EGFR to form a 
homodimer or another family member (HER2, ErbB3, or ErbB4) to form a heterodimer.  A 
conformational change associated with dimer formation activates the tyrosine kinase 
domain, which binds adenosine triphosphate (ATP) and autophosphorylates multiple 
tyrosine residues in the C-terminal domain of EGFR (186, 187).  The primary signaling 
pathways activated by EGFR include MAPK, PI3K/Akt, PLC, signal transducer and activator 
of transcription (STAT), and SRC/FAK (185, 188). 
Overexpression of EGFR leads to dysregulation of signaling pathways, and results in 
enhanced cell survival, proliferation, migration, invasion, and support of angiogenesis to 
contribute to tumor growth and metastatic spread (184, 189).  In 30-50% of patients with 
EGFR amplification, a mutant form of EGFR, EGFRvIII is overexpressed (190).  EGFRvIII 
has deletion of exons 2-7, resulting in truncated extracellular domain, which is weakly, but 
constitutively active (191).  Weak signaling through EGFRvIII results in inefficient 
internalization and degradation, causing sustained signaling (192).  Overexpression of 
EGFRvIII causes proliferation of cells and can induce transformation (193-195). Prognostic 
implications of EGFR overexpression have been contradictory.  Several reports describe no 
impact of EGFR amplification on survival when analyzing the whole population of 
glioblastoma patients (196-199).  By stratifying into groups based on age, EGFR may be 
linked to poor prognosis in younger patients, less than 60 years old (197, 198, 200). Further 
division based on p53 mutation status identified EGFR as a significant indicator of poor 
prognosis only in younger patients with no p53 mutations (198).  A recent study analyzing 
the impact of EGFR expression on newly diagnosed patients with uniform diagnosis of 
glioblastoma identified EGFR amplification as a poor indicator of survival, and described 
EGFRvIII overexpression correlating with worse survival within EGFR amplified tumors 
(190).  In contrast, EGFR has been reported as a predictor of prolonged survival, particularly 
in patients over 60 years old with glioblastoma (180, 183). EGFR gene amplification has 
also be associated with improved prognosis when present concomitant with homozygous 
p16/INK4A deletion, and worse prognosis when present concomitant with chromosome 7 
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polysomy (200).  Thus, impact of EGFR on survival in patients with glioblastoma is 
influenced by age and complex relationships with other molecular characteristics of the 
tumor.  
1.3.3   Targeting EGFR in glioblastoma: tyrosine kinase inhibitors 
Because EGFR is overexpressed in glioblastoma and does not have expression 
reported in normal CNS tissue, it has been the target of many novel therapeutic strategies 
for glioblastoma treatment (189, 201).  Small molecule tyrosine kinase inhibitors, such as 
erlotinib and gefitinib, compete for the ATP-binding site in the tyrosine kinase domain of 
EGFR to inhibit phosphorylation and downstream signal propagation (189).  Studies with 
head and neck and colorectal cancer cell lines showed induction of cell cycle arrest and 
apoptosis when treated with erlotinib (202).  In vitro inhibition of glioblastoma cell lines with 
erlotinib demonstrated inhibition of anchorage-independent cell proliferation and inhibition of 
molecular effectors of cell invasion, such as serine proteases and metallaproteases (203, 
204).  Phase III clinical trials for non-small cell lung carcinoma, erlotinib demonstrated 
significant improvement in median survival (205).  However, trials in patients with newly 
diagnosed or recurrent glioblatoma have demonstrated limited or no therapeutic benefit of 
erlotinib treatment (206, 207).  In vitro study of gefitinib demonstrated inhibition of growth in 
a variety of EGFR-expressing cell lines, such as breast, colon and ovarian, and evidence of 
induction of cell cycle arrest and apoptosis (208-210).  However, in clinical trials with newly 
diagnosed or recurrent glioblastoma, patients given gefitinib given concomitant with or 
following radiation therapy did not demonstrate improvement in survival (211, 212). Analysis 
of tumor tissue from glioblastoma patients following gefitinib treatment showed efficient 
dephosphorylation of EGFR, but not significant inhibition of downstream signaling pathways, 
demonstrating the role of compensatory signaling pathways and altered signaling regulation 
in drug resistance (213).  Irreversible tyrosine kinase inhibitors, which form covalent bonds 
to tyrosine kinase domain of EGFR to permanently inhibit function, enhance EGFR inhibition 
and are in preclinical development (185, 189). 
1.3.4   Targeting EGFR in glioblastoma: Monoclonal antibodies 
Monoclonal antibodies specific for EGFR can also be used to inhibit EGFR signaling, 
such as cetuximab, which binds the extracellular domain III of EGFR to prevent ligand 
binding and extracellular dimerization, thus inhibiting EGFR signaling (214).  Treatment of 
murine intracranial and subcutaneous glioma xenografts with cetuximab has demonstrated 
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decreased tumor cell proliferation and improved overall survival (215, 216). In a phase II 
clinical trial of cetuximab as a monotherapy in recurrent gliomas, minimal anti-tumor activity 
was reported and was found to be independent of EGFR amplification status (217).  
However, patients with EGFR-amplified glioblastoma that did not express EGFRvIII 
demonstrated improved progression-free survival relative to those expressing EGFRvIII 
(218). Similar to finding with tyrosine kinase inhibitors, cetuximab inhibits EGFR 
phosphorylation, but does not sufficiently inhibit downstream pathways, reaffirming the role 
of compensatory signaling and pathway regulation as mechanisms of therapy resistance 
(219).  Activation of other ErbB family members, such as HER2 or ErbB3, can overcome 
cetuximab inhibition of EGFR, therefore, targeting multiple EGFR family members may be a 
strategy for enhanced therapeutic efficacy (220). While largely ineffective as a monotherapy, 
cetuximab has been shown to enhance radiosensitivity when combined with radiotherapy in 
vitro and in vivo (215, 221).  Clinical evaluation of cetuximab in combination with 
temozolomide and radiation is underway (222). 
Nimotuzumab is an EGFR-specific monoclonal antibody which binds to an epitope in 
domain III of EGFR that highly overlaps with that of cetuximab, and inhibits ligand binding 
and EGFR activation (223, 224).  Similar to cetuximab, nimotuzumab sensitizes cells to 
radiation (225). Treatment with nimotuzumab as a monotherapy administered following 
standard treatment in newly diagnosed glioblastoma patients demonstrated no significant 
improvement in overall survival, but may benefit a subset of patients with EGFR amplified 
tumors with non-methylated MGMT promoters (226). When combined with radiation therapy, 
nimotuzumab demonstrated significant survival benefit for patients with high grade gliomas 
(grade III anaplastic astrocytomas and grade IV glioblastomas) and excellent tolerability 
(227). 
While cetuximab and nimotuzumab bind an overlapping epitope on EGFR and have 
similar mechanisms of action, there are notable differences between the two antibodies 
(Table 2). Clinical trials with nimotuzumab have noted no incidence of EGFR-related toxicity, 
in contrast to trials with cetuximab in which grade III and IV acneiform rash is common (228-
230).  Further investigation into differences between cetuximab and nimotuzumab have 
identified a role of the intermediate affinity of nimotuzumab, with a Kd value ~1 log higher 
than cetuximab and 59-fold slower rate of association, in reduction of normal tissue toxicity 
(231).  Nimotuzumab has demonstrated a requirement for bivalent binding to recognize 
EGFR resulting in reduced binding when EGFR is expressed at low levels, such as the  
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Table 2. Differences and similarities between cetuximab and nimotuzumab.  
Nimotuzumab has a 1-log higher dissociation constant than cetuximab, characterized by 59-
fold decreased rate of association and 5.3-fold decreased rate of dissociation, resulting in a 
5.3-fold longer half-life of interaction with EGFR than cetuximab.  Both antibodies are class 
IgG1, and therefore can mediate antibody-dependent cell cytotoxicity (ADCC) and 
complement activation.  Both antibodies function by inhibiting cell proliferation and inducing 
apoptosis, but only nimotuzumab inhibits angiogenesis.  While patients treated with 
cetuximab commonly develop a grade 3-4 skin rash, patients treated with nimotuzumab do 
not. 
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levels expressed in normal tissue, but efficient binding of high density. In contrast, 
cetuximab binds EGFR when expressed as a monovalent fragment or bivalent antibody, and 
does not show any ability to distinguish low EGFR density from high EGFR density, offering 
at least a partial explanation for the reduced normal tissue toxicity observed in patients 
treated with nimotuzumab.  While nimotuzumab demonstrates reduced normal tissue 
binding, the intermediate affinity of nimotuzumab does not result in reduced activity relative 
to cetuximab against in vivo A431 xenografts, which express high levels of EGFR (231). 
Consequently, because cetuximab has a higher binding affinity than nimotuzumab, lower 
doses of cetuximab are required for EGFR inhibition, and at the same dose, cetuximab more 
markedly inhibits downstream EGFR signaling (224, 225, 232). Direct in vivo comparison of 
treatment of A431 xenografts shows that while nimotuzumab inhibited cell proliferation and 
reduced blood vessel formation, presumably by inhibiting vascular endothelial growth factor 
(VEGF) production, cetuximab does not, indicating some difference in mechanism of action 
(225). Despite these differences, both cetuximab and nimotuzumab are IgG1 isotype 
antibodies, and thus can mediate NK-cell cytolysis and activation of complement. 
1.3.5   Targeting EGFR in glioblastoma: EGFRvIII peptide vaccine 
Vaccination strategies have also been developed to activate the immune system to 
target glioblastoma.  The most advanced of these strategies involves vaccination with a 
peptide or peptide-pulsed dendritic cells to activate T cells specific for a peptide of the fusion 
region of mutated EGFRvIII existing within the patient’s natural TCR repertoire.  A phase II 
clinical trial in newly diagnosed glioblastoma patients revealed treatment with peptide-based 
EGFRvIII vaccine significantly increased time to progression and overall survival (233).  
Similarly, a phase II trial in which newly diagnosed glioblastoma patients were treated with 
autologous, mature dendritic cells pulsed with the same peptide increased median survival 
of glioblastoma patients with only grade II side effects noted, demonstrating the immune 
system can be harnessed within the CNS to mediate anti-tumor effects without severe 
toxicity (234). However, despite prolonged time to progression in treated patients relative to 
control cohort, tumors eventually recurred and 82% were negative for EGFRvIII, 
demonstrating immunological escape as a mechanism of resistance (235). Vaccination 
approaches for glioblastoma treatment are promising; however, they face several limitations.  
Successful priming of a T-cell response in a patient requires a pre-requisite T-cell population 
with specificity for antigenic peptide. In addition, because the self-reactive T cells are 
tolerized during development, vaccination requires use of tumor-specific neoantigens.  
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Finally, vaccinations activate the immune system within the patient, often in the presence of 
immunosuppressive factors that may blunt the T-cell response to the vaccine. 
1.3.6   Mechanisms of resistance to therapy of glioblastoma 
The molecular heterogeneity of glioblastoma endows the ability to escape 
monotherapy targeted to inhibit EGFR activation, such as TK inhibitors and monoclonal 
antibodies, through activation of compensatory signaling through other receptor tyrosine 
kinases (RTK), most commonly hepatocyte growth factor receptor (MET) and platelet-
derived growth factor receptor α and β (PDGFR α and β) (219, 236-238). Expression of 
EGFR and PDGFRα in distinct subpopulations of glioblastoma cells demonstrates a mosaic-
like pattern of intratumoral heterogeneity and inhibition of both required to completely 
abrogate PI3K signaling (236, 237). Likewise, expression of MET has been shown to 
compensate EGFR inhibition in glioblastoma cell lines and inhibiting c-Met and EGFR 
restored sensitivity to treatment (239).  Another potential explanation for reduced activity of 
TKIs and monoclonal antibodies in glioblastoma relates to their relatively large size and 
difficulty crossing the blood-brain barrier (BBB).  While the BBB is compromised at the site 
of the tumor, intact BBB surrounding normal tissue with infiltrating glioblastoma is more 
difficult to access by such therapies, reducing overall anti-tumor efficacy.  There is mounting 
evidence that a population of glioma-initiating stem cells play an important role in resistance 
to chemotherapy and radiotherapy, due altered DNA checkpoint activation and enhanced 
capacity for DNA repair (240, 241). 
1.3.7   Immunosuppressive mechanisms of glioblastoma 
Glioblastomas also exploit multiple immunosuppressive mechanisms to avoid 
recognition by the immune system (242, 244-247).  Secretion of immunosuppressive factors 
transforming growth factor-β (TGF-β), interleukin-10 (IL-10), prostaglandin E2 (PGE2), and 
galectin-3 by glioma and glioma-initiating cells have been associated with inhibited T-cell 
proliferation, cytokine production and T-cell apoptosis (247, 248).  Glioma cells also express 
cell surface receptors that inhibit T cell function, such as programmed death receptor ligand 
1 (PD-L1) and Fas ligand (Fas-L) (249, 250).  PD-L1 expression has been associated with 
induction of T-cell apoptosis, anergy, and T cells with T regulatory (Treg) phenotype and cell 
contact dependent and independent suppressive function.  Increased presence of Tregs has 
been observed in glioblastoma patients, both in tumors and peripheral blood, relative to 
normal donor peripheral blood (251). Myeloid-derived suppressor cells (MDSC) have also 
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been described to be present at a higher frequency in glioblastoma patients and suppress T-
cell functions by secretion of immunosuppressive cytokines, expression of PD-L1, and 
induction of activated T-cell apoptosis (252). 
1.3.8   CARs for glioblastoma 
To avoid activation of tumor-specific T cells within immunosuppressed glioblastoma 
patients, and to avoid the requirement of a population of pre-existing T cells with desired 
specificity, CAR-modified T cells for adoptive transfer have been developed for glioblastoma 
with specificity for IL13Rα2, HER2, EGFRvIII and EphA2.  An IL13 zetakine to is a CAR-
based strategy in which and IL13 mutein with specific binding to IL13Rα2, present on 50-
60% of glioblastomas, is fused to CD3ζ (253, 254).  IL13 zetakine T cells display 
proliferation through zetakine stimulation, cytokine production, in vitro lysis of tumor targets 
and mediate regression of glioblatoma cell lines in an in vivo xenograft model (150, 254, 
255).  Importantly, IL13Rα2 zetakine T cells have demonstrated the ability to lyse glioma 
stem-like cells, indicating susceptibility of this chemotherapy and radiotherapy resistant 
population to T cell-mediated cytotoxicity (149).  Early reports from a phase I trial with first 
generation IL13Rα2 CAR T cells injected intratumorally have shown good tolerability and 
some clinical benefit (256).  However, studies with a second generation IL13Rα2 zetakine 
have demonstrated activity against normal tissue expressing IL13Rα1 (148). The potential 
for normal tissue toxicity may restrict IL13Rα2 CAR T cells from systemic administration.  
Second generation CAR specific for HER2, reported to be expressed in as many as 80% 
glioblastoma patients, has shown HER-2 specific cytokine production and tumor cell lysis, as 
well as cytotoxicity against CD133+ glioma stem cells and regression of autologous patient 
gliobastoma xenografts (257, 258). A phase I clinical trial for treatment of glioblastoma 
patients with a HER2-specific CAR T cells is currently underway, however, HER2 is 
expressed on normal tissue, and there is potential for deleterious normal tissue toxicity 
(143).  Likewise, targeting EGFRvIII on glioblatoma via an EGFRvIII-specific third generation 
CAR has exhibited specific T cell responses to EGFRvIII, but not wild type EGFR, 
expressing cells, including cytokine production and cytotoxicity of glioma cell lines as well as 
glioma stem cell lines, and in vivo anti-tumor activity against glioblastoma xenografts (145-
147).  Third generation EGFRvIII-specific CAR T cells are currently in clinical trial in 
combination with a chemotherapeutic lymphodepletion prior to T cell transfer (256).  
EGFRvIII is an ideal target for CAR-based T cell therapy as it is a true neo-antigen with no 
normal tissue expression, however, vaccine trials targeting EGFRvIII have demonstrated 
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immunologic escape of EGFRvIII negative glioma cells (235). Similarly, preclinical studies 
with HER2-specific CAR have also shown ability for immunological escape by outgrowth of 
HER2neg glioma cells.  Because of the significant inter- and intra-tumoral heterogeneity of 
glioblastomas, it is very likely that targeting of two or more antigens will be required to 
completely eliminate tumor.  Simultaneous targeting of two glioma antigens via introduction 
of two CAR constructs enhances anti-tumor efficacy and minimizes antigen escape 
mechanisms, demonstrating the potential for combinatorial antigen targeting within CAR-
based therapies to mediate more complete anti-tumor responses (259). 
Specific Aims 
EGFR is an attractive target for glioblastoma therapy, however, expression on 
normal tissue and risk of on-target, off-tissue toxicity does not make it an ideal target 
traditional CAR-based T-cell immunotherapy approaches.  The overarching goal of this 
dissertation is to develop an EGFR-targeted, CAR-based T cell therapy that minimizes the 
potential on-target, off-tissue deleterious toxicity without hampering anti-tumor activity. 
Specific Aim 1: To reduce the potential for deleterious on-target, off-tissue toxicity, 
the goal of this specific aim is to transiently express EGFR-specific CAR derived from 
cetuximab, Cetux-CAR, by RNA transfer to human primary T cells and evaluate specific 
function relative to T cells stably expressing Cetux-CAR by DNA modification.  In order to 
transfer RNA into human primary T cells on a scale feasible for clinical adaptation, we 
explored activating T cells with aAPC to facilitate numeric expansion prior to RNA transfer 
and optimized a protocol to transfer RNA into numerically expanded, activated T cells. DNA-
modified and RNA-modified T cells were compared for (i) phenotype by flow cytometry, (ii) 
production of IFN-γ and TNF-α in response to EGFR+ target cells by intracellular cytokine 
staining, (iii) specific lysis of EGFR+ target cells by chromium release assay, and (iv) stability 
of CAR expression by flow cytometry.  The hypothesis of this specific aim is that RNA-
modification of T cells to express EGFR-specific CAR derived from cetuximab, Cetux-CAR, 
will result in (i) transient expression of Cetux-CAR, (ii) redirected specificity of RNA-modified 
T cells to EGFR similar to DNA-modified T cells, and (iii) loss of CAR expression which will 
coincide with loss of specific T-cell function in response to EGFR-expressing targets. 
Specific Aim 2: Because the loss of CAR expression in RNA-modified T cells also 
abrogates anti-tumor activity, the goal of this specific aim is to generate a CAR with the 
capacity to distinguish between malignant and normal tissue by altering the scFv of CAR.  
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Recognizing that EGFR on glioblastoma is expressed at a higher density than EGFR on 
normal tissue, we developed a CAR based on the scFv on nimotuzumab, a monoclonal 
antibody that demonstrates reduced capacity to bind to low EGFR density on normal tissue 
while maintaining binding to high EGFR density on malignant tissue, Nimo-CAR.  Cetux-
CAR+ T cells and Nimo-CAR+ T cells were compared for T-cell phenotype by flow cytometry.  
CAR+ T-cell function was compared by (ii) phosphorylation of signaling molecules Erk1/2 
and p38 by phosflow cytometry, (iii) production of IFN-γ and TNF-α by intracellular cytokine 
staining, and (iv) specific cytotoxicity in response to EGFR+  target cells with expressing 
EGFR at varying densities.  The hypothesis of this specific aim is that Nimo-CAR+ T cells will 
exhibit similar levels of T-cell activation, cytokine production, and specific lysis of targets at 
Cetux-CAR+ T cells in response to target cells with high EGFR density, but reduced 
activation, cytokine production and specific lysis in response to target cells with low EGFR 
density.   
Specific Aim 3: The goal of this specific aim is to determine anti-tumor activity of 
Cetux-CAR+ T cells and Nimo-CAR+ T cells in vivo against intracranial glioma xenografts 
with intermediate or low EGFR density.  Mice bearing glioma xenografts were treated by 
intratumoral injection of CAR+ T cells.  Anti-tumor activity of Cetux-CAR+ and Nimo-CAR+ T 
cells was determined by (i) comparing relative tumor burden as determined by serial 
bioluminescent imaging of tumor to mice receiving no treatment and (ii) comparing overall 
survival of mice compared to mice receiving no treatment. The hypothesis of this specific 
aim is that Cetux-CAR+ and Nimo-CAR+ T cells will demonstrate equivalent anti-tumor 
activity and control of xenografts with intermediate EGFR density, but only Cetux-CAR+ T 
cells and not Nimo-CAR+ T cells will demonstrate anti-tumor activity and control of 
xenografts with low EGFR density. 
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CHAPTER 2 
Transient expression of EGFR-specific CAR by RNA-modification 
2.1   Introduction 
T cells can be genetically modified to express a CAR to redirect specificity for tumor-
associated antigen (TAA) and adoptively transferred to patients for the purpose of tumor 
immunotherapy (94, 260).  In recent clinical successes reported from CD19-specific CAR+ T-
cell therapy trials, complete response in 2 patients was observed with concomitant in vivo 
expansion of T cells and measurable IFN-γ response (111, 112).  Patients experienced 
persistent B-cell aplasia, indicating the ability of infused CAR+ T cells to persist in vivo and 
target normal tissue expressing CD19 antigen.  While such toxicities are considered 
tolerable in the setting of CD19-redirected activity due to restriction of antigen expression to 
cell of B-cell lineage, antigens restricted or absent from normal tissue are rare.  Serious 
adverse events in trials with CAIX-specific CAR, resulting in significant liver toxicity, and 
HER2-specific CAR, resulting in one patient death, demonstrate intolerable toxicities that 
can occur when targeting tumor antigen also expressed on normal tissue (140, 143).   
Glioblastoma is the most common and aggressive primary brain and central nervous 
system malignancy (261).  With conventional therapy, including surgical resection, radiation 
and chemotherapy with alkylating agents, overall median survival is approximately 1 year 
from diagnosis (170).  EGFR is aberrantly overexpressed in more than 60% of adult primary 
glioblastoma and contributes to gliomagenesis by promoting cell division and invasion, 
promoting angiogenesis and inhibiting apoptosis (182, 262).  However, current methods to 
target EGFR in glioblastoma, including tyrosine kinase inhibitors or monoclonal antibody 
therapy, have been largely negative due to the molecular complexity and heterogeneity of 
glioblastoma, drug resistance mechanisms, and poor penetration of blood brain barrier (171, 
173, 177, 263).  Targeting EGFR can cause toxicity, primarily observed in skin, 
gastrointestinal system, and kidney, due to its wide distribution of normal tissue expression 
(201).  
Introducing an EGFR-specific CAR to T cells as RNA species has the potential 
transiently express CAR to reduce normal tissue toxicity by limiting CAR expression.  
Previous studies have demonstrated efficient transfer of CAR and TCR transgenes into 
human primary T cells following ex vivo stimulation (165, 167, 169, 264, 265).  Expression of 
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CAR as RNA species has been shown to transiently redirect T-cell specificity to the desired 
antigen and mediate tumor regression by multiple injections in preclinical models of 
mesothelioma and leukemia and two patients with mesothelioma in a recently published 
case study (152, 168, 266).  T-cell activation has been shown to be a prerequisite for 
successful introduction of RNA species (169).  In addition, numeric expansion of T cells prior 
to introduction of RNA species is necessary to achieve clinically relevant T-cell numbers. T-
cell activation for RNA transfer has been most commonly achieved by stimulation with anti-
CD3 and anti-CD28 antibodies covalently linked to paramagnetic beads, however, while 
anti-CD3 and anti-CD28 beads mediate robust expansion of CD4+ T cells, they do not 
efficiently expand CD8+ T cells (97, 267). Development of a cell-based artificial antigen 
presenting cell platform derived from the erythroid leukemia cell line K562 for ex vivo T-cell 
expansion has several advantages over bead based approaches (95, 97). First, K562 do not 
express HLA-A, HLA-B, or HLA-DR, and therefore limit allogeneic-mediated T-cell 
expansion, but do express ICAM-1 and LFA-3 to mediate stable, stimulatory interactions 
with T cells.  Additionally, K562 can be stably, genetically modified to express desired 
costimulatory molecules to support T-cell expansion (95).  Stable expression of CD64, the 
high affinity Fc receptor, allows monoclonal antibodies to be “loaded” on the surface of K562 
via Fc binding to CD64 to provide additional stimulatory properties (268). Studies evaluating 
K562 loaded with anti-CD3 (OKT3) and co-expressing co-stimulatory molecules CD86 and 
41BB-L have demonstrated robust numeric expansion of CD8+ T cells with improved 
production of IFN-γ and perforin (269).  
We sought to transiently express an EGFR-specific CAR by RNA transfer to limit 
CAR expression and limit the potential for on-target, off-tissue toxicity. To achieve clinically 
relevant T-cell numbers, we evaluated RNA transfer to human primary T cells that had 
undergone numeric expansion by stimulation with OKT3-loaded K562 and compared their 
function to EGFR-specific CAR+ T cells modified by stable DNA integration. We 
hypothesized that (i) stimulation of T cells with OKT3-loaded K562 could mediate numeric 
expansion of CD8+ T cells favorable for RNA transfer, (ii) EGFR-specific CAR+ T cells 
modified through RNA transfer would have equivalent lytic function as EGFR-specific CAR+ 
T cells modified by stable DNA integration, and (iii) EGFR-specific CAR+ T cells modified by 
RNA transfer would have transient redirected specificity for EGFR. 
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2.2   Results 
2.2.1 Numeric expansion of T cells by artificial antigen presenting cells loaded with anti-CD3 
Antigen-dependent stimulation through stable CAR expression achieved by DNA 
integration can be used to numerically expand CAR+ T cells to clinically feasible numbers. 
The transient nature of CAR expression via RNA transfer requires numeric expansion of T 
cells to clinically feasible numbers to be achieved prior to RNA transfer of CAR. To 
determine the ability of aAPC to numerically expand T cells independent of antigen, we 
loaded anti-CD3 (OKT3) onto K562 via stable expression of the high affinity Fc receptor 
CD64 (Figure 4A). K562 also expressed CD86, 41BB-L, and a membrane bound IL-15 for 
additional T-cell costimulation. To determine the impact of aAPC density in co-culture to 
stimulate T cell expansion, peripheral blood mononuclear cells (PBMC) derived from healthy 
human donors were co-cultured with γ-irradiated aAPC at low density, 10 T cells to 1 aAPC 
(10:1), or high density, 1 T cell to 2 aAPC (1:2), in the presence of IL-2. T cells were 
restimulated with aAPC after 9 days.  Following two cycles of aAPC addition, T cells 
numerically expanded when stimulated 10:1 and 1:2 with aAPC, however T cells with higher 
density of aAPC (1:2) achieved statistically superior numerical expansion (10:1 = 1083 ± 
420 fold expansion, 1:2 = 1891 ± 376 fold expansion, mean ± S.D., n=6) (p<0.0001) (Figure 
4B).   
T cells expanded with lower density of aAPC contained a higher proportion of CD8+ 
T cells than T cells expanded with higher density aAPC (10:1 = 53.9 ± 11.6% CD8, 1:2 = 
28.1 ± 16.2% CD8, mean ± S.D., n=6) (p<0.001) (Figure 5A).  CD8+ T cells demonstrated 
similar fold expansion when stimulated with either ratio of aAPC, however, CD4+ T cells 
demonstrated inferior fold expansion when stimulated with fewer aAPC (10:1 = 369 ± 227 
CD4+ fold expansion, 1:2 = 1267 ± 447 CD4+ fold expansion, mean ± S.D., n=6) (p<0.0001) 
(Figure 5B).  To determine if reduced fold expansion was due to increased CD4+ T-cell 
death in cultures with fewer aAPC, CD4+ and CD8+ T cells were stained with annexin V and 
propidium iodide (PI) and analyzed by flow cytometry to determine cell viability.  There was 
no difference in the proportion of viable cells in CD4+ or CD8+ T cells when stimulated with 
low or high density aAPC (Figure 5C).  To determine if reduced fold expansion of CD4+ T 
cells was due to decreased rate of proliferation, we stained T cells 9 days following 
stimulation with aAPC for intracellular Ki-67 expression and analyzed by flow cytometry.  
CD8+ T cells demonstrated similar proliferation when stimulated with either low or high  
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Figure 4. Numeric expansion of human primary T cells with artificial antigen 
presenting cells loaded with anti-CD3.  (A) Phenotype of K562 clone 4 loaded to express 
anti-CD3 (OKT3) and irradiated to 100 gray measured by flow cytometry.  (B)  Numeric 
expansion of CD3+ T cells following stimulation with low density of OKT3-loaded K562 (10 T 
cells to 1 aAPC) or high density of OKT3-loaded K562 (1 T cell to 2 aAPC). Inferred cell 
count calculated by multiplying fold expansion following a stimulation cycle to the total 
number of T cells prior to stimulation cycle.  Data represented as mean ± SD, n=6, **** 
p<0.0001, two-way ANOVA (Tukey’s post-test). 
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Figure 5.  T cells expanded on low density aAPC contain higher ratio of CD8+ T cells. 
(A)  T cells expanded with low density aAPC (10 T cells to 1 aAPC) contain significantly 
more CD8+ T cells and less CD4+ T cells than T cells expanded with high density aAPC (1 T 
cell to 2 aAPC) as measured by flow cytometry following two stimulation cycles. Data 
represented as mean, n=6, *** p<0.001, **** p<0.0001, two-way ANOVA (Tukey’s post-test). 
(B) Differences in CD4/CD8 ratio in T cells expanded with low density aAPC and high 
density aAPC is due to reduced fold expansion of CD4+ T cells when expanded with low 
density aAPC.  Data represented as mean ± SD, n=6, **** p<0.0001, two-way ANOVA 
(Tukey’s post-test). (C)  Differences in CD4/CD8 ratio in T cells expanded with low density 
aAPC and high density aAPC is not due to differences in cell viability.  Viability of cells was 
determined by flow cytometry for Annexin V and PI staining following two stimulation cycles 
where Annexin Vneg PIneg cells are considered live cells. Data represented as mean ± SD, 
n=3. (D) CD4+ T cells have less proliferation when stimulation was low density aAPC than 
high density aAPC.  Ki-67 was measured by intracellular flow cytometry as a marker for 
cellular proliferation following two stimulation cycles. Data shown as representative 
histogram of three independent donors.   
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density of aAPC, however CD4+ T cells demonstrated reduced proliferation when stimulated 
with low density aAPC (Figure 5D).  These data indicate that stimulating T cells with low 
density of aAPC results in less total T-cell expansion than T cells stimulated with high 
density of aAPC, characterized by increased proportion of CD8+ T cells due to reduced 
proliferation of CD4+ T cells.   
2.2.2 T cells expanded with lower density aAPC demonstrate a more memory-like 
phenotype than T cells expanded with higher density aAPC 
 To determine if expansion with low density or high density aAPC impacted T-cell 
phenotype, we analyzed expression of a panel of mRNA transcripts (Appendix A) by 
multiplex digital profiling using nCounter analysis (Nanostring Technologies, Seattle, WA).  
Significant differential gene expression was determined by a p<0.01 and fold change greater 
than 1.5 in sorted CD4+ or CD8+ T cells expanded with low density (10:1 T cell:aAPC) or 
high density (1:2 T cell:aAPC) aAPC.  CD4+ and CD8+ T cells expanded with high density 
aAPC demonstrated increased expression of genes associated with T-cell activation, such 
as CD38 and granzyme A in CD4+ T cells and CD38 and NCAM-1 in CD8+ T cells (Figure 
6).  In contrast, CD4+ and CD8+ T cells expanded with low density aAPC showed increased 
expression of genes associated with central memory or naïve T cells, including Wnt 
signaling pathway transcription factors Lef1 and Tcf7, CCR7, CD28, and IL7Rα (270, 271).   
 To further evaluate differential phenotype of T cells expanded with low or high 
density aAPC, we analyzed T cells for phenotypic markers by flow cytometry and evaluated 
subsets by coexpression of CCR7 and CD45RA where CCR7+CD45RA+ indicates naïve 
phenotype, CCR7+CD45RAneg indicates central memory phenotype, CCR7negCD45RAneg 
indicates effector memory, and CCR7negCD45RA+ indicates a CD45RA+ effector memory 
phenotype (272).  CD4+ T cells expanded with low density aAPC contained less T cells with 
effector memory phenotype (10:1 = 61.9 ± 9.1%, 1:2 = 92.1 ± 3.9%, mean ± S.D., n=3) 
(p<0.05), but more T cells with a central memory phenotype (10:1 = 36.5 ± 9.4%, 1:2 = 13.6 
± 2.4%, mean ± S.D., n=3) (p<0.05) T cells (Figure 7A). Similarly, CD8+ T cells expanded 
with low density aAPC contained significantly fewer T cells with effector memory phenotype 
(10:1 = 66.1 ±12.5%, 1:2 = 89.1 ± 1.7%, mean ± S.D., n=3) (p<0.05), but more central 
memory phenotype (10:1 = 32.3 ± 11.7%, 1:2 = 6.5 ± 2.8%, mean ± S.D., n=3) (p<0.05). 
When stimulated with low density aAPC, fewer CD4+ T cells produce granzyme B (p<0.001) 
and fewer CD8+ T cells produce granzyme B (p<0.05) and perforin (p<0.001) (Figure 7B). 
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Figure 6. Differential gene expression in T cells stimulated with low or high density 
aAPC. Differential gene expression between CD4+ and CD8+ T cells stimulated with low or 
high density aAPC measured by multiplexed digital profiling of mRNA species following two 
cycles of stimulation.  Significant up- or down-regulated transcripts was determined by 
greater than 1.5 fold difference in transcript level in 2/3 donors and p<0.01.  Data 
represented by heat-map of fold difference, n=3. 
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Figure 7. T cells expanded with low density aAPC have more central-memory 
phenotype T cells. (A) Memory marker analysis of T cells expanded with low density or 
high density aAPC was measured by flow cytometry for CCR7 and CD45RA following two 
cycles of stimulation. Cell populations in gated CD4+ and CD8+ T cell populations were 
defined as follows: effector memory = CCR7negCD45RAneg, central memory = 
CCR7+CD45RAneg, naïve = CCR7+CD45RA+, effector memory RA = CCR7negCD45RA+.  
Data represented as mean ± SD, n=3,* p<0.05, two-way ANOVA (Tukey’s post-test). (B) 
Intracellular staining for granzyme and perforin in T cells following two stimulation cycles 
was measured by flow cytometry in CD4+ and CD8+ gated T-cell populations.  Data 
represented as mean ± SD, n=3, *p<0.05, *** p<0.001, two-way ANOVA (Tukey’s post-test). 
(C) Cytokine production following stimulation with PMA/Ionomycin was measured by 
intracellular cytokine staining in T cells following two cycles of stimulations by flow cytometry 
in CD4+ and CD8+ gated T cell populations. Data represented as mean ± SD, n=3, *p<0.05, 
*** p<0.001, two-way ANOVA (Tukey’s post-test). 
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When stimulated with PMA/Ionomycin, CD4+ T cells expanded with low and high density 
aAPC demonstrated equivalent production of IFN-γ, TNF-α, and IL-2, but CD8+ T cells 
stimulated with low density aAPC demonstrated significantly less production of IFN-γ 
(p<0.001) and TNF-α (p<0.05), and more production of IL-2 (p<0.05) (Figure 7C). 
Collectively, these data suggest that T cells expanded with lower density of aAPC contain 
an increased proportion of T cells with central memory phenotype, reduced production of 
effector molecules granzyme B and perforin, and reduced production of effector cytokines 
IFN-γ and TNF-α compared to T cells expanded with higher density of aAPC. 
2.2.3 Numeric expansion of T cells results in minimal change in TCRαβ diversity 
 We profiled TCRα and TCRβ diversity prior to and following expansion with low and 
high density aAPC by multiplex digital profiling using nCounter analysis (Nanostring 
Technologies, Seattle, WA) and calculated the relative abundance of each TCRα and TCRβ 
chain as a percentage of total T-cell population (Appendix B).  Following ex vivo expansion 
with low and high density aAPC, CD4+ and CD8+ T cells expressed diverse TCRα and TCRβ 
alleles, indicating that the resulting population maintained oligoclonal TCRα and TCRβ 
repertoire (Figure 8 and Figure 9).  High throughput sequencing of CDR3 regions using the 
ImmunoSEQ platform (Adaptive TCR Technologies, Seattle, WA) in the TCRβ chain in T 
cells prior to and following expansion with low and high density of aAPC was performed to 
determine if ex vivo expansion resulted in change in clonal composition of T cells.  Relative 
counts of individual CDR3 sequence prior to and following expansion were plotted and fitted 
with a linear regression.  If the number of CDR3 sequences prior to and following expansion 
were identical, the slope of the linear regression would be expected to be 1.0.  In T cells 
expanded with low density aAPC, the slope of the linear regression was 0.75 ± 0.001, while 
in T cells expanded with high density aAPC the slope of the linear regression was 0.29 ± 
0.003 (Figure 10). This indicates that T-cell populations expanded with low density aAPC 
maintain more CDR3 sequences from the input T-cell population than T cells expanded with 
high density aAPC. In sum, ex vivo expansion of T cells results in oligoclonal T-cell 
population when expanded with low and high density aAPC, but T cells expanded with low 
density aAPC may demonstrate less clonal loss following expansion. 
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Figure 8. Diversity of TCR Vα after numeric expansion of T cells on aAPC. Diversity of 
TCR Vα in T cells expanded with low or high density aAPC was measured by digital 
multiplexed profiling of mRNA species and relative abundance of each TCR Vα was 
calculated as percent of total TCR Vα transcripts.  Data represented as mean ± SD, n=3. 
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Figure 9. Diversity of TCR Vβ after numeric expansion of T cells on aAPC. Diversity of 
TCR Vβ in T cells expanded with low or high density aAPC was measured in sorted CD4+ 
and CD8+ T cells by digital multiplexed profiling of mRNA species and relative abundance of 
each TCR Vα was calculated as percent of total TCR Vα transcripts.  Data represented as 
mean ± SD, n=3 
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Figure 10. Diversity of CDR3 sequences in T cells after numeric expansion on aAPC.  
CDR3 sequences of TCR Vβ chain were determined by high-throughput sequences on 
ImmunoSEQ platform.  Numbers of each unique sequence before numeric expansion were 
plotted against the numbers of the same sequence after numeric expansion with low density 
(10 T cells to 1 aAPC) or high density (1 T cell to 2 aAPC) aAPC. Data were fit with a linear 
regression and slope was determined.  Data representative of two individual donors. 
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2.2.4 Optimization of RNA transfer to T cells numerically expanded with aAPC 
To determine the ability of T cells stimulated with low and high density aAPC to accept RNA 
by electro-transfer, we electro-transferred in vitro transcribed RNA encoding green 
fluorescent protein (GFP) using the Amaxa Nucleofector 4D transfection system (Lonza, 
Cologne, Germany) using a variety of electroporation programs, including program EO-115, 
the manufacturer’s recommended program for stimulated T cells, 4 days following 
stimulation with aAPC. Plotting the mean fluorescent intensity (MFI) of GFP versus the 
viability of T cells determined by PI staining revealed an inverse correlation between GFP 
expression and T-cell viability following RNA transfer.  Compared to T cells stimulated with 
low density aAPC, T cells stimulated with high density aAPC demonstrated both reduced 
expression of GFP by RNA transfer and reduced viability in response to every 
electroporation program evaluated (Figure 11A).  As a result, T cells stimulated with low 
density aAPC (10 T cells to 1 aAPC) were used for further experimentation.  Because T-cell 
numeric expansion prior to RNA transfer is desirable to achieve clinically relevant T-cell 
numbers for infusion, we evaluated the capacity of T cells undergoing multiple rounds of 
stimulation by recursive addition of aAPC every 9 days to accept RNA transcripts by electro-
transfer.  In each successive round of stimulation, expression of GFP following RNA electro-
transfer decreased (Figure 11B, left panel). However, following two rounds of stimulation, T 
cells demonstrated improved viability after electro-transfer compared to T cells undergoing a 
one or three rounds of stimulation (Figure 11B, right panel). Therefore, a protocol of two 
rounds of stimulation with 10 T cells to 1 aAPC was selected for further optimization of RNA 
transcript transfer.  Because RNA is less toxic to cells and transferred more readily into 
many cell types than DNA (165), we reasoned RNA transfer efficiency could be improved 
without compromising T-cell viability by altering the strength of the manufacturer 
recommended electroporation program for stimulated T cells, EO-115.  By plotting the 
percentage of cells expressing GFP versus viability determined by PI staining, we identified 
a program that resulted in ~100% GFP expression 24 hours following electroporation and 
similar T-cell viability as T cells that were not electroporated, program DQ-115 (Figure 11C). 
T-cell phenotype was assessed following electroporation with the optimized protocol and no 
changes in T-cell phenotype were detected following electroporation (Figure 11D). Thus, we 
developed a platform for RNA transfer to T cells that following numeric expansion via co-
culture with aAPC that resulted in high expression of RNA transcript without compromising 
T-cell viability.   
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Figure 11. Optimization of RNA transfer to T cells numerically expanded with aAPC. 
(A) Expression of GFP RNA and viability of T cells electroporated with various programs.  
Median fluorescence intensity of GFP was determined by flow cytometry.  Viability was 
determined by PI stain and flow cytometry. Data representative of two individual donors. (B) 
Expression of GFP RNA and viability in T cells expanded with aAPC at low density (10 T 
cells to 1 aAPC) following one, two or three cycles of stimulation. Percentage of T cells 
expressing GFP was determined by flow cytometry.  Viability was determined by PI stain 
and flow cytometry. Data representative of two individual donors. (C) Expression of GFP 
RNA and viability of T cells stimulated at an aAPC density of 10 T cells to 1 aAPC for two 
stimulation cycles after electroporation with various programs.  Percentage of T cells 
expressing GFP was determined by flow cytometry.  Viability was determined by PI stain 
and flow cytometry. Data representative of two individual donors. (D) Expression of memory 
markers CCR7 and CD45RA measured by flow cytometry in CD4+ and CD8+ gated T cells 
following two cycles of stimulation with aAPC at a density of 10 T cells to 1 aAPC, mock 
electroporated with no RNA, and electroporated with RNA. Data represented as mean ± SD, 
n=3. 
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2.2.5 CAR expression and phenotype T cells modified by DNA or RNA transfer 
To compare expression of CAR and function of CAR+ T cells manufactured by RNA 
and DNA modification, we developed an EGFR-specific CAR from the scFv of cetuximab, a 
clinically available anti-EGFR monoclonal antibody.  The scFv of cetuximab was fused to an 
IgG4 hinge region, CD28 transmembrane and cytoplasmic domains, and CD3-ζ cytoplasmic 
domain to form a second generation CAR, termed Cetux-CAR, and expressed in a Sleeping 
Beauty transposon for permanent DNA integration as well as under a T7 promoter in the 
pGEM/A64 vector for in vitro transcription of RNA transcripts.  For stable DNA integration, 
Cetux-CAR expressed in SB transposon was electroporated into human primary T cells with 
the SB11 transposase, a cut-and-paste enzyme, which excises the CAR from the 
transposon and inserts into the host T-cell genome at inverted TA repeats.  Recursive 
stimulation with γ-irradiated EGFR+ K562 aAPC results in selective expansion of CAR-
expressing T cells over time, and T cells were evaluated for CAR expression following 28 
days consisting of 5 cycles of recursive aAPC addition, every 7 days (Figure 12A). RNA-
modification of T cells was achieved by electro-transferring in vitro transcribed Cetux-CAR 
into T cells stimulated twice with OKT3-loaded K562 aAPC, four days following the second 
stimulation (Figure 12B). CAR expression was evaluated 24 hours following electro-
transfer. Expression of Cetux-CAR by RNA-modification and DNA-modification in CD4+ and 
CD8+ as determined by flow cytometry for the IgG4 hinge region of CAR was not statistically 
different (p>0.05), however, RNA-modification resulted in greater variation in expression 
intensity (Figure 13A).  Of Cetux-CAR-expressing T cells, the proportion of CD4+ and CD8+ 
T cells was not statistically different between T cells modified with RNA or DNA, however, 
there was greater variability in the proportion of CD4+ and CD8+ T cells present in DNA-
modified than RNA-modified CAR+ T cells (Figure 13B).   
To compare the phenotype of T-cell populations modified by RNA or DNA transfer, 
we measured phenotypic markers by flow cytometry. CD4+ RNA-modified CAR+ T cells had 
more T cells with central memory phenotype (CCR7+CD45RAneg) than CD4+ DNA-modified 
CAR+ T cells (DNA-modified = 6.6 ± 1.9%, RNA-modified = 49.6 ± 3.0%, mean ± S.D., n=3) 
(p<0.0001), but fewer T cells with effector memory phenotype (CCR7negCD45RAneg) (DNA-
modified = 89.8 ± 2.6%, RNA- modified=48.1 ± 3.3%, mean ± S.D., n=3) (p<0.0001) (Figure 
13C).  Similarly, CD8+ RNA-modified CAR+ T cells had significantly more T cells with central 
memory phenotype than CD8+ DNA-modified CAR+ T cells (DNA-modified = 10.4 ± 4.9%, 
RNA-modified = 32.8 ± 4.2%, mean ± S.D., n=3) (p<0.001), but fewer T cells with effector  
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Figure 12. Schematic of CAR expression by DNA and RNA modification. (A) DNA 
modification of T cells by electroporation with SB transposon/transposase.  Normal donor 
PBMCs were electroporated with SB transposon containing CAR and SB11 transposase to 
result in stable CAR expression in a fraction of T cells.  Stimulation with γ-irradiated antigen 
expressing aAPC in the presence of IL-21 (30 ng/mL) and IL-2 (50 U/mL) culled out CAR+ T 
cells over time, resulting in >85% CAR+ T cells following 5 stimulation cycles and T cells 
were evaluated for CAR-mediated function. (B) Modification of T cells by RNA electro-
transfer.  Normal donor PBMCs were stimulated with γ-irradiated anti-CD3 (OKT3) loaded 
K562 clone 4 aAPC. Three to five days following second stimulation, T cells were 
electroporated with RNA to result in >95% CAR+ T cells 24 hours after RNA electro-transfer, 
and evaluated for CAR-mediated function. 
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Figure 13. Phenotype of Cetux-CAR+ T cells modified by DNA and RNA. (A) Median 
fluorescence intensity of CAR expression in RNA-modified and DNA-modified T cells was 
determined by flow cytometry for IgG region of CAR in CD4+ and CD8+ gated T-cell 
populations.  Data represented as mean ± SD, n=8. (B) Proportion of CD4+ and CD8+ T-cell 
populations in RNA- and DNA-modified T cells determined by flow cytometry for CD4 and 
CD8 in CAR+ gated T cells.  Data represented as mean ± SD, n=8.  (C)  Expression of 
memory markers CCR7 and CD45RA determined by flow cytometry in CD4+ and CD8+ 
gated T-cell populations. Memory populations were defined as follows: effector memory = 
CCR7negCD45RAneg, central memory = CCR7+CD45RAneg, naïve = CCR7+CD45RA+, 
effector memory RA = CCR7negCD45RA+.  Data represented as mean ± SD, n=3, **** 
p<0.0001, two-way ANOVA (Tukey’s post-test).  (D) Expression of inhibitory receptor PD-1 
and marker of replicative senescence CD57 as determined in CD4+ and CD8+ gated T-cell 
populations by flow cytometry. Data represented as mean ± SD, n=3, ** p<0.01, two-way 
ANOVA (Tukey’s post-test). (E) Expression of granzyme B and perforin determined by 
intracellular cytokine staining in CD4+ and CD8+ gated T-cell populations by flow cytometry. 
Data represented as mean ± SD, n=3. 
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memory phenotype (DNA-modified = 83.5 ± 5.4%, RNA-modified = 51.1 ± 6.6%, mean ± 
S.D., n=3) (p>0.0001). CD4+ Cetux-CAR+ T cells modified by RNA also demonstrated 
significantly higher expression  of the inhibitory receptor programmed death receptor 1 (PD-
1) than CD4+ Cetux-CAR+ T cells, (p<0.01), but similar, low expression of CD57, a marker of 
T-cell senescence (Figure 13D). CD8+ Cetux-CAR+ T cells expressed low levels of PD-1 
and CD57 and there was no appreciable difference RNA-modified and DNA-modified CAR+ 
T cells.  Finally, expression of the cytotoxic molecules perforin and granzyme B, was similar 
in CD4+ and CD8+ T cells modified by DNA or RNA transfer of Cetux-CAR (Figure 13E). In 
sum, RNA-modification and DNA-modification of CAR+ T cells resulted in similar expression 
levels of CAR, though RNA transfer resulted in increased variability of the intensity of CAR 
expression.  RNA-modified T cells expressed more central memory phenotype CD4+ and 
CD8+ T cells, less effector memory phenotype CD4+ and CD8+ T cells, and had higher 
expression of inhibitory receptor PD-1 on CD4+ CAR+ T cells than DNA-modified T cells. 
2.2.6 DNA-modified CAR+ T cells produce more cytokine and display slightly more 
cytotoxicity than RNA-modified CAR+ T cells 
Cytokine production of RNA-modified or DNA-modified CAR+ T cells was evaluated 
in response to a mouse T cell lymphoma cell line EL4 modified to express truncated EGFR, 
tEGFR+ EL4, or irrelevant antigen, CD19, and EGFR+ cell lines, including human 
glioblastoma cell lines U87, T98G, LN18 and human epidermoid carcinoma cell line A431. 
Fewer CD8+ CAR+ T cells modified by RNA transfer produced IFN-γ in response to all 
EGFR-expressing cell lines (Figure 14A, left panel).  Because fewer RNA-modified T cells 
produced IFN-γ in response to antigen-independent stimulation with PMA/Ionomycin, it is not 
likely that reduced IFN-γ production is due to reduced sensitivity of CAR to antigen, but 
rather reduced capacity of T cells expressing CAR by RNA-modification to produce cytokine.  
It was noted that DNA-modified CAR+ T cells also demonstrated higher background 
production of IFN-γ in the absence of T-cell stimulation.  Similarly, fewer RNA-modified CD8+ 
CAR+ T cells produced TNF-α in response to EGFR-specific stimulation from T98G, LN18, 
A431 and antigen-independent stimulation from PMA/Ionomycin than DNA-modified CD8+ 
CAR+ T cells (Figure 14A, right panel). 
Because RNA-modified CAR+ T cells demonstrated reduced capacity to produce 
cytokine relative to DNA-modified CAR+ T cells, cytotoxicity of RNA-modified and DNA-
modified T cells was compared to determine the cytotoxic potential of RNA-modified CAR+ T 
57 
 
 
58 
 
Figure 14. DNA-modified CAR+ T cells produce more cytokine and display slightly 
more cytotoxicity than RNA-modified CAR+ T cells. (A) Cytokine production of DNA-
modified (following 5 stimulation cycles) and RNA-modified CAR+ T cells (24 hours post RNA 
transfer) was measured by intracellular staining and flow cytometry following 4 hr incubation 
with targets or PMA/Ionomycin in CD8+ gated T cells.  Data represented as mean ± SD, 
n=3, * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001, two-way ANOVA (Tukey’s post-test). 
(B) Specific cytotoxicity of DNA-modified (following 5 stimulation cycles) and RNA-modiifed 
CAR+ T cells (24 hours post RNA transfer) was determined by standard 4-hour chromium 
release assay.  Data represented as mean ± SD, n=3, *p<0.05, two-way ANOVA (Tukey’s 
post-test). (C) Specific cytotoxicity of A431 by RNA-modified CAR+ T cells at 10:1 
effector:target ratio plotted against median fluorescence intensity of CAR.  Linear regression 
was fit to the data, yielding a slope of slope=0.0237±0.030, not significantly different from a 
slope of 0, p=0.4798. 
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cells relative to DNA-modified CAR+ T cells. In response to CD19+ EL4 cells, RNA-modified 
and DNA-modified CAR+ T cells had low levels of background killing, although at high 
effector to target ratio (E:T = 20:1), RNA-modified CAR+ T cells demonstrated significantly 
more background lysis than DNA-modified CAR+ T cells (p<0.05) (Figure 14B). Similarly, 
RNA-modified and DNA-modified CAR+ T cells demonstrated low and equivalent levels of 
background lysis against B-cell lymphoma cell line, NALM-6.  In response to tEGFR+ EL4 
and A431, there was no appreciable difference in cytotoxicity mediated by RNA-modified or 
DNA-modified CAR+ T cells.  In response to the three glioma cell lines U87, T98G, and 
LN18, DNA-modified CAR+ T cells demonstrated slightly increased cytotoxicity over RNA-
modified CAR+ T cells only detected at low E:T ratios. Because RNA-modified T cells have 
more variability in CAR expression than DNA-modified T cells from donor to donor, we 
evaluated the impact of CAR expression, as determined by median fluorescence intensity of 
CAR expression, on specific lysis of A431.  Median fluorescence intensity of CAR 
expression was plotted versus specific lysis of A431, and a linear regression of the 
relationship yielded a slope not significantly different than zero, and therefore, showed no 
significant trend detected between CAR expression and specific lysis (slope = 0.0237 ± 
0.030, p=0.4798) (Figure 14C).  In sum, these findings suggest that DNA-modified CAR+ T 
cells have significantly increased production of effector cytokines IFN-γ and TNF-α relative 
to RNA-modified CAR+ T cells, may demonstrate slightly more cytotoxicity when present at 
low E:T ratios, and that the variability of CAR expression in RNA-modified CAR+ T cells 
does not significantly impact specific lysis of targets. 
2.2.7 Transient expression of Cetux-CAR by RNA modification of T cells 
To determine the stability of CAR expression by RNA transfer, T cells were modified 
to express CAR by RNA transfer, and CAR expression was measured over time by flow 
cytometry.  Following RNA transfer, expression of Cetux-CAR on T cells decreased over 
time, and 96 hours following electro-transfer, CAR was expressed at low levels (Figure 
15A). Because RNA transcripts are divided between daughter cells during T-cell 
proliferation, stimulation of T-cell proliferation should accelerate the loss of CAR expressed 
by RNA-modification. To determine the effect of cytokine stimulation on CAR expression 
level, exogenous IL-2 and IL-21 were added to RNA-modified CAR+ T cell culture 24 hours 
after RNA transfer and CAR expression was monitored by flow cytometry. Stimulation of 
CAR+ T cells with IL-1 and IL-21 accelerated the loss of CAR expression (Figure 15B). 
Following 72 hours, CAR expression was low on RNA-modified T cells, and 96 hours after 
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Figure 15. Transient expression of Cetux-CAR by RNA-modification of T cells. (A) 
Expression of CAR measured daily by flow cytometry for IgG portion of CAR with no 
cytokines or stimulus added to T cells. Data representative of three independent donors. (B) 
Expression of CAR measured daily by flow cytometry for IgG portion of CAR following 
addition of IL-2 (50 U/mL) and IL-21 (30 ng/mL) 24 hours after RNA transfer. Data 
representative of three independent donors. (A) Expression of CAR measured daily by flow 
cytometry for IgG portion of CAR after addition of tEGFR+ EL4 cells 24 hours after RNA 
transfer. Data representative of three independent donors. 
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transfer, T cells no longer expressed CAR at a detectable level. Stimulation of RNA-modified 
CAR+ T cells with tEGFR+ EL4 24 hours after RNA transfer accelerated the loss of CAR 
expression even further (Figure 15C).  While CAR was detected at high level in RNA-
modified CAR+ T cells prior to addition of tEGFR+ EL4, 24 hours after tEGFR+ EL4 addition 
(48 hours following RNA transfer), CAR expression was low.  Collectively, these data 
indicate the CAR expression by RNA transfer is transient, detectable at low levels up to 120 
hours after RNA transfer, however, stimulation of T cells through cytokine or recognition of 
antigen accelerated the loss of CAR expression.   
2.2.8 Transient expression of Cetux-CAR by RNA modification reduces cytokine production 
and cytotoxicity to EGFR-expressing cells. 
 Activity of T cells modified to express Cetux-CAR by RNA transfer was measured 24 
and 120 hours after RNA transfer to determine the effect of loss of CAR expression on 
activity of T cells in response to EGFR-expressing cells. While RNA-modified T cells 
demonstrated equivalent production of IFN-γ by PMA/Ionomycin stimulation when assessed 
at 24 hours and 120 hours after RNA transfer, production of IFN-γ in response to tEGFR+ 
EL4 by T cells was abrogated 120 hours after RNA transfer (24 hrs = 14.2 ± 2.5%, 120 hrs = 
1.1 ± 0.03%, mean ± S.D., n=3) (p=0.012) (Figure 16A). In contrast, DNA-modified CAR+ T 
cells demonstrated equivalent production of IFN-γ in response to tEGFR+ EL4 at both time 
points assessed (24 hrs = 40.3 ± 9.6%, 120 hrs = 48.6 ± 10.0%, mean ± S.D., n=3) 
(p=0.490).  Similarly, specific cytotoxicity was measured against epidermoid carcinoma cell 
line A431 and human normal renal cortical epithelial cells (HRCE), a primary kidney cell line 
which expresses EGFR. RNA-modified and DNA-modified CAR+ T cells demonstrated 
equivalent specific lysis of A431, and similar cytotoxicity against HRCE, statistically 
equivalent at higher effector to target ratios (20:1 and 10:1, p>0.05) (Figure 16B).  Similar to 
observations with other cell lines, DNA-modified CAR+ T cells mediated slightly higher 
specific lysis of HRCE than RNA-modified CAR+ T cells at lower E:T ratios (5:1, p<0.05; 
2.5:1, p<0.01, 1.25:1, p<0.05).  However, 120 hours after RNA transfer, when CAR 
expression of RNA-modified T cells is abrogated, DNA-modified T cells mediated 
significantly higher specific lysis in response to A431 and HRCE at every E:T ratio evaluated  
(A431, all E:T ratios, p<0.0001; HRCE, all E:T ratios, p<0.0001).  While DNA-modified T 
cells demonstrated no change in specific lysis of HRCE at each time point (10:1 E:T ratio, 24 
hrs = 45.5 ± 8.0%, 120 hrs = 51.6 ± 7.8%, p>0.05, n=3), RNA-modified T cells significantly 
reduced specific lysis of HRCE 120 hours after RNA transfer (10:1 E:T ratio, 24 hrs = 39.5 
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Figure 16. Transient expression of Cetux-CAR by RNA modification reduces cytokine 
production and cytotoxicity to EGFR-expressing cells. (A) Production of IFN-γ 
measured by intracellular staining and flow cytometry in DNA-modified and RNA-modified 
CD8+ T cells 24 hours and 120 hours after RNA transfer after 4 hour incubation with target 
cells or PMA/Ionomycin. Data represented as mean ± SD, n=3, * p<0.05, two-way ANOVA 
(Tukey’s post-test). (B) Specific cytotoxicity of DNA-modified and RNA-modified T cells 
measured by standard chromium release assay 24 hours and 120 hours after RNA transfer. 
Data represented as mean ± SD, n=3, * p<0.05, ** p<0.01, **** p<0.0001, two-way ANOVA 
(Tukey’s post-test). (C)  Change in specific cytotoxicity of DNA-modified and RNA-modified 
T cells from 24 hours post RNA transfer to 120 hours post RNA transfer measured by 
standard chromium release assay at an effector to target ratio of 10:1. Data represented as 
mean ± SD, n=3, * p<0.05, two-way ANOVA (Tukey’s post-test).  
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± 5.9%, 120 hrs = 19.8 ± 10.2%, mean ± S.D., n=3) (Figure 16C).  These data indicate that 
activity of RNA-modified T cells in response to EGFR-expressing targets is reduced by loss 
of CAR expression. 
2.3   Discussion 
 Transient expression of CAR by RNA transfer has been proposed to reduce the 
potential for long-term, on-target, off-tissue toxicity of CAR T cell therapy directed against 
antigens with normal tissue expression.  Numeric expansion of T cells prior to RNA transfer 
is appealing to obtain clinically relevant T cell numbers needed for patient infusion.  We 
explored numeric expansion of T cells independent of antigen-specificity by co-culturing on 
aAPC loaded with anti-CD3 antibody, OKT3.  Altering the ratio of aAPC to T cells in culture 
altered the phenotype of the resultant T cell population.  T cells expanded with low density 
of aAPC (10 T cells to 1 aAPC) were associated with increased proportion of CD8+ T cells, 
increased presence of central memory phenotype T cells, reduced production of IFN-γ and 
TNF-α, but increased production of IL-2, and potentially less clonal loss of TCR diversity 
following expansion relative to T cells expanded with high density aAPC. T cells expanded 
with low density aAPC were more amenable to RNA electro-transfer, demonstrating higher 
expression of RNA transcripts and improved T-cell viability following electro-transfer than T 
cells expanded with high density aAPC.   
 A potential benefit of use of aAPC for T-cell expansion is the ability to form stable 
interactions with T cells by virtue of expression of adhesion molecules LFA-3 and ICAM-1 
(95, 97). Additionally, aAPC can be modified with relative ease to express desired arrays of 
costimulatory molecules. Thus, aAPC for numeric T-cell expansion provides a platform to 
evaluate various combinations of costimulatory molecules for T-cell expansion to achieve 
determine and achieve an optimal T-cell phenotype for adoptive T-cell therapy.  In addition 
to modification of aAPC, we have described the impact of the density of aAPC in T cell 
culture on the phenotype of resulting T-cell populations. While CD8+ T cells, or cytotoxic T 
cells, are often thought of as the ideal T-cell population for anti-tumor immunotherapy, 
evidence suggests that CD8+ T cells require CD4+ T-cell help in vivo to achieve optimal anti-
tumor response and memory formation (273-275).  However, the ideal ratio of CD4+ to CD8+ 
T cells is unknown (276).  By altering density of aAPC in expansion cultures to skew 
CD4/CD8 ratio in T cells for adoptive immunotherapy, whether they be TIL isolated from 
patients or gene-modified T cells, these questions may be addressed in clinical trials.  
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Finally, reducing density of aAPC in culture resulted in more T cells with a central memory 
phenotype (CCR7+CD45RAneg) than T cells expanded with higher density of aAPC.  While 
the benefit of enhanced persistence of central memory phenotype T cells may not extend to 
RNA-modified T cells, which are only transiently redirected for tumor antigen, persistence of 
T cells has been shown to improve the anti-tumor efficacy of T-cell therapy (104, 277-279).  
Therefore, future studies will examine the ability of ex vivo expansion with low density aAPC 
to reprogram stably genetically modified T cells or TIL to a central memory phenotype for 
enhanced persistence. 
 Expression of CAR by RNA-modification in ex vivo expanded T cells was found to be 
more variable than expression of CAR by non-viral DNA-modification and donor-dependent. 
Expression of CAR at different densities did not impact the ability of the T cells to specifically 
lyse targets, although it is reasonable to expect that below a certain threshold, low CAR 
expression would have a negative impact on specific lysis of targets, as previously reported 
(123). Others have described tunable expression of CAR by RNA modification of T cells, 
such that the dose of RNA determines the level of transgene expression (165-167).  RNA 
modification of T cells in the present study was conducted using the same quantity of RNA, 
therefore, alteration of RNA dose does not account for variability of CAR expression. 
Instead, it is likely that variability between donors accounts for differences in CAR 
expression intensity following electro-transfer. Our novel protocol for T-cell expansion prior 
to RNA transfer may play a role in altering the sensitivity of T cells from certain donors to 
RNA uptake, and increasing the RNA quantity in electro-transfers may increase expression 
of CAR in these donors.   High expression of CAR by transferring relatively high quantities of 
RNA can result in prolonged CAR expression and CAR-mediated activity over an extended 
period of time (167). Prolonged CAR expression from RNA transfer may be beneficial for 
anti-tumor activity, particularly since stimulation of T cells seems to accelerate the loss of 
CAR expression.  However, prolonging the expression of CAR may also increase T-cell 
activity in response to normal tissue antigen. Thus, optimization of CAR expression to 
determine the optimal duration of expression to maximize anti-tumor activity while reducing 
normal tissue toxicity warrants further investigation.  
RNA-modification of T cells did not alter the proportion of effector memory and 
central memory T cells found in ex vivo expanded T cells prior to electro-transfer of RNA, 
similar to previous reports (280).  Only T cells expanded at relatively low aAPC density, 10 T 
cells to 1 aAPC, were capable of efficient RNA transcript uptake without significant toxicity, 
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even with various electroporation conditions evaluated. This population of T cells also 
demonstrated a substantial proportion of T cells with a central memory phenotype 
(CCR7+CD45RAneg) that had reduced production of IFN-γ and TNF-α, and cytotoxic effector 
molecules granzyme B and perforin.  As a result, RNA-modified T cells contained 
significantly more central memory phenotype T cells than DNA-modified T cells, 
demonstrated reduced production of IFN-γ and TNF-α in response to EGFR-expressing cells 
and slightly less specific lysis at low E:T ratios.  Thus, the precursor T-cell population for 
RNA-modification has a strong influence on CAR-mediated T-cell function following RNA 
transfer and the reduced cytokine production and slightly less specific lysis of RNA-modified 
T cells may translate to reduced anti-tumor efficacy in an in vivo model where cytotoxic 
potential of T cells is short-lived and the enhanced persistence of a central memory T-cell 
population may not be beneficial. RNA-modification of T cells expanded at 1 T cell to 2 
aAPC, which demonstrated a more significant proportion of effector memory phenotype T 
cells, similar to DNA-modified CAR+ T cells, and consequently the capacity for higher 
production of IFN-γ and TNF-α is desirable.  Future work evaluating the addition of cytokines 
prior to RNA transfer to improve viability and additional electroporation programs may 
identify a protocol to efficiently transfer RNA into these T cells. 
 Importantly, Cetux-CAR introduced to T cells through RNA transfer was transiently 
expressed, and loss of expression was accelerated by stimulus to T cells, including addition 
of cytokines IL-2 and IL-21 and antigenic-stimulus through addition of EGFR-expressing cell 
lines. Concomitant with loss of CAR expression, RNA-modified T cells demonstrated 
reduced cytotoxicity against EGFR-expressing cell lines, including tumor cells and normal 
renal cells. One concern for the use of RNA-modified T cells is that their inherently reduced 
capacity to target tumor over time will result in reduced anti-tumor efficacy relative to stably-
modified T cells. Multiple injections of T cells modified to express a mesothelin-specific CAR 
by RNA transfer for the treatment of murine model of mesothelioma demonstrated that 
biweekly, intratumoral injections controlled tumor growth, but following cessation of 
treatment, tumors relapsed (152).  Treatment of an in vivo disseminated leukemia murine 
model has shown that while RNA-modified CAR+ T cells specific for CD19 have anti-tumor 
activity after a single injection, tumors often relapse after a time period consistent with CAR 
degradation (167). In contrast, a single intratumoral injection of T cells stably expressing 
mesothelin-specific CAR mediated superior anti-tumor activity and was capable of curing 
most mice.  Optimization of dosing of RNA-modified T cells demonstrated that a combination 
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of cyclophosphamide to eliminate residual CARneg T cells before subsequent infusions and a 
weighted, split-dosing regimen was more effective in controlling disease burden, and was 
similar in anti-tumor efficacy to stably modified T cells (168). Thus, it appears that optimizing 
a dosing regimen can improve the anti-tumor activity of RNA-modified T cells. 
A clinical trial of RNA-modified T cells expressing mesothelin-specific CAR for 
treatment of patients with mesothelin-expressing tumors, such as mesothelioma, is currently 
underway.  Early reports have demonstrated tolerability of multiple injections mesothelin-
specific CAR+ T cells in most patients, despite normal tissue expression of mesothelin at low 
levels of mesothelial surfaces of peritoneal, pleural and pericardial spaces (266).  In 
addition, anti-tumor activity has been demonstrated by radiographic measurement of tumor 
remission and measurement of serum biomarkers. One serious adverse event has been 
reported from this trial directly related to CAR+ T cell treatment in which a patient 
experienced anaphylactic shock and cardiac arrest within minutes of receiving a T-cell 
infusion, attributed to development of an IgE antibody response to murine moieties of the 
CAR (160). Therefore, the trial was revised dose multiple infusions over a span of no more 
than 21 days with individual infusions no more than 10 days apart in order to complete 
treatment within a time frame shorter than that required for isotype switching of antibody 
responses from IgG to IgE to occur. While anaphylactic response to CAR+ T cells might best 
be avoided by single infusion of stably modified T cells to avoid multiple dosing strategies, 
even stably modified T cells are often given over multiple infusions due to limited in vivo 
persistence.   
An additional limitation of RNA-modified Cetux-CAR+ T cells lies in their capacity to 
recognize EGFR on normal human renal cells prior to appreciable degradation of CAR. 
While transient expression of CAR by RNA modification reduces potential of Cetux-CAR+ T 
cells to recognize normal tissue EGFR in the long-run, it does not protect normal tissue 
expressing EGFR from the potential of immediate toxicity mediated by CAR+ T cells.  Since  
CAR loss is accelerated following interaction with EGFR and normal tissue in the CNS are 
not reported to express EGFR, intratumoral delivery of Cetux-CAR+ T cells to ensure 
encounter with tumor prior to normal tissue expressing EGFR may reduce the potential for 
on-target, off-tissue normal tissue toxicity. However, for many other EGFR-expressing tumor 
types, there is not such a distinct separation between location of tumor and normal tissue 
expressing EGFR.  To expand CAR+ T cell therapy to other EGFR-expressing malignancies 
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that may reside in close proximity to EGFR-expressing normal cell, additional mechanisms 
to reduce the potential for normal tissue recognition are needed. 
In sum, numeric expansion of T cells prior to RNA transfer can be achieved through 
co-culture with OKT3-loaded K562 aAPC.  While CAR+ T cells modified through RNA 
transfer may exhibit reduced cytokine production and reduced cytotoxicity relative to DNA-
modified CAR+ T cells, the expression of CAR is transient and following loss of CAR 
expression, activity of T cells in response to EGFR-expressing targets is greatly reduced.  
However, transient expression of Cetux-CAR by RNA modification is limited by the potential 
for reduced anti-tumor activity due to transient nature of CAR expression and by the 
capability of Cetux-CAR+ T cells to exert specific cytotoxicity on normal tissue expressing 
EGFR prior to appreciable degradation of CAR. Thus, investigation of additional 
mechanisms to reduce toxicity of stably modified CAR+ T cells is ongoing.  
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CHAPTER 3 
CAR+ T cells can distinguish malignant cells from normal cells based on 
EGFR density 
3.1   Introduction 
In Chapter 2, we acknowledged that Cetux-CAR+ T cells can recognize normal tissue 
antigen, which could result in on-target, off-tissue toxicity and investigated expression of 
CAR as RNA species as a method to control on-target, off-tissue toxicity through transient 
expression of CAR. While CAR expression was transient and reduced potential for 
cytotoxicity against normal tissue EGFR after degradation of CAR, it did not address the 
potential for immediate T-cell effector function upon recognition of normal tissue EGFR 
before considerable degradation of CAR. Additionally, by limiting CAR expression, T cells 
are rendered non-responsive to EGFR-expressing tumor following CAR degradation, and 
the potential for lasting anti-tumor activity is compromised by this approach.  Therefore, we 
continued to investigate mechanisms to control CAR activity in the presence of normal 
tissue to limit deleterious on-target, off-tissue toxicity without compromising anti-tumor 
activity. 
Endogenous T-cell activation is dependent on both affinity of the TCR and density of 
peptide presented via MHC (17, 59-61).  T cells are activated by a cumulative signal through 
the TCR that surpasses a certain threshold required for elicitation of effector functions (16, 
17, 59).  For high affinity TCRs, relatively low antigen density is sufficient to trigger T-cell 
responses; however, low affinity TCRs required higher antigen density to achieve similar 
effector T cell responses (60).   Many tumors overexpress TAA at higher densities than their 
normal tissue expression (281-283).  Amplification and overexpression of EGFR in glioma 
highlight this relationship as EGFR is overexpressed in glioma relative to normal tissue, and 
overexpression correlates with tumor grade, such that grade IV glioblastoma expresses the 
highest density of EGFR (180, 182, 199).  Therefore, we sought to determine if EGFR-
specific CAR-modified T cells could target distinguish malignant cells from normal cells 
based on EGFR density by reducing the binding affinity of the CAR.   
The portion of Cetux-CAR that endows antigenic specificity is derived from the scFv 
portion of the monoclonal antibody cetuximab, which is characterized by a high affinity 
(Kd=1.9x10-9) (223). Therefore, we generated a CAR from the monoclonal antibody 
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nimotuzumab, which shares a highly overlapping epitope with cetuximab and a 10-fold 
higher dissociation constant (Kd=2.1x10-8), characterized by a 59-fold reduced rate of 
association (223, 231, 284, 285).  The reduced association rate and subsequent reduction in 
overall affinity imposes a requirement for bivalent recognition of EGFR by nimotuzumab 
which only occurs when EGFR is expressed at high density. We hypothesized that a CAR 
derived from nimotuzumab would enable T cells to distinguish malignant tissue from normal 
tissue based on density of EGFR expression. 
3.2   Results 
3.2.1 Cetux-CAR+ and Nimo-CAR+ T cells are phenotypically similar  
A second generation CAR derived from nimotuzumab, designated Nimo-CAR, was 
generated in a Sleeping Beauty transposon by fusing the scFv of nimotuzumab with an IgG4 
hinge region, CD28 transmembrane domain and CD28 and CD3ζ intracellular domains, an 
identical configuration to Cetux-CAR. Cetux-CAR and Nimo-CAR were expressed in primary 
human T cells by electroporation of each transposon with SB11 transposase into peripheral 
blood mononuclear cells (PBMC). T cells with stable integration of Cetux-CAR or Nimo-CAR 
were selectively propagated by weekly recursive stimulation with γ-irradiated tEGFR+ K562 
artificial antigen presenting cells (aAPC) (Figure 17A).  Both CARs mediated ~1000-fold 
expansion of CAR+ T cells over 28 days of co-culture with aAPC, yielding T cells which 
almost all expressed CAR (Cetux-CAR = 90.8 ± 6.2%, Nimo-CAR = 90.6 ± 6.1%; mean ± 
SD, n=7) (Figure 17B and 17C). Proportion of Cetux-CAR and Nimo-CAR+ T cells 
expressing CAR was statistically similar following 28 days of numeric expansion (p=0.92, 
student’s two-tailed t-test). Density of CAR expression, represented by median fluorescence 
intensity, was measured by flow cytometry and was statistically similar between Cetux-CAR+ 
and Nimo-CAR+ T-cell populations (Cetux-CAR = 118.5 ±2 5.0 A.U., Nimo-CAR = 112.6 ± 
21.2 A.U.; mean ± SD, n=7) (p=0.74) (Figure 17D). 
In order to determine the impact of CAR scFv on T-cell function, we first established 
that electroporation and propagation of Cetux-CAR+ and Nimo-CAR+ T cells resulted in 
phenotypically similar T-cell populations.   Each donor yielded variable ratios of CD4+ and 
CD8+ T cells (Table 1), however, there was no statistical difference in the CD4/CD8 ratio 
between Cetux-CAR+ and Nimo-CAR+ T cells (p=0.44, student’s two-tailed t-test) (Figure 
18A).  Expression of differentiation markers CD45RO, CD45RA, CD28, CD27, CCR7 and 
CD62L were not statistically significant (p>0.05), and indicate a heterogeneous T-cell 
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Figure 17. Numeric expansion of Cetux-CAR+ and Nimo-CAR+ T cells.  (A) Phenotype of 
γ-irradiated tEGFR+ K562 clone 27 determined by flow cytometry. (B) Numeric expansion of 
Cetux-CAR+ and Nimo-CAR+ T cells. Prior to each stimulation cycle, percentage of 
CD3+CAR+ T cells was determined by flow cytometry.  Inferred cell count was calculated by 
multiplying the fold expansion following a stimulation cycle by the number of CAR+ T cells 
resulting from previous stimulation.  Data represented as mean ± SD, n=7. (C) Expression of 
CAR in CD3+ T cells was determined 24 hours after electroporation of CAR and after 28 
days of expansion by flow cytometry for the IgG portion of CAR. Data represented as mean, 
n=7. (D) Median fluorescence intensity of CAR expression was determined by flow 
cytometry for the IgG portion of CAR after 28 days of expansion.  Data represented as mean 
± SD, n=7. 
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Table 3. Ratio of CD4 and CD8 in Cetux-CAR+ and Nimo CAR+ T cells. Expression of 
CD4 and CD8 in Cetux-CAR+ and Nimo-CAR+ T cells after 28 days of expansion was 
determined by flow cytometry.  Data from 7 independent donors. 
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population (Figure 18B).  Likewise, markers for senescence CD57 and KLRG1 and the 
inhibitory receptor programmed death receptor 1 (PD-1) were found to be low and not 
statistically different between Cetux-CAR+ and Nimo-CAR+ T-cell populations (p>0.05) 
(Figure 18C). In aggregate, these findings indicate that Cetux-CAR+ and Nimo-CAR+ T cells 
have no detectable phenotypic differences, including CAR expression after electroporation 
and propagation, enabling direct comparison. 
3.2.2 Cetux-CAR+ and Nimo-CAR+ T cells have equivalent capacity for CAR-dependent T-
cell activation 
To verify Cetux-CAR and Nimo-CAR were functional in response to stimulation with 
EGFR, we incubated CAR+ T cells with A431 epidermoid carcinoma cell line, which is 
reported to express high levels of EGFR, about 1x106 molecules of EGFR/cell (231).  Cetux- 
and Nimo-CAR+ T cells produced IFN-γ during co-culture with A431, which was reduced in 
the presence of anti-EGFR monoclonal antibody that blocks binding to EGFR (Figure 19A).  
To verify that Cetux-CAR and Nimo-CAR are equivalently capable of activating T cells, we 
generated targets that could be recognized by both CARs independent of the scFv domain.   
This was accomplished by expressing the scFv region of an activating antibody specific for 
the IgG4 region of CAR (CAR-L) on immortalized mouse T cell line EL4 (286).  Activation of 
T cells by CAR-L+ EL4 was compared to activation by an EL4 cell line expressing tEGFR.  
Quantitative flow cytometry was performed to measure the density of tEGFR expressed on 
EL4. In this method, intensity of fluorescence from microspheres with a known antibody 
binding capacity labeled with fluorescent antibody is measured by flow cytometry and used 
to derive a standard curve, which defines a linear relationship between known antibody 
binding capacity and mean fluorescence intensity (MFI). The standard curve can then be 
used to derive the mean density of antigen expression from the mean fluorescence intensity 
of an unknown sample labeled with the same fluorescent antibody. tEGFR+ EL4 expressed 
tEGFR at a relatively low density, about 45,000 molecules/cell (Figure 19B). Cetux-CAR+ 
and Nimo-CAR+ CD8+ T cells demonstrated statistically similar amounts of IFN-γ in 
response to CAR-L+ EL4s, indicating equivalent capacity for CAR-dependent activation 
(p>0.05) (Figure 19C).  While Cetux-CAR+ T cells produced IFN-γ in response to EGFR+, 
there was no appreciable IFN-γ production from Nimo-CAR+ T cells (Figure 19C), which is 
consistent with the affinity of the scFv of CAR impacting T-cell activation in response to low 
antigen density.  In addition to measuring cytokine production, we analyzed CD8+ T cells for 
phosphorylation of molecules downstream of T-cell activation, Erk1/2 and p38.  There was 
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Figure 18. Cetux-CAR+ and Nimo-CAR+ T cells are phenotypically similar. (A) 
Proportion of CD4 and CD8 T cells in total T-cell population after 28 days of expansion 
measured by flow cytometry on gated CD3+ CAR+ cells.  Data represented as mean ± SD, 
n=7.  (B,C)  Expression of T-cell memory and differentiation markers after 28 days of T-cell 
expansion measured by flow cytometry in gated CD4+ and CD8+ T-cell populations. Data 
represented as mean ± SD, n=4. 
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Figure 19. Cetux-CAR+ and Nimo-CAR+ T cells are activated equivalently through 
affinity-independent triggering of CAR.  (A) Production of IFN-γ in response to EGFR+ 
A431 in the presence of EGFR blocking monoclonal antibody.  CAR+ T cells were co-
cultured with A431 with anti-EGFR blocking antibody or isotype control and IFN-γ production 
was measured by intracellular flow cytometry. Percent of production was calculated as mean 
fluorescence intensity of IFN-γ in gated CD8+ T cells relative to unblocked CD8+ T cell 
production.  Data represented as mean ± SD, n=3, *** p<0.001, two-way ANOVA (Tukey’s 
post-test). (B)  Representative histograms of expression of tEGFR (top panel) and CAR-L 
(bottom panel) on EL4 cells relative to cell lines negative for antigen. Density of EGFR 
expression was determined by quantitative flow cytometry. (C) Production of IFN-γ by gated 
CD8+ CAR+ T cells after co-culture with CD19+, tEGFR+, or CARL+ EL4 cells measured by 
intracellular staining and flow cytometry. Data represented as mean ± SD, n=4, ** p<0.01, 
two-way ANOVA (Tukey’s post-test).  (D) Phosphorylation of p38 and Erk1/2 by phosflow 
cytometry in gated CD8+ CAR+ T cells 30 minutes after co-culture with CD19+, EGFR+, or 
CARL+ EL4 cells.  Data represented as mean ± SD, n=2, * p<0.05, two-way ANOVA 
(Tukey’s post-test). (E)  Specific lysis of CD19+, EGFR+ and CARL+ EL4 cells measured by 
standard 4-hour chromium release assay. Data represented as mean ± SD, n=4, **** 
p<0.0001, two-way ANOVA (Tukey’s post-test). (F) Relative proportion of T cells to EL4 
cells in long term co-culture.   Fraction of co-culture containing T cells to EL4 cells measured 
by flow cytometry for human and murine CD3, respectively, with non-species cross reactive 
antibodies. Data represented as mean ± SD, n=4, ** p<0.01, two-way ANOVA (Tukey’s 
post-test). 
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no statistical difference in phosphorylation of Erk1/2 (p>0.05) or p38 (p>0.05) between 
Cetux-CAR+ and Nimo-CAR+ T cells in response to CAR-L+ EL4 (Figure 19D). While Cetux-
CAR+ T cells exhibited phosphorylation of Erk1/2 and p38 in response to tEGFR+ EL4, Nimo-
CAR+ T cells failed to appreciably phosphorylate either molecule.  Similarly, Cetux-CAR+ 
and Nimo-CAR+ T cells demonstrated equivalent specific lysis against CAR-L+ EL4 (10:1 
E:T ratio, Cetux-CAR = 64.5 ± 6.7%, Nimo-CAR = 57.5 ± 12.9%, mean ± SD, n=4)(p>0.05).  
While Cetux-CAR+ T cells demonstrated significant specific lysis in response to tEGFR+ EL4 
over non-specific lysis of irrelevant antigen expression on CD19+ EL4 (tEGFR+EL4 = 57.5 ± 
9.4%, tCD19+EL4 = 17.3 ± 13.0, mean ± SD, n=4) (p<0.0001), there was not significant lysis 
of tEGFR+ EL4 by Nimo-CAR+ T cells (tEGFR+EL4 = 21.2 ± 16.9%, CD19+EL4 = 12.3 ± 
13.0, mean ± SD, n=4) (p>0.05) (Figure 19E).  Endogenous, low-affinity T-cell responses 
may require longer interaction with antigen to achieve effector function (16), therefore, we 
evaluated the ability of CAR+ T cells to control growth of tEGFR+ and CAR-L+ EL4 cells in an 
extended co-culture. Cetux-CAR+ T cells and Nimo-CAR+ T cells controlled growth of CAR-
L+ EL4s equivalently (p>0.05), as demonstrated by low proportion of CAR-L+ EL4 cells in co-
culture after 5 days (Figure 19F).  Cetux-CAR+ T cells controlled growth of tEGFR+EL4, 
resulting in less than 10% of tEGFR+ EL4 in the co-culture after 5 days.  Nimo-CAR+ T cells 
were less capable of controlling tEGFR+ EL4 cell growth, resulting in tEGFR+ EL4 
accounting for 80% of the co-culture after 5 days, significantly more than co-culture with 
Cetux-CAR+T cells (p<0.01).  Therefore, reduced response by Nimo-CAR+ T cells to low 
tEGFR density on tEGFR+ EL4 is not likely due to insufficient time for activation.   In sum, 
these data demonstrate that Cetux-CAR+ and Nimo-CAR+ T cells have functional specificity 
for EGFR and can be equivalently activated by CAR-dependent, scFv-independent 
stimulation. Cetux-CAR+ T cells were capable of specific activation in response to low 
tEGFR density on tEGFR+ EL4; however, this density of EGFR expression was not sufficient 
for activation Nimo-CAR+ T cells to produce cytokine, phosphorylate downstream molecules 
Erk1/2 and p38, or initiate specific lysis. 
3.2.3 Activation and functional response of Nimo-CAR+ T cells is impacted by density of 
EGFR expression on target cells. 
To investigate the impact of EGFR expression density on activation of Cetux-CAR+ 
and Nimo-CAR+ T cells, we compared T-cell function against cell lines with a range of EGFR 
expression density:  NALM-6, U87, LN18, T98G, and A431.  First, we evaluated EGFR 
expression density by quantitative flow cytometry (Figure 20A).  NALM-6, a B-cell leukemia 
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cell line, expressed no EGFR.  U87, a human glioblastoma cell line, expressed EGFR at low 
density (~30,000 molecule/cell). LN18 and T98G, both human glioblastoma cell lines, 
expressed EGFR at intermediate density (~160,000 and ~205,000 molecules/cell, 
respectively), and A431 was found to expression EGFR at high density (~780,000 
molecules/cell), similar to previous reports (231).  Cetux-CAR+ and Nimo-CAR+ CD8+ T cells 
demonstrated statistically similar IFN-γ production in response to A431 with high EGFR 
density (p>0.05) and LN18 with intermediate EGFR density (p>0.05).  However, Nimo-CAR+ 
T cells demonstrated reduced IFN-γ production in response to T98G with intermediate 
EGFR density (p<0.001) and U87 with low EGFR density (p<0.001) relative to Cetux-CAR+ 
T cells (Figure 20B).  Similarly, while Cetux-CAR+ and Nimo-CAR+ T cells demonstrated 
statistically equivalent lysis of A431 cells (5:1 E:T ratio, p>0.05) and T98G cells (5:1 E:T 
ratio, p>0.05),  Nimo-CAR+ T cells demonstrated some reduced capacity for specific lysis of 
LN18 cells (5:1 E:T ratio, p<0.05) and reduced capacity for specific lysis of U87 cells (5:1 
E:T ratio, p< 0.01) (Figure 20C). These data support that activation of Nimo-CAR+ T cells is 
impacted by the density of EGFR expression.   
3.2.4 Activation of function of Nimo-CAR+ T cells is directly and positively correlated with 
EGFR expression density 
Evaluating function against EGFR density in the context of different cellular 
backgrounds is not ideal since different cell lines may have different propensity for T-cell 
activation and susceptibility to T-cell mediated lysis.  Therefore, to determine the impact of 
EGFR expression density on a syngeneic cellular background, we developed a series of 
U87 cell lines expressing varying densities of EGFR: unmodified, parental U87 (~30,000 
molecules of EGFR/cell), U87low (130,000 molecules of EGFR/cell), U87med (340,000 
molecules of EGFR/cell), and U87high (630,000 molecules of EGFR/cell) (Figure 21A).  To 
compare phosphorylation of Erk1/2 and p38 following scFv-dependent CAR stimulation, we 
ensured there was not a distinction in kinetics of phosphorylation between Nimo-CAR+ T 
cells and Cetux-CAR+ T cells following stimulation U87 and U87high.  Both CD8+CAR+ T cells 
demonstrated peak phosphorylation of Erk1/2 and p38 45 minutes after interaction and 
phosphorylation began to decrease by 120 minutes after interaction (Figure 21B).  There 
was no appreciable distinction in phosphorylation kinetics between Cetux-CAR+ T cells and 
Nimo-CAR+ T cells and future experiments assessed phosphorylation of Erk1/2 and p38 45 
minutes following interaction for all future experiments.  Cetux-CAR+ CD8+ T cells  
79 
 
 
Figure 20. Activation and functional response of Nimo CAR T cells is impacted by 
density of EGFR expression.  (A) Representative histograms of EGFR expression on 
A431, T98G, LN18, U87 and NALM-6 cell lines measured by flow cytometry.  Number of 
molecules per cell determined by quantitative flow cytometry. Data representative of three 
replicates.  (B) Production of IFN-γ by CD8+CAR+ T cells in response to co-culture with 
A431, T98G, LN18, U87 and NALM-6 cell lines measured by intracellular flow cytometry 
gated on CD8+ cells.  Data represented as mean ± SD, n=4, *** p<0.001, two-way ANOVA 
(Tukey’s post-test)  (C) Specific lysis of A431, T98G, LN18, U87 and NALM-6 by CAR+ T 
cells measured by standard 4 hour chromium release assay.  Data represented as mean ± 
SD, n=4, **** p<0.0001, ** p<0.01, * p<0.05, two-way ANOVA (Tukey’s post-test). 
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Figure 21. Activation of function of Nimo-CAR+ T cells is directly and positively 
correlated with EGFR expression density. (A) Representative histogram of EGFR 
expression on series of four U87-derived tumor cell lines (U87, U87low, U87med, and U87high) 
measured by flow cytometry.  Number of molecules per cell determined quantitative flow 
cytometry. Data representative of triplicate experiments.  (B) Phosphorylation of Erk1/2 and 
p38 in gated CD8+ T cells following co-culture with U87 or U87high for 5, 45, and 120 minutes 
measured by phosflow cytometry. Data represented as mean fluorescence intensity ± SD, 
n=2. (C) Phosphorylation of Erk1/2 and p38 MAP kinase family members in gated CD8+ T 
cells after 45 minutes of co-culture with U87 cell lines with increasing levels of EGFR 
measured by phosflow cytometry.  Data represented as mean fluorescence intensity ± SD, 
n=4, **** p<0.0001, *** p<0.001, ** p<0.01, two-way ANOVA (Tukey’s post-test). (D)  
Production of IFN-γ and TNF-α  by gated CD8+ CAR+ T cells in response to co-culture with 
U87 cell lines with increasing levels of EGFR measured by intracellular staining and flow 
cytometry. Data represented as mean ± SD, n=4, **** p<0.0001, *** p<0.001, ** p<0.01, two-
way ANOVA (Tukey’s post-test). (E) Specific lysis of U87 cell lines with increasing density of 
EGFR by CAR+ T cells measured by standard 4-hour chromium release assay. Data 
represented as mean ± SD, n=5, **** p<0.0001, ** p<0.01, * p<0.05, two-way ANOVA 
(Tukey’s post-test). 
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phosphorylated Erk1/2 and p38 in response to all four U87 cell lines and showed no 
correlation with density of EGFR expression (one-way ANOVA with post-test for linear trend; 
Erk1/2, p=0.88; p38, p=0.09) (Figure 21C).  In contrast, phosphorylation of Erk1/2 and p38 
by Nimo-CAR+ CD8+ T cells directly correlated with EGFR expression density (one-way 
ANOVA with post-test for linear trend; Erk1/2, p = 0.0030 and p38, p=0.0044). We noted 
that Nimo-CAR+ T cells demonstrated significantly less phosphorylation of Erk1/2 and p38 
than Cetux-CAR+ T cells, even in response to high EGFR density on U87high (Erk1/2, 
p<0.0001; p38, p<0.01).  Similarly, production of IFN-γ and TNF-α by Cetux-CAR+ CD8+ T 
cells in response to U87, U87low, U87med and U87high did not correlate with EGFR density on 
target cells (one-way ANOVA with post-test for linear trend; IFN-γ, p=0.5703 and TNF-α,  
p=0.6189) (Figure 21D).  In contrast, Nimo-CAR+ CD8+ T cells produced IFN-γ and TNF-α in 
direct correlation with EGFR expression density (one-way ANOVA with post-test for linear 
trend; IFN-γ, p=0.0124 and TNF-α, p=0.0006).  Cetux-CAR+ CD8+ T cells produced 
significantly more cytokine than Nimo-CAR+ CD8+ T cells in response to stimulation with 
U87 (IFN-γ, p<0.0001; TNFα, p<0.01) or U87low (IFN-γ, p<0.001; TNFα, p<0.01),  however, 
Cetux-CAR+ T cells and Nimo-CAR+ T cells demonstrated statistically similar cytokine 
production in response to stimulation  with U87med (IFN-γ, p>0.05; TNFα, p>0.05) or U87high 
(IFN-γ, p>0.05; TNFα, p>0.05).  Likewise, Cetux-CAR+ T cells demonstrated significantly 
more lysis of U87 (10:1 E:T ratio, p<0.0001) and U87low (10:1 E:T ratio, p<0.05) than Nimo-
CAR+ T cells, but statistically similar lysis of U87med (10:1 E:T ratio, p>0.05) and U87high 
(10:1 E:T ratio, p>0.05) (Figure 21E).  In sum, these data show that activation of Nimo-
CAR+ T cells is directly correlated to EGFR expression density on target.  As a result, Cetux-
CAR+ and Nimo-CAR+ T cells demonstrate equivalent T-cell activity in response to high 
EGFR density, but Nimo-CAR+ T cells demonstrate significantly reduced activity in response 
to low EGFR density.  
Because endogenous, low-affinity T-cell responses may require longer interaction 
with antigen to acquire effector function (16), we verified that the observed differences in T-
cell activity between Cetux-CAR+ T cells and Nimo-CAR+ T cells was not due to a similar 
requirement for Nimo-CAR+ T cells.  Extending interaction of CAR+ T cells with targets did 
not substantially increase cytokine production and did not alter the relationship of cytokine 
production between Cetux-CAR+ and Nimo-CAR+ CD8+ T cells (Figure 22A).  Similarly, we 
evaluated the ability of Cetux-CAR+ and Nimo-CAR+ T cells to control growth of U87 and 
U87high over time and found that Cetux-CAR+ and Nimo-CAR+ T cells demonstrated 
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statistically similar ability to control the growth of U87high, resulting in 80% reduction in cell 
number relative to controls grown in the absence of CAR+ T cells (p>0.05). Cetux-CAR+ T 
cells controlled growth of U87 with endogenously low EGFR expression, resulting in 40% 
reduction in cell number relative to controls grown in the absence of CAR+ T cells.  However, 
Nimo-CAR+ T cells demonstrated significantly less control of U87 growth, with no apparent 
reduction in cell number (p<0.001) (Figure 22B).  These data indicate that Nimo-CAR+ T-
cell activity in response to low EGFR on U87 is not improved by increasing interaction time 
of T cells with targets, making it unlikely that reduced activity of Nimo-CAR+ T cells is due to 
a requirement for prolonged interaction to activate T cells.  
Expression of CAR above a minimum density is required for CAR-dependent T-cell 
activation, and increasing density of CAR expression has been shown to impact sensitivity 
of CAR to antigen (123, 124). Therefore, to determine if expressing Nimo-CAR with higher 
density improves recognition of low EGFR density, we sought to overexpress Cetux-CAR 
and Nimo-CAR in human primary T cells.  Load of DNA in electroporation transfection is 
limited due to toxicity of DNA to cells; however, transfer of RNA is relatively non-toxic and 
more amenable to overexpression by increasing amount of CAR RNA transcript delivered.  
Therefore, we in vitro transcribed Cetux-CAR and Nimo-CAR as RNA species and electro-
transferred into human primary T cells.  RNA transfer resulted in 2-5 fold increased 
expression of CAR when compared to donor-matched DNA-modified T cells (Figure 23A).  
Overexpression of CAR did not render Nimo-CAR+ T cells more sensitive to low EGFR 
density on U87 and both Cetux-CAR and Nimo-CAR demonstrated similar cytokine 
production in response to U87high (Figure 23B).  Thus, increasing CAR density on Nimo-
CAR+ T cells does not restore sensitivity to low EGFR density.  
3.2.5 Nimo-CAR+ T cells have reduced activity in response to basal EGFR levels on normal 
renal epithelial cells 
To determine if Nimo-CAR+ T cells have reduced activation in response to low, basal 
EGFR density on normal cells, we evaluated activity of Nimo-CAR+ T cells in response to 
normal human renal cortical epithelial cells, HRCE.  HRCE express ~15,000 molecules of 
EGFR per cell, lower than expression on EGFR+ tumor cell lines, including U87 (Figure 
24A).  While Cetux-CAR+ T cells produced IFN-γ and TNF-α in response to HRCE, Nimo-
CAR+ T cells produced significantly less IFN-γ or TNF-α in response to HRCE (IFN-γ, 
p<0.05; TNF-α, p<0.01) (Figure 24B).  In fact, Nimo-CAR+ T cells did not demonstrate  
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Figure 22. Increasing interaction time does not restore Nimo-CAR+ T-cell function in 
response to low EGFR density. (A) Production of IFN-γ was measured by intracellular 
staining and flow cytometry following stimulation with U87 or U87high over time in CD8+ gated 
cells.  Data represented as mean ± SD, n=3. (B) Fraction of U87 and U87high cells remaining 
after co-culture with Cetux-CAR+ or Nimo-CAR+ T cells. U87 cell lines were co-cultured with 
CAR+ T cells at an E:T ratio of 1:5 in triplicate. Suspension T cells were separated from 
adherent target cells, and adherent fraction was counted by trypan blue exclusion.  Percent 
surviving was calculated as [cell number harvested after co-culture]/[cell number without T 
cells]*100. Data represented as mean ± SD, n=3, *** p<0.001, two-way ANOVA (Tukey’s 
post-test). 
 
 
 
 
 
 
 
 
85 
 
 
Figure 23. Increasing CAR density on T-cell surface does not restore sensitivity of 
Nimo-CAR+ T cells to low density EGFR. A) Representative histograms of CAR 
expression in T cells modified by RNA transfer and traditional DNA electroporation via SB 
system.  Data representative of 2 independent experiments.  B)  Production of IFN-γ in T 
cells overexpressing CAR by RNA electro-transfer in response to low and high antigen 
density.  Production of IFN-γ was measured by intracellular flow cytometry in CD8+ gated 
cells following stimulation with U87 or U87high target cells.  Data represented as mean ± SD, 
n=2.   
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Figure 24. Nimo-CAR+ T cells have less activity in response to basal EGFR levels on 
normal renal epithelial cells than Cetux-CAR+ T cells. (A) Representative histogram of 
expression of EGFR on HRCE measured by flow cytometry. Number of molecules per cell 
determined by quantitative flow cytometry. Data representative of three replicates. (B) 
Production of IFN-γ and TNF-α by CD8+ CAR+ T cells after co-culture with HRCE measured 
by intracellular staining and flow cytometry gated on CD8+ cells. Data represented as mean 
± SD, n=4, ** p<0.01, * p<0.05, two-way ANOVA (Tukey’s post-test). (C) Specific lysis of 
HRCE by CAR+ T cells measured by standard 4-hour chromium release assay. Data 
represented as mean ± SD, n=3, **** p<0.0001, *** p<0.001, two-way ANOVA (Tukey’s 
post-test). 
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significant production of IFN-γ or TNF-α above background production without stimulation 
(IFN-γ, p>0.05; TNF-α, p>0.05). Nimo-CAR+ T cells displayed less than 50% of the specific 
lysis executed by Cetux-CAR+ T cells in response to HRCE (Cetux-CAR = 81.1 ± 4.5%, 
Nimo-CAR = 30.4 ± 16.7%, mean ± SD, n=3), which was significantly less (10:1 E:T ratio, 
p<0.001) (Figure 24C). These findings indicate that Nimo-CAR+ T cells have reduced T-cell 
function in response to cells with very low EGFR density compared to Cetux-CAR+ T cells. 
3.2.6 Cetux-CAR+ T cells proliferate less following stimulation than Nimo-CAR+ T cells, but 
do not have increased propensity for activation induced cell death (AICD) 
Strength of endogenous TCR signal, impacted by affinity of binding and antigen 
density, can influence proliferation of T cells in response to antigenic stimulus (60, 61).  To 
evaluate proliferative response of Cetux-CAR+ T cells and Nimo-CAR+ T cells following 
stimulation with antigen, we measured intracellular expression of Ki-67 by flow cytometry 
after two days of co-culture with U87 or U87high in absence of exogenous cytokines. In 
response to low EGFR density on U87, Cetux-CAR+ and Nimo-CAR+ T cells demonstrated 
statistically similar proliferation (p>0.05) (Figure 25A). In response to U87high, Nimo-CAR+ T 
cells demonstrated increased proliferation over Cetux-CAR+ (p<0.01), which did not show 
any statistical difference in proliferation in response to U87 and U87high (p>0.05).   
To determine if affinity of CAR or antigen density increases the propensity of CAR+ T cells to 
undergo AICD, we co-cultured Cetux-CAR+ and Nimo-CAR+ T cells with U87 or U87high in 
the absence of exogenous cytokines and evaluated T-cell viability by annexin V and 7-AAD 
staining. In response to U87, Cetux-CAR+ T showed reduction in viability compared to 
unstimulated Cetux-CAR+ T cells,  however, Nimo-CAR+ T cells did not show any 
appreciable change in viability (Figure 25B).   In response to U87high, Cetux-CAR+ and 
Nimo-CAR+ T cells demonstrated statistically similar reduction in viability relative to 
unstimulated CAR+ T cells (p>0.05).  We noted that Cetux-CAR+ T cells stimulated with 
U87high did not show any statistical difference in viability relative to Cetux-CAR+ T cells 
stimulate with U87 (p>0.05).  These data suggest that antigen density impact induction of 
AICD for Nimo-CAR+ T cells, but not Cetux-CAR+ T cells, supporting previous data that 
activity of Nimo-CAR is dependent on antigen density. However, in response to high antigen 
density that is capable of Cetux-CAR+ T cells and Nimo-CAR+ T-cell activation, affinity of 
scFv domain of CAR does not appear to impact the induction of AICD.  
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Figure 25. Cetux-CAR+ T cells proliferate less following stimulation than Nimo-CAR+ T 
cells, but do not have increased propensity for AICD. (A) Proliferation of CD8+ CAR+ T 
cells after stimulation with U87 or U87high measured by intracellular flow cytometry for Ki-67 
gated on CD8+ cells. Data represented as mean fluorescence intensity ± SD, n=4, ** p<0.01, 
two-way ANOVA (Tukey’s post-test). (B) Viability of T cells after stimulation with U87 or 
U87high measured by flow cytometry for Annexin V and 7-AAD gated on CD8+ cells. Percent 
live cells determined by percent Annevin Vneg 7-AADneg.  Data represented as mean ± SD, 
n=4, *** p<0.001, two-way ANOVA (Tukey’s post-test). 
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3.2.7 Cetux-CAR+ T cells demonstrate enhanced downregulation of CAR 
Endogenous TCR can be downregulated following interaction with antigen, and the degree 
of downregulation is influenced by the strength of TCR binding (20).  Similarly, CAR can be 
downregulated following interaction with antigen, but the effect of affinity on CAR 
downregulation is unknown (117, 122).  Therefore, we sought to determine if Cetux-CAR+ T 
cells have a higher propensity for antigen-induced downregulation.   To accomplish this, we 
co-cultured Cetux-CAR+ T cells and Nimo-CAR+ T cells with U87 or U87high and monitored 
CAR expression relative to unstimulated controls.  In response to low EGFR density on U87, 
Cetux-CAR expression was significantly less than Nimo-CAR following 12 hours of 
interaction (Cetux-CAR = 68.0 ± 27.8%, Nimo-CAR = 126.5 ± 34.9%, mean ± SD, n=3) 
(p<0.05) (Figure 26A, left panel). By 48 hours of interaction with low density EGFR, Cetux-
CAR returned to the T-cell surface, and Cetux-CAR and Nimo-CAR were expressed in a 
statistically similar proportion of T cells (Cetux-CAR = 95.5 ± 40.7, Nimo-CAR = 94.4 ± 
11.8%, mean ± SD, n=3) (p>0.05). In response to high EGFR density on U87high, expression 
of Cetux-CAR was significantly reduced relative to Nimo-CAR, which showed no appreciable 
downregulation after 12 hours of interaction (Cetux-CAR = 37.4 ± 11.5%, Nimo-CAR= 124.4 
±1 5.3%, mean ± SD, n=3) (p<0.01) (12 hrs, p<0.01; 24 hrs, p<0.01; 48 hrs, p<0.05) (Figure 
26A, right panel). However, in contrast to stimulation with low EGFR density, Cetux-CAR did 
not recover surface expression after 48 hours of interaction and remained reduced relative 
to Nimo-CAR expression (Cetux-CAR = 42.6 ± 5.9%, Nimo-CAR = 95.7 ± 11.6%, mean ± 
SD, n=3)(p<0.05). Cetux-CAR and Nimo-CAR were both detected intracellularly following 
stimulation, even when Cetux-CAR was reduced from the T-cell surface, signifying that 
reduced CAR expression was due to internalization of CAR and not outgrowth of genetically 
unmodified T cells (Figure 26B). In response to CAR-dependent, scFv-independent 
stimulation by CAR-L+ EL4, Cetux-CAR and Nimo-CAR showed mild and statistically similar 
downregulation of ~20% (Figure 26C). Similar to previous results, Cetux-CAR showed slight 
downregulation in response to tEGFR+ EL4, whereas Nimo-CAR showed no appreciable 
downregulation. In sum, these data show that Cetux-CAR demonstrates rapid and 
prolonged downregulation relative to Nimo-CAR that is dependent on interaction of the scFv 
domain of CAR with antigen and antigen density.   
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Figure 26. Cetux-CAR+ T cells demonstrate enhanced downregulation of CAR. (A) 
Surface expression of CAR during co-culture (E:T 1:5)  with U87 or U87high measured by 
flow cytometry for IgG portion of CAR.  Percent CAR remaining calculated as [%CAR+ in co-
culture] / [%CAR+ in unstimulated culture] x 100. Data represented as mean ± SD, n=3, ** 
p<0.01. * p<0.05, two-way ANOVA (Tukey’s post-test) (B) Representative histograms of 
Intracellular and surface expression of CAR determined by flow cytometry after 24 hours of 
co-culture with U87 or U87high in CD8+ gated T cells. Data representative of three 
independent donors. (C) Surface expression of CAR during co-culture (E:T 1:1)  with EGFR+ 
EL4 or CAR-L+ EL4 measured by flow cytometry for Fc portion of CAR.  Percent CAR 
remaining calculated as [%CAR+ in co-culture] / [%CAR+ in unstimulated culture] x 100. Data 
represented as mean, n=2, * p<0.05, two-way ANOVA (Tukey’s post-test). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
92 
 
3.2.8 Cetux-CAR+ T cells have reduced response to re-challenge with antigen 
Strength of prior stimulus in endogenous CD8+ T cell responses can be correlated 
with T-cell response upon re-challenge with antigen (287). Therefore, we evaluated the 
ability of Cetux-CAR+ and Nimo-CAR+ T cells to respond to antigen re-challenge. CAR+ T 
cells were co-cultured with U87 or U87high for 24 hours, then harvested and re-challenged 
with U87 or U87high to assess production of IFN-γ. Following initial challenge with U87 and 
U87high, Cetux-CAR+ T cells had reduced production of IFN-γ in response to rechallenge with 
both U87 and U87high (Figure 27) However, after initial challenge with U87 or U87high, Nimo-
CAR+ T cells retained IFN-γ production in response to re-challenge with U87 and U87high.  
As a result, Nimo-CAR+ T cells demonstrated statistically similar IFN-γ production in 
response to U87 (p>0.05) and statistically more IFN-γ in response to rechallenge with 
U87high (initial challenge with U87, p<0.001; initial challenge with U87high p<0.01).  This is in 
contrast to IFN-γ production in response to initial challenge, in which Nimo-CAR+ T cells 
produce less IFN-γ in response to U87(p<0.05)  and demonstrate statistically similar IFN-γ 
production in response to U87high (p>0.05).  Thus, while Nimo-CAR+ T cells retain their ability 
to recognize and respond to antigen, Cetux-CAR+ T cells have reduced capacity to respond 
to subsequent encounter with antigen, which is likely to be at least partially due to 
downregulation of CAR and may indicate increased propensity for functional exhaustion of 
Cetux-CAR T+ cells after initial antigen exposure. 
3.3   Discussion 
Recent clinical success in patients with CLL and ALL note persistent B-cell in 
patients with complete tumor response to CD19-CAR+ T-cell therapy, but this toxicity is 
considered tolerable as CD19 is a lineage-restricted antigen and B cell aplasia is considered 
a tolerable toxicity in the setting of advanced lymphoma (111, 112).  Serious adverse events 
in clinical trials targeting HER2 and CAIX with CAR-modified T cells  makes obvious the 
need to control CAR+ T-cell activity against normal tissue antigen expression in order to 
broaden the range of safely targetable antigens beyond lineage and tumor restricted 
antigens (140, 143).  Aberrantly expressed TAAs are often overexpressed on tumor relative 
to normal tissue, such as EGFR expression in glioblastoma (180, 182, 199).  We sought to 
develop a CAR specific to EGFR with reduced capacity to respond to low antigen density to 
minimize the potential for normal tissue, while maintaining adequate effector function in 
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Figure 27. Cetux-CAR+ T cells have reduced response to re-challenge with antigen. 
After 24-hours of incubation with U87 or U87high, CAR+ T cells were rechallenged with U87 
or U87high and production of IFN-γ CAR+ T cells measured by intracellular staining and flow 
cytometry gated on CD8+ cells.  Data represented as mean ± SD, n=3, *** p<0.001, ** 
p<0.01, * p<0.05, two-way ANOVA (Tukey’s post-test). 
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response to high antigen density.  This was accomplished by developing an EGFR-specific 
CAR from nimotuzumab, a monoclonal antibody with a highly-overlapping epitope with 
cetuximab, yet reduced binding kinetics (223, 231).  While Cetux-CAR+ T cells are capable 
of targeting low and high EGFR density, Nimo-CAR+ T cells are able to tune T-cell activity to 
antigen density and T-cell response is dependent on EGFR density on target cells. While 
Nimo-CAR+ T cells demonstrate reduced activity relative to Cetux-CAR+ T cells in response 
to low EGFR density on tumor cells and normal renal cells, they are capable of equivalent 
redirected specificity and function in response to high EGFR density.  We observed that 
CAR affinity influenced proliferation after antigen challenge, Cetux-CAR+ T cells 
demonstrated impaired proliferation when compared with Nimo-CAR+ T cells after antigen 
challenge, but no increased propensity for AICD.  Additionally, we observed that CAR 
affinity influences downregulation of CAR from T-cell surface after interaction with antigen. 
Cetux-CAR exhibited rapid and prolonged downregulation from the cell surface after 
interaction with high EGFR density, whereas Nimo-CAR did not appreciably downregulate 
from T-cell surface. Cetux-CAR+ T cells had impaired ability to respond to re-challenge with 
antigen, which is likely due, at least in part, to downregulation of CAR, and may indicate 
functional exhaustion of Cetux-CAR+ T cells (122, 287).   
Complications in delineating the impact of scFv affinity on CAR-mediated T-cell 
function stem from considerable debate surrounding the biochemical parameter of 
endogenous TCR binding pepMHC that best predicts T-cell function.  The kinetics of TCR 
binding can be described by the equation:  
𝐾𝑑= 𝑘𝑜𝑓𝑓𝑘𝑜𝑛  
such that the dissociation constant, Kd, is equal to the ratio of the rate of dissociation (koff) 
and the rate of association, (kon) (14). Both the dissociation constant (Kd) and the 
dissociation rate (koff) have been reported as important determinants of T-cell function 
following TCR recognition of pepMHC, however these two parameters are often strongly 
correlated, so it is difficult to separate their respective impact on T-cell function (15, 22, 23). 
The kinetic proofreading model of T-cell triggering states that koff impact T-cell function, such 
that sufficiently long dwell time is required to trigger T-cell signaling and activation.  This has 
been amended to include a window of optimal dwell time, in which prolonged dwell time may 
be detrimental to T-cell activation by impairing the ability of serial triggering of multiple TCR 
by a single pepMHC complex (27).  However, these models are contradicted by reports of 
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very short dwell time interactions capable of producing functional T-cell responses (25, 26, 
34, 60).  Recent analysis aiming to reduce previous dataset bias by reducing the high 
degree of correlation between Kd and koff values and expanding dynamic range of kon values 
uncovered an important role in contribution of kon to T-cell activation, encompassed in a T-
cell confinement model of T-cell triggering, in which T-cell function is directly correlated with 
the duration of T-cell confinement derived from a mathematical relationship between rate of 
association, rate of dissociation, and diffusion of TCR and pepMHC in their relative 
membranes (25, 34).  Interestingly, as kon becomes low, TCR and pepMHC are able to 
diffuse in their relative membranes before rebinding, thus the duration of interaction reduces 
to the koff value.  In contrast, as kon becomes high, the TCR is capable of rapid rebinding to 
extend the dwell time, and the duration of interaction and resulting T-cell function is best 
predicted by Kd.  This ongoing debate to define role of TCR affinity components that control 
T-cell functional avidity cautions against universal models relying on one biochemical 
parameter of binding as a superior indicator of function over others. Instead, it is likely a 
combination of rates of association and dissociation as well as density of antigen freely 
moving through target cell membrane that defines functional response. 
Endogenous TCR responses are generally described as much lower affinity than the 
binding of monoclonal antibodies, which are used to derive CARs (14). However, SPR 
techniques used to measure TCR binding affinity measure are typically performed in three 
dimensions, and do not recapitulate physiological interaction of a T cells with an antigen 
presenting cell, in which both binding partners are constrained in their respective 
membranes, increasing the probability of binding due to constrained intercellular space and 
proper molecule orientation (38).  Measurement of TCR binding kinetics in 2D suggests that 
TCR binding is of higher affinity than suggested by 3D measurements characterized by 
increased rates of association and decreased rates of dissociation (37, 39).  However, 
binding kinetics of other ligand/receptor pairs, such as ICAM-1 or LFA-1 did not show a 
difference between affinity measurements taken in 3D or 2D assays.  Interestingly, ablation 
of cytoskeletal polymerization reduces measurements made in 2D to measurements to 
those made in 3D, highlighting the role of dynamic cellular and cytoskeletal processes in 
enhancing T-cell binding to antigen (39). Whether similar cytoskeletal interactions or 
enhancement of binding affinity of CAR occurs is currently unknown, and therefore, it is 
unclear if assumptions made about binding affinity of the scFv domain of CAR can be 
directly made from measurements of monoclonal antibody affinity in 3D assays. In addition, 
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several factors contribute to enhance overall T-cell binding avidity, such as co-receptor 
binding to MHC and TCR nanocluster and microcluster formation on the T-cell surface prior 
to and following T-cell activation (31, 40-42, 47). While it appears that CARs can be 
expressed in oligomeric form on the T cell surface, the degree of involvement of CAR with 
endogenous T cell signaling complexes in unclear. Reports of first generation CARs, 
signaling through only CD3-ζ demonstrate a requirement for association with endogenous 
CD3-ζ to achieve CAR-dependent T cell activation; however, second generation CARs 
signaling through transmembrane CD28 and intracellular CD28 and CD3-ζ demonstrate no 
difference in CAR-dependent activation ability when endogenous TCR-CD3 complexes are 
restricted from the T cell surface (125, 127). Therefore, the association of CAR with 
endogenous TCR signaling machinery may be dependent on CAR configuration. In sum, the 
contribution of dynamic cellular processes that occur during endogenous TCR activation to 
CAR-dependent T-cell activation requires further investigation. However, due to the 
contribution of these processes to enhancing avidity of T-cell interaction with antigen, the 
difference between CAR and TCR binding affinities may not be as disparate as initially 
thought. 
Specific studies addressing the role of scFv affinity in CAR design are limited, and 
focus on contribution of the dissociation constant, Kd.  Recent studies with ROR1-specific 
CAR compared a with 6-fold lower Kd, thus higher affinity, resulting from both increased kon 
and decreased koff and demonstrated that higher affinity ROR-1 specific CAR increased T-
cell function in vitro, including production of cytokines  and specific lysis, without increased 
propensity for AICD (119). Additionally, high affinity ROR-1-specific CAR+ T cells mediated 
superior anti-tumor activity in vivo. Similarly, we found the higher affinity of Cetux-CAR+ T 
cells did not increase propensity for AICD, and had increased T-cell function, including 
production of cytokines and specific lysis, in response to reduced EGFR density.  However, 
a previous study of a series of CARs derived from a panel of affinity-matured HER2-specific 
monoclonal antibodies with a wide range of Kd values, found that an affinity threshold 
existed, below which CAR-dependent T-cell activation was impaired; however, above this 
threshold, activation of T cells in response to various levels of HER2 did not improve with 
increased affinity (120). In contrast, the present study identified different ability of high 
affinity CAR and low affinity CAR to target based on antigen density. Higher affinity Cetux-
CAR+ T cells were associated with increased cytokine production and specific lysis in 
response to reduced EGFR density relative to Nimo-CAR+ T cells. While, Nimo-CAR is lower 
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affinity relative to Cetux-CAR, the Kd value of Nimo-CAR is above the affinity threshold and 
within the range predicted to have effector function by the previous study.  Similar to studies 
with endogenous TCRs, these results indicate that descriptions of CAR affinity should not be 
described solely by the dissociation constant, and support that relationship between 
individual dissociation and association rates be taken into consideration for CAR design.  
The contradictions between the influence of affinity on CAR function between studies 
may be explained by the distinct relationships of the biochemical parameters koff and kon that 
constitute the dissociation constant Kd. The HER2-specific CARs were derived from 
antibodies that displayed a wide range of Kd values differing primarily in koff, with minimal 
correlation of kon values (120).  Thus, higher affinity interactions did not have increased rates 
of association, but increased duration of interaction with antigen. In contrast, the higher 
affinity of the ROR-1-specific CAR and Cetux-CAR were both influenced by increased 
association rates of binding.  The higher affinity monoclonal antibody used to derive the 
ROR-1-specific CAR had a 6-fold lower Kd, from contributions of both increased kon and 
decreased koff, such that the higher affinity was characterized by both increased association 
rates and increased duration of interaction (119).  The 10-fold difference in Kd between 
cetuximab and nimotuzumab is primarily impacted by a 59-fold increase in the kon and a 5.3-
fold increase in the koff of cetuximab, such that cetuximab has greatly enhanced rate of 
association relative to nimotuzumab, but in contrast to most higher affinity interactions, a 
shorter duration of interaction (223). Therefore, altering association rate rather than the 
dissociation rate of scFv domain in CAR design may have a greater impact on CAR-
mediated T-cell function. 
Nimotuzumab with combination radiotherapy has been evaluated in clinical trial for 
the treatment of head and neck squamous cell carcinoma and high grade glioma and has 
demonstrated significant survival benefit for both malignancies (227, 288-290). Clinical trials 
have noted the absence of grade III/IV acneiform rash that is common in treatment with 
cetuximab, despite strongly overlapping epitopes of nimotuzumab and cetuximab and 
similar mechanisms of action (223, 228).  In vitro studies have demonstrated that while 
cetuximab can bind any density of EGFR expression, nimotuzumab bindings directly 
correlates with EGFR density and at the highest EGFR density tested, nimotuzumab was 
able to bind EGFR with similar efficiency as cetuximab (231). Interestingly, when dissociated 
into monovalent fragments, cetuximab maintains ability to bind EGFR independent of 
expression density, but nimotuzumab binding to EGFR is completely abrogated. This 
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indicates that nimotuzumab has a requirement for bivalent recognition of antigen not present 
for cetuximab and attributed to the lower affinity of nimotuzumab.  Thus, the low rate of 
association of nimotuzumab enforces a requirement for bivalent binding of EGFR that may 
be responsible for decreased sensitivity to low EGFR density. 
While it appears the lower association rate of nimotuzumab relative to cetuximab 
may account for the reduced activity of Nimo-CAR in response to low density EGFR, it is 
possible that dissociation rate of nimotuzumab binding also plays a role. With all other things 
being equal, a lower dissociation rate (koff) and therefore increased duration of interaction is 
typically associated with higher affinity interactions. In the case of cetuximab and 
nimotuzumab, however, the much lower association rate (kon) overshadows the slightly 
lower dissociation rate of nimotuzumab, resulting in dissociation constant (Kd) that describes 
nimotuzumab as a lower affinity antibody, even though it has a longer duration of interaction.  
The kon value is sufficiently low that rapid rebinding is not likely to occur to amplify T cell 
signal. Thus, according to the T-cell confinement model of T-cell triggering (34), a sufficiently 
long duration of interaction from low koff may be necessary in the setting of low kon for CAR+ 
T cells to adequately initiate and sustain signaling cascades for T-cell activation. Therefore, 
it is unclear that this time which biochemical parameters are responsible for the ability of 
nimotuzumab to discriminate based on tissue antigen density. Future work, including 
mutation of the scFvs of nimotuzumab and cetuximab to alter kon and koff, may elucidate 
whether a single biochemical parameter or a more complex interaction of multiple 
biochemical parameters of binding can account for reduced ability to bind low density 
EGFR.  Determining the precise biochemical parameter or relationship between biochemical 
parameters that imparts the ability of nimotuzumab to discriminate between low and high 
EGFR density may aid in identification of other monoclonal antibodies with potential to 
discriminate between high and low antigen density to apply this CAR design strategy to 
other TAAs. 
Previous studies have established that a minimum CAR density is required for T-cell 
activation, below which T-cell activation is abrogated (122). However, sufficiently high 
antigen expression can mitigate this requirement and achieve CAR-dependent T-cell 
activation when CAR is expressed at low density (117, 122, 123). The interplay between 
CAR expression density, antigen density and CAR affinity and impact on CAR+ T cell 
function were evaluated in a study using high and low affinity HER2-specific CARs. This 
study reported that reduced T-cell function of T cells with low CAR density in response to 
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low antigen density was only apparent when T cells expressed a higher affinity HER2-
specific CAR (124).  However, when CAR was expressed at higher density, CAR-mediated 
cytotoxicity was irrespective of affinity or antigen density.  The authors attributed the 
reduced response of high affinity CAR when expressed low density to low HER2 density to a 
failure to induce serial triggering.  Although it has been reported that CARs to do not serially 
trigger as endogenous TCRs do (122), it is possible that this is specific to individual CARs, 
and that different transmembrane regions, endodomains, and scFv affinity may impact 
ability to serially trigger.  We did not observe any defect in Cetux-CAR+ T cells in initial 
response to low antigen density, however, the level of CAR expression culled out through 
repetitive stimulation on EGFR+ aAPC may select for an optimum CAR density, with T cells 
expressing suboptimal levels of CAR failing to expand and thus falling out of the repertoire.  
Our findings suggest that the lower affinity Nimo-CAR+ T cells demonstrate reduced 
sensitivity to low antigen expression, but increasing density of Nimo-CAR did not restore 
Nimo-CAR+ T cell sensitivity to low antigen, thus it is likely controlled by a different 
mechanism. Although expression CAR at low density can reduce sensitivity to antigen, this 
is not likely to be an optimal strategy selectively target high antigen density in vivo, primarily 
because CAR expressed at low density demonstrate reduced sensitivity to all levels of 
antigen, and therefore the potential for reduced anti-tumor activity (122, 123).  Additionally, 
CAR downregulates from the T-cell surface at a constant number of CAR molecules per 
antigen molecule (122). Thus, T cells expressing CAR at lower density are more susceptible 
to downregulation below the minimum density to achieve T-cell activation. 
T-cell function can be influenced by antigen quality, dictated by the affinity of the 
interaction, and antigen quantity, or the density of antigen expression (17).  While increasing 
quantity of low affinity antigen can increase T-cell proliferation, it does not restore IL-2 
production, highlighting the distinct regulation of T-cell responses by quality and quantity of 
signal (60). Distinction between quality and quantity of signaling between Cetux-CAR and 
Nimo-CAR is evident by reduced phosphorylation of Erk1/2 and p38, enhanced proliferation, 
and reduced CAR downregulation of Nimo-CAR+ T cells in response to high EGFR density, 
in spite of comparable functional responses.  Efficient phosphorylation by CAR-L+ EL4 cells 
indicates that Nimo-CAR+ T cells have equivalent capacity for phosphorylation as Cetux-
CAR+ T cells when triggering in a CAR-dependent but scFv-independent manner.  
Endogenous, low-affinity TCRs can accumulate signal through transient and undetectable 
phosphorylation intermediates to culminate in functional T-cell responses (60). This may be 
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an explanation for functional response of Nimo-CAR+ T cells even when phosphorylation of 
Erk1/2 and p38 is lacking.   
Superior proliferation of Nimo-CAR+ T cells over Cetux-CAR+ T cells in response to 
high EGFR density in the absence of exogenous cytokine support may be due to reduced 
stimulation to Cetux-CAR+ T cells following CAR downregulation, or may indicate functional 
exhaustion of Cetux-CAR+ T cells.  In endogenous T-cell responses, downregulation of TCR 
is enhanced in response to strong stimulation as a mechanism to regulated T-cell 
responses. Thus, reduced expression of Cetux-CAR may be responsible for reduced 
proliferation of Cetux-CAR+ T cells.  Although cell surface markers for differentiation and 
exhaustion showed no difference between Cetux-CAR+ T cells and Nimo-CAR+ T cells, it is 
possible that reiterative stimulation with aAPC through Cetux-CAR with higher affinity could 
drive a more exhausted or anergic phenotype.  Future studies to profile expression of gene 
transcripts important in T-cell biology will determine potential differences in Cetux-CAR+ and 
Nimo-CAR+ T cell phenotype throughout ex vivo culture.   
Cetux-CAR+ T cells were less capable of responding to re-challenge with antigen, 
which may be a result of downregulated CAR expression following antigen exposure or 
functional exhaustion. A similar finding was reported in studies with CD22-specific CAR, in 
which downregulation of CAR was correlated with antigen density, and impaired T-cell 
activity in response to antigen re-challenge (122).  However, impairment of lytic activity was 
noted at antigen densities that induced minimal CAR downregulation, therefore, the authors 
concluded that both CAR downregulation and functional impairment after antigenic exposure 
contributed to impairment of T-cell response to antigen re-challenge. Whether due to 
reduced CAR expression or functional exhaustion, reduced response of Cetux-CAR+ T cells 
to re-challenge with antigen may indicate reduced ability of Cetux-CAR+ T cells serially kill 
tumor cells, resulting in potentially reduced anti-tumor efficacy.  
In summary, affinity of scFv in CAR design and impact CAR-mediated T-cell function.  
In this study, Nimo-CAR, predicted to have lower affinity due to reduced association rate of 
binding relative to Cetux-CAR, mediated T-cell activation that directly correlated with EGFR 
expression density and reduced activity in response to low EGFR density. Additionally, 
Nimo-CAR+ T cells showed enhanced proliferation and reduced CAR downregulation 
relative to Cetux-CAR+ T cells.  Targeting EGFR on glioblastoma by Nimo-CAR+ T cells has 
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the potential to mediate anti-tumor activity while reducing the potential for on-target, off-
tissue toxicity.   
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CHAPTER 4 
In vivo anti-tumor efficacy of Cetux-CAR+ and Nimo-CAR+ T cells in an 
intracranial glioma model 
4.1   Introduction 
In Chapter 3, we acknowledged that some tumors, such as glioblastoma, 
overexpress EGFR at a higher density relative to normal tissue expression and 
hypothesized that altering the scFv domain of CAR to reduce binding affinity could 
preferentially activate T cells in the presence of high EGFR density but reduce T-cell activity 
in the presence of low EGFR density.  Cetux-CAR and Nimo-CAR bind overlapping epitopes 
on EGFR with distinct affinities and binding kinetics, such that Cetux-CAR has a 5.3-fold 
lower dissociation constant, and therefore higher affinity, characterized by a 59-fold higher 
rate of association. In vitro studies also demonstrated Cetux-CAR had reduced proliferation 
in response to antigen in the absence of exogenous cytokine, enhanced downregulation of 
CAR that was dependent on scFv domain of CAR binding EGFR and density of EGFR, and 
impaired cytokine production in response to re-challenge with antigen.  
 Previous studies have reported that affinity of TCRs up to a threshold increase 
effector functions in vitro and in vivo (23, 62).  In contrast, high affinity TCRs have also been 
described to have impaired function in vivo, characterized by deletion in tumor and 
periphery, failure to infiltrate tumor, and loss of cytotoxic effector functions despite potent in 
vitro function (65-67).  Therefore, in vitro function does not necessarily correlate with 
effective treatment of in vivo tumor models.(65) 
To determine if in vitro findings that Nimo-CAR+ T cells are cytotoxic in response to 
high EGFR density, but have reduced activity in response to low EGFR density, extend to in 
vivo observations, we compared Cetux-CAR+ T cells and Nimo-CAR+ T cells delivered 
intratumorally in the treatment of intracranial glioma xenografts with low or intermediate 
EGFR density. We hypothesized that Nimo-CAR+ T cells would be equally capable of in vivo 
activity against xenograft with intermediate EGFR density, but reduced anti-tumor activity 
against xenograft with low EGFR density. 
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4.2   Results 
4.2.1 Establishment of an intracranial glioma model using U87 cells in NSG mice 
 To evaluate anti-tumor efficacy of Cetux-CAR+ T cells and Nimo-CAR+ T cells in vivo, 
we elected to establish an intracranial glioma xenograft of U87 cells modified to express 
firefly luciferase (ffLuc) reporter for serial, non-invasive imaging of relative tumor burden by 
bioluminescence (BLI). We adopted the previously described guide-screw method for 
directed infusion of tumor and T cells (291). The guide screw was implanted into the right 
frontal lobe of the cranium of NOD/Scid/IL2Rg-/- (NSG) mice and mice recovered for two 
weeks (Figure 28A). A timeline from guide screw implantation through T-cell treatment and 
evaluation of relative tumor burden by BLI is depicted in Figure 28B.  250,000 U87 cells 
with endogenously low EGFR or intermediate EGFR expression through enforced 
expression of tEGFR were injected through the center of the guide screw at depth of 2.5mm.  
Mice were imaged prior to T-cell treatment to evaluate tumor burden and mice were 
stratified to evenly distribute tumor burden into three groups: mice to receive no treatment, 
Cetux-CAR+ T cells, or Nimo-CAR+ T cells.  Five days after injection of tumor, the initial dose 
of 4x106 T cells was injected intratumorally through the center of the guide screw.  
Subsequent T-cell doses were administered through the guide screw weekly for a total of 
three T-cell doses.  Measurement of BLI six days after each T-cell treatment was used to 
assess relative tumor burden.  Following treatment, mice were evaluated for end point 
criteria, including rapid weight loss of greater than 5% of body mass in a 24 hour period, 
progressive weight loss of more than 25% of body mass, or obvious clinical signs of illness, 
including ataxia, labored respiration, and hind-limb paralysis.  Mice were sacrificed when 
end-point criteria were met, suggesting imminent animal death, and survival of Cetux-CAR+ 
T-cell treated mice and Nimo-CAR+ T-cell treated mice relative to mice receiving no 
treatment was assessed. 
4.2.2 Nimo-CAR+ T cells inhibit growth of xenografts with moderate EGFR density similar to 
Cetux-CAR+ T cells, but without T-cell related toxicity. 
Four days after injection of U87med, mice were imaged by BLI to assess tumor burden 
(Figure 29A).  Mice were distributed into three groups to evenly distribute relative tumor 
burden and then randomly assigned treatment: no treatment, Cetux-CAR+ T cells, or Nimo-
CAR+ T cells (Figure 29B).  On the day of T-cell treatment, CAR+ T cells that had 
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Figure 28.  Schematic of animal model and treatment schedule. (A) Schematic of guide 
screw placement.  A 1-mm hole is drilled for insertion of guide screw in the right frontal lobe, 
1 mm from the coronal suture and 2.5 mm from the sagittal suture.  (B) Timeline of treatment 
schedule.  Guide-screw is implanted into the right frontal lobe of mice no less than 14 days 
prior to injection of tumor.  Injection of tumor is designated as day 0 of study.  Tumor was 
imaged by BLI four days after injection, which was the day prior to initiation of T-cell 
treatment.  CAR+ T cells were administered intracranially through the guide-screw weekly for 
three weeks. Tumor growth was assessed by BLI the prior to and following T-cell treatment 
while mice were actively receiving treatments, then weekly throughout remainder of 
experiment. 
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undergone 3 rounds of stimulation and numeric expansion on EGFR+ aAPC were 
phenotyped by flow cytometry to determine expression of CAR and ratio of CD8+ and CD4+ 
T cells (Figure 29C).  CAR expression was similar between Cetux-CAR+ T cells and Nimo-
CAR+ T cells (92% and 85%, respectively).  Both Cetux-CAR+ and Nimo-CAR+ T cells 
contained a mixture of CD4+ and CD8+ T cells, however, Cetux-CAR+ T cells contained 
about 20% fewer CD8+ T cells than Nimo-CAR+ T cells (31.8% and 51.2%, respectively). 
Cetux-CAR+ T cells and Nimo-CAR+ T cells were both capable of inhibiting tumor growth as 
assayed by BLI (day 18; Cetux-CAR, p<0.01 and Nimo-CAR, p<0.05) (Figure 30A,B). 
There was no difference between the ability of Cetux-CAR+ T cells and Nimo-CAR+ T cells 
to control tumor growth (p>0.05). Reduced tumor burden assessed by BLI was evident in 
3/7 mice treated with Cetux-CAR+ T cells and 4/7 mice treated with Nimo-CAR+ T cells past 
100 days post-tumor injection, when all mice which did not receive treatment had 
succumbed to disease. 
Cetux-CAR+ T-cell treated mice showed significant toxicity resulting in death of 6/14 
mice from two independent experiments within 7 days of T-cell treatment (p=0.0006) 
(Figure 31A).  Overall, Cetux-CAR+ T-cell treatment did not statistically improve survival 
compared to untreated mice, possibly due to early deaths soon after T-cell treatment 
(untreated median survival = 88 days, Cetux-CAR median survival = 105 days, p=0.19) 
(Figure 31B).  Interestingly, the survival curve depicts an inflection point, before which 
Cetux-CAR+ T-cell treatment results in reduced survival compared to untreated mice, and 
after which mice surviving initial T-cell toxicity show improved survival. When only 
considering mice surviving initial T-cell related toxicity, Cetux-CAR+ T cells improve survival 
in 3/4 mice, relative to untreated mice (p=0.0065).  In contrast, Nimo-CAR+ T cells mediate 
effective tumor regression and extend survival in 4/7 of mice without any noted toxicity 
(untreated median survival = 88 days, Nimo-CAR median survival = 158 days, p=0.0269).  
These results indicate that Cetux-CAR+ T cells and Nimo-CAR+ T cells are effective at 
controlling growth of tumor with intermediate antigen density, however Cetux-CAR+ T cells 
demonstrate notable toxicity soon after T-cell treatment. 
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Figure 29. Engraftment of U87med and CAR+ T-cell phenotype prior to T-cell treatment. 
(A) Four days after tumor injection, tumors were imaged by BLI following injection with D-
luciferin and 10 minute incubation. (B) Mice were divided into three groups to evenly 
distribute relative tumor burden as determined by day 4 BLI measurements. (C) Cetux-CAR+ 
and Nimo-CAR+ T cells expanded through 3 stimulation cycles were evaluated for CAR 
expression and CD4/CD8 ratio by flow cytometry.  
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Figure 30. Cetux-CAR+ and Nimo-CAR+ T cells inhibit growth of U87med intracranial 
xenografts. (A) Serial BLI assessed relative size of tumor. (B) Relative tumor growth as 
assessed by serial BLI of tumor. Background luminescence (gray shading) was defined by 
BLI of mice with no tumors. Significant difference in BLI between mice with no treatment vs. 
treatment (n=7) with Cetux-CAR+ T cells (n=7, p<0.01) and no treatment (n=7) vs. treatment 
with Nimo-CAR+ T cells (n=7, p<0.05) at day 18, two-way ANOVA (Sidak’s post-test). 
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Figure 31.  Survival of mice bearing U87med intracranial xenografts treated with Cetux-
CAR+ and Nimo-CAR+ T cells. (A) Survival of mice with U87med-ffLuc-mKate intracranial 
xenografts from two independent experiments within 7 days of T-cell treatment.  Significant 
reduction in survival in Cetux-CAR+ T cell treated mice 8/14 surviving) relative to untreated 
mice (14/14 surviving) determined by Mantel-Cox log-rank test, p=0.0006. (B) Survival of 
mice with U87med-ffLuc-mKate intracranial xenografts receiving no treatment, Cetux-CAR+ 
T cells or Nimo-CAR+ T cells. Significant extension in survival in Nimo-CAR+ T cell treatment 
group determined by Mantel-Cox log-rank test, p=0.0269. 
 
 
 
 
 
 
 
*** 
* 
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4.2.3  Cetux-CAR+ T cells, but not Nimo-CAR+ T cells, inhibit growth of xenografts with low 
EGFR density 
Because Nimo-CAR+ T cells are predicted to have reduced T-cell activity in response 
to targets with low EGFR density, we evaluated activity of T cells in response to U87 with 
endogenous, low density EGFR expression.  Mice were injected with U87, then four days 
later relative tumor burden was assessed by BLI (Figure 32A).  Relative tumor burden was 
evenly distributed into three groups and randomly assigned treatment: no treatment, Cetux-
CAR+ T cells, or Nimo-CAR+ T cells (Figure 32B).  On the day of T-cell treatment, CAR+ T 
cells that had undergone 3 rounds of stimulation and numeric expansion on EGFR+ aAPC 
were phenotyped by flow cytometry to determine expression of CAR and ratio of CD8+ and 
CD4+ T cells (Figure 32C).  CAR expression was similar between Cetux-CAR+ T cells and 
Nimo-CAR+ T cells (92% and 85%, respectively).  Both Cetux-CAR+ and Nimo-CAR+ T cells 
contained a mixture of CD4+ and CD8+ T cells, however, Cetux-CAR+ T cells contained 
about 20% fewer CD8+ T cells than Nimo-CAR+ T cells (31.8% and 51.2%, respectively).  
Mice received T-cell treatment and tumor was assessed by BLI as previously 
described (Figure 28B).  Treatment of mice with Cetux-CAR+ T cells resulted in significant 
reduction of tumor burden compared to untreated mice (day 25, p< 0.01) (Figure 33A and 
33B).  In contrast, treatment with Nimo-CAR+ T cells did not significantly reduce tumor 
burden compared to untreated mice (Nimo-CAR, p>0.05). Reduced tumor burden in mice 
treated with Cetux-CAR+ T cells was transient, however, and following cessation of T-cell 
treatment, tumors resumed growth.   
Cetux-CAR+ T cell treatment significantly extended survival in 3/6 mice compared to 
mice receiving no treatment (untreated median survival = 38.5 days, Cetux-CAR median 
survival = 53 days, p=0.0150) (Figure 34). In contrast, treatment with Nimo-CAR+ T cells did 
not significantly improve survival (untreated median survival 38.5 days, Nimo-CAR median 
survival 46 days, p=0.0969).  These data indicate that while Cetux-CAR+ T cells are 
effective against low EGFR density, Nimo-CAR+ T cells do not mediate significant activity 
against xenografts with low EGFR density. 
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Figure 32. Engraftment of U87 and CAR+ T-cell phenotype prior to T-cell treatment.  (A) 
Four days after tumor injection, tumors were imaged by BLI following injection with D-
luciferin and 10 minute incubation. (B) Mice were divided into three groups to evenly 
distribute relative tumor burden as determined by day 4 BLI flux measurements. (C) Cetux-
CAR+ and Nimo-CAR+ T cells expanded through 3 stimulation cycles were evaluated for 
CAR expression and CD4/CD8 ratio by flow cytometry.  
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Figure 33. Cetux-CAR+, but not Nimo-CAR+ T cells inhibit growth of U87 intracranial 
xenografts(A) Serial BLI assessed relative size of tumor. (B) Relative tumor growth as 
assessed by serial BLI of tumor. Significant difference in BLI between mice with no 
treatment vs. treatment (n=6) with Cetux-CAR+ T cells (n=6, p<0.01) reached at day 25, two-
way ANOVA (Sidak’s post-test). 
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Figure 34. Survival of mice bearing U87 intracranial xenografts treated with  
Cetux-CAR+ and Nimo-CAR+ T cells. Survival of mice with U87-ffLuc-mKate intracranial 
xenografts receiving no treatment, Cetux-CAR+ T cells or Nimo-CAR+ T cells.  Significant 
extension in survival in Cetux-CAR+ T cell treatment group determined by Mantel-Cox log-
rank test, p=0.0150. 
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4.3   Discussion 
Evaluation of efficacy of Cetux-CAR+ and Nimo-CAR+ T cells in treatment of 
intracranial glioma xenografts supported in vitro conclusions by demonstrating that Cetux-
CAR+ T cells and Nimo-CAR+ T cells can mediate anti-tumor activity against U87med, 
expressing intermediate EGFR density, but only Cetux-CAR+ T cells demonstrated anti-
tumor activity against U87 with endogenously low EGFR density. 
Some studies have demonstrated that higher affinity TCR interactions can result in 
superior in vivo activity (23, 62), however, it has been demonstrated that in vitro T-cell 
activity does not always mirror in vivo efficacy (65, 67). High affinity T cells with high potency 
in vitro have been shown to have attenuated responses in vivo, characterized by decreased 
signaling, expansion, and T-cell mediated function (63). Similarly, low affinity interaction 
have been demonstrated to have curtailed T-cell expansion in vivo, resulting in fewer T cells 
present at each stage of the immune response (64). Models assessing the role of TCR 
affinity in anti-tumor efficacy have demonstrated that high affinity TCR interactions have 
impaired anti-tumor function, characterized by decreased presence in tumor and impaired 
cytolytic function (65-67). Thus, it has been suggested that T cells with intermediate affinity 
may better control tumor growth relative to high affinity T cells (63, 67).  Combining these 
observation with in vitro observations that Cetux-CAR+ T cells have decreased proliferative 
capacity when stimulated in the absence of exogenous cytokine, enhanced CAR 
downregulation following engagement with antigen, and reduced ability to respond to re-
challenge with antigen, it is reasonable to expect that Cetux-CAR+ T cells may have reduced 
anti-tumor efficacy in vivo.  We did not observe impaired anti-tumor efficacy relative to Nimo-
CAR+ T cells, however, the fate of CAR+ after intratumoral injection was not followed, and 
therefore, differences in vivo T-cell expansion were not assessed.  Intratumoral injection of 
CAR+ T cells was chosen to avoid the confounding variable of disparate abilities of CAR+ T 
cells to home to tumor when evaluating anti-tumor activity; however, it is possible that 
Cetux-CAR+ T cells may have reduced tumor infiltration due to retention in tumor periphery.  
Therefore, future studies in which CAR+ T cells are labeled and their fate, including tumor 
infiltration and in vivo expansion, should be undertaken.  Additionally, isolating T cells 
following tumor infiltration and evaluating their retained cytotoxic capacity may provide 
interesting information about the role of the scFv domain affinity in CAR design and function 
in vivo.   
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 Nimo-CAR+ T-cell treatment did not significantly reduce tumor burden or improve the 
survival of mice relative to untreated mice in response to low EGFR density on U87, which is 
about 2-fold higher than EGFR density measured on normal renal epithelial cells (Figure 21 
and Figure 24). In contrast, Cetux-CAR+ T cells demonstrated tumor control and extended 
survival in 3/6 mice with low EGFR density. While Nimo-CAR+ T-cell treatment may have 
reduced cytotoxic potential against normal tissue with very low EGFR density, they also 
have the potential for tumor escape variants expressing low EGFR density. Due to the 
substantial heterogeneity in glioblastoma, it is unlikely for a single target to be expressed on 
all of the tumor cells within a given patient (237, 292). Treatment of experimental 
glioblastoma models with HER2-specific CAR+ T cells has also demonstrated escape of 
HER2null tumor cells (257, 259).  Profiling patient tumors can identify combinations of 
antigens to target the maximum number of cells in a given tumor, and targeting multiple 
antigens by CAR+ T cells has been shown to improve treatment efficacy of treatment of 
CAR+ T cells with single specificity (259). In vivo experimentation with U87 with uniform 
EGFR density does not recapitulate antigen heterogeneity in patient tumors, therefore, 
evaluation of Cetux-CAR+ T cells or Nimo-CAR+ T cells in combination with CAR+ T cells of 
different specificities can be evaluated against glioblastoma specimens derived from 
patients that may better recapitulate tumor heterogeneity in vivo (257).  
Unexpectedly, Cetux-CAR+ T cells showed significant toxicity within 7 days of T-cell 
treatment, with 6/14 mice dying within 7 days of a T-cell injection.  Previously, an EGFR-
specific CAR has been reported to have no detectable in vivo toxicity by measurement of 
liver enzymes 48 hours after T-cell infusion in mice bearing no tumor (293).  Because this 
CAR was derived from a murine antibody, it is unlikely that the EGFR-specific CAR would 
recognize murine EGFR on normal tissue. Additionally, measurement of toxicity in the 
absence of antigen does not replicate physiologic CAR+ T-cell activation in patients 
expressing antigen on tumors, as these cells will activate, proliferate, and produce cytokine 
in response to tumor lysis, which could all contribute to measureable toxicity (158).  In fact, 
in the present study, treatment of mice with Cetux-CAR+ T cells bearing low antigen tumor or 
no tumor did not result in detectable toxicity (Figure 7 and unpublished observations), 
highlighting the role of in vivo T-cell activation to observed T-cell toxicity.   
Because cetuximab does not recognize murine EGFR, on-target, off-tissue toxicity is 
not likely a cause of Cetux-CAR+ T cell-related toxicity (294).  Possible mechanisms for 
Cetux-CAR mediated toxicity in this model include cytokine-related toxicity resulting from T-
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cell activation or possibly enhanced avidity of Cetux-CAR due to clustering, immune 
synapse formation or association with T-cell cytoskeleton that reduces antigenic-specificity, 
as has been described in the contribution of CD8 coreceptor binding to enhance avidity of 
high affinity TCRs, resulting in loss of specificity (295).  
Although tumor xenografts in immunosuppressed mice are the standard in the field 
to assess efficacy of CAR-modified T-cell therapies due to their readiness to accept human 
grafts, this model is limited in ability to measure toxicity responses. The inability of human 
CAR+ T cells to recognize murine EGFR makes this model incapable of determining the 
potential of on-target, off-tissue toxicity from CAR+ T cells.  In addition, because these mice 
are immunosuppressed, the interaction of Cetux-CAR+ T cells with other components of the 
immune system, such as the effect of secreted cytokines from CAR+ T cells, which have 
been attributed with significant toxicity in clinical trials, cannot be fully assessed.  
Additionally, a recent clinical trial has demonstrated the potential for anaphylaxis in 
response to CAR+ T cell treatment when multiple doses of T cells are given, hypothesized to 
be due to development of IgE antibodies specific to CAR moieties (160). Therefore, 
evaluation of EGFR-specific CAR in an immunocompetent host in which EGFR on normal 
tissue is capable of recognition is necessary for adequate pre-clinical evaluation of 
occurrence and mechanism of T-cell mediated toxicity.  
Expression of a fully murine CAR specific EGFRvIII expressed in murine T cells was 
able to mediate complete tumor regression against syngeneic intracranial, orthotopic murine 
glioblastoma in an immune competent mouse model (296). Interestingly, following 
regression of EGFRvIII-expressing glioblastoma, immunocompetent mice showed protection 
against challenge with syngeneic EGFRvIIInull tumor cells, providing evidence of antigen-
spreading against unindentified epitopes. Likewise, a recent clinical trial of mesothelin-
specific CAR+ T cells for the treatment of mesolthelioma have demonstrated development of 
novel anti-self antibodies following CAR+ T cell therapy, indicative of antigen-spreading 
when CAR+ T cells function in the context of a complete immune response (266).  Thus, 
evaluation of CAR+ T cell activity in an immunocompetent model may demonstrate 
additional anti-tumor efficacy through interaction with an intact immune system.  
Because cetuximab and nimotuzumab do not bind murine EGFR, the Cetux-CAR 
and Nimo-CAR are not amenable to testing in a fully murine, immunocompetent model.  
However, canines develop spontaneous glioma that overexpress EGFR and because 
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canine EGFR is highly homologous to human EGFR and cross-reactive with cetuximab, a 
trial with owner-initiated treatment of canine patients diagnosed with glioblastoma with a 
chimeric Cetux-CAR or Nimo-CAR to include canine signaling endodomains expressed in 
canine T cells may be a good preclinical model to evaluate complex pre-clinical issues 
surrounding EGFR-specific CARs (297, 298).  However, initial steps to ensure that affinity of 
Cetux-CAR and Nimo-CAR binding to canine EGFR maintain their equivalent kinetic 
parameters will be of primary importance to ensure translatability to human treatment.  
 In summary, Nimo-CAR+ T cells demonstrate anti-tumor activity and improved 
survival comparable to higher affinity Cetux-CAR+ T cells in an intracranial orthotopic 
xenograft model, without T-cell related toxicity associated with Cetux-CAR+ T cells. In 
contrast, Cetux-CAR+ T cells, but not Nimo-CAR+ T cells demonstrate anti-tumor activity 
against tumor with low EGFR density. These findings are consistent with in vitro 
observations that Nimo-CAR+ T cells have reduced activity in response to low EGFR 
density.  Future experiments tracking CAR+ T cells in vivo, evaluating the potential for tumor 
escape variants, and evaluation of efficacy and toxicity in an immunocompetent canine 
model may provide further distinction between the in vivo anti-tumor activity of Cetux-CAR+ 
and Nimo-CAR+ T cells.   
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CHAPTER 5 
General Discussion and Future Directions 
5.1   Dissertation Summary 
 Adoptive immunotherapy with CAR+ T cells is proving to be a promising treatment 
modality for B-cell lineage malignancies in clinical trials (111, 112, 132), however, persistent 
B-cell aplasia demonstrates the longevity of CAR+ T-cell responses and limits applicability to 
TAA with widespread normal tissue expression, such as EGFR.  EGFR is overexpressed on 
many tumor types, including glioblastoma, but also is expressed on many epithelial surfaces 
throughout the body at low basal levels (185, 201). Therefore, targeting EGFR with EGFR-
specific CAR+ T cells poses the potential risk of toxicity to normal tissue expressing low 
density EGFR. Two strategies were evaluated to limit recognition of EGFR on normal tissue 
by EGFR-specific CAR+ T cells: (i) temporally limiting CAR expression through transient 
modification of T cell with RNA, and (ii) tuning CAR sensitivity to antigen density through 
scFv domain with lower affinity and reduced capacity to bind low density EGFR.   
RNA-modification of T cells resulted in transient expression of Cetux-CAR, an 
EGFR-specific CAR derived from the monoclonal antibody cetuximab.  Comparing Cetux-
CAR+ T cells modified by DNA or RNA transfer revealed that DNA-modified T cells were 
superior in production of cytokines IFN-γ and TNF-α in response to EGFR-expressing tumor 
cells, likely due to the enhanced proportion of effector memory/effector phenotype T cells in 
DNA-modified T cells relative to RNA-modified T cells.  However, RNA-modified T cells 
demonstrated similar specific lysis after RNA transfer in response to EGFR-expressing 
tumor cells as DNA-modified CAR+ T cells. Cetux-CAR expressed by RNA transfer was 
gradually lost over time, with very low CAR expression detected 4-5 days following RNA 
transfer, and the loss of CAR expression in RNA-modified T cells was accelerated by T-cell 
stimulation with cytokine or antigen.  Concomitant with loss of CAR, T cells lost ability to 
mediate cytotoxicity of EGFR-expressing tumor cells.  While this strategy can reduce normal 
tissue toxicity by temporally limiting CAR expression, it does not endow CAR+ T cells the 
ability to distinguish normal tissue from malignant tissue and when CAR+ T cells lose CAR 
expression, they lose the ability to target tumor as well as normal tissue antigen. Moreover, 
transient expression of CAR does not protect normal tissue from short-term targeting of 
EGFR-expressing normal tissue upon infusion of CAR+ T cells. Because of these limitations, 
we sought to develop an EGFR-specific CAR that could be stably expressed, but could 
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distinguish malignant cells from normal cells based on increased EGFR density on 
malignant tissue to prevent normal tissue toxicity while maintaining anti-tumor activity. 
To achieve this, another EGFR-specific CAR was developed from the monoclonal 
antibody nimotuzumab, termed Nimo-CAR.  Relative to cetuximab, nimotuzumab has a 1-
log lower affinity but is specific to an epitope on EGFR that highly overlaps with that of 
cetuximab (223, 231).  In clinical trials, nimotuzumab has demonstrated a low toxicity profile 
relative to cetuximab, with notable absence of the grade III/IV skin rash associated with 
cetuximab treatment (230, 289, 299). Nimo-CAR+ and Cetux-CAR+ T cells demonstrated 
equivalent capability of T-cell activation, measured by phosphorylation of Erk1/2 and p38, 
production of IFN-γ, and specific lysis, when stimulated in a CAR-dependent, scFv-
independent manner. By measuring activity of Nimo-CAR+ T cells and Cetux-CAR+ T cells in 
response to U87 cells expressing graded EGFR densities, we demonstrated the capacity of 
Nimo-CAR+ T cells to phosphorylate signaling molecules, produce cytokine and induce 
specific lysis of targets was directly correlated with density of EGFR expression, whereas 
Cetux-CAR+ T cells demonstrated equivalent activity against all EGFR-expressing U87 cell 
lines, regardless of density of EGFR expression. In response to low EGFR density on 
normal renal cells, Nimo-CAR+ T cells were unable to produce significant amounts of IFN-γ 
and had 50% less specific lytic activity than Cetux-CAR+ T cells, which produced IFN-γ and 
exhibited efficient specific lysis of normal human renal epithelial cells.  In addition to having 
reduced sensitivity to low EGFR density, Nimo-CAR+ T cells also demonstrated increased 
proliferation following stimulation in cytokine-free conditions, reduced downregulation of 
CAR following stimulation with antigen, and increased capacity to produce cytokine in 
response to secondary encounter with antigen in comparison to Cetux-CAR+ T cells. 
In vitro observations were supported by in vivo observations in an intracranial 
xenograft model in which Nimo-CAR+ T cells demonstrated equivalent anti-tumor efficacy as 
measured by relative tumor BLI in response to moderate EGFR density as Cetux-CAR+ T 
cells, resulting in significant extension of survival. Cetux-CAR+ T cells were associated with 
significant toxicity soon after T-cell treatment, which was notably absent in mice treated with 
Nimo-CAR+ T cells. However, in response to low EGFR density on U87, which is still twice 
the density measured on normal human renal cortical epithelial cells, only Cetux-CAR+ T 
cells and not Nimo-CAR+ T cells were capable of anti-tumor activity and significant extension 
of survival. In sum, we described a novel method of reducing T-cell activity to normal tissue 
by tuning CAR sensitivity to antigen density such that CAR-dependent T-cell activation 
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occurs in the presence of high antigen density on tumor tissue, but is reduced in the 
presence of low antigen density on normal tissue. 
5.2   Safely expanding repertoire of antigens for CAR+ T-cell therapy  
Methods developed to achieve safety of CAR+ T cells can be categorized into three 
main strategies: (i) restricting CAR+ T cells to tumor tissue, (ii) limiting CAR expression/T cell 
persistence, and (iii) restricting CAR-mediated T-cell activation to tumor (Figure 35). Co-
expression of homing molecules with CAR in T cells to home to site of the tumor, such as 
CCR2, CCR4 and CXCR2, has been described to sequester CAR+ T cells to site of the 
tumor (154, 156, 157).  While CAR+ T cells are enriched in tumor tissue when compared 
with CAR+ T cells without homing receptors, it is unclear what percentage of CAR+ T cells 
expressing homing receptors do not efficiently home to the tumor and could, therefore, 
target normal tissue.  Likewise, chemokines secreted by tumors can also be secreted in 
normal tissue during tissue trauma and healing. Therefore, combining these treatments with 
other treatment modalities, such as surgery, chemotherapy and radiation would risk 
attracting T cells to normal tissue non-specifically injured during treatment.  Development of 
CAR preferentially expressed in hypoxic condition, common in many tumors, has been 
achieved by fusing CAR to an oxygen-dependent degradation domain to limit CAR 
expression and capacity to target tissue in normoxia (unpublished data, O. Ang) (300). 
Because CAR degradation in T cells moving from hypoxia to normoxia may take minutes to 
hours, it is feasible for on-target, off-tissue toxicity may occur prior to CAR degradation.  In 
addition, while the center of many tumors are hypoxic, well-vascularized peripheral tumor 
regions may have sufficient oxygen concentration to degrade CAR, protecting peripheral  
regions from CAR-mediated T-cell activity (301). 
Strategies to temporally limit CAR+ T-cell presence include suicide gene modification 
of T cells, such as expression of CAR as a transient RNA species, and introduction of 
iCaspase9 suicide switch, which is specifically activated by a chemical inducer of 
dimerization (CID) to result in T-cell death (152, 163, 164, 167, 168).  Both methods have 
high penetrance and result in almost complete abrogation of CAR+ T cells, either after 
induction of apoptosis by drug delivery or loss of RNA transgene expression over time.  
Because both strategies permanently ablate CAR+ T cells, they also limit therapeutic 
efficacy against tumor while protecting normal tissue.  One limitation of these strategies is 
that before CAR reduction or T cell ablation, potent activity against normal cells exists, and  
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Figure 35. Summary of strategies to safely expand repertoire of antigens for CAR+ T 
cell therapy. Strategies fall into three main categories: (i) limiting CAR expression by drug-
induced suicide or transient CAR expression, (ii) targeting CAR to tumor site by limiting 
expression to hypoxic regions or co-expressing homing receptors, and (iii) limiting CAR 
activation by splitting signals to require two antigens to recognize tumor, expressing an 
inhibitory CAR to prevent activation to normal tissue, or expressing CAR conditionally 
activated by high antigen density. 
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there is no short-term limitation of toxicity.  Serious adverse events from T-cell therapy can 
progress rapidly from onset of clinical symptoms, therefore, it is desirable to have a strategy 
to protect normal tissue from the moment of CAR+ T-cell infusion (111, 112).   
Dual-specific, complementary CARs have achieved selective activation in response 
to co-expression of two antigens mutually expressed only on tumor by dissociating signaling 
domains and expressing two chimeric receptors with two specificities.  In this strategy, one 
specificity is fused to CD3ζ to express a first generation CAR and a different, 
complementary specificity is fused to costimulation endodomains, termed a chimeric  
costimulation receptor (CCR), such that full activation and T-cell function is only attained 
with simultaneous engagement of CAR and CCR by co-expression of by antigens (302-
304).  This approach has been piloted with different pairs of CAR and CCR with redirected 
specificities towards HER2 and MUC1 for breast cancer, PSMA and PSCA for prostate 
cancer and mesothelin and α-folate receptor for ovarian cancer treatment.  Early studies 
have demonstrated that T-cell activation and lytic function can occur against single antigen 
expressing targets via first generation CAR expression in the absence of CCR activation. 
Although this cytotoxicity is lower than that observed with second generation CARs, there is 
still some residual risk of CAR targeting normal tissue expressing single antigen (302, 303).  
One strategy to overcome this limitation is to develop a first generation CAR with suboptimal 
affinity, such that it barely renders T-cell function when activated by single antigen and 
toxicity is only rescued by ligation of CCR (304). However, this strategy functions by blunting 
T-cell sensitivity to tumor antigen.  While this strategy prevents recognition and targeting of 
single antigen expression tissue, thereby potentially reduced normal tissue toxicity, it also 
reduces anti-tumor activity. Additionally, the requirement for two antigens to be expressed 
for efficient T-cell activation and tumor elimination reduces the fraction of tumor capable of 
CAR activation and increases the potential for the development of tumor escape variants.  
An inhibitory CAR (iCAR) fusing specificity for antigen found only on normal tissue, 
and not on tumor to PD-1 signaling endodomains is capable of significantly inhibiting T-cell-
mediated killing and cytokine production in response to binding normal tissue antigen (305). 
Impressively, iCAR inhibition of T-cell function is reversible, and T cells are capable of 
subsequent functionally productive responses upon encounter with tumor antigen. The 
success of this strategy is dependent of stoichiometry of CAR, iCAR and both antigens.  
Therefore, it is reasonable to predict that normal tissue toxicity could occur if iCAR 
expression or antigen is insufficient in the presence of overwhelming CAR/tumor antigen 
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expression.  This stoichiometric parameter must evaluated and tightly control for each set of 
antigens for this strategy to be successful.   
We add to this array of methods to reduce normal tissue toxicity a novel method to 
control T-cell activation to the site of tumor based on the affinity of the scFv used in CAR 
design to mitigate activation of CAR+ T cells in response to low density of EGFR on normal 
tissue while mediating T-cell cytotoxicity in response to high EGFR density on tumor tissue. 
Advantages of this method are that (i) reduction of normal tissue toxicity is not associated 
with mitigated T-cell activity in response to tumor and (ii) activation/inhibition of T cells does 
not require recognition of multiple antigens, for which the stoichiometry of expression and 
binding to relative receptors must be tightly controlled.  Additionally, requiring multiple 
antigens for T cell activation further reduces the proportion of a tumor that will be efficiently 
targeted. None of the methods to restrict T-cell on-target, off-tissue tissue toxicity are 
mutually exclusive, and combinations of multiple strategies may provide improve avoidance 
of normal tissue destruction.   
5.3   Clinical implications 
Glioblastoma patients may be an ideal patient population for initial evaluation of 
safety of T cells specific for EGFR for cancer immunotherapy. EGFR is overexpressed in 40-
50% of patients with glioblastoma (176, 181), and EGFR expression is not reported in 
normal CNS tissue (201). Because EGFR is widespread on normal epithelial surfaces, 
intracavitary delivery of T cells following tumor resection can maximize anti-tumor potential 
while minimizing the potential for interaction with epithelial surfaces outside of the CNS.  
Following initial safety evaluation in patients with glioblastoma, it may be possible to extend 
EGFR-specific CAR+ T cell therapy to other EGFR-expressing malignancies, which include 
breast, ovarian, lung, head and neck, colorectal, and renal cell carcinoma (184).  
 Although transient expression of CAR through RNA modification of T cells may result 
in reduced anti-tumor efficacy due to limited presence of CAR+ T cells, multiple infusions of 
RNA-modified T cells, particularly with a weighted initial dose, may overcome these potential 
limitations, as previously demonstrated with CD19 CAR+ T cells modified by RNA transfer in 
an advanced leukemia murine model (168).  While clinical trials with mesothelin-specific 
CAR transferred by RNA expression have demonstrated the potential for anaphylaxis 
attributed to the development of IgE antibody responses specific for CAR moieties in 
response to repeated CAR infusions, a dosing strategy with no more than 10 days between 
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CAR+ T cell infusions and treatment to be completed over a course of 21 days has been 
proposed to avoid isotype switching of IgG antibodies to IgE antibodies and is currently 
being evaluated (160).  Despite these challenges, there are many attractive advantage of 
RNA modification to express CAR in clinical application.  First, RNA-modification of T cells 
does not involve genomic integration of transgenes, and thus have the potential for less 
cumbersome processes for regulatory approval, which may shorten the preclinical 
development period for CAR+ T-cell therapy.  In addition, generation of CAR-modified T cells 
by RNA transfer is much quicker than DNA-modification using the Sleeping Beauty 
transposon/transposase system, resulting in >90% CAR+ T cells in about half of the ex vivo 
culture time as is required for DNA-modification of T cells. Improving the speed of regulatory 
approval processes and ex vivo manufacture time could result in getting new CAR+ T cell 
therapies to the clinic faster, quicken the communication time from bench-to-bedside and 
back to mediate improved efficiency in fine-tuning these therapies for clinical application.  
RNA-modification may also provide a platform to test transiently modified T cells 
specific to widely expressed normal tissue antigens, such as EGFR, in patients to determine 
safety profiles of CAR structures prior to evaluating permanently integrated CARs as an 
additional measure of safety. Because Cetux-CAR demonstrates T-cell activation and lytic 
activity in response to low EGFR density, DNA-modification of T cells to permanently 
express Cetux-CAR is not likely to be a viable clinical strategy due to the high risk of normal 
tissue toxicity.  However, initial clinical evaluation of Nimo-CAR+ T cells modified by RNA 
transfer may determine the capacity of Nimo-CAR+ T cells to mediate normal tissue toxicity 
with the additional safety feature of transient CAR expression to alleviate concerns of long-
term normal tissue toxicity. 
 While the reduced capacity of Nimo-CAR+ T cells to mediate cytotoxicity against low 
density EGFR functions to reduce normal tissue toxicity, it also may reduce effectiveness 
against tumors that express low density EGFR, increasing the potential for outgrowth of 
tumor escape variants expressing EGFR at low density. In contrast, specific lytic activity of 
Cetux-CAR+ T cells against all levels of EGFR expression may reduce the risk of outgrowth 
of low EGFR expressing tumor escape variants, but does so at the expense of potential 
toxicity against normal tissue with low EGFR expression. In addition, Cetux-CAR+ T cells 
appear to mediate some degree of T-cell related toxicity independent of targeting normal 
tissue expressing EGFR, as demonstrated in treatment of intracranial U87 expressing 
moderate density of EGFR, perhaps due to enhanced cytokine production or induction of 
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local inflammation. The relationship between Cetux-CAR+ and Nimo-CAR+ T cells highlight 
the balance that must be achieved between safety and efficacy of gene-modified T-cell 
therapies. Choosing which strategy might have better clinical outcome, Cetux-CAR+ T cells 
with increased risk of toxicity but potential for greater tumor control or Nimo-CAR+ T cells 
with reduced risk of toxicity, but greater potential for development of tumor escape variants, 
does not have a simple solution. One potential clinical strategy for coping with this balance 
may be infusing Nimo-CAR+ T cells modified by DNA for stable control of high EGFR-
expressing tumor variants combined with multiple infusions of Cetux-CAR+ T cells modified 
by RNA to eliminate low EGFR-expressing tumor cells.  
5.4   Future directions 
It is currently unclear how CARs are similar or dissimilar from TCRs in mechanisms 
of action.  For example, it is unknown if CARs cluster after initiation of signaling, are involved 
in formation of immunological synapses, or interact with the actinomysoin cytoskeleton 
during signaling as endogenous TCRs do. Each of these processes contributes to 
enhancing avidity of interaction with antigen, and therefore, extrapolating findings from 
studies of TCR affinity to designing CARs with desirable attributes is difficult. Wild-type 
endogenous TCRs have monomeric affinities orders of magnitude lower than monomeric 
affinities of CARs, and yet are often characterized by enhanced sensitivity relative to CARs, 
requiring few complexes of peptide in the context of MHC and few TCRs triggered to 
activate cytolytic T-cell responses, highlighting the likelihood of some distinction in 
mechanism of action. Reduced sensitivity of CAR+ T cells can be explained by reports that 
they fail to induce serial triggering, where one antigen molecule can activate many 
molecules of CAR, potentially due to the reduced dissociation rate resulting in longer 
interactions with antigen than observed with wild-type TCR. Questions of whether CARs 
form functional immune synapses and whether they interact with actin cytoskeleton of T 
cells to enhance avidity of interaction as endogenous TCRs do remain to be answered.  
Better understanding of these basic mechanisms of CAR function can inform rational design 
of CAR structures for future clinical evaluation.  
The stromal microenvironment of glioblastoma is immunosuppressive, and may 
reduce the effectiveness of T-cell immunotherapy strategies for treatment. Murine xenograft 
models for glioblastoma do not recapitulate the stromal environment of glioblastoma, and 
therefore, it is difficult to determine its impact on CAR+ T cells in preclinical studies. 
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Manipulation of the microenvironment to potentiate T-cell therapy can be achieved by 
combining therapies that modulate T cell function with CAR+ T cell therapy. For example, 
PD-L1 is expressed on ~60% of glioblastoma and binds to PD-1 expressed on T cells to 
inhibit function (249). Blockade the interaction of PD-L1 and PD-1 has demonstrated 
promising results in early phase clinical studies in patients with non-small cell lung 
carcinoma, melanoma, and renal cell carcinoma, and has extended survival in a murine 
model of glioma  (243, 306). Combination of PD-L1 blockade with CAR+ T cell therapy may 
improve T-cell function to overcome immunosuppression through this pathway.  TGF-β is 
also secreted in the glioblastoma microenvironment and linked to immune suppression and 
poor outcomes in glioblastoma patients (307). Clinical trials inhibiting TGF-β with the 
chemical inhibitor trabesdersin has demonstrated some improvement in tumor control 
relative to patients receiving chemotherapy (308). Treatment of a model of spontaneous 
arising prostate cancer in transgenic mice engineered to express SV40 antigen 
demonstrated that treatment with SV40-specific TCR transgenic T cells was significantly 
improved by coexpression of a dominant negative TGF-β receptor (309). Co-expression of a 
dominant negative TGF-β receptor on Cetux-CAR+ or Nimo-CAR+ T cells may overcome 
immunosuppressive effects of TGF-β in glioblastoma.  
Due to the heterogeneous nature of glioblastoma, the risk of tumor escape variants 
null for EGFR expression is likely present regardless of complete elimination of tumor cells 
expressing all levels of EGFR density, due to the notorious complexity of glioblastoma.  
Kloss et. al. demonstrated that treatment of a glioblastoma cell line with a HER2-specific 
resulted in outgrowth of HER2 negative cells.  For that reason, combination therapy 
targeting additional tumor antigens is an attractive strategy to prevent tumor escape.  Other 
CARs for treatment of GBM with promising preclinical results have been described, targeting 
EphA2, HER2, and EGFRvIII, IL13Rα2, the latter three currently in phase I/II clinical trials 
(147-150, 257, 310, 311). Development of a bispecific CAR to able to target HER2 and 
IL13Rα2 in one transgenic receptor displayed dual specificity and synergistic enhancement 
of T-cell function upon simultaneous engagement with both antigens (259, 312). While 
targeting HER2 and IL13Rα2 improved GBM clearance over single modal therapy, a small, 
resistant population negative for antigen remained. Expanding repertoire of targetable 
antigens by including EGFR may contribute to finding combinations of two or more 
targetable antigens to account for all tumor cells. Because cetuximab and nimotuzumab are 
both capable of recognizing EGFRvIII with similar affinity as wild type EGFR (313, 314), 
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combination of Cetux-CAR+ T cell or Nimo-CAR+ T cell therapy should be evaluated with 
CARs specific for HER2, EphA2 and IL13Rα2. Additionally, mutually exclusive mosaic-like 
expression of PDGFRα and EGFR has been reported in glioblastoma patients.  Thus, a 
combination of CARs targeting these two RTKs may be beneficial for covering a large 
proportion of tumor and should be evaluated, although, to date, preclinical studies 
evaluating PDGFR-α as a target for CAR therapy are lacking. Autologous glioblastoma 
patient samples can be used to establish intracranial xenografts in mice to evaluate T-cell 
therapies. While they do not recapitulate the host’s immune interactions or the stromal 
microenvironment of the tumor, autologous models of glioblastoma do recapitulate 
intratumoral and intertumoral heterogeneity.  Therefore, evaluation of target expression on 
patient glioblastoma samples and evaluation and combination therapies in an autologous 
murine model of glioblastoma may inform combinations of CARs worthy of clinical 
evaluation.  
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CHAPTER 6 
Materials and Methods 
6.1   Plasmids 
6.1.1 Cetuximab-derived CAR transposon 
Cetuximab-derived CAR is composed of the following: a signal peptide from human 
GMCSFR2 signal peptide (amino acid 1-22; NP_758452.1), variable light chain of cetuximab 
(PDB:1YY9_C) whitlow linker (AAE37780.1), variable heavy chain of cetuximab  
(PDB:1YY9_D), human IgG4 (amino acids 161-389, AAG00912.1), human CD28 
transmembrane and signaling domains (amino acids 153-220, NP_006130), and human 
CD3-ζ intracellular domain (amino acids 52 through 164, NP_932170.1).  Sequence of 
GMCSFR2, variable light chain, whitlow linker, variable heavy chain and partial IgG4 were 
human codon optimized and generated by GeneART (Regensburg, Germany) as 
0700310/pMK.  Previously described CD19CD28mZ(CoOp)/pSBSO under control of human 
elongation factor 1-alpha (HEF1α) promoter was selected as backbone for SB transposon.  
0700310/pMK and previously described CD19CD28mZ/pSBSO (93, 94) underwent double 
digestion with NheI and XmnI restriction enzymes.  CAR insert and transposon backbone 
were identified as DNA fragments of 1.3 kb and 5.2 kb, respectively, by agarose gel 
electrophoresis in a 0.8% agarose gel run at 150 volts for 45 minutes and stained with 
ethidium bromide for visualization under ultraviolet light exposure.  Bands were excised and 
purified (Qiaquick Gel Extraction kit, Qiagen, Valencia, CA), then ligated using T4 DNA 
ligase (Promega, Madison, WI) at a molar ratio of insert to backbone of 3:1.  Heat shock 
transformation of TOP10 chemically competent bacteria (Invitrogen, Grand Island, NY) and 
selection on kanamycin-containing agar plates cultured at 37ºC for 12-16 hours identified 
bacteria clones positive for transposon backbone.  Six clones were selected for mini-culture 
in TB media with kanamycin selection at 37ºC for 8 hours.  Preparation of DNA from mini-
cultures was done via MiniPrep kit (Qiagen) and subsequent analytical digestion with 
restriction enzymes and analysis of fragment size by agarose gel electrophoresis identified 
clones positive for CetuxCD28mZ(CoOp)/pSBSO (Figure 36A).  A positive clone was 
inoculated 1:1000 into large culture in TB media with kanamycin antibiotic selection and 
cultured on shaker at 37ºC for 16 hours, until log-phase growth was achieved.  DNA was 
isolated from bacteria using EndoFree Maxi Prep kit (Qiagen).  Spectrophotometer analysis 
of DNA verified purity by OD260/280 reading between 1.8 and 2.0. 
128 
 
 
 
 
129 
 
Figure 36.  Vector maps of constructed plasmids. (A) Cetuximab-derived CAR 
transposon.  Annotated as follows: HEF-1α/p: promoter for human elongation factor-1α; 
BGH: bovine growth hormone poly adenylation sequence; IR/DR: inverted repeat/direct 
repeat; ColE1: a minimal E.coli origin of replication; Kan/R: gene for kanamycin resistance; 
Kan/p: promoter for kanamycin resistance gene. (B) Nimotuzumab-derived CAR transposon. 
Annotated as follows: HEF-1α/p: promoter for human elongation factor-1α; BGH: bovine 
growth hormone poly adenylation sequence; IR/DR: inverted repeat/direct repeat; ColE1: a 
minimal E.coli origin of replication; Kan/R: gene for kanamycin resistance; Kan/p: promoter 
for kanamycin resistance gene.(C) Cetuximab-derived CAR/pGEM-A64 plasmid. Annotated 
as follows: amp/R: gene for ampicillin resistance, SpeI: restriction site for linearization. (D) 
Nimotuzumab-derived CAR/pGEM-A64 plasmid. Annotated as follows: amp/R: gene for 
ampicillin resistance, SpeI: restriction site for linearization. (E) tEGFR-F2A-Neo transposon.  
Annotated as follows: HEF-1α/p: promoter for human elongation factor-1α; BGH: bovine 
growth hormone poly adenylation sequence; F2A: self-cleavable peptide F2A; Neo/r: gene 
for neomycin resistance;  IR/DR: inverted repeat/direct repeat; ColE1: a minimal E.coli origin 
of replication; Kan/R: gene for kanamycin resistance; Kan/p: promoter for kanamycin 
resistance gene. (F) CAR-L transposon. Annotated as follows: HEF-1α/p: promoter for 
human elongation factor-1α; Zeocin R: gene for zeomycin resistance; BGH: bovine growth 
hormone poly adenylation sequence; IR/DR: inverted repeat/direct repeat; ColE1: a minimal 
E.coli origin of replication; Kan/R: gene for kanamycin resistance; Kan/p: promoter for 
kanamycin resistance gene. 
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6.1.2 Nimotuzumab-derived CAR transposon 
Nimotuzumab-derived CAR is composed of the following: a signal peptide from 
human GMCSFR2 signal peptide (amino acids 1-19, NP_001155003.1), variable light chain 
of nimotuzumab (PDB:3GKW_L) whitlow linker (GenBank: AAE37780.1), variable heavy 
chain of nimotuzumab  (PDB:3GKW_H), human IgG4 (amino acids 161-389, AAG00912.1), 
human CD28 transmembrane and signaling domains (amino acids 153-220, NP_006130), 
and human CD3-ζ intracellular domain (amino acids 52 through 164, NP_932170.1).  
Sequence of GMCSFR2, variable light chain, whitlow linker, variable heavy chain and partial 
IgG4 were human codon optimized and generated by GeneART as 0841503/pMK.  
08541503/pMK and previously described CD19CD28mZ/pSBSO (93, 94) underwent double 
digestion with NheI and XmnI restriction enzymes, ligation, transformation, large scale 
amplification and purification of plasmid NimoCD28mZ(CoOp)/pSBSO (Figure 36B) were 
performed as described above. 
6.1.3 SB11 transposase 
The hyperactive SB11 transposase under control of CMV promoter (Kan-CMV-SB11) 
was used as previously described (94, 315). 
6.1.4 pGEM/GFP/A64 
GFP under control of of a T7 promoter followed by 64 A-T base pairs and a SpeI site 
was use to in vitro transcribe GFP RNA.  The cloning of pGEM/GFP/A64 has been 
previously described (316). 
6.1.5 Cetuximab-derived CAR/pGEM-A64 
Cetuximab-derived CAR was cloned into an intermediate vector, pSBSO-MCS, by 
NheI and XmnI double digestion of CetuxCD28mZ(CoOp)/pSBSO and 
CD19CD28mZ(CoOp)/pSBSO-MCS. Cetux-CAR insert and pSBSO-MCS backbone were 
isolated by extraction from agarose gel after electrophoresis and ligated, transformed, and 
amplified on large-scale as described in generation of CetuxCD28mZ(CoOp)/pSBSO. 
CetuxCD28mZ(CoOp) was cloned into pGEM/GFP/A64 plasmid to place Cetux-CAR under 
control of a T7 promoter for in vitro transcription of RNA with artificial poly-A tail 64 
nucleotides in length. CetuxCD28mZ(CoOp)/pSBSO-MCS was digested with NheI and 
EcoRV at 37ºC while pGEM/GFP/A64 was sequentially digested with XbaI at 37ºC then 
SmaI at 25ºC. Digested Cetux-CAR insert and pGEM/A64 backbone were separated by 
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electrophoresis in 0.8% agarose gel run at 150 volts for 45 minutes and visualized by 
ethidium bromide staining and UV light exposure.  Fragments were excised from gel and 
purified by Qiaquick Gel Extraction (Qiagen) and ligated using T4 DNA ligase (Promega) at 
3:1 insert to vector molar ratio and incubated at 16ºC overnight.  Dam -/- C2925 chemcially 
competent bacteria (Invitrogen) were transformed by heat shock and cultured overnight at 
37ºC on ampicillin-containing agar for selection of clones containing pGEM/A64 backbone. 
Eight clones were selected for small-scale DNA amplification by inoculation in TB media with 
ampicillin antibiotic selection and cultured on a shaker at 37ºC for 8 hours.  Purification of 
DNA was performed using MiniPrep kit (Qiagen) and analytical restriction enzyme digest 
and subsequent electrophoresis determined which clones expressed correct ligation 
product, CetuxCD28mZ/pGEM-A64 (Figure 36C).  A positive clone was selected an 
inoculated 1:1000 in TB containing ampicillin. After 18 hours of culture at 37ºC, DNA was 
purified using EndoFree Plasmid Purification kit (Qiagen).  Spectrophotometry analysis 
confirmed high quality DNA by OD260/280 ration between 1.8 and 2.0. 
6.1.6 Nimotuzumab-derived CAR/pGEM-A64 
NimoCD28mZ(CoOp)/pSBSO was digested sequentially with NheI at 37ºC and SfiI 
at 50ºC while pGEM/GFP/A64 was digested sequentially with XbaI at 37ºC and SfiI at 50ºC.  
NimoCD28mZ(CoOp) was cloned into pGEM/GFP/A64 plasmid to place Nimo-CAR under 
control of a T7 promoter for in vitro transcription of RNA with artificial polyA tail 64 
nucleotides in length. Digested Nimo-CAR insert and pGEM/A64 backbone were separated 
by electrophoresis in 0.8% agarose gel run at 150 volts for 45 minutes and visualized by 
ethidium bromide staining and UV light exposure.  Fragments were excised from gel and 
purified by Qiaquick Gel Extractions (Qiagen) and ligated using T4 DNA ligase (Promega) at 
3:1 insert to vector molar ratio and incubated at 16ºC overnight.  Dam-/- C2925 chemically 
competent bacteria (Invitrogen) were transformed by heat shock and cultured overnight at 
37ºC on ampicillin-containing agar for selection of clones containing pGEM/A64 backbone. 
Eight clones were selected for small-scale DNA amplification by inoculation in TB media with 
ampicillin antibiotic selection and cultured on a shaker at 37ºC for 8 hours.  Purification of 
DNA was performed using MiniPrep kit (Qiagen) and analytical restriction enzyme digest 
and subsequent electrophoresis determined which clones expressed correct ligation 
product, NimoCD28mZ/pGEM-A64 (Figure 36D).  A positive clone was selected an 
inoculated 1:1000 in TB containing ampicillin. After 18 hours of culture at 37ºC, DNA was 
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purified using EndoFree Plasmid Purification kit (Qiagen).  Spectrophotometry analysis 
confirmed high quality DNA by OD260/280 ration between 1.8 and 2.0. 
6.1.7 Truncated EGFR transposon 
Truncated EGFR was cloned into a SB transposon linked via self-cleavable peptide 
sequence F2A to a gene for neomycin resistance.  A codon-optimized truncated form of 
human EGFR (accession NP_005219.2) containing only extracellular and transmembrane 
domains, 0909312 ErbB1/pMK-RQ, was synthesized by GeneArt (Regensburg, Germany).  
ErbB1/pMK-RQ was digested with NheI and SmaI at 37ºC while tCD19-F2A-Neo/pSBSO 
(produced by S. Olivares) was sequentially digested with NheI at 37ºC, then NruI at 37ºC 
with a purification step between (Qiaquick Gel Extraction kit, Qiagen).  tEGFR insert and 
F2A-Neo/pSBSO backbone were separated by gel electrophoresis on 0.8% agarose gel run 
at 150 volts for 45 minutes.  Bands of predicted sizes were isolated (Qiaquick Gel Extraction 
kit, Qiagen) and ligated with T4 DNA Ligase (Promega) overnight at 16ºC. TOP10 
chemically competent cells (Invitrogen) were heat-shock transformed with ligation production 
and cultured overnight on agar containing kanamycin.  Five clones were inoculated for small 
scale DNA amplification by culture in TB containing kanamycin for 8 hours.  DNA purification 
by Mini Prep kit (Qiagen) and subsequent analytical restriction enzyme digest identified 
clones positive for tErbB1-F2A-Neo/pSBSO (Figure 36E).  A positive clone was inoculated 
into culture at 1:1000 for large-scale DNA amplification and cultured on a shaker at 37ºC for 
16 hours. Purification of DNA from bacteria in log-phase growth was performed using 
EndoFree Plasmid Purification kit (Qiagen) and spectrophotometry verified DNA purity by 
OD 260/280 reading between 1.8 and 2.0.   
6.1.8 CAR-L transposon 
A previously described 2D3 hybridoma (94) was used to derive the scFv sequence of 
CAR-L.  Briefly, RNA was extracted from hybridoma by RNeasy Mini Kit (Qiagen), according 
to manufacturer’s instructions.  Reverse transcription via Superscript III First Strand kit 
(Invitrogen) generated a cDNA library. PCR using degenerate primers for the FR1 region 
amplified mouse variable heavy and light chains, which were subsequently ligated into 
TOPO TA vector. CAR-L was constructed as a codon optimized sequence, as follows: 
Following a human GMCSFR signal peptide (amino acid 1-22; NP_758452.1), 2D3-derived 
scFv was fused to human CD8α extracellular domain (amino acid 136-182; NP_001759.3) 
and transmembrane and intracellular domains of human CD28 (amino acid 56-123; 
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NP_001230006.1) and terminates in human intracellular domain of CD3ζ (amino acid. 48-
163; NP_ 000725.1).  The CAR-L protein was synthesized at GeneART, then excised and 
ligated into a SB transposon with a self-cleavable 2A peptide fused to a Zeomycin 
resistance gene, designated CAR-L-2A-Zeo (Figure 36F) (286) (Performed by D. 
Rushworth). 
6.2  Cell lines: propagation and modification 
All cell lines were maintained in complete media, defined as Dulbecco’s modified 
eagle media (DMEM) (Life Technologies, Grand Island, NY), supplemented with 10% heat 
inactivated fetal bovine serum (FBS) (HyClone, ThermoScientific) and 2mM Glutamax-100 
(Gibco, Life Technologies) at 5% CO2, 95% humidity and 37ºC, unless otherwise noted.  
Adherent cell lines were routinely cultured to 70-80% confluency, then passaged 1:10 
following dissociation with 0.05% Trypsin-EDTA (Gibco). Identity of cell lines was validated 
by STR DNA fingerprinting using the AmpF_STR Identifier kit according to manufacturer's 
instructions (Applied Biosystems, cat# 4322288).  The STR profiles were compared to 
known ATCC fingerprints (ATCC.org), and to the Cell Line Integrated Molecular 
Authentication database (CLIMA) version 0.1.200808 (http://bioinformatics.istge.it/clima/) 
(Nucleic Acids Research 37:D925-D932 PMCID: PMC2686526). The STR profiles matched 
known DNA fingerprints. 
6.2.1 OKT3-loaded K562 clone 4 
K562 clone 4 was received as a gift from Carl June, M.D. at the University of 
Pennsylvania and has been previously described (95, 97).  Clone 4 are modified to express 
tCD19, CD86, CD137L, CD64 and a membrane IL15-GFP fusion protein and have been 
manufactured as a working cell bank for pre-clinical and clinical studies under PACT.  K562 
clone 4 can be made to express anti-CD3 antibody, OKT3, through binding to the CD64 high 
affinity Fc receptor.  To load OKT3 onto K562 clone 4, cells are cultured overnight in X-VIVO 
serum free media (Lonza, Cologne, Germany) with 2% N-acetylcysteine at a density of 
1x106 cells/mL. This step clears the Fc receptors for optimal binding of OKT3.  The following 
day, cells are washed and resuspended at 1x106 cells/mL in X-VIVO media with 2% N-
acetylcysteine and irradiated at achieve 100 Gy.  Cells are washed and resuspended at 
1x106 cells/mL in PBS and OKT3 (eBioscience, San Diego, CA) is added at a concentration 
of 1 mg/mL and incubated on roller at 4ºC for 30 minutes.  Cells are washed again, stained 
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to verify expression of costimulatory molecules and OKT3 by flow cytometry, and 
cryopreserved. 
6.2.2 tEGFR+ K562 clone 27 
K562 clone 27 was derived from K562 clone 9, gift from Carl June, M.D. at the 
University of Pennsylvania. K562 clone 9 was lentivirally transduced, as previously 
described (95, 97), to express tCD19, CD86, CD137L, and CD64.  Clone 27 were modified 
from clone 9 to stably express a membrane tethered IL15-IL15Rα fusion protein (317) via 
SB transfection, cloned by limiting dilution, and verified to have high expression of all 
transgenes by flow cytometry (performed by L. Hurton).  K562 clone 27 was modified to 
express truncated EGFR by SB transfection of tErbB1-F2A-Neo/pSBSO.  K562 clone 27 
expressing EGFR were incubated with PE-labeled EGFR-specific antibody (BD Biosciences, 
Carlsbad, CA, cat# 555997) and  anti-PE beads (Miltenyi Biotec, Auburn, CA), then 
separated from non-labeled cells by flow through a magnetic column (Miltenyi Biotec).  
Following magnetic selection, tEGFR+ K562 clone 27 were cultured in the presence of 1 
mg/mL G418 (Invivogen, San Diego, CA) to maintain high EGFR expression. 
6.2.3 EL4, CD19+ EL4, tEGFR+ EL4, and CAR-L+ EL4 
EL4 were obtained from ATCC and modified to express tCD19-F2A-Neo, tEGFR-
F2A-Neo or CAR-L-F2A-Neo by SB non-viral gene modification.  EL4 were electroporated in 
using Amaxa Nucelofector (Lonza) and primary mouse T cell kit (Lonza) according to 
manufacturer’s instructions.  Briefly, 2x106 EL4 cells were centrifuged at 90xg for 10 minutes 
and resuspended in 100 uL primary mouse T cell buffer with 3 ug transposon (tCD19-F2A-
Neo, tEGFR-F2A-Neo, or CAR-L-2A-Zeo) and 2 ug SB11 transposase and electroporated 
using Amaxa program X-001.  Following electroporation, cells were immediately transferred 
to pre-warmed and supplemented primary mouse T cell media, supplied with kit (Lonza).  
The following day, 1 mg/mL G418 was added to select for EL4 cells modified to express 
transgenes.  Expression was verified by flow cytometry 7 days post-modification. 
6.2.4 U87, U87low, U87med, and U87high 
U87, formally designated U87MG, were obtained from ATCC (Manassas, VA).  
U87low and U87med were generated to overexpress EGFR by modification with tErbB1-F2A-
Neo/pSBSO and SB11 using Amaxa Nucleofector and cell line Nucleofector kit T (Lonza, 
cat#VACA-1002), according to manufacturer’s instructions.  Briefly, U87 cells were cultured 
to 80% confluency, then harvested by dissociation in 0.05% Trypsin-EDTA (Gibco) and 
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counted via trypan blue exclusion using and automated cell counter (Cellometer, Auto T4 
Cell Counter, Nexcelcom, Lawrence, MA).  1x106 U87 cells were suspended in 100 uL cell 
line kit T electroporation buffer in the presence of 3 ug of tErbB1-F2A-Neo/pSBSO 
transposon and 2 ug SB11 transposase, transferred to a cuvette and electroporated via 
program U-029.  Immediately following electroporation, cells were transferred to 6-well plate 
and allowed to recover in complete DMEM media.  The following day, 0.35 mg/mL G418 
(Invivogen) was added to select for transgene expression.  After propagation to at least 
1x106 cells, flow cytometry was performed to assess EGFR expression. Electroporated U87 
cells demonstrated modest increase in EGFR expression relative to unmodified U87 and 
were designated U87low.  To generate U87med cells, U87 cells were lipofectamine-transferred 
with tErbB1-F2A-Neo and SB11 using Lipofectamine 2000 (Invitrogen) according to 
manufacturer’s instructions.  The following day, 0.35 mg/mL G418 was added to culture to 
select for neomycin resistance.  After propagation of cells to significant number, flow 
cytometrey revealed a two-peak population, with mutually exclusive modest or high EGFR 
overexpression, relative to U87 cells.  Cells were stained with anti-EGFR-PE and FACS 
sorted for the top 50% of highest peak.  Careful subcloning when cells reached no greater 
than 70% confluence and flow cytometry analysis was routinely performed to ensure cells 
maintained EGFR expression.  U87high are U87-172b cells overexpressing wtEGFR, and 
were a kind gift from Oliver Bölger, Ph.D. 
6.2.5 U87-ffLuc-mKate and U87med-ffLuc-mKate 
U87 and U87med cells were lentivirally transduced to express ffLuc-mKate transgene 
(Figure 37), similar to a previously described protocol (318). Briefly, 293-METR packaging 
cells were transfected with pcMVR8.2, VSV-G and pLVU3GeffLuc-T2AmKates158A in the 
presence of Lipofectamine 2000 (Invitrogen), according to manufacturer’s instructions. After 
48 hours, virus-like particles (VLP) were harvested and concentrated on 100 kDa NMWL 
filters (Millipore, Billerica, MA).  To transduce U87 and U87med, cells were plated in 6 well 
plates until 70-80% confluent, then ffLucmKate VLPs were added in conjunction with 8 
µg/mL polybrene.  The plate was centrifuged at 1800 rpm for 1.5 hours, then incubated for 6 
hours. Following incubation, supernatant was removed. Twenty-four hours after 
transduction, cells reached confluency and were subcultured and FACS sorted for cells 
expressing moderate levels of ffLuc-mKate (Performed by D. Deniger). 
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Figure 37.  Vector map of pLVU3G-effLuc-T2A-mKateS158A.  Annotations are as 
follows: B1: Gateway donor site B1; effLuc: enhanced firefly luciferase; T2A: T2A ribosomal 
slip site; mKateS158A: enhanced mKate red fluorescent protein; B2: Gateway donor site B2, 
HBV PRE: Hepatitis B post-translational regulatory element; HIV SIN LTR: HIV self-
inactivating long terminal repeat; ampR: ampicillin resistance; LTR: long terminal repeat; HIV 
cPPT: HIV central polypurine tract. 
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6.2.6 Human renal cortical epithelial cells (HRCE) 
HRCE were obtained from Lonza, described to be taken from proximal and distal 
renal tubules of healthy individuals, and were cultured in complete Renal Growth Media 
(Lonza, cat# CC-3190) supplemented with recombinant human epidermal growth factor 
(rhEGFR), epinephrine, insulin, triiodothyronine, hydrocortisone, transferrin, 10% heat-
inactivated FBS (HyClone), and 2mM Glutamax-100 (Gibco). HRCE have finite lifespan in 
vitro, therefore, all assays were performed with cells that underwent less than 10 passages.  
Cells were cultured to 70-80% confluency, then detached by 0.05% Trypsin-EDTA (Gibco) 
and passaged 1:5 in fresh, complete Renal Growth Media. 
6.2.7 NALM-6, T98G, LN18 and A431 
NALM-6, T98G, LN18, and A431 were all obtained from ATCC and cultured as 
described for cell lines. 
6.3 T cell modification and culture 
Peripheral blood mononuclear cells were obtained from healthy donors from Gulf 
Coast Regional Blood Bank and isolated by Ficoll-Paque (GE Healthcare, Milwaukee, WI) 
and cryopreserved.  All T-cell cultures were maintained in complete RPMI-1640 (HyClone), 
supplemented with 10% FBS (HyClone) and 2mM Glutamax (Gibco).  
6.3.1 Electroporation with SB Transposon/Transposase 
SB electroporation was performed as previously described (94).  PBMC were thawed 
on the day of electroporation and rested in cytokine-free media complete RPMI-1640 at a 
density of 1x106 cells/mL for 2 hours.  Following resting period, cells were centrifuged at 
200xg for 8 minutes, then resuspended in media and counted by trypan blue exclusion using 
an automated cell counter (Cellometer, Auto T4 Cell Counter, Nexcelcom). PBMC were 
centrifuged again and resuspended at 2x108/mL in human T cell electroporation buffer 
(Lonza, cat# VPA-1002), then 100 µL of cell suspension was mixed with 15 µg transposon 
(either Cetux- or Nimo-CAR) and 5 µg SB11 transposase, transferred to electroporation 
cuvette, and electroporated via Amaxa Nucleofector (Lonza) using program U-014 for 
unstimulated human T cells.  Following electroporation, cells were immediately transferred 
to phenol-free RPMI supplemented with 20% heat-inactivated FBS (HyClone), and 2 mM 
Glutamax-100 (Gibco) to recover overnight.  The next day, cells were analyzed by flow 
cytometry for CD3 and Fc (IgG portion of CAR). 
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6.3.2 Stimulation and Culture of CAR+ T cells 
Twenty-four hours after electroporation, cells were stimulated with 100 Gy-irradiated 
EGFR+ K562 clone 27 artificial antigen presenting cells (aAPC) at a ratio of 2 CAR+ T cells:1 
aAPC.  T cells were restimulated every 7-9 days following evaluation of CAR expression by 
flow cytometry.  Throughout culture period, T cells received 30 ng/mL IL-21 (Peprotech, 
Rocky Hill, NJ) added to culture every 2-3 days.  IL-2 (Aldeleukin, Novartis, Switzerland) 
was added to culture after second stimulation cycle at 50 U/mL, every 2-3 days.  At day 14, 
cultures were evaluated for the presence of NK cells, designated as CD3negCD56+ cells 
present in culture.  If NK cells represented >10% of cell population, NK cell depletion was 
performed by labeling NK cells with CD56-specific magnetic beads (Miltenyi Biotec) and 
sorting on LS column (Miltenyi Biotec).  Flow cytometry of negative flow through containing 
CAR+ T cells verified successful depletion of NK cell subset from culture.  Cultures were 
evaluated for function when CAR was expressed on >85% of CD3+ T cells, usually following 
5 stimulation cycles. 
6.3.3 In vitro transcription of RNA 
CetuxCD28mZ/pGEM-A64, NimoCD28mZ/pGEM-A64, or GFP/pGEM-A64 was 
digested with SpeI at 37 ºC for 4 hours to provide linear template for in vitro RNA 
transcription. Complete linearization of template confirmed by agarose gel electrophoresis in 
0.8% agarose gel and presence of single band and remaining digest purified by QiaQuick 
PCR Purification (Qiagen) and eluted in low volume to achieve concentration of 0.5 µg/µL. In 
vitro transcription reaction was performed using T7 mMACHINE mMESSAGE Ultra (Ambion, 
Life Technologies, cat# AM1345) according to manufacturer’s protocol and incubated at 
37ºC for 2 hours.  After transcription of mRNA, DNA template was degraded by addition of 
supplied Turbo DNAse at 1 unit/µg DNA template and incubated an additional 30 minutes at 
37ºC.  Transcribed RNA was purified using RNeasy Mini kit (Qiagen).  Concentration and 
purity (OD 260/280 value = 2.0-2.2) were determined by spectrophotometry and frozen in 
single-thaw aliquots at -80ºC. Quality of RNA product evaluated by gel electrophoresis on 
formaldehyde-containing agarose gel (1% agarose, 10% 10x MOPS Running Buffer, 6.7% 
formaldehyde) at 75 volts for 80 minutes in 1xMOPS Running Buffer and visualization of 
single, delineated band. 
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6.3.4 Polyclonal T-cell expansion 
Numeric expansion of T cells independent of antigen was achieved by culture with 
100 Gy-irradiated K562 clone 4 loaded with OKT3 delivering proliferative stimulus through 
cross-linking CD3.  aAPC were added at a density of 10:1 or 1:2 (T cells: aAPC) every 7-10 
days, 50 U/mL IL-2 was added every 2-3 days.  Media changes were performed throughout 
culture to keep T cells at a density between 0.5-2x106 cells/mL. 
6.3.5 RNA electro-transfer to T cells 
T cells underwent stimulation 3-5 days prior to RNA transfer by co-culture with 100 
Gy-irradiated OKT3-loaded K562 clone 4 as described above. Prior to electro-transfer, T 
cells were harvested and counted by trypan blue exclusion using an automated cell counter 
(Cellometer, Auto T4 Cell Counter, Nexcelcom). During preparation of cells, RNA was 
removed from -80ºC freezer and thawed on ice. T cells were centrifuged at 90xg for 10 
minutes, and supernatant was carefully aspirated to ensure complete removal without 
disruption of cell pellet. T cells were suspended in P3 Primary Cell 4D-Nucleofector buffer 
(Lonza, cat # V4XP-3032) to a concentration of 1x108/mL and 20 µL of each T-cell 
suspension was mixed with 3 µg of in vitro transcribed RNA, then transferred to 
Nucleofector cuvette strip (Lonza, cat # V4XP-3032).  Cells were electroporated in Amaxa 
4D Nucleofector (Lonza) using program DQ-115, then allowed to rest in cuvette up to 15 
minutes.  Following rest period, warm recovery media, phenol-free RPMI 1640 (HyClone) 
supplemented with 2mM Glutamax-100 (Gibco) and 20% heat-inactivated FBS (HyClone), 
was added to cuvette and cells were gently transferred to 6 well plate containing recovery 
media and transferred to a tissue culture incubator. After 4 hours, 50 U/mL IL-2 and 30 
ng/mL IL-21 were added to the T cells.  Four to twenty-four hours after RNA transfer, T cells 
were analyzed for expression of CAR by flow cytometry for Fc.  All functional assays were 
carried out at 24 hours post-RNA transfer. 
6.4 Immunostaining and Flow Cytometry 
6.4.1 Acquisiton and analysis: 
Flow cytometry data were collected on FACS Calibur (BD Biosciences, San Jose, 
CA) and acquired using CellQuest software (version 3.3, BD Biosciences).  Analysis of flow 
cytometry data was performed using FlowJo software (version x.0.6, TreeStar, Ashland, 
OR). 
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6.4.2 Surface Immunostaining and Antibodies: 
Immunostaining of up to 1x106 cells was performed with monoclonal antibodies 
conjugated to the following dyes at the following dilutions (unless otherwise stated): 
fluorescein (FITC, 1:25), phycoerythrin (PE, 1:40), peridinin chlorophyll protein conjugated to 
cyanine dye (PerCPCy5.5, 1:25), allophycocyanin (APC, 1:40), AlexaFluor488 (1:20), 
AlexaFluor647 (1:20). All antibodies were purchased from BD Biosciences, unless otherwise 
stated.  Antibodies specific for the following were human-specific, unless otherwise noted:  
CD3 (clone SK7), CD3 (clone UCHT1), CD3 (hamster anti-mouse, clone 500A2), CD4 
(clone RPA-T4), CD8 (clone SK1), CD19 (HIB19), CD27 (clone L128), CD28 (clone L293), 
CD45RA (clone HI100), CD45RO (clone HI100), CD56 (clone B159), CD62L (clone DREG-
56), CCR7 (clone GD43H7, Biolegend, San Diego, CAR PerCPCy5.5 diluted 1:45), EGFR 
(clone EGFR.1, PE diluted 1:13.3), Fc (to detect CAR, clone HI10104, Invitrogen), IL15 
(clone 34559, R&D Systems, Minneapolis, MN, PE diluted 1:20), murine F(ab’)2 (to detect 
OKT3 loaded on K562, Jackson Immunoresearch, West Grove, PA, cat# 115-116-072, PE 
diluted 1:100), TNF-α (clone mAb11, PE diluted 1:40) and IFN-γ (clone 27, APC diluted 
1:66.7), pErk1/2 (clone 20A, AlexaFluor 647), pp38 (clone 36/p38, PE) and Ki-67 (clone 
B56, FITC, 1:20, BD Biosciences).  Surface molecules were stained in FACS buffer (PBS, 
2% FBS, 0.5% sodium azide) for 30 minutes in the dark at 4ºC. 
6.4.3 Quantitative Flow Cytometry: 
Quantitative flow cytometry was performed using Quantum Simply Cellular 
polystyrene beads (Bangs Laboratories, Fishers, IN).  Five bead populations are provided, 
four populations with increasing amounts of anti-murine IgG, and therefore a known 
antibody binding capacity (ABC) and one blank population.  EGFR-PE (BD Biosciences, 
cat#555997) was incubated with beads at a saturated concentration (1:3 dilution, per 
manufacturer’s recommendation) synchronously with immunostaining of target cells.  MFI of 
EGFR-PE binding to microspheres was used to create a standard curve, to which a linear 
regression was fit using QuickCal Data Analysis Program (version 2.3, Bangs Laboratories) 
(Figure 38).  Applying measured MFI of EGFR-PE binding to target cells, less the amount of 
background autofluroescence, to the linear regression yielded a mean number of EGFR 
molecules expressed per cell. 
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Figure 38. Standard curve for relating MFI to ABC for quantitative flow cytometry. 
Following incubation with saturating amounts anti-EGFR-PE, microsphere bead standard 
samples with known antibody binding capacity were acquired on flow cytometer.  Standard 
curve was generated by plotting known antibody binding capacity against measured mean 
fluorescence intensity acquired by flow cytometry.  
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6.4.4 Intracellular cytokine staining and flow cytometry 
T cells were co-cultured with target cells at a ratio of 1:1 for 4-6 hours in the 
presence of 4000 x diluted GolgiStop (BD Biosciences). Unstimulated T cells served as 
negative controls, while T cells treated with Leukocyte Activation Cocktail, containing 
PMA/Ionomycin and brefeldin A (BD Biosciences) diluted 1000x served as positive controls. 
An EGFR-specific monoclonal antibody (clone LA1, Millipore) was used to block interaction 
of CAR and EGFR interaction. Intracellular cytokine staining was performed after surface 
immunostaining by fixation/permeabilization in Cytofix/Cytoperm buffer (BD Biosciences) for 
20 minutes in the dark at 4ºC, followed by staining of intracellular cytokine in 1x Perm/Wash 
Buffer (BD Biosciences) for 30 minutes, in the dark at 4ºC. Antibodies used were TNF-α (BD 
Biosciences, clone mAb11, PE diluted 1:40) and IFN-γ (BD Biosciences, clone 27, APC 
diluted 1:66.7).  Following intracellular cytokine staining, cells were fixed with 0.5% 
paraformaldehyde (CytoFix, BD Biosciences) until samples were acquired on FACS Calibur. 
6.4.5 Measuring phosphorylation by flow cytometry:  
T cells were co-cultured with target cells at a ratio of 1:1 for 45 minutes, unless 
otherwise indicated. Following activation, T cells centrifuged 300xg for 5 min and 
supernatant decanted. T cells were lysed and fixed by addition of 20 volumes of 1x 
PhosFlow Lyse/Fix buffer (BD Biosciences), pre-warmed to 37ºC and incubated at 37ºC for 
10 minutes.  Following centrifugation, T cells are permeabilized by addition of ice-cold 
PhosFlow Perm III Buffer (BD Biosciences) while vortexing and incubated on ice in the dark 
for 20 minutes.  After incubation, cells were washed with FACS Buffer and resuspended in 
100 µL staining solution.  Staining solution was composed of antibodies against CD4 (clone 
SK3, FITC), CD8 (clone SK1, PerCPCy5.5), pErk1/2 (clone 20A, AlexaFluor 647), pp38 
(clone 36/p38, PE) and FACS buffer, all present at the same ratio and incubated for 20 
minutes in the dark at room temperature.  Cells were fixed with 0.5% paraformaldehyde and 
analyzed by flow cytometry within 24 hours.   
6.4.6 Viability Staining 
Staining for Annexin V (BD Biosciences) and 7-AAD (BD Biosciences) or propidium 
iodide (PI) (BD Biosciences) was used to determine cell viability and was performed in 1x 
Annexin Binding buffer, with staining for CD4 or CD8, for 20 minutes, in the dark, at room 
temperature.  Percentage of viable cells was determined as %AnnexinVneg7-AADneg or 
%AnnexinVnegPIneg in CD4 or CD8 gated T-cell population. 
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6.4.7 Staining for cellular proliferation marker Ki-67: 
Proliferation marker Ki-67 was measured by intracellular flow cytometry. T cells were 
co-cultured with adherent target cells at a ratio of 1:5 for 36 hours, then T cells were 
harvested from culture by removing supernatant and centrifugation at 300xg. T cells were 
then fixed and permeabilized by drop-wise addition of ice-cold 70% ethanol while vortexing 
at high speed.  T cells were then stored at -20ºC for 2-24 hours before staining. Cells were 
stained with Ki-67 (clone B56, FITC, 1:20, BD Biosciences), CD4 (clone RPA-T4), and CD8 
(clone SK1) in 100 µL FACs Buffer for 30 min in the dark at room temperature, then 
immediately analyzed by flow cytometry. 
6.5 T-cell functional assays 
6.5.1 CAR downregulation: 
CAR+ T cells and targets were harvested and counted by trypan blue exclusion using 
an automated cell counter (Cellometer, Auto T4 Cell Counter, Nexcelcom), then mixed at a 
1:1 ratio in a 12-well plate, and individual wells were harvested at each time point to 
measure CAR surface expression on T cells.  Negative controls for downregulation were T 
cells plated without stimuli.  Staining for T cells by CD3, CD4 and CD8 expression and co-
staining for CAR by Fc was analyzed on flow cytometer.  Percent downregulation of CAR 
was calculated as [CAR expression following stimuli]/[CAR expression without stimuli] x 100.   
6.5.2 Secondary activation and cytokine production 
CAR+ T cells and adherent targets were harvested and counted by trypan blue 
exclusion using an automated cell counter (Cellometer, Auto T4 Cell Counter, Nexcelcom), 
then mixed at a ratio of 1:1 in a 12-well plate.  After 24 hours of co-culture, T cells were 
harvested from culture by removing supernatant and washing adherent cells with PBS. T 
cells were spun at 300xg for 5 minutes, then resuspended in media and counted by trypan 
blue exclusion using an automated cell counter (Cellometer, Auto T4 Cell Counter, 
Nexcelcom). T cells were stimulated with targets at 1:1 ratio and intracellular cytokine 
production analysis as described above. 
6.5.3 Long-term cytotoxicity assay 
The day prior to initiation of assay, adherent U87 and U87high cells were harvested, 
counted, and 40,000 target cells were plated in each well of a 6-well plate in complete 
DMEM and incubated in tissue culture incubator overnight.  On the day of assay, CAR+ T 
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cells were harvested, counted by trypan blue exclusion, and added at a 1:5 E:T ratio to 
plated target cells.  Negative control wells had no T cells added.  At each assay time point, T 
cells were removed by discarding supernatant and washing the well with PBS.  Adherent 
cells were dissociated from wells by 0.05% Trypsin-EDTA (Gibco).  Microscopy was 
performed to visually ensure complete detachment of cells from well.  Harvested cells were 
spun down and resuspended in 100 uL of media, then counted by trypan blue exclusion 
using a hemacytometer. Percent surviving cells was calculated as [cell number after T cell 
co-culture]/[cell number with no T cell co-culture] x 100.  
Long-term co-culture with EL4 was performed by mixing T cells and either tEGFR+ 
EL4 or CAR-L+ EL4 at a ratio of 1:1 and monitoring relative proportion of CAR+ T cell to EL4 
cell over time by flow cytometry.  Human T cells were detected by anti-human CD3 antibody 
(clone UCHT1), not cross-reactive for murine CD3.  EL4 cells were detected by anti-murine 
CD3 (clone 500A2), not cross-reactive for human CD3.  
6.5.4 Chromium release assay 
Specific cytotoxicity was assessed via standard 4-hour chromium release assay, as 
previously described (94). Target cells were harvested and counted by trypan blue exclusion 
using an automated cell counter (Cellometer, Auto T4 Cell Counter). No less than 250,000 
cells were aliquoted, then centrifuged at 300xg for 5 minutes and supernatant was 
discarded.  Next, 0.1 µCi of 51Cr was added to each target and incubated for 1-1.5 hours in a 
tissue culture incubator at 37ºC.  100,000 T cells per well were plated in triplicate and 
serially diluted at 1:2 ratio to give a final effector to target (E:T) ratio of 20:1, 10:1, 5:1, 2.5:1 
and 1.25:1 in a 96-well V-bottom plate (Corning, Corning, NY) and placed in a tissue culture 
incubator. Media only was placed in wells designated for minimum chromium release 
control.  Following labeling with chromium, targets were washed three times with 10 mL 
PBS, then resuspended at a final concentration of 125,000 cells/mL, thoroughly mixed, and 
100 µL was added to each row, included all T-cell containing rows, a minimum release row, 
and a maximum release row.  Plates were centrifuged at 300xg for 3 minutes.  Following 
centrifugation, 100 µL of 0.1% Triton X-100 (Sigma-Aldrich, St. Louis, MO) was added to 
maximum release row, and plates were placed in tissue culture incubator for 4 hours. 
Following incubation, plates were then harvested by removal of 50 µL supernatant, without 
disrupting cell pellet, which was transferred to LumaPlate-96 (Perkin-Elmer, Waltham, MA) 
and allowed to dry overnight.  The following day, plates were sealed with Top-Seal (Perkin-
Elmer) and scintillation measured on TopCount NXT (Perkin-Elmer).  Percent specific lysis 
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was calculated as [(51Cr released – minimum) / (maximum– minimum)] x 100 where 
maximum and minimum values were averaged for each triplicate. 
6.6 High-throughput gene expression and CDR3 sequencing 
6.6.1 Analysis of gene expression by direct imaging of mRNA transcripts 
Direct imaging and quantification of mRNA molecules was performed as previously 
described (319-322).  Cells prior to or following expansion were positively sorted for CD4 
and CD8 expression by incubating with CD4 and CD8 magnetics beads (Miltenyi Biotec), 
respectively, and sorting on LS column.  Flow cytometry was used to verify purity of CD4 
and CD8 separated populations.  1x106 T cells were lysed in 165 µL of RLT Buffer (Qiagen) 
and frozen at -80ºC in single-thaw aliquots.  RNA lysates were thawed and hybridized with 
multiplexed target-specific, color-coded reporter and biotinylated capture probes at 65ºC for 
12 hours.  Lymphocyte specific mRNA transcripts of interest were identified and two 
CodeSets were generated from RefSeq accessions were used to generate reporter and 
capture probe pairs, a Lymphocyte CodeSet, and TCR Vα and Vβ CodeSet (Appendices A 
and B).  Following hybridization, samples were processed in nCounter Prep (NanoString 
Technologies, Seattle, WA), and analyzed in nCounter Digital Analyzer (NanoString 
Technologies).  Reference genes were identified that span wide range of RNA expression 
levels: ACTB, G6PD, OA21, POLR1B, RPL27, RPS13, and TBP and were used to 
normalize data.  Normalization to positive-, negative-, and house-keeping genes was using 
nCounter RCC Collector (version 1.6.0, NanoString Technologies). A statistical test 
developed for digital gene expression profiling was used to determine differential expression 
of genes between sample pairs (322, 323). After normalization, significant differential gene 
expression in the Lymphocyte CodeSet was identified by a combination of p<0.01 and a fold 
change greater than 1.5 in at least 2/3 pairs, as previously described (322).  Heat-mapping 
of normalized values for differentially RNA transcripts was performed by hierarchical 
clustering and TreeView software, version 1.1 (324). After normalization, percentage of TCR 
Vα and Vβ were derived from count data as previously described (319). 
6.6.2 High-throughput CDR3 deep-sequencing 
TCRβ CDR3 regions were amplified and sequenced from DNA extracted from 1x106 
T cells (Qiagen DNeasy Blood and Tissue Kit, Qiagen) and carried out on ImmunoSEQ 
platform (Adaptive Technologies, Seattle, WA), as previously described (325).  
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6.7 In vivo evaluation of T cells in intracranial glioma xenograft murine model 
All animal experiments were carried out under guidance and regulation from the 
Institutional Animal Care and Use Committee (IACUC) at MD Anderson Cancer Center 
under the approved animal protocol ACUF 11-11-13131.  All mice used were 7-8 week old 
female NOD.Cg-PrkdcscidIL2Rγtm1Wjl/Sz strain (NSG) (Jackson Laboratory, Bar Harbor, ME).   
6.7.1 Implantation of guide-screw 
Mice aged 7-8 weeks were anesthetized using ketamine/xylazine cocktail (10 mg/mL 
ketamine, 0.5 mg/mL xylazine) dosed at 0.1 mL/10 g.  Implantation of guide-screw was 
performed as previously described (291). Once unresponsive to stimuli, surgical area on 
head was prepared by shaving fur and treating with povidone-iodine (polyvinylpyrrolidone 
complexed with elemental iodine) antiseptic solution.  Using surgically ascpetic technique, a 
1 cm incision was made down the middle of the cranium. An opening was made using a 1 
mm drill bit (DH#60, Plastics One, Roanoke, VA) extending 1 mm from drill (DH-0, Plastics 
One) using firm circular pressure in the right frontal lobe, 1 mm from coronal suture and 2.5 
mm from the sagittal suture..  A guide-screw (Plastics One, cat # C212SG) with a 0.50 mm 
opening in the center and a 1.57 mm shaft diameter was inserted into the drill site using a 
screwdriver (SD-80, Plastics One). Incision sites were sutured and mice were given 
0.01mg/mL buprenorphine dosed at 0.1 mL/10 grams as post-surgical analgesic. Mice 
recovered from surgery on low-power heat source until full mobility was regained.   
6.7.2 Implantation of U87-ffLucm-Kate or U87med-ffLuc-mKate tumor cells 
Mice recovered from guide-screw implantation for 2-3 weeks before intracranial 
tumors were established, as previously described (291).  U87-ffLuc-mKate or U87med-ffLuc-
mKate were dissociated from tissue culture vessel following 10 minute incubation with Cell 
Dissociation Buffer, enzyme-free, PBS (Gibco) at room temperature.  Cells were counted by 
trypan blue exclusion using hemacytometer and centrifuged at 200xg for 8 minutes.  
Following centrifugation, cells were resuspended in sterile PBS to a final concentration of 
50,000 cells/µL.  Mice were anesthetized with isoflurane (2-chloro-2-(difluoromethoxy)-1,1,1-
trifluoro-ethane), and prepared for incision as described above. While mice were undergoing 
surgical preparation, 26 gauge, 10 µL Hamilton syringes with blunt needle (Hamilton 
Company, Reno, NV cat# 80300) were prepared by placing plastic guard 2.5 mm from the 
end of syringe and loading 5 µL of cell suspension containing 250,000 cells.  After incision 
site was opened, syringes were inserted into guide screw opening and cells were injected 
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with constant slow pressure.  After completion of injection, syringes were held in place an 
additional 30 seconds to allow intracranial pressure to dissipate, then slowly removed.  
Incisions were sutured and mice were removed from isoflurane exposure.  Day of 
implantation is designated as day 0 of study.  On day 1 and 4 tumors were imaged via non-
invasive bioluminescent imaging, as described above to ensure successful tumor 
engraftment.  Mice were then divided into three groups to evenly distribute relative tumor 
flux, and then randomly assigned to receive Cetux-CAR+ T-cell treatment, Nimo-CAR+ T-cell 
treatment and no treatment. 
6.7.3 Non-invasive bioluminescent imaging of U87-ffLuc-mKate or U87med-ffLuc-mKate 
Intracranial glioma was non-invasively and serially imaged and used as a measure of 
relative tumor burden.  Ten minutes after sub-cutaneous injection of 215 µg D-luciferin 
potassium salt (Caliper Life Sciences, Perkin-Elmer), tumor flux (photons/s/cm2/steradian) 
was measured using Xenogen Spectrum (Caliper Life Sciences, Perkin-Elmer) and Living 
Image software (version 2.50, Caliper Life Sciences, Perkin-Elmer).  Tumor flux was 
measured in a delineated region of interest encompassing entire cranial region of mice.     
6.7.4 Delivery of CAR+ T cells to intracranially established U87-ffLuc-mKate or U87med-ffLuc-
mKate glioma 
Treatment of intracranial glioma xenografts began on day 5 of tumor establishment 
and continued weekly for a total of 3 T cell injections.  CAR+ T cells having completed 3 
stimulation cycles were confirmed to be >85% CAR-expressing by flow cytometry, then 
viable cells were counted by trypan blue exclusion using an automated cell counter 
(Cellometer, Auto T4 Cell Counter, Nexcelcom). CAR+ T cells were spun at 300xg for 5 
minutes, and resuspended at a concentration of 0.6x106/µL in sterile PBS.  Mice were 
prepared for cranial incision as described above, and anesthetized by isoflurane exposure. 
While mice were being prepared, 26 gauge, 10 µL Hamilton syringes with blunt needle 
(Hamilton Company, cat# 80300) were prepared by placing plastic guard 2.5 mm from the 
end of syringe and loading 5 µL of cell suspension containing 3x106 T cells.  Syringes were 
inserted into the guide-screw, extending 2.5 mm into intracranial space, and injected with 
slow, constant pressure.  After syringe was emptied, it was held in place an addition 30 
seconds to allow intracranial pressure to dissipate.  Following injection, incisions were 
sutured closed and mice were removed from isoflurane exposure.   
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6.7.5 Assessing survival of mice 
Mice were sacrificed when they displayed progressive weight loss (>25% of body 
mass), rapid weight loss (>10% loss of body mass within 48 hours) or hind limb paralysis, or 
any two of the following clinical symptoms of illness: ataxia, hunched posture, irregular 
respiration rate, ulceration of exposed tumor, or palpable tumor diameter exceeding 1.5 cm. 
6.8 Statistics 
All statistical analyses were performed in GraphPad Prism, version 6.03. Statistical 
analyses of all in vitro cell culture experimentation, including flow cytometry analysis of 
cytokine production, viability, proliferation, and surface phenotype, kinetics of cell expansion, 
long term cytotoxicity, and chromium release assay by two-way ANOVA with donor-
matching and Tukey’s post-test for multiple comparisons.  Correlation of function with 
antigen density was performed by one-way ANOVA with post-test for linear trend.  Analyses 
of in vivo bioluminescent imaging of tumor were performed using two-way ANOVA with 
repeated measures and Sidak’s post-test for multiple comparisons. Statistical analysis of 
animal survival data was performed by log-rank (Mantel-Cox) test.  Significance of findings 
defined as follows: * p<0.05, ** p<0.01, *** p<0.001, **** p <0.0001. 
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APPENDICES 
Appendix A: Lymphocyte-specific CodeSet 
Gene Name Accession 
Target 
Region Target Sequence 
ABCB1 NM_000927.3 3910-4010 
TATAGCACTAAAGTAGGAGACAAAGGAACTCAGCTCTCTGGTGGCCAGAAACAAC
GCATTGCCATAGCTCGTGCCCTTGTTAGACAGCCTCATATTTTGC 
ABCG2 NM_004827.2 285-385 AGGATTTAGGAACGCACCGTGCACATGCTTGGTGGTCTTGTTAAGTGGAAACTGCTGCTTTAGAGTTTGTTTGGAAGGTCCGGGTGACTCATCCCAACAT 
ACTB NM_001101.2 1010-1110 
TGCAGAAGGAGATCACTGCCCTGGCACCCAGCACAATGAAGATCAAGATCATTGC
TCCTCCTGAGCGCAAGTACTCCGTGTGGATCGGCGGCTCCATCCT 
ADAM19 NM_023038.3 1690-1790 
GAGAAGGTGAATGTGGCAGGAGACACCTTTGGAAACTGTGGAAAGGACATGAAT
GGTGAACACAGGAAGTGCAACATGAGAGATGCGAAGTGTGGGAAGA 
AGER NM_001136.3 340-440 GAAAGGAGACCAAGTCCAACTACCGAGTCCGTGTCTACCAGATTCCTGGGAAGCCAGAAATTGTAGATTCTGCCTCTGAACTCACGGCTGGTGTTCCCAA 
AHNAK NM_001620.1 15420-15520 
GGATTTGACCTGAATGTTCCTGGGGGTGAAATTGATGCCAGCCTCAAGGCTCCG
GATGTAGATGTCAACATCGCAGGGCCGGATGCTGCACTCAAAGTCG 
AIF1 NM_032955.1 315-415 AAAAGCGAGAGAAAAGGAAAAGCCAACAGGCCCCCCAGCCAAGAAAGCTATCTCTGAGTTGCCCTGATTTGAAGGGAAAAGGGATGATGGGATTGAAGGG 
AIM2 NM_004833.1 607-707 ACGTGCTGCACCAAAAGTCTCTCCTCATGTTAAGCCTGAACAGAAACAGATGGTGGCCCAGCAGGAATCTATCAGAGAAGGGTTTCAGAAGCGCTGTTTG 
AIMP2 NM_006303.3 507-607 CCCTCTCCCTGCTTGTGCTGCACAGGCTGCTCTGTGAGCACTTCAGGGTCCTGTCCACGGTGCACACGCACTCCTCGGTCAAGAGCGTGCCTGAAAACCT 
AKIP1 NM_020642.3 570-670 GAACATCTCTAAGGACCTCTACATAGAAGTATATCCAGGGACCTATTCTGTCACTGTGGGCTCAAATGACTTAACCAAGAAGACTCATGTGGTAGCAGTT 
AKT1 NM_005163.2 1772-1872 
TTCTTTGCCGGTATCGTGTGGCAGCACGTGTACGAGAAGAAGCTCAGCCCACCCT
TCAAGCCCCAGGTCACGTCGGAGACTGACACCAGGTATTTTGATG 
ALDH1A1 NM_000689.3 11-111 ATTGCTGAGCCAGTCACCTGTGTTCCAGGAGCCGAATCAGAAATGTCATCCTCAGGCACGCCAGACTTACCTGTCCTACTCACCGATTTGAAGATTCAAT 
ANXA1 NM_000700.1 515-615 GAAATCAGAGACATTAACAGGGTCTACAGAGAGGAACTGAAGAGAGATCTGGCCAAAGACATAACCTCAGACACATCTGGAGATTTTCGGAACGCTTTGC 
ANXA2P2 NR_003573.1 257-357 ATATTGTCTTCTCCTACCAGAGAAGGACCAAAAAGGAACTTGCATCAGCACTGAAGTCAGCCTTATCTGGCCACCTGGAGACGGTGATTTTGGGCCTATT 
APAF1 NM_181869.1 1160-1260 
TTCTGATGAAACTGCAGAATCTTTGCACACGGTTGGATCAGGATGAGAGTTTTTCC
CAGAGGCTTCCACTTAATATTGAAGAGGCTAAAGACCGTCTCCG 
ARG1 NM_000045.2 505-605 AAGGAACTAAAAGGAAAGATTCCCGATGTGCCAGGATTCTCCTGGGTGACTCCCTGTATATCTGCCAAGGATATTGTGTATATTGGCTTGAGAGACGTGG 
ARRB2 NM_004313.3 1652-1752 
CATTAATTTTTTGACTGCAGCTCTGCTTCTCCAGCCCCGCCGTGGGTGGCAAGCT
GTGTTCATACCTAAATTTTCTGGAAGGGGACAGTGAAAAGAGGAG 
ATF3 NM_001030287.2 600-700 GGCTCAGAATGGGAGGACTCCAGAAGATGAGAGAAACCTCTTTATCCAACAGATAAAAGAAGGAACATTGCAGAGCTAAGCAGTCGTGGTATGGGGGCGA 
ATM NM_000051.3 30-130 ACGCTAAGTCGCTGGCCATTGGTGGACATGGCGCAGGCGCGTTTGCTCCGACGGGCCGAATGTTTTGGGGCAGTGTTTTGAGCGCGGAGACCGCGTGATA 
ATP2B4 NM_001684.3 7640-7740 
CTTCCCATAGTATCATCTGTCCTCTGGAATGACTCTCCTGTCCCTAAAGGGGTTAA
GAGAGAGATCACCTAGAAATCCCTCTGGACACTTGTGGGTTCTT 
AXIN2 NM_004655.3 1035-1135 
CTTGTCCAGCAAAACTCTGAGGGCCACGGCGAGTGTGAGGTCCACGGAAACTGT
TGACAGTGGATACAGGTCCTTCAAGAGGAGCGATCCTGTTAATCCT 
B2M NM_004048.2 25-125 CGGGCATTCCTGAAGCTGACAGCATTCGGGCCGAGATGTCTCGCTCCGTGGCCTTAGCTGTGCTCGCGCTACTCTCTCTTTCTGGCCTGGAGGCTATCCA 
B3GAT1 NM_018644.3 145-245 CTGGACAGCGACCCCTTCTCAGACTCCAGTTGGGCCGGACTCTCCAAACCTGCTTCCGCAATGGGTGGGTTGTGAGTGCTGGTAATGAGGAGCCGTGGGT 
BACH2 NM_021813.2 3395-3495 
TGTGGCACTGTTCATCTGCTGTCCCGAAGAAACCGAGAACACATTTGGTGCACAC
TACAGCGGTCTTAGCAGCAATACTGTTCCGAAGTATCCTCTCCTC 
BAD NM_004322.2 195-295 CAGCTGTGCCTTGACTACGTAACATCTTGTCCTCACAGCCCAGAGCATGTTCCAGATCCCAGAGTTTGAGCCGAGTGAGCAGGAAGACTCCAGCTCTGCA 
BAG1 NM_004323.3 1490-1590 
CTCTTGTGATCGTGTAGTCCCATAGCTGTAAAACCAGAATCACCAGGAGGTTGCA
CCTAGTCAGGAATATTGGGAATGGCCTAGAACAAGGTGTTTGGCA 
BATF NM_006399.3 825-925 CACTGTGGGTTGCAGGCCCAATGCAGAAGAGTATTAAGAAAGATGCTCAAGTCCCATGGCACAGAGCAAGGCGGGCAGGGAACGGTTATTTTTCTAAATA 
BAX NM_138761.2 694-794 ATTTTTCTGGGAGGGGTGGGGATTGGGGGACATGGGCATTTTTCTTACTTTTGTAATTATTGGGGGGTGTGGGGAAGAGTGGTCTTGAGGGGGTAATAAA 
BCL10 NM_003921.2 1250-1350 
TGAAAATACCATCTTCTCTTCAACTACACTTCCCAGACCTGGGGACCCAGGGGCT
CCTCCTTTGCCACCAGATCTACAGTTAGAAGAAGAAGGAACTTGT 
BCL11B NM_022898.1 3420-3520 
GAGATGTAGCACTCATGTCGTCCCGAGTCAAGCGGCCTTTTCTGTGTTGATTTCG
GCTTTCATATTACATAAGGGAAACCTTGAGTGGTGGTGCTGGGGG 
BCL2 NM_000633.2 1525-1625 
CCAAGCACCGCTTCGTGTGGCTCCACCTGGATGTTCTGTGCCTGTAAACATAGAT
TCGCTTTCCATGTTGTTGGCCGGATCACCATCTGAAGAGCAGACG 
150 
 
BCL2L1 NM_138578.1 1560-1660 
CTAAGAGCCATTTAGGGGCCACTTTTGACTAGGGATTCAGGCTGCTTGGGATAAA
GATGCAAGGACCAGGACTCCCTCCTCACCTCTGGACTGGCTAGAG 
BCL2L1 NM_001191.2 260-360 ATCTTGGCTTTGGATCTTAGAAGAGAATCACTAACCAGAGACGAGACTCAGTGAGTGAGCAGGTGTTTTGGACAATGGACTGGTTGAGCCCATCCCTATT 
BCL2L11 NM_138621.2 2825-2925 
TGTTGGCACCAGAACTTAAAGCGATGACTGGATGTCTCTGTACTGTATGTATCTG
GTTATCAAGATGCCTCTGTGCAGAAAGTATGCCTCCCGTGGGTAT 
BCL2L11 NM_138621.4 257-357 CGGACTGAGAAACGCAAGAAAAAAAGACCAAATGGCAAAGCAACCTTCTGATGTAAGTTCTGAGTGTGACCGAGAAGGTAGACAATTGCAGCCTGCGGAG 
BCL6 NM_001706.2 675-775 GTTGTGGACACTTGCCGGAAGTTTATTAAGGCCAGTGAAGCAGAGATGGTTTCTGCCATCAAGCCTCCTCGTGAAGAGTTCCTCAACAGCCGGATGCTGA 
BCL6B NM_181844.3 2135-2235 
CTTTATTTGTTCTAGGGCAGCTCTGGGAACATGCGGGATTGTGGAATTGGGTCAG
GAACCCTCTCTGGTATTCTGGATGTTGTAGGTTCTCTAGCAGTCT 
BHLHE41 NM_030762.2 655-755 CGCCCATTCAGTCCGACTTGGATGCGTTCCACTCGGGATTTCAAACATGCGCCAAAGAAGTCTTGCAATACCTCTCCCGGTTTGAGAGCTGGACACCCAG 
BID NM_197966.1 2095-2195 
GCTTAGCTTTAGAAACAGTGCAACACTGGTCTGCTGTTCCAGTGGTAAGCTATGT
CCCAGGAATCAGTTTAAAAGCACGACAGTGGATGCTGGGTCCATA 
BIRC2 NM_001166.3 1760-1860 
TGGGATCCACCTCTAAGAATACGTCTCCAATGAGAAACAGTTTTGCACATTCATTA
TCTCCCACCTTGGAACATAGTAGCTTGTTCAGTGGTTCTTACTC 
BLK NM_001715.2 990-1090 AGCTTCTTGCTCCAATCAACAAGGCCGGCTCCTTTCTTATCAGAGAGAGTGAAACCAACAAAGGTGCCTTCTCCCTGTCTGTGAAGGATGTCACCACCCA 
BMI1 NM_005180.5 1145-1245 
CCTGGAGAAGGAATGGTCCACTTCCATTGAAATACAGAGTTCGACCTACTTGTAA
AAGAATGAAGATCAGTCACCAGAGAGATGGACTGACAAATGCTGG 
BNIP3 NM_004052.2 325-425 CACCTCGCTCGCAGACACCACAAGATACCAACAGGGCTTCTGAAACAGATACCCATAGCATTGGAGAGAAAAACAGCTCACAGTCTGAGGAAGATGATAT 
BTLA NM_001085357.1 890-990 GCACCAACAGAATATGCATCCATATGTGTGAGGAGTTAAGTCTGTTTCTGACTCCAACAGGGACCATTGAATGATCAGCATGTTGACATCATTGTCTGGG 
C21orf33 NM_004649.5 1340-1440 
TTGAGTTAATCAGCGTAAGGGGATTTCTAAAGCAGGCAATCCCTGTAGCCGCAGA
GAATAAACGCCTTCCCAAAATGGCAACTTCCCACAGCCACATTTC 
CA2 NM_000067.2 575-675 AGCTGTGCAGCAACCTGATGGACTGGCCGTTCTAGGTATTTTTTTGAAGGTTGGCAGCGCTAAACCGGGCCTTCAGAAAGTTGTTGATGTGCTGGATTCC 
CA9 NM_001216.2 960-1060 CAGGTCCCAGGACTGGACATATCTGCACTCCTGCCCTCTGACTTCAGCCGCTACTTCCAATATGAGGGGTCTCTGACTACACCGCCCTGTGCCCAGGGTG 
CARD9 NM_052813.2 1850-1950 
CGCTGACTTGGCCTGGAACGAGGAATCTGGTGCCCTGAAAGGCCCAGCCGGACT
GCCGGGCATTGGGGCCGTTTGTTAAGCGGCACTCATTTTGCGGAGG 
CASP1 NM_033292.2 575-675 ACAGGCATGACAATGCTGCTACAAAATCTGGGGTACAGCGTAGATGTGAAAAAAAATCTCACTGCTTCGGACATGACTACAGAGCTGGAGGCATTTGCAC 
CAT NM_001752.2 1130-1230 
ATGCTTCAGGGCCGCCTTTTTGCCTATCCTGACACTCACCGCCATCGCCTGGGAC
CCAATTATCTTCATATACCTGTGAACTGTCCCTACCGTGCTCGAG 
CBLB NM_170662.3 3195-3295 
TAATGTCGAAGTTGCCCGGAGCATCCTCCGAGAATTTGCCTTCCCTCCTCCAGTA
TCCCCACGTCTAAATCTATAGCAGCCAGAACTGTAGACACCAAAA 
CCBP2 NM_001296.3 1345-1445 
GAACAGATGGGAACCAGCTCAATTGGGTGTCCACTCAAAGTGCTCTCTCCAGGG
GCCTCAGTGACTGTGTTGCTAAACCCAGTGGTCAGTTCTCAGTTCT 
CCL3 NM_002983.2 681-781 CTGTGTAGGCAGTCATGGCACCAAAGCCACCAGACTGACAAATGTGTATCGGATGCTTTTGTTCAGGGCTGTGATCGGCCTGGGGAAATAATAAAGATGC 
CCL4 NM_002984.2 35-135 TTCTGCAGCCTCACCTCTGAGAAAACCTCTTTGCCACCAATACCATGAAGCTCTGCGTGACTGTCCTGTCTCTCCTCATGCTAGTAGCTGCCTTCTGCTC 
CCL5 NM_002985.2 280-380 AGTGTGTGCCAACCCAGAGAAGAAATGGGTTCGGGAGTACATCAACTCTTTGGAGATGAGCTAGGATGGAGAGTCCTTGAACCTGAACTTACACAAATTT 
CCNB1 NM_031966.2 715-815 AACTTGAGGAAGAGCAAGCAGTCAGACCAAAATACCTACTGGGTCGGGAAGTCACTGGAAACATGAGAGCCATCCTAATTGACTGGCTAGTACAGGTTCA 
CCND1 NM_053056.2 690-790 TTGAACACTTCCTCTCCAAAATGCCAGAGGCGGAGGAGAACAAACAGATCATCCGCAAACACGCGCAGACCTTCGTTGCCCTCTGTGCCACAGATGTGAA 
CCR1 NM_001295.2 535-635 CATCATTTGGGCCCTGGCCATCTTGGCTTCCATGCCAGGCTTATACTTTTCCAAGACCCAATGGGAATTCACTCACCACACCTGCAGCCTTCACTTTCCT 
CCR2 NM_001123041.2 20-120 ACATTCTGTTGTGCTCATATCATGCAAATTATCACTAGTAGGAGAGCAGAGAGTGGAAATGTTCCAGGTATAAAGACCCACAAGATAAAGAAGCTCAGAG 
CCR4 NM_005508.4 35-135 GGTCCTTCTTAGCATCGTGCTTCCTGAGCAAGCCTGGCATTGCCTCACAGACCTTCCTCAGAGCCGCTTTCAGAAAAGCAAGCTGCTTCTGGTTGGGCCC 
CCR5 NM_000579.1 2730-2830 
TAGGAACATACTTCAGCTCACACATGAGATCTAGGTGAGGATTGATTACCTAGTAG
TCATTTCATGGGTTGTTGGGAGGATTCTATGAGGCAACCACAGG 
CCR6 NM_031409.2 935-1035 CTTTAACTGCGGGATGCTGCTCCTGACTTGCATTAGCATGGACCGGTACATCGCCATTGTACAGGCGACTAAGTCATTCCGGCTCCGATCCAGAACACTA 
CCR7 NM_001838.2 1610-1710 
TTCCGAAAACCAGGCCTTATCTCCAAGACCAGAGATAGTGGGGAGACTTCTTGGC
TTGGTGAGGAAAAGCGGACATCAGCTGGTCAAACAAACTCTCTGA 
CD160 NM_007053.2 500-600 TTGATGTTCACCATAAGCCAAGTCACACCGTTGCACAGTGGGACCTACCAGTGTTGTGCCAGAAGCCAGAAGTCAGGTATCCGCCTTCAGGGCCATTTTT 
CD19 NM_001770.4 1770-1870 
AGATTCACACCTGACTCTGAAATCTGAAGACCTCGAGCAGATGATGCCAACCTCT
GGAGCAATGTTGCTTAGGATGTGTGCATGTGTGTAAGTGTGTGTG 
CD19R-scfv SCFV013.1 204-304 GGCACCGACTACAGCCTGACCATCTCCAACCTGGAGCAGGAGGACATCGCCACCTACTTTTGCCAGCAGGGCAACACACTGCCCTACACCTTTGGCGGCG 
151 
 
CD19RCD28 MDA_00002.1 2-102 CAGGTGTTCCTGAAGATGAACAGCCTGCAGACCGACGACACCGCCATCTACTACTGTGCCAAGCACTACTACTACGGCGGCAGCTACGCCATGGACTACT 
CD2 NM_001767.2 1400-1500 
TGGGTCTCACTACAAGCAGCCTATCTGCTTAAGAGACTCTGGAGTTTCTTATGTGC
CCTGGTGGACACTTGCCCACCATCCTGTGAGTAAAAGTGAAATA 
CD20-scfv      
(rutuximab) SCFV002.1 8-108 
GCTGTCCCAGAGCCCCGCCATCCTGAGCGCCAGCCCTGGCGAGAAGGTGACCA
TGACCTGCCGGGCCAGCAGCTCTGTGAGCTACATGCACTGGTATCAG 
CD226 NM_006566.2 163-263 TAAACAGGATACGATAAAAGTCCTTAACCAAGACGCAGATGGGAAGAAGCGTTAGAGCGAGCAGCACTCACATCTCAAGAACCAGCCTTTCAAACAGTTT 
CD244 NM_016382.2 1150-1250 
AAGAGGAACCACAGCCCTTCCTTCAATAGCACTATCTATGAAGTGATTGGAAAGA
GTCAACCTAAAGCCCAGAACCCTGCTCGATTGAGCCGCAAAGAGC 
CD247 NM_198053.1 1490-1590 
TGGCAGGACAGGAAAAACCCGTCAATGTACTAGGATACTGCTGCGTCATTACAGG
GCACAGGCCATGGATGGAAAACGCTCTCTGCTCTGCTTTTTTTCT 
CD27 NM_001242.4 330-430 CCAGATGTGTGAGCCAGGAACATTCCTCGTGAAGGACTGTGACCAGCATAGAAAGGCTGCTCAGTGTGATCCTTGCATACCGGGGGTCTCCTTCTCTCCT 
CD274 NM_014143.2 684-784 TAGGAGATTAGATCCTGAGGAAAACCATACAGCTGAATTGGTCATCCCAGAACTACCTCTGGCACATCCTCCAAATGAAAGGACTCACTTGGTAATTCTG 
CD276 NM_001024736.1 2120-2220 
ACATTTCTTAGGGACACAGTACACTGACCACATCACCACCCTCTTCTTCCAGTGCT
GCGTGGACCATCTGGCTGCCTTTTTTCTCCAAAAGATGCAATAT 
CD28 NM_006139.1 305-405 GCTTGTAGCGTACGACAATGCGGTCAACCTTAGCTGCAAGTATTCCTACAATCTCTTCTCAAGGGAGTTCCGGGCATCCCTTCACAAAGGACTGGATAGT 
CD300A NM_007261.2 0-100 CGGGGAAGTGAGAGTCGGGGATCAGTCCTGCAAGCTACGGAGTCACTACAGGGAGAGGTCTCATCACTAGAAATAGCCGAAGAACCTGCAGCCTCAACCA 
CD38 NM_001775.2 1035-1135 
CCTTGACTCCTTGTGGTTTATGTCATCATACATGACTCAGCATACCTGCTGGTGCA
GAGCTGAAGATTTTGGAGGGTCCTCCACAATAAGGTCAATGCCA 
CD3D NM_000732.4 110-210 TATCTACTGGATGAGTTCCGCTGGGAGATGGAACATAGCACGTTTCTCTCTGGCCTGGTACTGGCTACCCTTCTCTCGCAAGTGAGCCCCTTCAAGATAC 
CD3E NM_000733.2 75-175 AAGTAACAGTCCCATGAAACAAAGATGCAGTCGGGCACTCACTGGAGAGTTCTGGGCCTCTGCCTCTTATCAGTTGGCGTTTGGGGGCAAGATGGTAATG 
CD4 NM_000616.3 835-935 AGACATCGTGGTGCTAGCTTTCCAGAAGGCCTCCAGCATAGTCTATAAGAAAGAGGGGGAACAGGTGGAGTTCTCCTTCCCACTCGCCTTTACAGTTGAA 
CD40LG NM_000074.2 1225-1325 
GCATTTGATTTATCAGTGAAGATGCAGAAGGGAAATGGGGAGCCTCAGCTCACAT
TCAGTTATGGTTGACTCTGGGTTCCTATGGCCTTGTTGGAGGGGG 
CD44 NM_000610.3 2460-2560 
GTGGGCAGAAGAAAAAGCTAGTGATCAACAGTGGCAATGGAGCTGTGGAGGACA
GAAAGCCAAGTGGACTCAACGGAGAGGCCAGCAAGTCTCAGGAAAT 
CD45R-scfv SCFV006.1 222-322 TTCACCCTGAACATCCACCCCGTGGAGGAAGAGGACGCCGCCACCTACTACTGCCAGCACAGCAGAGAGCTGCCCTTCACCTTCGGCTCCGGCACCAAGC 
CD47 NM_001777.3 897-997 GCCATATTGGTTATTCAGGTGATAGCCTATATCCTCGCTGTGGTTGGACTGAGTCTCTGTATTGCGGCGTGTATACCAATGCATGGCCCTCTTCTGATTT 
CD56R-scfv SCFV008.1 197-297 ATTCAGCGGCTCTGGCTCCGGCACCGACTTCACTCTGATGATCTCTCGGGTGGAGGCCGAGGACCTGGGCGTGTACTACTGCTTTCAGGGCAGCCACGTG 
CD58 NM_001779.2 478-578 GTGCTTGAGTCTCTTCCATCTCCCACACTAACTTGTGCATTGACTAATGGAAGCATTGAAGTCCAATGCATGATACCAGAGCATTACAACAGCCATCGAG 
CD63 NM_001780.4 350-450 GTCATCATCGCAGTGGGTGTCTTCCTCTTCCTGGTGGCTTTTGTGGGCTGCTGCGGGGCCTGCAAGGAGAACTATTGTCTTATGATCACGTTTGCCATCT 
CD69 NM_001781.1 460-560 AGGACATGAACTTTCTAAAACGATACGCAGGTAGAGAGGAACACTGGGTTGGACTGAAAAAGGAACCTGGTCACCCATGGAAGTGGTCAAATGGCAAAGA 
CD7 NM_006137.6 440-540 CCTACACCTGCCAGGCCATCACGGAGGTCAATGTCTACGGCTCCGGCACCCTGGTCCTGGTGACAGAGGAACAGTCCCAAGGATGGCACAGATGCTCGGA 
CD80 NM_005191.3 1288-1388 
AAAGATCTGAAGGTCCCACCTCCATTTGCAATTGACCTCTTCTGGGAACTTCCTCA
GATGGACAAGATTACCCCACCTTGCCCTTTACGTATCTGCTCTT 
CD86 NM_006889.3 146-246 TATGGGACTGAGTAACATTCTCTTTGTGATGGCCTTCCTGCTCTCTGGTGCTGCTCCTCTGAAGATTCAAGCTTATTTCAATGAGACTGCAGACCTGCCA 
CD8A NM_001768.5 1320-1420 
GCTCAGGGCTCTTTCCTCCACACCATTCAGGTCTTTCTTTCCGAGGCCCCTGTCT
CAGGGTGAGGTGCTTGAGTCTCCAACGGCAAGGGAACAAGTACTT 
CDH1 NM_004360.2 1230-1330 
CGATAATCCTCCGATCTTCAATCCCACCACGTACAAGGGTCAGGTGCCTGAGAAC
GAGGCTAACGTCGTAATCACCACACTGAAAGTGACTGATGCTGAT 
CDK2 NM_001798.2 220-320 TCGCTGGCGCTTCATGGAGAACTTCCAAAAGGTGGAAAAGATCGGAGAGGGCACGTACGGAGTTGTGTACAAAGCCAGAAACAAGTTGACGGGAGAGGTG 
CDK4 NM_000075.2 1055-1155 
ACTTTTAACCCACACAAGCGAATCTCTGCCTTTCGAGCTCTGCAGCACTCTTATCT
ACATAAGGATGAAGGTAATCCGGAGTGAGCAATGGAGTGGCTGC 
CDKN1A NM_000389.2 1975-2075 
CATGTGTCCTGGTTCCCGTTTCTCCACCTAGACTGTAAACCTCTCGAGGGCAGGG
ACCACACCCTGTACTGTTCTGTGTCTTTCACAGCTCCTCCCACAA 
CDKN1B NM_004064.2 365-465 GCTTCCGAGAGGGGTTCGGGCCGCGTAGGGGCGCTTTGTTTTGTTCGGTTTTGTTTTTTTGAGAGTGCGAGAGAGGCGGTCGTGCAGACCCGGGAGAAAG 
CDKN2A NM_000077.3 975-1075 AAGCGCACATTCATGTGGGCATTTCTTGCGAGCCTCGCAGCCTCCGGAAGCTGTCGACTTCATGACAAGCATTTTGTGAACTAGGGAAGCTCAGGGGGGT 
CDKN2C NM_001262.2 1295-1395 
ATAATGTAAACGTCAATGCACAAAATGGATTTGGAAGGACTGCGCTGCAGGTTAT
GAAACTTGGAAATCCCGAGATTGCCAGGAGACTGCTACTTAGAGG 
CEBPA NM_004364.2 1320-1420 
GAGCTGGGAGCCCGGCAACTCTAGTATTTAGGATAACCTTGTGCCTTGGAAATGC
AAACTCACCGCTCCAATGCCTACTGAGTAGGGGGAGCAAATCGTG 
152 
 
CFLAR NM_003879.3 445-545 CAAGACCCTTGTGAGCTTCCCTAGTCTAAGAGTAGGATGTCTGCTGAAGTCATCCATCAGGTTGAAGAAGCACTTGATACAGATGAGAAGGAGATGCTGC 
CFLAR NM_001127183.1 653-753 TAGAGTGCTGATGGCAGAGATTGGTGAGGATTTGGATAAATCTGATGTGTCCTCATTAATTTTCCTCATGAAGGATTACATGGGCCGAGGCAAGATAAGC 
CHPT1 NM_020244.2 1303-1403 
GATATGGTGATATACTTTAGTGCTTTGTGCCTGCAAATTTCAAGACACCTTCATCT
AAATATATTCAAGACTGCATGTCATCAAGCACCTGAACAGGTTC 
CIITA NM_000246.3 470-570 GCCTGAGCAAGGACATTTTCAAGCACATAGGACCAGATGAAGTGATCGGTGAGAGTATGGAGATGCCAGCAGAAGTTGGGCAGAAAAGTCAGAAAAGACC 
CITED2 NM_006079.3 965-1065 AGGAGCTGCCCGAACTCTGGCTGGGGCAAAACGAGTTTGATTTTATGACGGACTTCGTGTGCAAACAGCAGCCCAGCAGAGTGAGCTGTTGACTCGATCG 
CLIC1 NM_001288.4 310-410 GTGATGGGGCCAAGATTGGGAACTGCCCATTCTCCCAGAGACTGTTCATGGTACTGTGGCTCAAGGGAGTCACCTTCAATGTTACCACCGTTGACACCAA 
CLNK NM_052964.2 1108-1208 
GAAGGAGAACAAGGATGGTAGTTTCTTGGTCCGAGATTGTTCCACAAAATCCAAG
GAAGAGCCCTATGTTTTGGCTGTGTTTTATGAGAACAAAGTCTAC 
c-MET-scfv SCFV004.1 138-238 CTGATCTACGCCGCCAGCAGCCTGAAGAGCGGCGTGCCCAGCCGGTTTAGCGGCTCTGGCTCTGGCGCCGACTTCACCCTGACCATCAGCAGCCTGCAGC 
CREB1 NM_004379.3 4855-4955 
TTTGATGGTAGGTCAGCAGCAGTGCTAGTCTCTGAAAGCACAATACCAGTCAGGC
AGCCTATCCCATCAGATGTCATCTGGCTGAAGTTTATCTCTGTCT 
CREM NM_001881.2 260-360 CTCCACCTCCTCGCGTCCGTAATCAGTGACGAGGTCCGCTACGTAAATCCCTTTGCGGCGGACAAATGACCATGGAAACAGTTGAATCCCAGCATGATGG 
CRIP1 NM_001311.4 269-369 CAACCACCCCTGCTACGCAGCCATGTTTGGGCCTAAAGGCTTTGGGCGGGGCGGAGCCGAGAGCCACACTTTCAAGTAAACCAGGTGGTGGAGACCCCAT 
CRLF2 NM_022148.2 1420-1520 
CAAGGCAGCACGTCCAAAATGCTGTAAAACCATCTTCCCACTCTGTGAGTCCCCA
GTTCCGTCCATGTACCTGTTCCATAGCATTGGATTCTCGGAGGAT 
CSAD NM_015989.4 205-305 TCAAATTCTTCTGCCTAGCCTTAGCCATTAGAGAGAGGTCCTGCTAAAGATGGACTGCAAATGCGCTTGATGGAAGGAGATGTCAATTCCACTGAAGTCC 
CSF2 NM_000758.2 475-575 AGATGAGGCTGGCCAAGCCGGGGAGCTGCTCTCTCATGAAACAAGAGCTAGAAACTCAGGATGGTCATCTTGGAGGGACCAAGGGGTGGGCCACAGCCAT 
CSNK2A1 NM_177559.2 1930-2030 
CCATTCCCACCATTGTTCCTCCACCGTCCCACACTTTAGGGGGTTGGTATCTCGT
GCTCTTCTCCAGAGATTACAAAAATGTAGCTTCTCAGGGGAGGCA 
CTGF NM_001901.2 1100-1200 
ACCACCCTGCCGGTGGAGTTCAAGTGCCCTGACGGCGAGGTCATGAAGAAGAAC
ATGATGTTCATCAAGACCTGTGCCTGCCATTACAACTGTCCCGGAG 
CTLA4 NM_005214.3 405-505 AGTCTGTGCGGCAACCTACATGATGGGGAATGAGTTGACCTTCCTAGATGATTCCATCTGCACGGGCACCTCCAGTGGAAATCAAGTGAACCTCACTATC 
CTNNA1 NM_001903.2 75-175 TCGCCCAGCTAGCCGCAGAAATGACTGCTGTCCATGCAGGCAACATAAACTTCAAGTGGGATCCTAAAAGTCTAGAGATCAGGACTCTGGCAGTTGAGAG 
CTNNB1 NM_001098210.1 1815-1915 
TCTTGCCCTTTGTCCCGCAAATCATGCACCTTTGCGTGAGCAGGGTGCCATTCCA
CGACTAGTTCAGTTGCTTGTTCGTGCACATCAGGATACCCAGCGC 
CTNNBL1 NM_030877.3 855-955 TGATGCCAACAAACTGTATTGCAGTGAAGTGCTGGCCATATTGCTCCAGGACAATGATGAAAACAGGGAATTGCTTGGGGAGCTGGATGGAATCGATGTG 
CTSC NM_001114173.1 260-360 TGCTCGGTTATGGGACCACAAGAAAAAAAAGTAGTGGTGTACCTTCAGAAGCTGGATACAGCATATGATGACCTTGGCAATTCTGGCCATTTCACCATCA 
CTSD NM_001909.3 1495-1595 
GAAGCCGGCGGCCCAAGCCCGACTTGCTGTTTTGTTCTGTGGTTTTCCCCTCCCT
GGGTTCAGAAATGCTGCCTGCCTGTCTGTCTCTCCATCTGTTTGG 
CX3CL1 NM_002996.3 140-240 AGCACCACGGTGTGACGAAATGCAACATCACGTGCAGCAAGATGACATCAAAGATACCTGTAGCTTTGCTCATCCACTATCAACAGAACCAGGCATCATG 
CX3CR1 NM_001337.3 1040-1140 
GGGCGCTCAGTCCACGTTGATTTCTCCTCATCTGAATCACAAAGGAGCAGGCATG
GAAGTGTTCTGAGCAGCAATTTTACTTACCACACGAGTGATGGAG 
CXCL10 NM_001565.1 40-140 GCAGAGGAACCTCCAGTCTCAGCACCATGAATCAAACTGCGATTCTGATTTGCTGCCTTATCTTTCTGACTCTAAGTGGCATTCAAGGAGTACCTCTCTC 
CXCL12 NM_199168.2 505-605 GGGCCTGAGGTTTGCCAGCATTTAGACCCTGCATTTATAGCATACGGTATGATATTGCAGCTTATATTCATCCATGCCCTGTACCTGTGCACGTTGGAAC 
CXCL9 NM_002416.1 1975-2075 
CACCATCTCCCATGAAGAAAGGGAACGGTGAAGTACTAAGCGCTAGAGGAAGCA
GCCAAGTCGGTTAGTGGAAGCATGATTGGTGCCCAGTTAGCCTCTG 
CXCR1 NM_000634.2 1950-2050 
GCAGCCACCAGTCCATTGGGCAGGCAGATGTTCCTAATAAAGCTTCTGTTCCGTG
CTTGTCCCTGTGGAAGTATCTTGGTTGTGACAGAGTCAAGGGTGT 
CXCR3 NM_001504.1 80-180 GTGAGTGACCACCAAGTGCTAAATGACGCCGAGGTTGCCGCCCTCCTGGAGAACTTCAGCTCTTCCTATGACTATGGAGAAAACGAGAGTGACTCGTGCT 
CXCR4 NM_001008540.1 135-235 GTCACTATGGGAAAAGATGGGGAGGAGAGTTGTAGGATTCTACATTAATTCTCTTGTGCCCTTAGCCCACTACTTCAGAATTTCCTGAAGAAAGCAAGCC 
DAPL1 NM_001017920.2 190-290 CGAGAAAACAAGTGCCATTGCAAATGTTGCCAAAATACAGACACTGGATGCCCTGAATGACGCACTGGAGAAGCTCAACTATAAATTTCCAGCAACAGTG 
DEC1 NM_017418.2 190-290 AGGCCTTACTTTCCAGATCCAGATCCTTGTGCATACAACTGACTTGTGTGGGTGAGGCTTGCAGAAAAAATCAGCTAGAACAGCCTTGGGGGTAGTGGCA 
DECTIN-1R SCFV010.1 270-370 CTGAAGATCGACAGCAGCAACGAGCTGGGCTTCATCGTGAAGCAGGTGTCCAGCCAGCCCGACAACTCCTTCTGGATCGGCCTGAGCAGGCCCCAGACCG 
DGKA NM_001345.4 1375-1475 
TTCCTAACACCCACCCACTTCTCGTCTTTGTCAATCCTAAGAGTGGCGGGAAGCA
GGGGCAAAGGGTGCTCTGGAAGTTCCAGTATATATTAAACCCTCG 
DOCK5 NM_024940.6 630-730 TGCGAGATGACAATGGGAACATCCTAGACCCTGACGAAACCAGCACCATTGCCCTCTTCAAGGCCCATGAGGTGGCCTCCAAAAGGATTGAGGAAAAGAT 
153 
 
DOK2 NM_003974.2 650-750 GCCAGGGACCCAGCTGTACGACTGGCCCTACAGGTTTCTGCGGCGCTTTGGGCGGGACAAGGTAACCTTTTCCTTTGAGGCAGGCCGTCGCTGCGTCTCT 
DPP4 NM_001935.3 2700-2800 
CAGCAGTCAGCTCAGATCTCCAAAGCCCTGGTCGATGTTGGAGTGGATTTCCAGG
CAATGTGGTATACTGATGAAGACCATGGAATAGCTAGCAGCACAG 
DUSP16 NM_030640.2 615-715 ATGGGTTTAACTCTCCTTTTGCCAGTCACCACCAGCCTGACCTCATACACTTTTAGTACAATGGAGTGGCTGAGCCTTTGAGCACACCACCATTACATCA 
EGFR-scfv_    
(NIMO CAR) SCFV015.1 7-107 
AGATGACCCAGAGCCCTAGCAGCCTGAGCGCCAGCGTGGGCGACAGAGTGACC
ATCACCTGCCGGTCCAGCCAGAACATCGTGCACAGCAACGGCAACAC 
EGLN1 NM_022051.1 3975-4075 
AGCAGCATGGACGACCTGATACGCCACTGTAACGGGAAGCTGGGCAGCTACAAA
ATCAATGGCCGGACGAAAGCCATGGT 
EGLN3 NM_022073.3 800-900 AAGCTACATGGTGGGATCCTGCGGATATTTCCAGAGGGGAAATCATTCATAGCAGATGTGGAGCCCATTTTTGACAGACTCCTGTTCTTCTGGTCAGATC 
EIF1 NM_005801.3 869-969 CCTGAACAGTCCTCGGTGAATCTGAGAGGAGAGGATGGGGTAAGGCAGAAGCACCAGCTGTACTACTAGAAGGGAGCTTTTGGTGGTAGATCCCCTGGTG 
ELF4 NM_001421.3 335-435 AGCTCTGGAGGGCTCTGATAATCCCGTTGTCAGCTCTCTGAAAAGACAGCATGGCTATTACCCTACAGCCCAGTGACCTGATCTTTGAGTTCGCAAGCAA 
ELOF1 NM_032377.3 125-225 AGACCCAGTTCACCTGCCCCTTCTGCAACCACGAGAAATCCTGTGATGTGAAAATGGACCGTGCCCGCAACACCGGAGTCATCTCTTGTACCGTGTGCCT 
ENTPD1 NM_001776.4 225-325 TTCGAGTAACTTTAGGAAAATGAGCTGCTGGACTCCTCAGTCAATCTGTCCTTTCTAGTCAATGAAAAAGACAGGGTTTGAGGTTCCTTCCGAAACGGGG 
EOMES NM_005442.2 1670-1770 
ATCCCATGCCCTGGGGTATTACCCAGACCCAACCTTTCCTGCAATGGCAGGGTG
GGGAGGTCGAGGTTCTTACCAGAGGAAGATGGCAGCTGGACTACCA 
EPHA2 NM_004431.2 1525-1625 
GAGCCGAGTGTGGAAGTACGAGGTCACTTACCGCAAGAAGGGAGACTCCAACAG
CTACAATGTGCGCCGCACCGAGGGTTTCTCCGTGACCCTGGACGAC 
EPHA4 NM_004438.3 20-120 GCAGCGTTGGCACCGGCGAACCATGGCTGGGATTTTCTATTTCGCCCTATTTTCGTGTCTCTTCGGGATTTGCGACGCTGTCACAGGTTCCAGGGTATAC 
EPHB2 NM_017449.2 785-885 CAAAGCAGGCTTCGAGGCCGTTGAGAATGGCACCGTCTGCCGAGGTTGTCCATCTGGGACTTTCAAGGCCAACCAAGGGGATGAGGCCTGTACCCACTGT 
ETV6 NM_001987.4 3840-3940 
GTATGAATATGAAATCAGAGACCAGGGCATGATGTTGCTAGGATTAGAGCCTCTC
AGTCTGGCCTCTTCACCCAAGTGCAAGAACTCAGTCTCTTACTGT 
FADD NM_003824.2 1560-1660 
TGAGACTGCTAAGTAGGGGCAGTGATGGTTGCCAGGACGAATTGAGATAATATCT
GTGAGGTGCTGATGAGTGATTGACACACAGCACTCTCTAAATCTT 
FAM129A NM_052966.2 3526-3626 
TGCCCAATAGATTCAAGAGAAGCTAAGCGGAAATGGAGGGTGGAAGGTGTGATC
TGTGGGACTGTCTGGGCCTGTTACTCATCCTGCTATCAATTTCTTA 
FANCC NM_000136.2 2130-2230 
GACTCAGTCAGACATGTTCACTAATGACTCAAGTGAGCCTTCGGTACTCCTGGTG
CCCGCCCGGCCAGACCGTCAGCTTGATAATTACTAAAGCAAAGGC 
FAS NM_000043.3 90-190 CACCGGGGCTTTTCGTGAGCTCGTCTCTGATCTCGCGCAAGAGTGACACACAGGTGTTCAAAGACGCTTCTGGGGAGTGAGGGAAGCGGTTTACGAGTGA 
FASLG NM_000639.1 625-725 TCCATGCCTCTGGAATGGGAAGACACCTATGGAATTGTCCTGCTTTCTGGAGTGAAGTATAAGAAGGGTGGCCTTGTGATCAATGAAACTGGGCTGTACT 
FCGR3B NM_000570.3 73-173 CCTATTCCTGTTCTATGGTGGGGCTCCATTGCGAGACTTCAGATTGAGAAATCAGATGAAGTTTCAAGAAAAGGAAACTGGCAGGTGACAGAGATGGGTG 
FGL2 NM_006682.2 250-350 CAATTCAGCAGGATCGAGGAGGTGTTCAAAGAAGTCCAAAACCTCAAGGAAATCGTAAATAGTCTAAAGAAATCTTGCCAAGACTGCAAGCTGCAGGCTG 
FLT1 NM_002019.2 5615-5715 
TTCAACTGCTTTGAAACTTGCCTGGGGTCTGAGCATGATGGGAATAGGGAGACAG
GGTAGGAAAGGGCGCCTACTCTTCAGGGTCTAAAGATCAAGTGGG 
FLT3LG NM_001459.2 927-1027 CCTCCCCAGAATGGAGGCAACGCCAGAATCCAGCACCGGCCCCATTTACCCAACTCTGTACAAAGCCCTTGTCCCCATGAAATTGTATATAAATCATCCT 
FOS NM_005252.2 1475-1575 
ACTCAAGTCCTTACCTCTTCCGGAGATGTAGCAAAACGCATGGAGTGTGTATTGTT
CCCAGTGACACTTCAGAGAGCTGGTAGTTAGTAGCATGTTGAGC 
FOXO1 NM_002015.3 1526-1626 
TCTCATCACCAACATCATTAACTGTTTCGACCCAGTCCTCACCTGGCACCATGATG
CAGCAGACGCCGTGCTACTCGTTTGCGCCACCAAACACCAGTTT 
FOXO3 NM_001455.2 1860-1960 
CCGGAACGTGATGCTTCGCAATGATCCGATGATGTCCTTTGCTGCCCAGCCTAAC
CAGGGAAGTTTGGTCAATCAGAACTTGCTCCACCACCAGCACCAA 
FOXP1 NM_032682.5 6758-6858 
CCTGAAAATCAGATTTACAATGCTGAAGGCATTTCTTGGGCCCAGTGTAGCTCAC
GCAATCTCTGCTACCCATAAGCCTTGATGAAGATGATACAGTCCG 
FOXP3 NM_014009.3 1230-1330 
GGGCCATCCTGGAGGCTCCAGAGAAGCAGCGGACACTCAATGAGATCTACCACT
GGTTCACACGCATGTTTGCCTTCTTCAGAAACCATCCTGCCACCTG 
FYN NM_002037.3 765-865 GTCTTTGGAGGTGTGAACTCTTCGTCTCATACGGGGACCTTGCGTACGAGAGGAGGAACAGGAGTGACACTCTTTGTGGCCCTTTATGACTATGAAGCAC 
FZD1 NM_003505.1 2430-2530 
GTGCCAATCCTGACATCTCGAGGTTTCCTCACTAGACAACTCTCTTTCGCAGGCT
CCTTTGAACAACTCAGCTCCTGCAAAAGCTTCCGTCCCTGAGGCA 
G6PD NM_000402.2 1155-1255 
ACAACATCGCCTGCGTTATCCTCACCTTCAAGGAGCCCTTTGGCACTGAGGGTCG
CGGGGGCTATTTCGATGAATTTGGGATCATCCGGGACGTGATGCA 
GABPA NM_002040.3 1160-1260 
GACCAAGTCCTGCATTGGGTGGTTTGGGTAATGAAGGAATTCAGCATGACCGATA
TAGACCTCACCACACTCAACATTTCGGGGAGAGAATTATGTAGTC 
GADD45A NM_001924.2 865-965 GTTACTCCCTACACTGATGCAAGGATTACAGAAACTGATGCCAAGGGGCTGAGTGAGTTCAACTACATGTTCTGGGGGCCCGGAGATAGATGACTTTGCA 
GADD45B NM_015675.2 365-465 TGTGGACCCAGACAGCGTGGTCCTCTGCCTCTTGGCCATTGACGAGGAGGAGGAGGATGACATCGCCCTGCAAATCCACTTCACGCTCATCCAGTCCTTC 
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GAL3ST4 NM_024637.4 1140-1240 
CGAGCCCAAACCCTCAATCCCAATGCCCTCATCCATCCTGTTTCCACTGTTACTGA
TCATCGCAGCCAGATATCAAGCCCTGCCTCTTTCGATTTGGGGT 
GAS2 NM_005256.3 915-1015 GATCTCCCGTGTGGATGGCAAAACATCCCCTATCCAAAGCAAATCTCCAACTCTAAAGGACATGAATCCAGATAACTACTTGGTGGTCTCTGCCAGTTAT 
GATA2 NM_032638.3 1495-1595 
GAAGAAGGAAGGGATCCAGACTCGGAACCGGAAGATGTCCAACAAGTCCAAGAA
GAGCAAGAAAGGGGCGGAGTGCTTCGAGGAGCTGTCAAAGTGCATG 
GATA3 NM_001002295.1 2835-2935 
AAGAGTCCGGCGGCATCTGTCTTGTCCCTATTCCTGCAGCCTGTGCTGAGGGTA
GCAGTGTATGAGCTACCAGCGTGCATGTCAGCGACCCTGGCCCGAC 
gBAD-1R-scfv SCFV001.1 1-101 AGACAGACACCCTGCTCCTCTGGGTGTCCGGCACCTGTGGCGACATCGTGATGAGCAGAAGCCCCAGCAGCCTGGCCGTGTCCGTGGGCGAGAAAGTGAC 
GEMIN2 NM_001009182.1 537-637 ACAAGCAACAGTAACTAGTGTCTTGGAATATCTGAGTAATTGGTTTGGAGAAAGAGACTTTACTCCAGAATTGGGAAGATGGCTTTATGCTTTATTGGCT 
GFI1 NM_005263.2 2235-2335 
TCATCACTGGAGGTAAAAGCACAAGCAATGCCTGTGGACAAGATGTCATTCATTC
ACTCAGCAAATGTTCATGGATCACCGGCTACCAAGGTACCAGGCA 
GLIPR1 NM_006851.2 255-355 CTGCGTTCGAATCCATAACAAGTTCCGATCAGAGGTGAAACCAACAGCCAGTGATATGCTATACATGACTTGGGACCCAGCACTAGCCCAAATTGCAAAA 
GLO1 NM_006708.1 1240-1340 
GGAAATGATATGGTACCCAGACACTGGGCTAGGCTGCAACTTTATCTCATTTAATA
CTCCCAGCTGTCATGTGAGAAAGAAAGCAGGCTAGGCATGTGAA 
GNLY NM_006433.2 305-405 CAGGAGCTGGGCCGTGACTACAGGACCTGTCTGACGATAGTCCAAAAACTGAAGAAGATGGTGGATAAGCCCACCCAGAGAAGTGTTTCCAATGCTGCGA 
GSK3B NM_002093.2 925-1025 ACTGATTATACCTCTAGTATAGATGTATGGTCTGCTGGCTGTGTGTTGGCTGAGCTGTTACTAGGACAACCAATATTTCCAGGGGATAGTGGTGTGGATC 
GZMA NM_006144.2 155-255 AGACCCTACATGGTCCTACTTAGTCTTGACAGAAAAACCATCTGTGCTGGGGCTTTGATTGCAAAAGACTGGGTGTTGACTGCAGCTCACTGTAACTTGA 
GZMB NM_004131.3 540-640 ACACTACAAGAGGTGAAGATGACAGTGCAGGAAGATCGAAAGTGCGAATCTGACTTACGCCATTATTACGACAGTACCATTGAGTTGTGCGTGGGGGACC 
GZMH NM_033423.3 705-805 AAAAAAGGGACACCTCCAGGAGTCTACATCAAGGTCTCACACTTCCTGCCCTGGATAAAGAGAACAATGAAGCGCCTCTAACAGCAGGCATGAGACTAAC 
HCST NM_001007469.1 132-232 ATCCTCTTCCTGCTTTTGCTCCCAGTGGCTGCAGCTCAGACGACTCCAGGAGAGAGATCATCACTCCCTGCCTTTTACCCTGGCACTTCAGGCTCTTGTT 
HDAC1 NM_004964.2 785-885 CAAGCCGGTCATGTCCAAAGTAATGGAGATGTTCCAGCCTAGTGCGGTGGTCTTACAGTGTGGCTCAGACTCCCTATCTGGGGATCGGTTAGGTTGCTTC 
HDAC2 NM_001527.1 930-1030 AAGCCTATTATCTCAAAGGTGATGGAGATGTATCAACCTAGTGCTGTGGTATTACAGTGTGGTGCAGACTCATTATCTGGTGATAGACTGGGTTGTTTCA 
HER2-scfv SCFV014.1 64-164 CCTGCAGCGCCAGCAGCAGCGTGTCCTACATGCACTGGTATCAGCAGAAGTCCGGCACTAGCCCCAAGCGGTGGATCTACGACACCTACAAGCTCGCCAG 
HERV-K          
6H5-scfv SCFV012.1 137-237 
CGGCGGCACCAGCTACAACCAGAAGTTCAAGGACAAGGCCATCCTGACCGTGGA
CAAGAGCAGCAGCACCGCCTACATGGAACTGCGGAGCCTGACCAGC 
HLA-A NM_002116.5 1000-1100 
GGAAGAGCTCAGATAGAAAAGGAGGGAGTTACACTCAGGCTGCAAGCAGTGACA
GTGCCCAGGGCTCTGATGTGTCCCTCACAGCTTGTAAAGTGTGAGA 
HMGB2 NM_001130688.1 125-225 CTGTCAACATGGGTAAAGGAGACCCCAACAAGCCGCGGGGCAAAATGTCCTCGTACGCCTTCTTCGTGCAGACCTGCCGGGAAGAGCACAAGAAGAAACA 
HOPX NM_001145460.1 1117-1217 
AACAATAGGAAGCTATGTGTATCTTCTGTGTAAAGCAGTGGCTTCACTGGAAAAAT
GGTGTGGCTAGCATTTCCCTTTGAGTCATGATGACAGATGGTGT 
HOXA10 NM_018951.3 1503-1603 
TTCTATAGAGATAGATATTGTCCTAAGTGTCAAGTCCTGACTGGGCTGGGTTTGCT
GTCTTGGGGTCCCACTGCTCGAAATGGCCCCTGTCTTCGGCCGA 
HOXA9 NM_152739.3 1015-1115 
GGCTCTAAACCTCAGGCCACATCTTTTCCAAGGCAAACCCTGTTCAGGCTGGCTC
GTAGGCCTGCCGCTTTGATGGAGGAGGTATTGTAAGCTTTCCATT 
HOXB3 NM_002146.4 60-160 TGTCCGTTTAAATGCTGCTGGGAGACTCGTAAAAAAATCATCGTGGACCTGGAGGATGAGAGGGGCGAGCTTTATTTCGGTCGGATTGCGGTGTGGTGGT 
HOXB4 NM_024015.4 1340-1440 
CCTTTCTTTGTCCCCCACTCCCGATACCCAGCGAAAGCACCCTCTGACTGCCAGA
TAGTGCAGTGTTTTGGTCACGGTAACACACACACACTCTCCCTCA 
HPRT1 NM_000194.1 240-340 TGTGATGAAGGAGATGGGAGGCCATCACATTGTAGCCCTCTGTGTGCTCAAGGGGGGCTATAAATTCTTTGCTGACCTGCTGGATTACATCAAAGCACTG 
HRH1 NM_000861.2 3055-3155 
GTGGCAGCTCAAAATGATATGTTTGAGTAGACGAACAGCTGACATGGAGTTCCCG
TGCACCTACGGAAGGGGACGCTTTGAAGGAACCAAGTGCATTTTT 
HRH2 NM_022304.1 600-700 GCGGTCCTCATCCTCATCACCGTTGCTGGCAATGTGGTCGTCTGTCTGGCCGTGGGCTTGAACCGCCGGCTCCGCAACCTGACCAATTGTTTCATCGTGT 
Human CD19R-
scfv SCFV009.1 215-315 
CTTCACCATCAGCAGCCTGCAGCCCGAGGACATCGCCACCTACTACTGCCAGCA
GTACCAGAGCCTGCCCTACACCTTCGGCCAGGGCACCAAGCTGCAG 
ICOS NM_012092.2 640-740 AACTCTGGCACCCAGGCATGAAGCACGTTGGCCAGTTTTCCTCAACTTGAAGTGCAAGATTCTCTTATTTCCGGGACCACGGAGAGTCTGACTTAACTAC 
ICOSLG NM_015259.4 1190-1290 
CTGCTGGCGTTGGCTGTGATCCTGGAATGAGGCCCTTTCAAAAGCGTCATCCACA
CCAAAGGCAAATGTCCCCAAGTGAGTGGGCTCCCCGCTGTCACTG 
ID2 NM_002166.4 505-605 CGGATATCAGCATCCTGTCCTTGCAGGCTTCTGAATTCCCTTCTGAGTTAATGTCAAATGACAGCAAAGCACTGTGTGGCTGAATAAGCGGTGTTCATGA 
ID3 NM_002167.3 195-295 AGGAAGCCTGTTTGCAATTTAAGCGGGCTGTGAACGCCCAGGGCCGGCGGGGGCAGGGCCGAGGCGGGCCATTTTGAATAAAGAGGCGTGCCTTCCAGGC 
IDO1 NM_002164.3 50-150 CTATTATAAGATGCTCTGAAAACTCTTCAGACACTGAGGGGCACCAGAGGAGCAGACTACAAGAATGGCACACGCTATGGAAAACTCCTGGACAATCAGT 
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IFNA1 NM_024013.1 585-685 ATCCCTCTCTTTATCAACAAACTTGCAAGAAAGATTAAGGAGGAAGGAATAACATCTGGTCCAACATGAAAACAATTCTTATTGACTCATACACCAGGTC 
IFNG NM_000619.2 970-1070 ATACTATCCAGTTACTGCCGGTTTGAAAATATGCCTGCAATCTGAGCCAGTGCTTTAATGGCATGTCAGACAGAACTTGAATGTGTCAGGTGACCCTGAT 
IFNGR1 NM_000416.1 1140-1240 
CCCGGGCAGCCATCTGACTCCAATAGAGAGAGAGAGTTCTTCACCTTTAAGTAGT
AACCAGTCTGAACCTGGCAGCATCGCTTTAAACTCGTATCACTCC 
IGF1R NM_000875.2 455-555 TCGGGGGGCCATCAGGATTGAGAAAAATGCTGACCTCTGTTACCTCTCCACTGTGGACTGGTCCCTGATCCTGGATGCGGTGTCCAATAACTACATTGTG 
IKZF1 NM_006060.3 4485-4585 
CCGCTGTGTACTACTGTGTGCCTAGATTCCATGCACTCTCGTTGTGTTTGAAGTAA
ATATTGGAGACCGGAGGGTAACAGGTTGGCCTGTTGATTACAGC 
IKZF2 NM_001079526.1 945-1045 CCATGTACCTCCTATGGAAGATTGTAAGGAACAAGAGCCTATTATGGACAACAATATTTCTCTGGTGCCTTTTGAGAGACCTGCTGTCATAGAGAAGCTC 
IL10 NM_000572.2 230-330 AAGGATCAGCTGGACAACTTGTTGTTAAAGGAGTCCTTGCTGGAGGACTTTAAGGGTTACCTGGGTTGCCAAGCCTTGTCTGAGATGATCCAGTTTTACC 
IL10RA NM_001558.2 150-250 TGCCCAGCCCTCCGTCTGTGTGGTTTGAAGCAGAATTTTTCCACCACATCCTCCACTGGACACCCATCCCAAATCAGTCTGAAAGTACCTGCTATGAAGT 
IL12A NM_000882.2 775-875 CTTTCTAGATCAAAACATGCTGGCAGTTATTGATGAGCTGATGCAGGCCCTGAATTTCAACAGTGAGACTGTGCCACAAAAATCCTCCCTTGAAGAACCG 
IL12B NM_002187.2 1435-1535 
GCAAGGCTGCAAGTACATCAGTTTTATGACAATCAGGAAGAATGCAGTGTTCTGA
TACCAGTGCCATCATACACTTGTGATGGATGGGAACGCAAGAGAT 
IL12RB1 NM_005535.1 1292-1392 
AGGAAAAGTGTTACTACATTACCATCTTTGCCTCTGCGCACCCCGAGAAGCTCAC
CTTGTGGTCTACGGTCCTGTCCACCTACCACTTTGGGGGCAATGC 
IL12RB2 NM_001559.2 1315-1415 
CCTCCGTGGGACATTAGAATCAAATTTCAAAAGGCTTCTGTGAGCAGATGTACCC
TTTATTGGAGAGATGAGGGACTGGTACTGCTTAATCGACTCAGAT 
IL13 NM_002188.2 516-616 TTTCTTTCTGATGTCAAAAATGTCTTGGGTAGGCGGGAAGGAGGGTTAGGGAGGGGTAAAATTCCTTAGCTTAGACCTCAGCCTGTGCTGCCCGTCTTCA 
IL15 NM_172174.1 1685-1785 
AGGGTGATAGTCAAATTATGTATTGGTGGGGCTGGGTACCAATGCTGCAGGTCAA
CAGCTATGCTGGTAGGCTCCTGCCAGTGTGGAACCACTGACTACT 
IL15RA NM_002189.2 39-139 CGCTCGCCCGGGGAGTCCAGCGGTGTCCTGTGGAGCTGCCGCCATGGCCCCGCGGCGGGCGCGCGGCTGCCGGACCCTCGGTCTCCCGGCGCTGCTACTG 
IL17A NM_002190.2 240-340 TACTACAACCGATCCACCTCACCTTGGAATCTCCACCGCAATGAGGACCCTGAGAGATATCCCTCTGTGATCTGGGAGGCAAAGTGCCGCCACTTGGGCT 
IL17F NM_052872.3 210-310 GCCCGCCTGTGCCAGGAGGTAGTATGAAGCTTGACATTGGCATCATCAATGAAAACCAGCGCGTTTCCATGTCACGTAACATCGAGAGCCGCTCCACCTC 
IL17RA NM_014339.4 3020-3120 
CTACTATGTGGCGGGCATTTGGGATACCAAGATAAATTGCATGCGGCATGGCCCC
AGCCATGAAGGAACTTAACCGCTAGTGCCGAGGACACGTTAAACG 
IL18 NM_001562.2 48-148 GACAGTCAGCAAGGAATTGTCTCCCAGTGCATTTTGCCCTCCTGGCTGCCAACTCTGGCTGCTAAAGCGGCTGCCACCTGCTGCAGTCTACACAGCTTCG 
IL18R1 NM_003855.2 2025-2125 
GAATGAGGGGATTTTAAGTGTCTGAAGAGGCATTTTCTAGGGACCAGTGGGTGAC
TGAGTAACTGAAATGCTGCTTTCACTCCCTAACACCATGGATCTG 
IL18RAP NM_003853.2 2412-2512 
GCTTGATGGACAATGGAGTGGGATTGAGACTGTGGTTTAGAGCCTTTGATTTCCT
GGACTGGACTGACGGCGAGTGAATTCTCTAGACCTTGGGTACTTT 
IL1A NM_000575.3 1085-1185 
ACTCCATGAAGGCTGCATGGATCAATCTGTGTCTCTGAGTATCTCTGAAACCTCTA
AAACATCCAAGCTTACCTTCAAGGAGAGCATGGTGGTAGTAGCA 
IL1B NM_000576.2 840-940 GGGACCAAAGGCGGCCAGGATATAACTGACTTCACCATGCAATTTGTGTCTTCCTAAAGAGAGCTGTACCCAGAGAGTCCTGTGCTGAATGTGGACTCAA 
IL2 NM_000586.2 300-400 AGGATGCAACTCCTGTCTTGCATTGCACTAAGTCTTGCACTTGTCACAAACAGTGCACCTACTTCAAGTTCTACAAAGAAAACACAGCTACAACTGGAGC 
IL21R NM_021798.2 2080-2180 
CGTGTTTGTGGTCAACAGATGACAACAGCCGTCCTCCCTCCTAGGGTCTTGTGTT
GCAAGTTGGTCCACAGCATCTCCGGGGCTTTGTGGGATCAGGGCA 
IL22 NM_020525.4 319-419 CTATCTGATGAAGCAGGTGCTGAACTTCACCCTTGAAGAAGTGCTGTTCCCTCAATCTGATAGGTTCCAGCCTTATATGCAGGAGGTGGTGCCCTTCCTG 
IL23A NM_016584.2 411-511 CAGGGACAACAGTCAGTTCTGCTTGCAAAGGATCCACCAGGGTCTGATTTTTTATGAGAAGCTGCTAGGATCGGATATTTTCACAGGGGAGCCTTCTCTG 
IL23R NM_144701.2 710-810 AACTGCAAATTCACCTGGATGATATAGTGATACCTTCTGCAGCCGTCATTTCCAGGGCTGAGACTATAAATGCTACAGTGCCCAAGACCATAATTTATTG 
IL27 NM_145659.3 143-243 CAGGAGCTGCGGAGGGAGTTCACAGTCAGCCTGCATCTCGCCAGGAAGCTGCTCTCCGAGGTTCGGGGCCAGGCCCACCGCTTTGCGGAATCTCACCTGC 
IL2RA NM_000417.1 1000-1100 
CTTGGTAAGAAGCCGGGAACAGACAACAGAAGTCATGAAGCCCAAGTGAAATCAA
AGGTGCTAAATGGTCGCCCAGGAGACATCCGTTGTGCTTGCCTGC 
IL2RB NM_000878.2 1980-2080 
GTCCTGCTGCCCGAGCCAGGAACTGTGTGTGTTGCAGGGGGGCAGTAACTCCCC
AACTCCCTCGTTAATCACAGGATCCCACGAATTTAGGCTCAGAAGC 
IL2RG NM_000206.1 595-695 CCACAGCTGGACTGAACAATCAGTGGATTATAGACATAAGTTCTCCTTGCCTAGTGTGGATGGGCAGAAACGCTACACGTTTCGTGTTCGGAGCCGCTTT 
IL4 NM_000589.2 625-725 GACACTCGCTGCCTGGGTGCGACTGCACAGCAGTTCCACAGGCACAAGCAGCTGATCCGATTCCTGAAACGGCTCGACAGGAACCTCTGGGGCCTGGCGG 
IL4R NM_000418.2 705-805 ATCATCTCACCTATGCAGTCAACATTTGGAGTGAAAACGACCCGGCAGATTTCAGAATCTATAACGTGACCTACCTAGAACCCTCCCTCCGCATCGCAGC 
IL5 NM_000879.2 105-205 CCACAGAAATTCCCACAAGTGCATTGGTGAAAGAGACCTTGGCACTGCTTTCTACTCATCGAACTCTGCTGATAGCCAATGAGACTCTGAGGATTCCTGT 
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IL6 NM_000600.1 220-320 TGACAAACAAATTCGGTACATCCTCGACGGCATCTCAGCCCTGAGAAAGGAGACATGTAACAAGAGTAACATGTGTGAAAGCAGCAAAGAGGCACTGGCA 
IL6R NM_000565.2 993-1093 CTTTCTACATAGTGTCCATGTGCGTCGCCAGTAGTGTCGGGAGCAAGTTCAGCAAAACTCAAACCTTTCAGGGTTGTGGAATCTTGCAGCCTGATCCGCC 
IL7R NM_002185.2 1610-1710 
TTGCTTTGACCACTCTTCCTGAGTTCAGTGGCACTCAACATGAGTCAAGAGCATC
CTGCTTCTACCATGTGGATTTGGTCACAAGGTTTAAGGTGACCCA 
IL9 NM_000590.1 300-400 AAGTACTAAAGAACAACAAGTGTCCATATTTTTCCTGTGAACAGCCATGCAACCAAACCACGGCAGGCAACGCGCTGACATTTCTGAAGAGTCTTCTGGA 
IRF1 NM_002198.1 510-610 CTGTGCGAGTGTACCGGATGCTTCCACCTCTCACCAAGAACCAGAGAAAAGAAAGAAAGTCGAAGTCCAGCCGAGATGCTAAGAGCAAGGCCAAGAGGAA 
IRF2 NM_002199.2 1375-1475 
CAGTACCTGGAGCTTCTCTTTAACTCAGGACTCCAGCCCATTGGTAGACGTGTGT
TTCTAGAGCCTGCTGGATCTCCCAGGGCTACTCACTCAAGTTCAA 
IRF4 NM_002460.1 325-425 GGGCACTGTTTAAAGGAAAGTTCCGAGAAGGCATCGACAAGCCGGACCCTCCCACCTGGAAGACGCGCCTGCGGTGCGCTTTGAACAAGAGCAATGACTT 
ITCH NM_031483.4 155-255 ACTGTGAGAACTTCAGGTTTTCCAACCTATTGGTGGTATGTCTGACAGTGGATCACAACTTGGTTCAATGGGTAGCCTCACCATGAAATCACAGCTTCAG 
ITGA1 NM_181501.1 1875-1975 
AAGTGGCAAGACTATAAGGAAAGAGTATGCACAACGTATTCCATCAGGTGGGGAT
GGTAAGACACTGAAATTTTTTGGCCAGTCTATCCACGGAGAAATG 
ITGA4 NM_000885.4 975-1075 GCCCACTGCCAACTGGCTCGCCAACGCTTCAGTGATCAATCCCGGGGCGATTTACAGATGCAGGATCGGAAAGAATCCCGGCCAGACGTGCGAACAGCTC 
ITGA5 NM_002205.2 925-1025 AGAAGACTTTGTTGCTGGTGTGCCCAAAGGGAACCTCACTTACGGCTATGTCACCATCCTTAATGGCTCAGACATTCGATCCCTCTACAACTTCTCAGGG 
ITGAL NM_002209.2 3905-4005 
GTGAGGGCTTGTCATTACCAGACGGTTCACCAGCCTCTCTTGGTTTCCTTCCTTG
GAAGAGAATGTCTGATCTAAATGTGGAGAAACTGTAGTCTCAGGA 
ITGAM NM_000632.3 515-615 GCCCTCCGAGGGTGTCCTCAAGAGGATAGTGACATTGCCTTCTTGATTGATGGCTCTGGTAGCATCATCCCACATGACTTTCGGCGGATGAAGGAGTTTG 
ITGAX NM_000887.3 700-800 CCCCTCAGCCTGTTGGCTTCTGTTCACCAGCTGCAAGGGTTTACATACACGGCCACCGCCATCCAAAATGTCGTGCACCGATTGTTCCATGCCTCATATG 
ITGB1 NM_033666.2 2000-2100 
TTTTAACATTACCAAGGTAGAAAGTCGGGACAAATTACCCCAGCCGGTCCAACCT
GATCCTGTGTCCCATTGTAAGGAGAAGGATGTTGACGACTGTTGG 
ITGB7 NM_000889.1 1278-1378 
CAACGTGGTACAGCTCATCATGGATGCTTATAATAGCCTGTCTTCCACCGTGACC
CTTGAACACTCTTCACTCCCTCCTGGGGTCCACATTTCTTACGAA 
ITK NM_005546.3 3430-3530 
GCCAGTAAAGAAGTCAGTATAGAACCACTAGCGAATAGTGTTGCTCTGGCACAGA
CCACTGTGGTTGATGGCATGGCCCTCCAACTTGGAATAGGATTTT 
JAK1 NM_002227.1 285-385 GAGAACACCAAGCTCTGGTATGCTCCAAATCGCACCATCACCGTTGATGACAAGATGTCCCTCCGGCTCCACTACCGGATGAGGTTCTATTTCACCAATT 
JAK2 NM_004972.2 455-555 CTCCTCCCGCGACGGCAAATGTTCTGAAAAAGACTCTGCATGGGAATGGCCTGCCTTACGATGACAGAAATGGAGGGAACATCCACCTCTTCTATATATC 
JAK3 NM_000215.2 1715-1815 
GTGCTGCTGAAGGTCATGGATGCCAAGCACAAGAACTGCATGGAGTCATTCCTG
GAAGCAGCGAGCTTGATGAGCCAAGTGTCGTACCGGCATCTCGTGC 
JUN NM_002228.3 140-240 ACACAGCCAGCCAGCCAGGTCGGCAGTATAGTCCGAACTGCAAATCTTATTTTCTTTTCACCTTCTCTCTAACTGCCCAGAGCTAGCGCCTGTGGCTCCC 
JUNB NM_002229.2 1155-1255 
GCGCGCCTGGAGGACAAGGTGAAGACGCTCAAGGCCGAGAACGCGGGGCTGTC
GAGTACCGCCGGCCTCCTCCGGGAGCAGGTGGCCCAGCTCAAACAGA 
KIR2DL1 NM_014218.2 881-981 GCAGGAAACAGAACAGCGAATAGCGAGGACTCTGATGAACAAGACCCTCAGGAGGTGACATACACACAGTTGAATCACTGCGTTTTCACACAGAGAAAAA 
KIR2DL2 NM_014219.2 814-914 TCTCCTTCATCGCTGGTGCTCCAACAAAAAAAATGCTGCGGTAATGGACCAAGAGTCTGCAGGGAACAGAACAGCGAATAGCGAGGACTCTGATGAACAA 
KIR2DL3 NM_015868.2 741-841 CTCCGAAACCGGTAACCCCAGACACCTGCATGTTCTGATTGGGACCTCAGTGGTCATCATCCTCTTCATCCTCCTCCTCTTCTTTCTCCTTCATCGCTGG 
KIR2DL4 NM_002255.5 15-115 GCGTCCTGGCAGCAGAAGCTGCACCATGTCCATGTCACCCACGGTCATCATCCTGGCATGTCTTGGGTTCTTCTTGGACCAGAGTGTGTGGGCACACGTG 
KIR2DL5A NM_020535.3 1451-1551 
GACACGTGCTGTTCCACCTTCCCTCATGCTGTTTCACCTTTCCTCAGACTATTTTC
CAGCCTTCTGTCAGTCAGCAGTGAAACTTATAAAATTTTTTGTG 
KIR2DS1 NM_014512.1 698-798 CTTCACCCACTGAACCAAGCTCCGAAACCGGTAACCCCAGACACCTACATGTTCTGATTGGGACCTCAGTGGTCAAAATCCCTTTCACCATCCTCCTCTT 
KIR2DS2 NM_012312.2 856-956 CAAGAGCCTGCAGGGAACAGAACAGTGAACAGCGAGGATTCTGATGAACAAGACCATCAGGAGGTGTCATACGCATAATTGGATCACTGTGTTTTCACAC 
KIR2DS3 NM_012313.1 693-793 GGCCTTCACCCACTGAACCAAGCTCCAAAACCGGTAACCCCAGACACCTACACGTTCTGATTGGGACCTCAGTGGTCAAACTCCCTTTCACCATCCTCCT 
KIR2DS4 NM_012314.3 1427-1527 
ACATACAAGAGGCTGCCTCTTAACACAGCACTTAGACACGTGCTGTTCCACCTCC
CTTCAGACTATCTTTCAGCCTTCTGCCAGCAGTAAAACTTATAAA 
KIR2DS5 NM_014513.2 204-304 CTTCCTTCTGCACAGAGAGGGGACGTTTAACCACACTTTGCGCCTCATTGGAGAGCACATTGATGGGGTCTCCAAGGGCAACTTCTCCATCGGTCGCATG 
KIR3DL1 NM_013289.2 1054-1154 
CCAAATCTGGTAACCCCAGACACCTGCACATTCTGATTGGGACCTCAGTGGTCAT
CATCCTCTTCATCCTCCTCCTCTTCTTTCTCCTTCATCTCTGGTG 
KIR3DL2 NM_006737.2 884-984 TGCCACCCACGGAGGGACCTACAGATGCTTCGGCTCTTTCCGTGCCCTGCCCTGCGTGTGGTCAAACTCAAGTGACCCACTGCTTGTTTCTGTCACAGGA 
KIR3DL3 NM_153443.3 508-608 CCTTGCGCCTCGTTGGACAGCTCCACGATGCGGGTTCCCAGGTCAACTATTCCATGGGTCCCATGACACCTGCCCTTGCAGGGACCTACAGATGCTTTGG 
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KIR3DS1 NM_001083539.1 1000-1100 
CTCCAAATCTGGTAACCTCAGACACCTGCACATTCTGATTGGGACCTCAGTGGTC
AAAATCCCTTTCACCATCCTCCTCTTCTTTCTCCTTCATCGCTGG 
KIT NM_000222.1 5-105 CATCGCAGCTACCGCGATGAGAGGCGCTCGCGGCGCCTGGGATTTTCTCTGCGTTCTGCTCCTACTGCTTCGCGTCCAGACAGGCTCTTCTCAACCATCT 
KLF10 NM_005655.1 570-670 GCTCAGGCAACAAGTGTGATTCGTCATACAGCTGATGCCCAGCTATGTAACCACCAGACCTGCCCAATGAAAGCAGCCAGCATCCTCAACTATCAGAACA 
KLF2 NM_016270.2 1015-1115 
GGAAGTTTGCGCGCTCAGACGAGCTCACGCGCCACTACCGAAAGCACACGGGCC
ACCGGCCATTCCAGTGCCATCTGTGCGATCGTGCCTTCTCGCGCTC 
KLF4 NM_004235.4 1980-2080 
CGAGCATTTTCCAGGTCGGACCACCTCGCCTTACACATGAAGAGGCATTTTTAAA
TCCCAGACAGTGGATATGACCCACACTGCCAGAAGAGAATTCAGT 
KLF6 NM_001008490.1 1165-1265 
GGGATGCGTGTTCCAGCCAAAGCATGCCGTTCTGCACCCTACCCAGTTGCCTCC
AGGGCCTCTCCTTGGAAGGTCTTTTGAGGGCTAAAAAGGTCCTGTA 
KLF7 NM_001270943.1 1546-1646 
GTACTATTGAGATCTTTCGCGTCGATCCCAACGGCCTTAGCGGCGGCAGACTGG
AATAACACCTTACACCTTTCTGGCCTGCATTTCTGTAGACTTCACT 
KLRAP1 NR_028045.1 414-514 CCTTCAGAGTCACAGAATAGATTAAGGCCTGATGATACTCAAAGGCCTGGGAAAACTGATGACAAAGAATTTTCAGTGCCCTGGCACCTCATTGCAGTGA 
KLRB1 NM_002258.2 85-185 TGAGTTAAACTTACCCACAGACTCAGGCCCAGAAAGTTCTTCACCTTCATCTCTTCCTCGGGATGTCTGTCAGGGTTCACCTTGGCATCAATTTGCCCTG 
KLRC1 NM_002259.3 335-435 ACCTATCACTGCAAAGATTTACCATCAGCTCCAGAGAAGCTCATTGTTGGGATCCTGGGAATTATCTGTCTTATCTTAATGGCCTCTGTGGTAACGATAG 
KLRC2 NM_002260.3 942-1042 TATGTGAGTCAGCTTATAGGAAGTACCAAGAACAGTCAAACCCATGGAGACAGAAAGTAGAATAGTGGTTGCCAATGTCTCAGGGAGGTTGAAATAGGAG 
KLRC3 NM_002261.2 760-860 ACTCCTGAGCTCAAGAAATCAACACATCTTGGCCTCCCAAGTTGCTGGGATTACTGACACAAGCCACCGCCCCTGAGTGCTCATGTACCATTTAGCTTGT 
KLRC4 NM_013431.2 29-129 TTATATTGGTCAACAGCAAAATGAACATTACTACTCAGCCTCCAACACATGCAGTTTGCCTATACCAGGGATCCTGTCAAAATATACACCACTTATAGCT 
KLRD1 NM_002262.3 542-642 AGCCTGCTTCAGCTTCAAAACACAGATGAACTGGATTTTATGAGCTCCAGTCAACAATTTTACTGGATTGGACTCTCTTACAGTGAGGAGCACACCGCCT 
KLRF1 NM_016523.1 275-375 AAAAAGGAAGTTGTTCAAATGCCACTCAGTATGAGGACACTGGAGATCTAAAAGTGAATAATGGCACAAGAAGAAATATAAGTAATAAGGACCTTTGTGC 
KLRG1 NM_005810.3 45-145 TGCCTACGGCAACCCAAGCCCAGAATGACTATGGACCACAGCAAAAATCTTCCTCTTCCAGGCCTTCTTGTTCTTGCCTTGTGGCAATAGCTTTGGGGCT 
KLRK1 NM_007360.1 760-860 GGACCAGGATTTACTTAAACTGGTGAAGTCATATCATTGGATGGGACTAGTACACATTCCAACAAATGGATCTTGGCAGTGGGAAGATGGCTCCATTCTC 
LAG3 NM_002286.5 1735-1835 
CTTTTGGTGACTGGAGCCTTTGGCTTTCACCTTTGGAGAAGACAGTGGCGACCAA
GACGATTTTCTGCCTTAGAGCAAGGGATTCACCCTCCGCAGGCTC 
LAIR1 NM_002287.3 1195-1295 
GCACCTGAGGGTAGAAAGTCACTCTAGGAAAAGCCTGAAGCAGCCATTTGGAAG
GCTTCCTGTTGGATTCCTCTTCATCTAGAAAGCCAGCCAGGCAGCT 
LAT NM_001014987.1 1290-1390 
TGTGTAATAGAATAAAGGCCTGCGTGTGTCTGTGTTGAGCGTGCGTCTGTGTGTG
CCTGTGTGCGAGTCTGAGTCAGAGATTTGGAGATGTCTCTGTGTG 
LAT2 NM_014146.3 1863-1963 
TGCAGAGCTGATTAAACAGTGTTGTGACTGTCTCATGGGAAGAGCTGGGGCCCA
GAGGGACCTTGAGTCAGAAATGTTGCCAGAAAAAGTATCTCCTCCA 
LCK NM_005356.2 1260-1360 
ATTAAGTGGACAGCGCCAGAAGCCATTAACTACGGGACATTCACCATCAAGTCAG
ATGTGTGGTCTTTTGGGATCCTGCTGACGGAAATTGTCACCCACG 
LDHA NM_005566.1 985-1085 CAGAATGGAATCTCAGACCTTGTGAAGGTGACTCTGACTTCTGAGGAAGAGGCCCGTTTGAAGAAGAGTGCAGATACACTTTGGGGGATCCAAAAGGAGC 
LEF1 NM_016269.3 1165-1265 
CCGTCACACATCCCATCAGATGTCAACTCCAAACAAGGCATGTCCAGACATCCTC
CAGCTCCTGATATCCCTACTTTTTATCCCTTGTCTCCGGGTGGTG 
LGALS1 NM_002305.3 60-160 GGTGCGCCTGCCCGGGAACATCCTCCTGGACTCAATCATGGCTTGTGGTCTGGTCGCCAGCAACCTGAATCTCAAACCTGGAGAGTGCCTTCGAGTGCGA 
LGALS3 NM_002306.2 120-220 CAGCCGTCCGGAGCCAGCCAACGAGCGGAAAATGGCAGACAATTTTTCGCTCCATGATGCGTTATCTGGGTCTGGAAACCCAAACCCTCAAGGATGGCCT 
LIFR NM_002310.3 2995-3095 
CCTATTGTCCACCCATCATTGAGGAAGAAATACCAAACCCAGCCGCAGATGAAGC
TGGAGGGACTGCACAGGTTATTTACATTGATGTTCAGTCGATGTA 
LILRB1 NM_001081637.1 2332-2432 
AGCTGAGAAAACTAAGTCAGAAAGTGCATTAAACTGAATCACAATGTAAATATTAC
ACATCAAGCGATGAAACTGGAAAACTACAAGCCACGAATGAATG 
LOC282997 NR_026932.1 665-765 TGATCACATTCTACCTGGCATTATTTCATCTGAGTCCCTGTCCTAGCCCTTCTGCCCATTAGACTGTAACCTTGTTTAGGGAAAGACCTGTGTCTTACTC 
LRP5 NM_002335.1 2515-2615 
TGGACACCAACATGATCGAGTCGTCCAACATGCTGGGTCAGGAGCGGGTCGTGA
TTGCCGACGATCTCCCGCACCCGTTCGGTCTGACGCAGTACAGCGA 
LRP6 NM_002336.1 2185-2285 
CTTAGATTATCCAGAAGGCATGGCAGTAGACTGGCTTGGGAAGAACTTGTACTGG
GCAGACACAGGAACGAATCGAATTGAGGTGTCAAAGTTGGATGGG 
LRRC32 NM_005512.2 3470-3570 
CACCCTGGTGTGGGTTCTCCTGTTCTCTCTGTGCTCTTGCATTCTCTCATTCCCTT
TTCCTCTATTGAGCAGAGCCTGGAGTTTGAGACTATGGAATCCA 
LTA NM_000595.2 885-985 CTGATCAAGTCACCGGAGCTTTCAAAGAAGGAATTCTAGGCATCCCAGGGGACCACACCTCCCTGAACCATCCCTGATGTCTGTCTGGCTGAGGATTTCA 
LTBR NM_002342.1 1435-1535 
CTAACAGGGGCCCAAGGAACCAATTTATCACCCATGACTGACGGAGTCTGAGAAA
AGGCAGAAGAAGGGGGGCACAAGGGCACTTTCTCCCTTGAGGCTG 
LYN NM_002350.1 1285-1385 
TCCTGAAGAGCGATGAAGGTGGCAAAGTGCTGCTTCCAAAGCTCATTGACTTTTC
TGCTCAGATTGCAGAGGGAATGGCATACATCGAGCGGAAGAACTA 
158 
 
MAD1L1 NM_003550.2 306-406 GAAGACCTGGGGGAAAACACCATGGTTTTATCCACCCTGAGATCTTTGAACAACTTCATCTCTCAGCGTGTGGAGGGAGGCTCTGGACTGGATATTTCTA 
MAP2K1 NM_002755.2 970-1070 ACGGAATGGACAGCCGACCTCCCATGGCAATTTTTGAGTTGTTGGATTACATAGTCAACGAGCCTCCTCCAAAACTGCCCAGTGGAGTGTTCAGTCTGGA 
MAPK14 NM_001315.1 450-550 TGGGCTCTGGCGCCTATGGCTCTGTGTGTGCTGCTTTTGACACAAAAACGGGGTTACGTGTGGCAGTGAAGAAGCTCTCCAGACCATTTCAGTCCATCAT 
MAPK3 NM_002746.2 580-680 AACGTGCTCCACCGAGATCTAAAGCCCTCCAACCTGCTCATCAACACCACCTGCGACCTTAAGATTTGTGATTTCGGCCTGGCCCGGATTGCCGATCCTG 
MAPK8 NM_139049.1 945-1045 TCTCTGTAGATGAAGCTCTCCAACACCCGTACATCAATGTCTGGTATGATCCTTCTGAAGCAGAAGCTCCACCACCAAAGATCCCTGACAAGCAGTTAGA 
MBD2 NM_003927.3 2015-2115 
ATTTACATTCAACTCTGATCCCTGGGCCTTAGGTTTGACATGGAGGTGGAGGAAG
ATAGCGCATATATTTGCAGTATGAACTATTGCCTCTGGACGTTGT 
MCL1 NM_021960.3 1260-1360 
GCTGTAACTTCCTAGAGTTGCACCCTAGCAACCTAGCCAGAAAAGCAAGTGGCAA
GAGGATTATGGCTAACAAGAATAAATACATGGGAAGAGTGCTCCC 
MIF NM_002415.1 319-419 TCCTACAGCAAGCTGCTGTGCGGCCTGCTGGCCGAGCGCCTGCGCATCAGCCCGGACAGGGTCTACATCAACTATTACGACATGAACGCGGCCAATGTGG 
MMP14 NM_004995.2 1470-1570 
GACAAGATTGATGCTGCTCTCTTCTGGATGCCCAATGGAAAGACCTACTTCTTCC
GTGGAAACAAGTACTACCGTTTCAACGAAGAGCTCAGGGCAGTGG 
MPL NM_005373.2 895-995 CAGTGGCACTTGGACTGCAATGCTTTACCTTGGACCTGAAGAATGTTACCTGTCAATGGCAGCAACAGGACCATGCTAGCTCCCAAGGCTTCTTCTACCA 
MTOR NM_004958.2 5095-5195 
TTAGTGTTGCTCCTGGGAGTTGATCCGTCTCGGCAACTTGACCATCCTCTGCCAA
CAGTTCACCCTCAGGTGACCTATGCCTACATGAAAAACATGTGGA 
MXD1 NM_002357.2 880-980 GAGAATAAAGCTGCAGGACAGTCACAAGGCGTGTCTTGGTCTCTAAGAGAGTGGGCACTGCGGCTGTCTCCTTGAAGGTTCTCCCTGTTGGTTCTGATTA 
MYB NM_005375.2 3145-3245 
AACTGTTGCATGGATCCTGTGTTTGCAACTGGGGAGACAGAAACTGTGGTTGATA
GCCAGTCACTGCCTTAAGAACATTTGATGCAAGATGGCCAGCACT 
MYC NM_002467.3 1610-1710 
TCGGACACCGAGGAGAATGTCAAGAGGCGAACACACAACGTCTTGGAGCGCCAG
AGGAGGAACGAGCTAAAACGGAGCTTTTTTGCCCTGCGTGACCAGA 
MYO6 NM_004999.3 6655-6755 
AAGTTGGGGAGATGGCACCTTCTCAGAGGATTGTGAAAATATGAGGAAGAAACAA
AACAGTGCATGTAGGAGCACAGGGCCACACAAAGGCATTCTATTG 
NANOG NM_024865.2 1100-1200 
CTACTCCATGAACATGCAACCTGAAGACGTGTGAAGATGAGTGAAACTGATATTA
CTCAATTTCAGTCTGGACACTGGCTGAATCCTTCCTCTCCCCTCC 
NBEA NM_015678.3 8645-8745 
CTGAGAGCCCTTGAAGGACCAGAAAACTGCTTATTCCCACGCTTGATATCTGTCT
CCAGCGAAGGCCACTGTATCATATACTATGAACGAGGGCGATTCA 
NCAM1 NM_000615.5 1620-1720 
GGTATTTGCCTATCCCAGTGCCACGATCTCATGGTTTCGGGATGGCCAGCTGCTG
CCAAGCTCCAATTACAGCAATATCAAGATCTACAACACCCCCTCT 
NCL NM_005381.2 1492-1592 
GAACAGAGATCGATGGGCGATCTATTTCCCTGTACTATACTGGAGAGAAAGGTCA
AAATCAAGACTATAGAGGTGGAAAGAATAGCACTTGGAGTGGTGA 
NCR1 NM_001145457.1 145-245 TTTCATGGTTCCAAAGGAAAAGCAAGTGACCATCTGTTGCCAGGGAAATTATGGGGCTGTTGAATACCAGCTGCACTTTGAAGGAAGCCTTTTTGCCGTG 
NCR2 NM_004828.3 798-898 CTTCAACAGGTCACGGACCTTCCCTGGACCTCAGTTTCCTCACCTGTAGAGAGAGAAATATTATATCACACTGTTGCAAGGACTAAGATAAGCGATGATG 
NCR3 NM_147130.1 50-150 GCATCTGTCCTCTCTCCTCAGGGAGGCAAGCATTTGATGCTCGAGGTCCCTGGCAGTTGTGGTCCTTGGCAAGTGATGTGTGAGTCCCGTGTGTCATAGG 
NCRNA00185 NR_001544.2 143-243 GAGGCTGTCTGCCAACATCTTTCATCACTCTGCCTGCAACTATGAAAAATTTAGTTCTAAAAAATGCAACCTTGCTAAATTGAGTACTAATAGGATTGGT 
NEIL1 NM_024608.2 1675-1775 
TTAGCAGGAGGCTCTCCTTGCTTGCACTCACCCTTTCTTATTGTCTTGCCCTGCAT
CTGGGGGTCTGAATTTTTGGGAGCAGGCAATATCTGAAGGTGCA 
NEIL2 NM_145043.2 2570-2670 
GCCCGGTGGTGTGTAGAGAAAAGCTGCTTGTTTACTCCTTAAGTCAATGTATTGG
TGACTGTTGATTTGTTGAACAATTCAGGAATCAAGGGCTGTGGAG 
NFAT5 NM_173214.1 3290-3390 
CCCTGACAACTATTCAAACCCAGGACATCTCACAGCCTGGTACTTTTCCAGCAGTT
TCTGCTTCTAGTCAGCTGCCCAACAGCGATGCACTATTGCAGCA 
NFATC1 NM_172390.1 2510-2610 
CCAGTACCAGCGTTTCACCTACCTTCCCGCCAACGGTAACGCCATCTTTCTAACC
GTAAGCCGTGAACATGAGCGCGTGGGGTGCTTTTTCTAAAGACGC 
NFATC2 NM_012340.3 1815-1915 
GACGGACATTGGAAGAAAGAACACGCGGGTGAGACTGGTTTTCCGAGTTCACAT
CCCAGAGTCCAGTGGCAGAATCGTCTCTTTACAGACTGCATCTAAC 
NFATC3 NM_004555.2 2190-2290 
GTCCTTGAAGTTCCTCCATATCATAACCCAGCAGTTACAGCTGCAGTGCAGGTGC
ACTTTTATCTTTGCAATGGCAAGAGGAAAAAAAGCCAGTCTCAAC 
NFKB1 NM_001165412.1 2305-2405 
CTTGGGTAACTCTGTTTTGCACCTAGCTGCCAAAGAAGGACATGATAAAGTTCTCA
GTATCTTACTCAAGCACAAAAAGGCAGCACTACTTCTTGACCAC 
NOS2 NM_000625.4 605-705 TTGCCTGGGGTCCATTATGACTCCCAAAAGTTTGACCAGAGGACCCAGGGACAAGCCTACCCCTCCAGATGAGCTTCTACCTCAAGCTATCGAATTTGTC 
NOTCH1 NM_017617.3 735-835 CTGCCAGGCTTCACCGGCCAGAACTGTGAGGAAAATATCGACGATTGTCCAGGAAACAACTGCAAGAACGGGGGTGCCTGTGTGGACGGCGTGAACACCT 
NR3C1 NM_001018077.1 1665-1765 
GCTTTCTCCTCTGGCGGGAGAAGACGATTCATTCCTTTTGGAAGGAAACTCGAAT
GAGGACTGCAAGCCTCTCATTTTACCGGACACTAAACCCAAAATT 
NR4A1 NM_002135.3 155-255 CGGCCGGGTAGGGTGCAGCCTGAGGCTTGTTCAGCAGAACAGGTGCAAGCCACATTGTTGCCAAGACCTGCCTGAAGCCGGATTCTCCCCACTGCCTCCT 
NREP NM_001142474.1 990-1090 AAACTCATTGTTTCCTTGTGGTAAGTGACCGAGATGCTGCCACAGGACCTGAGACACTGATGAATGGTGCTATTTTGGACTTTCAACATGCTCCTTGGCG 
159 
 
NRIP1 NM_003489.2 335-435 TGACTCATGGAGAAGAGCTTGGCTCTGATGTGCACCAGGATTCTATTGTTTTAACTTACCTAGAAGGATTACTAATGCATCAGGCAGCAGGGGGATCAGG 
NRP1 NM_003873.5 370-470 GCCTCGCTGCTTTCTTTTCTCCAAGACGGGCTGAGGATTGTACAGCTCTAGGCGGAGTTGGGGCTCTTCGGATCGCTTAGATTCTCCTCTTTGCTGCATT 
NT5E NM_002526.2 1214-1314 
ATTCGGGTTTTGAAATGGATAAACTCATCGCTCAGAAAGTGAGGGGTGTGGACGT
CGTGGTGGGAGGACACTCCAACACATTTCTTTACACAGGCAATCC 
OAZ1 NM_004152.2 313-413 GGTGGGCGAGGGAATAGTCAGAGGGATCACAATCTTTCAGCTAACTTATTCTACTCCGATGATCGGCTGAATGTAACAGAGGAACTAACGTCCAACGACA 
OPTN NM_001008211.1 625-725 TGAAGCTAAATAATCAAGCCATGAAAGGGAGATTTGAGGAGCTTTCGGCCTGGACAGAGAAACAGAAGGAAGAACGCCAGTTTTTTGAGATACAGAGCAA 
P2RX7 NM_002562.4 340-440 AGTTGGTGCACAGTGTCTTTGACACCGCAGACTACACCTTCCCTTTGCAGGGGAACTCTTTCTTCGTGATGACAAACTTTCTCAAAACAGAAGGCCAAGA 
PAX5 NM_016734.1 2288-2388 
CTCCAAGAGGAGCACACTTTGGGGAGATGTCCTGGTTTCCTGCCTCCATTTCTCT
GGGACCGATGCAGTATCAGCAGCTCTTTTCCAGATCAAAGAACTC 
PDCD1 NM_005018.1 175-275 CTTCTTCCCAGCCCTGCTCGTGGTGACCGAAGGGGACAACGCCACCTTCACCTGCAGCTTCTCCAACACATCGGAGAGCTTCGTGCTAAACTGGTACCGC 
PDCD1LG2 NM_025239.3 235-335 TGTGGAGCTGTGGCAAGTCCTCATATCAAATACAGAACATGATCTTCCTCCTGCTAATGTTGAGCCTGGAATTGCAGCTTCACCAGATAGCAGCTTTATT 
PDE3A NM_000921.3 3010-3110 
CTGGCCAACCTTCAGGAATCCTTCATCTCTCACATTGTGGGGCCTCTGTGCAACT
CCTATGATTCAGCAGGACTAATGCCTGGAAAATGGGTGGAAGACA 
PDE4A NM_001111307.1 3855-3955 
AATAATGGTGTATACCCTCATTCTCATTCCTGGGCAGCCCTTCCTTCCACCCTGGC
ACCAAAATAATTTCTCCTCCATCCGTACCTTGCCTAGCCTCTCC 
PDE7A NM_002604.2 2210-2310 
GTAGCTCAACAAGGAATAGAGGGAGGAGTGTAATTTTGGTAGCTGGTGTTGAATA
GGGCCTTTGAGAATCAGACTGAACACAGTGAAATATGTGCCCAAA 
PDK1 NM_002610.3 1170-1270 
TGGATTGCCCATATCACGTCTTTACGCACAATACTTCCAAGGAGACCTGAAGCTG
TATTCCCTAGAGGGTTACGGGACAGATGCAGTTATCTACATTAAG 
PDXK NM_003681.3 580-680 TCCCGGAGGACCTCCTTCCCGTCTACAAAGAAAAAGTGGTGCCGCTTGCAGACATTATCACGCCCAACCAGTTTGAGGCCGAGTTACTGAGTGGCCGGAA 
PECAM1 NM_000442.3 1365-1465 
ATCTGCACTGCAGGTATTGACAAAGTGGTCAAGAAAAGCAACACAGTCCAGATAG
TCGTATGTGAAATGCTCTCCCAGCCCAGGATTTCTTATGATGCCC 
PHACTR2 NM_001100164.1 8350-8450 
GGCAGAATGCCACTCTACCCTCAGGTCAATTTTATGGTATATGAAAATGCCAGTAA
TATTTGTGCCACTTGCCAACTCGGGGGAGGAGGGGCTTTTCCCT 
PHC1 NM_004426.2 2905-3005 
ATACAGCTCCACCTACACCGGAATTACATGGCATCAACCCTGTGTTCCTGTCCAG
TAATCCCAGCCGTTGGAGTGTAGAGGAGGTGTACGAGTTTATTGC 
POLR1B NM_019014.3 3320-3420 
GGAGAACTCGGCCTTAGAATACTTTGGTGAGATGTTAAAGGCTGCTGGCTACAAT
TTCTATGGCACCGAGAGGTTATATAGTGGCATCAGTGGGCTAGAA 
POLR2A NM_000937.2 3775-3875 
TTCCAAGAAGCCAAAGACTCCTTCGCTTACTGTCTTCCTGTTGGGCCAGTCCGCT
CGAGATGCTGAGAGAGCCAAGGATATTCTGTGCCGTCTGGAGCAT 
POP5 NM_015918.3 560-660 GCTTCAGGCCCACTTGTTGAACAGAACAATCTGGGTAGCAACAGCATCTTCCACAGTTTTCCAAACTGGATAGCTGCCAACCAGCAGACATTACCCACTT 
POU5F1 NM_002701.4 1225-1325 
AAGTTCTTCATTCACTAAGGAAGGAATTGGGAACACAAAGGGTGGGGGCAGGGG
AGTTTGGGGCAACTGGTTGGAGGGAAGGTGAAGTTCAATGATGCTC 
PPARA NM_001001928.2 5220-5320 
GGGTGTGTTTGCTATACGAACATAATGGACGTGAAGTGGGGCAGAAACCCAGAA
CTCAGCATTCAAGGATGCCCAGGAGAGCTGTCCCTGTTTTAAAGAG 
PPP2R1A NM_014225.3 1440-1540 
AACTTAACTCCTTGTGCATGGCCTGGCTTGTGGATCATGTATATGCCATCCGCGA
GGCAGCCACCAGCAACCTGAAGAAGCTAGTGGAAAAGTTTGGGAA 
PRDM1 NM_182907.1 310-410 CATCCCTGCCAACCAGGAACTTCTTGTGTGGTATTGTCGGGACTTTGCAGAAAGGCTTCACTACCCTTATCCCGGAGAGCTGACAATGATGAATCTCACA 
PRF1 NM_005041.3 2120-2220 
ACTGTTTTTCAGGGAGGTGGCTGGGTTTACACGCTAATCCCGATTCACCCTGTCC
AAACTGCCTAAGCCCTCCGCCATTCTCAAGCCCTGCAGTCACAGC 
PRKAA2 NM_006252.2 975-1075 ATAGTGGTGACCCTCAAGACCAGCTTGCAGTGGCTTATCATCTTATCATTGACAATCGGAGAATAATGAACCAAGCCAGTGAGTTCTACCTCGCCTCTAG 
PRKCQ NM_006257.2 1325-1425 
GATGGACGATGATGTTGAGTGCACGATGGTAGAGAAGAGAGTTCTTTCCTTGGCC
TGGGAGCATCCGTTTCTGACGCACATGTTTTGTACATTCCAGACC 
PROM1 NM_006017.1 925-1025 AGCCTGCGGTCATCTCTCAATGACCCTCTGTGCTTGGTGCATCCATCAAGTGAAACCTGCAACAGCATCAGATTGTCTCTAAGCCAGCTGAATAGCAACC 
PTGER2 NM_000956.2 1410-1510 
GTCAGAAGGAGCTACAAAACCTACCCTCAGTGAGCATGGTACTTGGCCTTTGGAG
GAACAATCGGCTGCATTGAAGATCCAGCTGCCTATTGATTTAAGC 
PTK2 NM_005607.3 1005-1105 
GGTTCAAGCTGGATTATTTCAGTGGAACTGGCAATCGGCCCAGAAGAAGGAATCA
GTTACCTAACGGACAAGGGCTGCAATCCCACACATCTTGCTGACT 
PTPN11 NM_002834.3 4650-4750 
TAGTCCCTAGGTTGCTACGGCTTATCATGTGCTTGGTAAAAGGTGATCGCAGGTT
CTCAGACGAGTTTACTTTACATGAGATGGAATCAGGCAGAGAGGC 
PTPN4 NM_002830.2 705-805 TCGAGGCTTTTTTTCTCCAGCCGAGAGGACGCGGCTGTGATATACGAAGACTTTGTGTGGACAGTAATGACCTCACGTTTCCGATTGCCTGCTGGCAGAA 
PTPN6 NM_002831.5 1734-1834 
TGGTGCAGACGGAGGCGCAGTACAAGTTCATCTACGTGGCCATCGCCCAGTTCA
TTGAAACCACTAAGAAGAAGCTGGAGGTCCTGCAGTCGCAGAAGGG 
PTPRK NM_001135648.1 4315-4415 
GTGATCAACCGGATTTTTAGGATATGCAATCTAACAAGACCACAGGAAGGTTATCT
GATGGTGCAACAGTTTCAGTACCTAGGATGGGCTTCTCATCGAG 
RAB31 NM_006868.3 3800-3900 
TTTTGTAAAGAGCTTCCATCTGGGCTGGACCCAGTTCTTGCACATACAAGACACC
GCTGCAGTCAGCTAGGACCTTTCCGCCATGTATTCTATTCTGTAG 
160 
 
RAC1 NM_198829.1 1250-1350 
AAAGACCTTCGTCTTTGAGAAGACGGTAGCTTCTGCAGTTAGGAGGTGCAGACAC
TTGCTCTCCTATGTAGTTCTCAGATGCGTAAAGCAGAACAGCCTC 
RAC2 NM_002872.3 1069-1169 
GCTGCCACAACTTGTGTACCTTCAGGGATGGGGCTCTTACTCCCTCCTGAGGCCA
GCTGCTCTAATATCGATGGTCCTGCTTGCCAGAGAGTTCCTCTAC 
RAF1 NM_002880.2 1990-2090 
CCTATGGCATCGTATTGTATGAACTGATGACGGGGGAGCTTCCTTATTCTCACATC
AACAACCGAGATCAGATCATCTTCATGGTGGGCCGAGGATATGC 
RAP1GAP2 NM_015085.4 4140-4240 
CCCACGGCTGGAAAGAGGCCTGTACGTTCTGGACGCGTTTTGTTGGCTGGGCTT
CTGGAGGCACTGGCAAGGTCAAACTGCATTTCTTTAAGAACAGTTG 
RARA NM_000964.2 115-215 AGCCACCTAGCTGGGGCCCATCTAGGAGTGGCATCTTTTTTGGTGCCCTGAAGGCCAGCTCTGGACCTTCCCAGGAAAAGTGCCAGCTCACAGAACTGCT 
RBPMS NM_001008710.1 842-942 AAACAGCCTGTAGGTTTTGTCAGTTTTGACAGTCGCTCAGAAGCAGAGGCTGCAAAGAATGCTTTGAATGGCATCCGCTTCGATCCTGAAATTCCGCAAA 
RHOA NM_001664.2 1230-1330 
GGTACTCTGGTGAGTCACCACTTCAGGGCTTTACTCCGTAACAGATTTTGTTGGC
ATAGCTCTGGGGTGGGCAGTTTTTTGAAAATGGGCTCAACCAGAA 
RNF125 NM_017831.3 790-890 GCAAGGTGTGTATGTCCCTTTTGTCAGAGGGAACTGTATGAAGACAGCTTGCTGGATCATTGTATTACTCATCACAGATCGGAACGGAGGCCTGTGTTCT 
RORA NM_134261.2 1715-1815 
AAAATTAACCGAGACACTTTATATGGCCCTGCACAGACCTGGAGCGCCACACACT
GCACATCTTTTGGTGATCGGGGTCAGGCAAAGGAGGGGAAACAAT 
RORC NM_001001523.1 1350-1450 
CTCATCAATGCCCATCGGCCAGGGCTCCAAGAGAAAAGGAAAGTAGAACAGCTG
CAGTACAATCTGGAGCTGGCCTTTCATCATCATCTCTGCAAGACTC 
RPL27 NM_000988.3 23-123 GGGCCGGGTGGTTGCTGCCGAAATGGGCAAGTTCATGAAACCTGGGAAGGTGGTGCTTGTCCTGGCTGGACGCTACTCCGGACGCAAAGCTGTCATCGTG 
RPS13 NM_001017.2 331-431 GCATCTTGAGAGGAACAGAAAGGATAAGGATGCTAAATTCCGTCTGATTCTAATAGAGAGCCGGATTCACCGTTTGGCTCGATATTATAAGACCAAGCGA 
RUNX1 NM_001754.4 635-735 CAGCCATGAAGAACCAGGTTGCAAGATTTAATGACCTCAGGTTTGTCGGTCGAAGTGGAAGAGGGAAAAGCTTCACTCTGACCATCACTGTCTTCACAAA 
RUNX2 NM_004348.3 1850-1950 
GAAGCCACAGCAGTTCCCCAACTGTTTTGAATTCTAGTGGCAGAATGGATGAATC
TGTTTGGCGACCATATTGAAATTCCTCAGCAGTGGCCCAGTGGTA 
RUNX3 NM_004350.1 2085-2185 
GTGGTCTCATAATTCCATTTGTGGAGAGAACAGGAGGGCCAGATAGATAGGTCCT
AGCAGAAGGCATTGAGGTGAGGGATCATTTTGGGTCAGACATCAA 
S100A4 NM_002961.2 263-363 CAGGGACAACGAGGTGGACTTCCAAGAGTACTGTGTCTTCCTGTCCTGCATCGCCATGATGTGTAACGAATTCTTTGAAGGCTTCCCAGATAAGCAGCCC 
S100A6 NM_014624.3 539-639 TTCCTGGGGGCCTTGGCTTTGATCTACAATGAAGCCCTCAAGGGCTGAAAATAAATAGGGAAGATGGAGACACCCTCTGGGGGTCCTCTCTGAGTCAAAT 
SATB1 NM_001131010.1 1335-1435 
TTCCGAAATCTACCAGTGGGTACGCGATGAACTGAAACGAGCAGGAATCTCCCAG
GCGGTATTTGCACGTGTGGCTTTTAACAGAACTCAGGGCTTGCTT 
SCML1 NM_001037540.1 925-1025 GCAACGTATGGTTCTTCTTCAGGGCTCTGCCTTGGCAACCCTCGGGCTGACAGCATCCACAACACTTACTCAACTGACCATGCTTCTGCAGCACCACCTT 
SCML2 NM_006089.2 360-460 ATTGGAAGCCCGTGACCCTCGCAATGCCACTTCAGTATGTATTGCTACGGTTATTGGAATTACTGGGGCCAGGTTACGGTTACGACTGGATGGTAGTGAC 
SEL1L NM_005065.4 980-1080 GGGCAATCTAATAGCCCACATGGTTTTGGGTTACAGATACTGGGCTGGCATCGGCGTCCTCCAGAGTTGTGAATCTGCCCTGACTCACTATCGTCTTGTT 
SELL NM_000655.3 110-210 CTCCCTTTGGGCAAGGACCTGAGACCCTTGTGCTAAGTCAAGAGGCTCAATGGGCTGCAGAAGAACTAGAGAAGGACCAAGCAAAGCCATGATATTTCCA 
SELPLG NM_003006.3 2297-2397 
CATGGGCTGTTAGGTTGACTTCAGTTTTGCCTCTTGGACAACAGGGGGTCTTGTA
CATCCTTGGGTGACCAGGAAAAGTTCAGGCTATGGGGGGCCAAAG 
SERPINE2 NM_006216.2 240-340 CGCTGCCTTCCATCTGCTCCCACTTCAATCCTCTGTCTCTCGAGGAACTAGGCTCCAACACGGGGATCCAGGTTTTCAATCAGATTGTGAAGTCGAGGCC 
SH2B3 NM_005475.2 4285-4385 
CCTCCAGCCAGAAGTTAAACATCTGGGATATGACGTCTTCATGCCAGGGGCACTC
ATTTCTTAGCAGCCTCTCTACATACATCTCTCAGGTGGTGCCAAG 
SH2D2A NM_001161443.1 341-441 TGCTGGAGCCCAAGCCTCAGGGGTGCTACTTGGTGCGGTTCAGCGAGAGCGCGGTGACCTTCGTGCTGACTTACAGGAGCCGGACTTGCTGCCGCCACTT 
SIT1 NM_014450.2 720-820 GCCCCAGCCCCCCGTAGCAGGGGCATGACTGTTTCCCAACCAGCACCCAAAGACGGGCGCCATTGCCAAGTCACAGGATGTGATCTACCCCGGACTTCCT 
SKAP1 NM_003726.3 1360-1460 
AAGTGGGAAGAGGCACGTTCATCAAACCTGTTACTAAACCAGCCTAGTCATAGCT
CATCCCCATCTCTAAATGTGTCCACACAACCACATCTGCCTTTTC 
SKAP2 NM_003930.3 3374-3474 
TTTTACAGTTAATCCAGGAGAGGGAGTCCTTTGCCAACTGATGACCAACAGTTCC
AAGCCAGATAGTCTCGTGAACAGTGACAATACAGAAATAAGGTGT 
SLA2 NM_032214.2 1640-1740 
AAAGGAAAGCTGAGATGATGTCTTACCGTAGCAGCAGATCTTGGATGGTCCAGGC
TCTATGTGACCTCCAGAGCAAAGAGAAAGACTTCGGACAGTCTAG 
SLAMF1 NM_003037.2 580-680 GTGTCTCTTGATCCATCCGAAGCAGGCCCTCCACGTTATCTAGGAGATCGCTACAAGTTTTATCTGGAGAATCTCACCCTGGGGATACGGGAAAGCAGGA 
SLAMF7 NM_021181.3 215-315 GGGCACTATCATAGTGACCCAAAATCGTAATAGGGAGAGAGTAGACTTCCCAGATGGAGGCTACTCCCTGAAGCTCAGCAAACTGAAGAAGAATGACTCA 
SLC2A1 NM_006516.2 2500-2600 
AGGCTCCATTAGGATTTGCCCCTTCCCATCTCTTCCTACCCAACCACTCAAATTAA
TCTTTCTTTACCTGAGACCAGTTGGGAGCACTGGAGTGCAGGGA 
SMAD3 NM_005902.3 4220-4320 
TTAAAGGACAGTTGAAAAGGGCAAGAGGAAACCAGGGCAGTTCTAGAGGAGTGC
TGGTGACTGGATAGCAGTTTTAAGTGGCGTTCACCTAGTCAACACG 
SMAD4 NM_005359.3 1370-1470 
AGGTTGCACATAGGCAAAGGTGTGCAGTTGGAATGTAAAGGTGAAGGTGATGTTT
GGGTCAGGTGCCTTAGTGACCACGCGGTCTTTGTACAGAGTTACT 
161 
 
SNAI1 NM_005985.2 63-163 GACCACTATGCCGCGCTCTTTCCTCGTCAGGAAGCCCTCCGACCCCAATCGGAAGCCTAACTACAGCGAGCTGCAGGACTCTAATCCAGAGTTTACCTTC 
SOCS1 NM_003745.1 1025-1125 
TTAACTGTATCTGGAGCCAGGACCTGAACTCGCACCTCCTACCTCTTCATGTTTAC
ATATACCCAGTATCTTTGCACAAACCAGGGGTTGGGGGAGGGTC 
SOCS3 NM_003955.3 1870-1970 
GGAGGATGGAGGAGACGGGACATCTTTCACCTCAGGCTCCTGGTAGAGAAGACA
GGGGATTCTACTCTGTGCCTCCTGACTATGTCTGGCTAAGAGATTC 
SOD1 NM_000454.4 35-135 GCCTATAAAGTAGTCGCGGAGACGGGGTGCTGGTTTGCGTCGTAGTCTCCTGCAGCGTCTGGGGTTTCCGTTGCAGTCCTCGGAACCAGGACCTCGGCGT 
SOX13 NM_005686.2 3039-3139 
ATTTATTGAGTGCCCACTACGTGCCAGGCACTGTTGCTGAGTTCCTGTGGGTGTG
TCTCTCGATGCCACTCCTGCTTCTCTGGGGGCCTCTTTCTGTGCT 
SOX2 NM_003106.2 151-251 CTTAAGCCTTTCCAAAAAATAATAATAACAATCATCGGCGGCGGCAGGATCGGCCAGAGGAGGAGGGAAGCGCTTTTTTTGATCCTGATTCCAGTTTGCC 
SOX4 NM_003107.2 3040-3140 
GTTCACGGTCAAACTGAAATGGATTTGCACGTTGGGGAGCTGGCGGCGGCGGCT
GCTGGGCCTCCGCCTTCTTTTCTACGTGAAATCAGTGAGGTGAGAC 
SOX5 NM_152989.2 1885-1985 
TAGCCATGCAATGATGGATTTCAATCTGAGTGGAGATTCTGATGGAAGTGCTGGA
GTCTCAGAGTCAAGAATTTATAGGGAATCCCGAGGGCGTGGTAGC 
SPI1 NM_003120.1 730-830 CTCCGCAGCGGCGACATGAAGGACAGCATCTGGTGGGTGGACAAGGACAAGGGCACCTTCCAGTTCTCGTCCAAGCACAAGGAGGCGCTGGCGCACCGCT 
SPN NM_001030288.1 2798-2898 
AAGCCAGGCTTCATGGAAAGATCGTATGTGTGACCCAAATATGAGTTCTTCAGCT
CAGCCATGGTAATCCCTTCCTTGAAGTCTCCATTTCTGCAGTACA 
SPRY2 NM_005842.2 85-185 AAAGAGGAAATACTCCGCGTGCGCTTGTAGAAGGGGAGTCGTCTCCAGCTCCGAACCCCGGAGTGTTCATCAGCGGGGAATCTGGCTCCGAATTCTCTTT 
STAT1 NM_007315.2 205-305 TTTGCTGTATGCCATCCTCGAGAGCTGTCTAGGTTAACGTTCGCACTCTGTGTATATAACCTCGACAGTCTTGGCACCTAACGTGCTGTGCGTAGCTGCT 
STAT3 NM_139276.2 4535-4635 
AGACTTGGGCTTACCATTGGGTTTAAATCATAGGGACCTAGGGCGAGGGTTCAGG
GCTTCTCTGGAGCAGATATTGTCAAGTTCATGGCCTTAGGTAGCA 
STAT4 NM_003151.2 789-889 AGACAATGGATCAGAGTGACAAGAATAGTGCCATGGTGAATCAGGAAGTTTTGACACTGCAGGAAATGCTTAACAGCCTCGATTTCAAGAGAAAGGAGGC 
STAT5A NM_003152.2 3460-3560 
GAGACAGAGAGAGAGAAAGAGAGAGTGTGTGGGTCTATGTAAATGCATCTGTCCT
CATGTGTTGATGTAACCGATTCATCTCTCAGAAGGGAGGCTGGGG 
STAT5B NM_012448.3 200-300 AAGGAGAAGCCCTTCATCAGATGCAAGCGTTATATGGCCAGCATTTTCCCATTGAGGTGCGGCATTATTTATCCCAGTGGATTGAAAGCCAAGCATGGGA 
STAT6 NM_003153.3 2030-2130 
AGAACATCCAGCCATTCTCTGCCAAAGACCTGTCCATTCGCTCACTGGGGGACCG
AATCCGGGATCTTGCTCAGCTCAAAAATCTCTATCCCAAGAAGCC 
STMN1 NM_203401.1 287-387 CGTGGGTGGCGGCAGGACTTTCCTTATCCCAGTTGATTGTGCAGAATACACTGCCTGTCGCTTGTCTTCTATTCACCATGGCTTCTTCTGATATCCAGGT 
SYK NM_003177.3 1685-1785 
CGGACTCTCCAAAGCACTGCGTGCTGATGAAAACTACTACAAGGCCCAGACCCAT
GGAAAGTGGCCTGTCAAGTGGTACGCTCCGGAATGCATCAACTAC 
TAL1 NM_003189.2 4635-4735 
ACAGCATCTGTAGTCAGCCGACAACTATTTCGGCCTTTTGGGGGTGGGTCTGGCC
GTACTTGTGATTTCGATGGTACGTGACCCTCTGCTGAAGACTTGC 
TBP NM_003194.3 25-125 CGCCGGCTGTTTAACTTCGCTTCCGCTGGCCCATAGTGATCTTTGCAGTGACCCAGCAGCATCACTGTTTCTTGGCGTGTGAAGATAACCCAAGGAATTG 
TBX21 NM_013351.1 890-990 ACACAGGAGCGCACTGGATGCGCCAGGAAGTTTCATTTGGGAAACTAAAGCTCACAAACAACAAGGGGGCGTCCAACAATGTGACCCAGATGATTGTGCT 
TBXA2R NM_001060.3 385-485 CACACGCGCTCCTCCTTCCTCACCTTCCTCTGCGGCCTCGTCCTCACCGACTTCCTGGGGCTGCTGGTGACCGGTACCATCGTGGTGTCCCAGCACGCCG 
TCF12 NM_207037.1 1105-1205 
CACATGACCGCTTGAGTTATCCTCCACACTCAGTTTCACCAACAGACATAAACACG
AGTCTTCCACCAATGTCCAGCTTTCATCGCGGCAGTACCAGCAG 
TCF3 NM_003200.2 4325-4425 
ATACGTGTCAACACAGCTGGCTGGATGATTGGGACTTTAAAACGACCCTCTTTCA
GGTGGATTCAGAGACCTGTCCTGTATATAACAGCACTGTAGCAAT 
TCF7 NM_003202.2 2420-2520 
ATTCCATTTCCAGTTCATCTATGGCAGTCCAGCCAGCTCCTGGGCAGCTTGAGAG
GGCAAACCCAAAACCTCATGACAGCCAGAGCCTGTCTTTCAGCAT 
TDGF1 NM_003212.2 1567-1667 
AAGGAAAGAAAACATCTTTAAGGGGAGGAACCAGAGTGCTGAAGGAATGGAAGT
CCATCTGCGTGTGTGCAGGGAGACTGGGTAGGAAAGAGGAAGCAAA 
TDO2 NM_005651.1 0-100 AAGGTCAATGATAGCATCTGCCTAGAGTCAAACCTCCGTGCTTCTCAGACAGTGCCTTTTCACCATGAGTGGGTGCCCATTTTTAGGAAACAACTTTGGA 
TEK NM_000459.2 615-715 CGAGTTCGAGGAGAGGCAATCAGGATACGAACCATGAAGATGCGTCAACAAGCTTCCTTCCTACCAGCTACTTTAACTATGACTGTGGACAAGGGAGATA 
TERF1 NM_003218.3 1037-1137 
CTGAAAGCAGAATACCTGTTTCAAAGAGTCAGCCGGTAACTCCTGAAAAACATCG
AGCTAGAAAAAGACAGGCATGGCTTTGGGAAGAAGACAAGAATTT 
TERT NM_198253.1 2570-2670 
GGCTTCAAGGCTGGGAGGAACATGCGTCGCAAACTCTTTGGGGTCTTGCGGCTG
AAGTGTCACAGCCTGTTTCTGGATTTGCAGGTGAACAGCCTCCAGA 
TF NM_001063.2 640-740 CTGCTCCACCCTTAACCAATACTTCGGCTACTCGGGAGCCTTCAAGTGTCTGAAGGATGGTGCTGGGGATGTGGCCTTTGTCAAGCACTCGACTATATTT 
TFRC NM_003234.1 1220-1320 
CAGTTTCCACCATCTCGGTCATCAGGATTGCCTAATATACCTGTCCAGACAATCTC
CAGAGCTGCTGCAGAAAAGCTGTTTGGGAATATGGAAGGAGACT 
TGFA NM_003236.2 780-880 TGCCACAGACCTTCCTACTTGGCCTGTAATCACCTGTGCAGCCTTTTGTGGGCCTTCAAAACTCTGTCAAGAACTCCGTCTGCTTGGGGTTATTCAGTGT 
TGFB1 NM_000660.3 1260-1360 
TATATGTTCTTCAACACATCAGAGCTCCGAGAAGCGGTACCTGAACCCGTGTTGC
TCTCCCGGGCAGAGCTGCGTCTGCTGAGGCTCAAGTTAAAAGTGG 
162 
 
TGFB2 NM_003238.2 1125-1225 
AAGCCAGAGTGCCTGAACAACGGATTGAGCTATATCAGATTCTCAAGTCCAAAGA
TTTAACATCTCCAACCCAGCGCTACATCGACAGCAAAGTTGTGAA 
TGFBR1 NM_004612.2 4280-4380 
GGGGAAATACGACTTAGTGAGGCATAGACATCCCTGGTCCATCCTTTCTGTCTCC
AGCTGTTTCTTGGAACCTGCTCTCCTGCTTGCTGGTCCCTGACGC 
Thymidine 
Kinase SCFV007.1 100-200 
TCTACGTACCCGAGCCGATGACTTACTGGCAGGTGCTGGGGGCTTCCGAGACAA
TCGCGAACATCTACACCACACAACACCGCCTCGACCAGGGTGAGAT 
TIE1 NM_005424.2 2610-2710 
CATCGGGGAGGGGAACTTCGGCCAGGTCATCCGGGCCATGATCAAGAAGGACG
GGCTGAAGATGAACGCAGCCATCAAAATGCTGAAAGAGTATGCCTCT 
TLR2 NM_003264.3 180-280 CTGCTTTCAACTGGTAGTTGTGGGTTGAAGCACTGGACAATGCCACATACTTTGTGGATGGTGTGGGTCTTGGGGGTCATCATCAGCCTCTCCAAGGAAG 
TLR8 NM_138636.3 2795-2895 
GACAAAAACGTTCTCCTTTGTCTAGAGGAGAGGGATTGGGATCCGGGATTGGCCA
TCATCGACAACCTCATGCAGAGCATCAACCAAAGCAAGAAAACAG 
TNF NM_000594.2 1010-1110 
AGCAACAAGACCACCACTTCGAAACCTGGGATTCAGGAATGTGTGGCCTGCACA
GTGAAGTGCTGGCAACCACTAAGAATTCAAACTGGGGCCTCCAGAA 
TNFRSF14 NM_003820.2 916-1016 CTCAGGGAGCCTCGTCATCGTCATTGTTTGCTCCACAGTTGGCCTAATCATATGTGTGAAAAGAAGAAAGCCAAGGGGTGATGTAGTCAAGGTGATCGTC 
TNFRSF18 NM_004195.2 445-545 AGGGGAAATTCAGTTTTGGCTTCCAGTGTATCGACTGTGCCTCGGGGACCTTCTCCGGGGGCCACGAAGGCCACTGCAAACCTTGGACAGACTGCACCCA 
TNFRSF1B NM_001066.2 835-935 CCCAGCTGAAGGGAGCACTGGCGACTTCGCTCTTCCAGTTGGACTGATTGTGGGTGTGACAGCCTTGGGTCTACTAATAATAGGAGTGGTGAACTGTGTC 
TNFRSF4 NM_003327.2 200-300 CCGTGCGGGCCGGGCTTCTACAACGACGTGGTCAGCTCCAAGCCGTGCAAGCCCTGCACGTGGTGTAACCTCAGAAGTGGGAGTGAGCGGAAGCAGCTGT 
TNFRSF9 NM_001561.4 255-355 AGATTTGCAGTCCCTGTCCTCCAAATAGTTTCTCCAGCGCAGGTGGACAAAGGACCTGTGACATATGCAGGCAGTGTAAAGGTGTTTTCAGGACCAGGAA 
TNFSF10 NM_003810.2 115-215 GGGGGGACCCAGCCTGGGACAGACCTGCGTGCTGATCGTGATCTTCACAGTGCTCCTGCAGTCTCTCTGTGTGGCTGTAACTTACGTGTACTTTACCAAC 
TNFSF11 NM_003701.2 490-590 TACCTGATTCATGTAGGAGAATTAAACAGGCCTTTCAAGGAGCTGTGCAAAAGGAATTACAACATATCGTTGGATCACAGCACATCAGAGCAGAGAAAGC 
TNFSF14 NM_003807.2 270-370 ATTTTCAGAAGCCTCTGGAAAGTCGTGCACAGCCCAGGAGTGTTGAGCAATTTCGGTTTCCTCTGAGGTTGAAGGACCCAGGCGTGTCAGCCCTGCTCCA 
TOX NM_014729.2 3950-4050 
AATGAGCAGCTTTGACTTTGACAGGCGGTTTGTGCAGGAAAGCACAGTGCCGTGT
TGTTTACAGCTTTTCTAGAGCAGCTGTGCGACCAGGGTAGAGAGT 
TP53 NM_000546.2 1330-1430 
GGGGAGCAGGGCTCACTCCAGCCACCTGAAGTCCAAAAAGGGTCAGTCTACCTC
CCGCCATAAAAAACTCATGTTCAAGACAGAAGGGCCTGACTCAGAC 
TRAF1 NM_005658.3 3735-3835 
CGAGTGATGGGTCTAGGCCCTGAAACTGATGTCCTAGCAATAACCTCTTGATCCC
TACTCACCGAGTGTTGAGCCCAAGGGGGGATTTGTAGAACAAGCC 
TRAF2 NM_021138.3 1325-1425 
GTGGCCCTTCAACCAGAAGGTGACCTTAATGCTGCTCGACCAGAATAACCGGGA
GCACGTGATTGACGCCTTCAGGCCCGACGTGACTTCATCCTCTTTT 
TRAF3 NM_145725.1 1795-1895 
ATATGATGCCCTGCTTCCTTGGCCGTTTAAGCAGAAAGTGACACTCATGCTGATG
GATCAGGGGTCCTCTCGACGTCATTTGGGAGATGCATTCAAGCCC 
TSC22D3 NM_198057.2 1400-1500 
TTAAGCAGAGGCAACCTCTCTCTTCTCCTCTGTTTCGTGAAGGCAGGGGACACAG
ATGGGAGAGATTGAGCCAAGTCAGCCTTCTGTTGGTTAATATGGT 
TSLP NM_033035.3 395-495 CCGTCTCTTGTAGCAATCGGCCACATTGCCTTACTGAAATCCAGAGCCTAACCTTCAATCCCACCGCCGGCTGCGCGTCGCTCGCCAAAGAAATGTTCGC 
TXK NM_003328.1 800-900 ATGACTCGTCTCCGATATCCAGTTGGGCTGATGGGCAGTTGTTTACCAGCCACAGCTGGGTTTAGCTACGAAAAGTGGGAGATAGATCCATCTGAGTTGG 
TYK2 NM_003331.3 485-585 TCATCGCTGACAGCTGAGGAAGTCTGCATCCACATTGCACATAAAGTTGGTATCACTCCTCCTTGCTTCAATCTCTTTGCCCTCTTCGATGCTCAGGCCC 
TYROBP NM_003332.2 457-557 CTGCACCTCATTCCAACTCCTACCGCGATACAGACCCACAGAGTGCCATCCCTGAGAGACCAGACCGCTCCCCAATACTCTCCTAAAATAAACATGAAGC 
UBASH3A NM_001001895.1 1970-2070 
GAGATGCTGCTGTTTCCAGAGGCGTCTTAGTCTCACCCAATGTGATTTGTAGAAG
CACGAGACGCACTTTTATATCCCGGAATATTTCCCTCCGGCTTTC 
VAX2 NM_012476.2 871-971 CAGCGCCAGCAGCTGCAAGAAAGCTAACACTTAAGACTCCCACCCTGTGACACTGAGTCCCGAGCACAGCACCTTCCCAGTCTCCTGTGCCCCAGCGGAC 
VEGFA NM_001025366.1 1325-1425 
GAGTCCAACATCACCATGCAGATTATGCGGATCAAACCTCACCAAGGCCAGCACA
TAGGAGAGATGAGCTTCCTACAGCACAACAAATGTGAATGCAGAC 
WEE1 NM_003390.2 5-105 TGCGTTTGAGTTTGCCGCGAGCCGGGCCAATCGGTTTTGCCAACGCATGCCCACGTGCTGGCGAACAAATGTAAACACGGAGATCGTGTGCCGGGCACTT 
XBP1 NM_005080.2 440-540 GGAGTTAAGACAGCGCTTGGGGATGGATGCCCTGGTTGCTGAAGAGGAGGCGGAAGCCAAGGGGAATGAAGTGAGGCCAGTGGCCGGGTCTGCTGAGTCC 
XBP1 NM_001079539.1 935-1035 ATTCATTGTCTCAGTGAAGGAAGAACCTGTAGAAGATGACCTCGTTCCGGAGCTGGGTATCTCAAATCTGCTTTCATCCAGCCACTGCCCAAAGCCATCT 
YY1AP1 NM_139118.2 755-855 ATGGGAGCTATGCAGCTGATTGAAGACTTCAGCACACATGTCAGCATTGACTGCAGCCCTCATAAAACTGTCAAGAAGACTGCCAATGAATTTCCCTGTT 
ZAP70 NM_001079.3 1175-1275 
GGAGCTCAAGGACAAGAAGCTCTTCCTGAAGCGCGATAACCTCCTCATAGCTGAC
ATTGAACTTGGCTGCGGCAACTTTGGCTCAGTGCGCCAGGGCGTG 
ZBTB16 NM_006006.4 1585-1685 
TCCTGGATAGTTTGCGGCTGAGAATGCACTTACTGGCTCATTCAGCGGGTGCCAA
AGCCTTTGTCTGTGATCAGTGCGGTGCACAGTTTTCGAAGGAGGA 
ZC2HC1A NM_016010.2 665-765 ACGATTACCGCAGCCAAGTGGCGCTGGCAAAACTGTTGTAGGTGTTCCTTCAGGTAAAGTGTCTTCAAGTAGCAGCTCTTTGGGAAACAAACTTCAGACC 
163 
 
 
 
 
  
ZEB2 NM_014795.2 20-120 TCCCAGAGAGAAACTTGGCGATCACGTTTTCACATGATGCTCACGCTCAGGGCGCTTCAATTATCCCTCCCCACAAAGATAGGTGGCGCGTGTTTCAGGG 
ZNF516 NM_014643.2 4830-4930 
GGTGGGGGACGGCTTCATATACCTCTTCCTCAGTAATGCAAATGCGAGTTTTTGT
GGTGGGGGTTAAGGCCCATAACAAAGGATCTTAAACCATGCAGTG 
164 
 
Appendix B: TCRVα and TCRBβ CodeSet  
TCRVα genes Target region Target sequence 
TRAV1-1 192-292 
TACAATGCTCTGGATGGTTTGGAGGAGACAGGTCGTTTTTCTTCATTCCT 
TAGTCGCTCTGATAGTTATGGTTACCTCCTTCTACAGGAGCTCCAGATGA 
TRAV1-2 187-287 
TGTCTTACAATGTTCTGGATGGTTTGGAGGAGAAAGGTCGTTTTTCTTCA 
TTCCTTAGTCGGTCTAAAGGGTACAGTTACCTCCTTTTGAAGGAGCTCCA 
TRAV2 177-277 
TACCTTCACTTCCCGGGATGTGCACCAAGACTCCTTGTTAAAGGCTCAAA 
GCCTTCTCAGCAGGGACGATACAACATGACCTATGAACGGTTCTCTTCAT 
TRAV3 6-106 
TCTGCACCCATCTCGATGCTTGCGATGCTCTTCACATTGAGTGGGCTGAGA 
GCTCAGTCAGTGGCTCAGCCGGAAGATCAGGTCAACGTTGCTGAAGGGA 
TRAV4 159-259 
CAACAGTTTCCCAGCCAAGGACCACGATTTATTATTCAAGGATACAAGAC 
AAAAGTTACAAACGAAGTGGCCTCCCTGTTTATCCCTGCCGACAGAAAGT 
TRAV5 118-218 
TTATAAACTGCACTTACACAGACAGCTCCTCCACCTACTTATACTGGTAT 
AAGCAAGAACCTGGAGCAGGTCTCCAGTTGCTGACGTATATTTTTTCAAA 
TRAV6 183-283 
AGAGGCCCTGTTTTCTTGCTACTCATACGTGAAAATGAGAAAGAAAAAAG 
GAAAGAAAGACTGAAGGTCACCTTTGATACCACCCTTAAACAGAGTTTGT 
TRAV7 126-226 
AGCTGCACGTACTCTGTCAGTCGTTTTAACAATTTGCAGTGGTACAGGCA 
AAATACAGGGATGGGTCCCAAACACCTATTATCCATGTATTCAGCTGGAT 
TRAV8-1 108-208 
TCACTGGAGTTGGGATGCAACTATTCCTATGGTGGAACTGTTAATCTCTT 
CTGGTATGTCCAGTACCCTGGTCAACACCTTCAGCTTCTCCTCAAGTACT 
TRAV8-2 206-306 
CACATCAGCGGCCACCCTGGTTAAAGGCATCAACGGTTTTGAGGCTGAAT 
TTAAGAAGAGTGAAACCTCCTTCCACCTGACGAAACCCTCAGCCCATATG 
TRAV8-3 49-149 
CTGCCAGAGCCCAGTCAGTGACCCAGCCTGACATCCACATCACTGTCTCT 
GAAGGAGCCTCACTGGAGTTGAGATGTAACTATTCCTATGGGGCAACACC 
TRAV8-6 206-306 
TTTATCAGGATCCACCCTGGTTAAAGGCATCAACGGTTTTGAGGCTGAAT 
TTAACAAGAGTCAAACTTCCTTCCACTTGAGGAAACCCTCAGTCCATATA 
TRAV9-1 49-149 
GAATCAATGGAGATTCAGTGGTCCAGACAGAAGGCCAAGTGCTCCCCTCT 
GAAGGGGATTCCCTGATTGTGAACTGCTCCTATGAAACCACACAGTACCC 
TRAV9-2 31-131 
TACTCTTACTGCTTGGAAGAACCCGTGGAAATTCAGTGACCCAGATGGAA 
GGGCCAGTGACTCTCTCAGAAGAGGCCTTCCTGACTATAAACTGCACGTA 
TRAV10 164-264 
GTGGTATAAGCAAGATACTGGGAGAGGTCCTGTTTCCCTGACAATCATGA 
CTTTCAGTGAGAACACAAAGTCGAACGGAAGATATACAGCAACTCTGGAT 
TRAV11 135-235 
TATCAGGAGAGAACACTCTTCAATTTCCACTGGTTCCGGCAGGATCCGGG 
GAGAAGACTTGTGTCTTTGACCTTAATTCAATCAAGCCAGAAGGAGCAGG 
TRAV12-1 140-240 
CAACAGTGCTTCTCAGTCTTTCTTCTGGTACAGACAGGATTGCAGGAAAG 
AACCTAAGTTGCTGATGTCCGTATACTCCAGTGGTAATGAAGATGGAAGG 
TRAV12-2 116-216 
CATTGCCTCTCTCAACTGCACTTACAGTGACCGAGGTTCCCAGTCCTTCT 
TCTGGTACAGACAATATTCTGGGAAAAGCCCTGAGTTGATAATGTTCATA 
TRAV12-3 99-199 
AGTGTTCCAGAGGGAGCCATTGTTTCTCTCAACTGCACTTACAGCAACAG 
TGCTTTTCAATACTTCATGTGGTACAGACAGTATTCCAGAAAAGGCCCTG 
TRAV13-1 189-289 
CAGCTTATTATAGACATTCGTTCAAATGTGGGCGAAAAGAAAGACCAACG 
AATTGCTGTTACATTGAACAAGACAGCCAAACATTTCTCCCTGCACATCA 
TRAV13-2 99-199 
CAGGAGGGTGACAACTCTATTATCAACTGTGCTTATTCAAACAGCGCCTC 
AGACTACTTCATTTGGTACAAGCAAGAATCTGGAAAAGGTCCTCAATTCA 
TRAV14 232-332 
ATGCAACAGAAGGTCGCTACTCATTGAATTTCCAGAAGGCAAGAAAATCC 
GCCAACCTTGTCATCTCCGCTTCACAACTGGGGGACTCAGCAATGTATTT 
TRAV16 222-322 
ATCAAAGGCTTCACTGCTGACCTTAACAAAGGCGAGACATCTTTCCACCT 
GAAGAAACCATTTGCTCAAGAGGAAGACTCAGCCATGTATTACTGTGCTC 
TRAV17 201-301 
TTAATACGTTCAAATGAAAGAGAGAAACACAGTGGAAGATTAAGAGTCAC 
GCTTGACACTTCCAAGAAAAGCAGTTCCTTGTTGATCACGGCTTCCCGGC 
TRAV18 198-298 
CTGAAAAGTTCAGAAAACCAGGAGACGGACAGCAGAGGTTTTCAGGCCAG 
TCCTATCAAGAGTGACAGTTCCTTCCACCTGGAGAAGCCCTCGGTGCAGC 
TRAV19 227-237 
GCAAAATGAAATAAGTGGTCGGTATTCTTGGAACTTCCAGAAATCCACCA 
GTTCCTTCAACTTCACCATCACAGCCTCACAAGTCGTGGACTCAGCAGTA 
TRAV20 136-236 
ACACAGTCAGCGGTTTAAGAGGGCTGTTCTGGTATAGGCAAGATCCTGGG 
AAAGGCCCTGAATTCCTCTTCACCCTGTATTCAGCTGGGGAAGAAAAGGA 
165 
 
TRAV21 176-276 
TGGGAAAGGTCTCACATCTCTGTTGCTTATTCAGTCAAGTCAGAGAGAGC 
AAACAAGTGGAAGACTTAATGCCTCGCTGGATAAATCATCAGGACGTAGT 
TRAV22 183-283 
CAGCTCATCAACCTGTTTTACATTCCCTCAGGGACAAAACAGAATGGAAG 
ATTAAGCGCCACGACTGTCGCTACGGAACGCTACAGCTTATTGTACATTT 
TRAV23 159-259 
GAGAACACTGCGTTTGACTACTTTCCATGGTACCAACAATTCCCTGGGAA 
AGGCCCTGCATTATTGATAGCCATACGTCCAGATGTGAGTGAAAAGAAAG 
TRAV24 88-188 
CTCAGTCACTGCATGTTCAGGAGGGAGACAGCACCAATTTCACCTGCAGC 
TTCCCTTCCAGCAATTTTTATGCCTTACACTGGTACAGATGGGAAACTGC 
TRAV25 43-143 
CACAGGTGAATGGACAACAGGTAATGCAAATTCCTCAGTACCAGCATGTA 
CAAGAAGGAGAGGACTTCACCACGTACTGCAATTCCTCAACTACTTTAAG 
TRAV26-1 106-206 
ACCTGCCTTGTAATCACTCTACCATCAGTGGAAATGAGTATGTGTATTGG 
TATCGACAGATTCACTCCCAGGGGCCACAGTATATCATTCATGGTCTAAA 
TRAV26-2 11-111 
GACAAGCATTACTGTACTCCTATCTTTGGGTATTATGGGTGATGCTAAGA 
CCACACAGCCAAATTCAATGGAGAGTAACGAAGAAGAGCCTGTTCACTTG 
TRAV27 69-169 
CAGAGCCCTCAGTTTCTAAGCATCCAAGAGGGAGAAAATCTCACTGTGTA 
CTGCAACTCCTCAAGTGTTTTTTCCAGCTTACAATGGTACAGACAGGAGC 
TRAV29 193-293 
ACCCTGCTGAAGGTCCTACATTCCTGATATCTATAAGTTCCATTAAGGAT 
AAAAATGAAGATGGAAGATTCACTGTCTTCTTAAACAAAAGTGCCAAGCA 
TRAV30 141-241 
GCTTTATATTCTGTACACTGGTACAGGCAGAAGCATGGTGAAGCACCCGT 
CTTCCTGATGATATTACTGAAGGGTGGAGAACAGAAGGGTCATGAAAAAA 
TRAV34 169-269 
AAAAGTATGGTGAAGGTCTTATCTTCTTGATGATGCTACAGAAAGGTGGG 
GAAGAGAAAAGTCATGAAAAGATAACTGCCAAGTTGGATGAGAAAAAGCA 
TRAV35 216-316 
TTGACCTCAAATGGAAGACTGACTGCTCAGTTTGGTATAACCAGAAAGGA 
CAGCTTCCTGAATATCTCAGCATCCATACCTAGTGATGTAGGCATCTACT 
TRAV36 156-256 
AGCCTACTATGGTACAAGCAGGAAAAGAAAGCTCCCACATTTCTATTTAT 
GCTAACTTCAAGTGGAATTGAAAAGAAGTCAGGAAGACTAAGTAGCATAT 
TRAV38-1 250-350 
TCTCTGTGAACTTCCAGAAAGCAGCCAAATCCTTCAGTCTCAAGATCTCA 
GACTCACAGCTGGGGGACACTGCGATGTATTTCTGTGCTTTCATGAAGCA 
TRAV38-2 249-349 
TTCTCTGTGAACTTCCAGAAAGCAGCCAAATCCTTCAGTCTCAAGATCTCA 
GACTCACAGCTGGGGGATGCCGCGATGTATTTCTGTGCTTATAGGAGCG 
TRAV39 49-149 
GTGGAGAGCTGAAAGTGGAACAAAACCCTCTGTTCCTGAGCATGCAGGA 
GGGAAAAAACTATACCATCTACTGCAATTATTCAACCACTTCAGACAGACT 
TRAV40 6-106 
TCCTCTCTGGACTTTCTAATTCTGATCTTAATGTTTGGAGGAACCAGCAGC 
AATTCAGTCAAGCAGACGGGCCAAATAACCGTCTCGGAGGGAGCATCTG 
 
    TRAV41 38-138 
GCTTCAGCTAAGCTGTGTAAGTGCCGCCAAAAATGAAGTGGAGCAGAGTC 
CTCAGAACCTGACTGCCCAGGAAGGAGAATTTATCACAATCAACTGCAGT 
TCRVβ genes Target region Target sequence 
TRBV2 220-320 
CAGAGAAGTCTGAAATATTCGATGATCAATTCTCAGTTGAAAGGCCTGATG 
GATCAAATTTCACTCTGAAGATCCGGTCCACAAAGCTGGAGGACTCAGC 
TRBV3-1 86-186 
AATACCTGGTCACACAGATGGGAAACGACAAGTCCATTAAATGTGAACAA 
AATCTGGGCCATGATACTATGTATTGGTATAAACAGGACTCTAAGAAATT 
TRBV4-1 143-243 
CAGGGCTATGTATTGGTACAAGCAGAAAGCTAAGAAGCCACCGGAGCTC 
ATGTTTGTCTACAGCTATGAGAAACTCTCTATAAATGAAAGTGTGCCAAGT 
TRBV4-2 138-238 
GGGCATAACGCTATGTATTGGTACAAGCAAAGTGCTAAGAAGCCACTGG 
AGCTCATGTTTGTCTACAACTTTAAAGAACAGACTGAAAACAACAGTGTGC 
TRBV4-3 138-238 
GGTCATAACGCTATGTATTGGTACAAGCAAAGTGCTAAGAAGCCACTGGA 
GCTCATGTTTGTCTACAGTCTTGAAGAACGGGTTGAAAACAACAGTGTGC 
TRBV5-1 194-298 
TTTGAATACTTCAGTGAGACACAGAGAAACAAAGGAAACTTCCCTGGTCG 
ATTCTCAGGGCGCCAGTTCTCTAACTCTCGCTCTGAGATGAATGTGAGCA 
TRBV5-4 151-251 
CAACACTGTGTCCTGGTACCAACAGGCCCTGGGTCAGGGGCCCCAGTTTA 
TCTTTCAGTATTATAGGGAGGAAGAGAATGGCAGAGGAAACTTCCCTCCT 
TRBV5-5 148-248 
AGAGTGTGTCCTGGTACCAACAGGTCCTGGGTCAGGGGCCCCAGTTTATC 
TTTCAGTATTATGAGAAAGAAGAGAGAGGAAGAGGAAACTTCCCTGATCG 
TRBV5-6 145-245 
ACACTGTGTCCTGGTACCAACAGGCCCTGGGTCAGGGGCCCCAGTTTATC 
TTTCAGTATTATGAGGAGGAAGAGAGACAGAGAGGCAACTTCCCTGATCG 
TRBV5-8 131-231 
TATCTCTGGGCACACCAGTGTGTACTGGTACCAACAGGCCCTGGGTCTGG 
GCCTCCAGTTCCTCCTTTGGTATGACGAGGGTGAAGAGAGAAACAGAGGA 
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TRBV6-1 124-224 
GTGCCCAGGATATGAACCATAACTCCATGTACTGGTATCGACAAGACCCA 
GGCATGGGACTGAGGCTGATTTATTACTCAGCTTCTGAGGGTACCACTGA 
TRBV6-2 150-250 
ATGTACTGGTATCGACAAGACCCAGGCATGGGGCTGAGGCTGATTCATTA 
CTCAGTTGGTGAGGGTACAACTGCCAAAGGAGAGGTCCCTGATGGCTACA 
TRBV6-4 181-281 
GGCTAAGGCTCATCCATTATTCAAATACTGCAGGTACCACTGGCAAAGGA 
GAAGTCCCTGATGGTTATAGTGTCTCCAGAGCAAACACAGATGATTTCCC 
TRBV6-5 142-242 
ATGAATACATGTCCTGGTATCGACAAGACCCAGGCATGGGGCTGAGGCTG 
ATTCATTACTCAGTTGGTGCTGGTATCACTGACCAAGGAGAAGTCCCCAA 
TRBV6-6 159-259 
TATCGACAAGACCCAGGCATGGGGCTGAAGCTGATTTATTATTCAGTTGG 
TGCTGGTATCACTGATAAAGGAGAAGTCCCGAATGGCTACAACGTATCTG 
TRBV6-8 133-233 
ATATGAACCATGGATACATGTCCTGGTATCGACAAGACCCAGGCATGGGG 
CTGAGACTGATTTACTACTCAGCTGCTGCTGGTACTACTGACAAAGAAGT 
TRBV6-9 164-264 
GGCATGGGGCTGAGGCGCATTCATTACTCAGTTGCTGCTGGTATCACTGA 
CAAAGGAGAAGTCCCCGATGGCTACAATGTATCCAGATCAAACACAGAGG 
TRBV7-2 117-217 
CTCAGGTGTGATCCAATTTCAGGTCATACTGCCCTTTACTGGTACCGACA 
GAGCCTGGGGCAGGGCCTGGAGTTTTTAATTTACTTCCAAGGCAACAGTG 
TRBV7-3 163-263 
GACAAAGCCTGGGGCAGGGCCCAGAGTTTCTAATTTACTTCCAAGGCACG 
GGTGCGGCAGATGACTCAGGGCTGCCCAACGATCGGTTCTTTGCAGTCAG 
TRBV7-4 125-225 
TGATTCAATTTCGGGTCATGTAACCCTTTATTGGTACCGACAGACCCTGGG 
GCAGGGCTCAGAGGTTCTGACTTACTCCCAGAGTGATGCTCAACGAGAC 
TRBV7-6 76-176 
CTCCCAGGTACAAAGTCACAAAGAGGGGACAGGATGTAGCTCTCAGGTGT 
GATCCAATTTCGGGTCATGTATCCCTTTATTGGTACCGACAGGCCCTGGG 
TRBV7-7 74-174 
GTCTCCCAGGTACAAAGTCACAAAGAGGGGACAGGATGTAACTCTCAGGT 
GTGATCCAATTTCGAGTCATGCAACCCTTTATTGGTATCAACAGGCCCTG 
TRBV7-8 194-294 
GACTTATTTCCAGAATGAAGCTCAACTAGACAAATCGGGGCTGCCCAGTG 
ATCGCTTCTTTGCAGAAAGGCCTGAGGGATCCGTCTCCACTCTGAAGATC 
TRBV7-9 13-113 
TCCTCTGCTGGATGGCCCTGTGTCTCCTGGGGGCAGATCACGCAGATACT 
GGAGTCTCCCAGAACCCCAGACACAAGATCACAAAGAGGGGACAGAATGT 
TRBV9 175-275 
ACCAGGGCCTCCAGTTCCTCATTCAGTATTATAATGGAGAAGAGAGAGCA 
AAAGGAAACATTCTTGAACGATTCTCCGCACAACAGTTCCCTGACTTGCA 
TRBV10-1 176-276 
ACATGGGCTGAGGCTGATCCATTACTCATATGGTGTTCAAGACACTAACA 
AAGGAGAAGTCGCTGCCTCCTCCCAGACATCTGTATATTTCTGCGCCAGC 
TRBV10-2 62-162 
TGGAATCACCCAGAGCCCAAGATACAAGATCACAGAGACAGGAAGGCAG 
GTGACCTTGATGTGTCACCAGACTTGGAGCCACAGCTATATGTTCTGGTAT 
TRBV10-3 192-292 
ATCCATTACTCATATGGTGTTAAAGATACTGACAAAGGAGAAGTCTCAGA 
TGGCTATAGTGTCTCTAGATCAAAGACAGAGGATTTCCTCCTCACTCTGG 
TRBV11-1 131-231 
TATTTCTGGCCATGCTACCCTTTACTGGTACCGGCAGATCCTGGGACAGG 
GCCCGGAGCTTCTGGTTCAATTTCAGGATGAGAGTGTAGTAGATGATTCA 
TRBV11-2 131-231 
TATATCTGGCCATGCTACCCTTTACTGGTACCAGCAGATCCTGGGACAGG 
GCCCAAAGCTTCTGATTCAGTTTCAGAATAACGGTGTAGTGGATGATTCA 
TRBV11-3 73-173 
AGTCTCCCAGATATAAGATTATAGAGAAAAAACAGCCTGTGGCTTTTTGG 
TGCAATCCTATTTCTGGCCACAATACCCTTTACTGGTACCTGCAGAACTT 
TRBV12-3 150-250 
CTTTTCTGGTACAGACAGACCATGATGCGGGGACTGGAGTTGCTCATTTA 
CTTTAACAACAACGTTCCGATAGATGATTCAGGGATGCCCGAGGATCGAT 
TRBV12-5 120-220 
AGATGTCAGCCAATTTTAGGCCACAATACTGTTTTCTGGTACAGACAGAC 
CATGATGCAAGGACTGGAGTTGCTGGCTTACTTCCGCAACCGGGCTCCTC 
TRBV13 87-187 
GCTGCTGGAGTCATCCAGTCCCCAAGACATCTGATCAAAGAAAAGAGGGA 
AACAGCCACTCTGAAATGCTATCCTATCCCTAGACACGACACTGTCTACT 
TRBV14 233-333 
TATGCCCAACAATCGATTCTTAGCTGAAAGGACTGGAGGGACGTATTCTA 
CTCTGAAGGTGCAGCCTGCAGAACTGGAGGATTCTGGAGTTTATTTCTGT 
TRBV15 187-287 
CCCAAAGCTGCTGTTCCACTACTATGACAAAGATTTTAACAATGAAGCAG 
ACACCCCTGATAACTTCCAATCCAGGAGGCCGAACACTTCTTTCTGCTTT 
TRBV16 194-294 
GATTTCCTTCCAGAATGAAAATGTCTTTGATGAAACAGGTATGCCCAAGG 
AAAGATTTTCAGCTAAGTGCCTCCCAAATTCACCCTGTAGCCTTGAGATC 
TRBV18 156-256 
TGGTATCGGCAGCTCCCAGAGGAAGGTCTGAAATTCATGGTTTATCTCCA 
GAAAGAAAATATCATAGATGAGTCAGGAATGCCAAAGGAACGATTTTCTG 
 
TRBV19 195-295 
TACTACTCACAGATAGTAAATGACTTTCAGAAAGGAGATATAGCTGAAGG 
GTACAGCGTCTCTCGGGAGAAGAAGGAATCCTTTCCTCTCACTGTGACAT 
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TRBV20-1 95-195 
CAGAGAAGTCTGAAATATTCGATGATCAATTCTCAGTTGAAAGGCCTGAT 
GGATCAAATTTCACTCTGAAGATCCGGTCCACAAAGCTGGAGGACTCAGC 
TRBV24-1 124-224 
AATACCTGGTCACACAGATGGGAAACGACAAGTCCATTAAATGTGAACAA 
AATCTGGGCCATGATACTATGTATTGGTATAAACAGGACTCTAAGAAATT 
TRBV25-1 181-281 
CAGGGCTATGTATTGGTACAAGCAGAAAGCTAAGAAGCCACCGGAGCTC 
ATGTTTGTCTACAGCTATGAGAAACTCTCTATAAATGAAAGTGTGCCAAGT 
TRBV27 162-262 
GGGCATAACGCTATGTATTGGTACAAGCAAAGTGCTAAGAAGCCACTGG 
AGCTCATGTTTGTCTACAACTTTAAAGAACAGACTGAAAACAACAGTGTGC 
TRBV28 47-147 
GGTCATAACGCTATGTATTGGTACAAGCAAAGTGCTAAGAAGCCACTGGA 
GCTCATGTTTGTCTACAGTCTTGAAGAACGGGTTGAAAACAACAGTGTGC 
TRBV29-1 190-290 
TTTGAATACTTCAGTGAGACACAGAGAAACAAAGGAAACTTCCCTGGTCG 
ATTCTCAGGGCGCCAGTTCTCTAACTCTCGCTCTGAGATGAATGTGAGCA 
TRBV30 5-105 
CAACACTGTGTCCTGGTACCAACAGGCCCTGGGTCAGGGGCCCCAGTTTA 
TCTTTCAGTATTATAGGGAGGAAGAGAATGGCAGAGGAAACTTCCCTCCT 
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